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ABSTRACT 
 
Background: Myelin oligodendrocyte glycoprotein (MOG) has been a putative 
candidate antigen in demyelination for over three decades, based on experimental data 
in animal models. With the evolution and refinement of antibody detection methods 
and the advent of the cell based assay, MOG antibodies were initially identified as an 
important biomarker in children with demyelination. However, the role of MOG 
antibodies in adults was less clear, apart from the growing consensus that they were 
not present in most adults with multiple sclerosis (MS).  
 
Aims: We sought to identify the clinical phenotypes associated with MOG antibody-
associated demyelination in adults; identify radiological features of patients with first 
episode optic neuritis (ON) that could help differentiate between a diagnosis of ON 
due to MS (MS-ON), MOG antibodies (MOG-ON), and aquaporin-4 antibodies 
(AQP4-ON); and to evaluate the clinical course, treatment responses, and outcomes in 
patients with relapsing MOG antibody-associated demyelination. 
 
Methods: Firstly, we performed a flow cytometry live cell based assay using 
lentivirus-transduced human embryonic kidney 293 cells expressing full-length 
human surface MOG in cohorts of adults with AQP4 antibody-negative neuromyelitis 
optica spectrum disorder (NMOSD) (n=23) and Japanese opticospinal MS (OSMS) 
(n=50). Secondly, we performed blinded neuroradiological assessment on 50 patients 
presenting with first episode ON (MS-ON n=13, MOG-ON n=19, AQP4-ON n=11, 
and unclassified ON n=7). Finally, we evaluated clinical phenotypes, annualised 
relapse rates (ARRs) prior and on various immunotherapy, and expanded disability 
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status scales (EDSS), in 216 demyelinating episodes from 33 paediatric and 26 adult 
patients, with an average follow-up of five years. 
 
Results:  MOG antibodies were detected in 9/23 adults with AQP4 antibody-negative 
NMOSD, compared to 1/76 adults with MS and 0/52 controls (p<0.001). All nine 
MOG antibody-positive patients had simultaneous and recurrent bilateral optic 
neuritis (BON) with prominent optic disc swelling. As in Australian patients with MS, 
we found similarly low rates of MOG antibody-positivity in Japanese OSMS (2/50). 
With blinded neuroroadiological assessment, bilateral involvement was more 
common in MOG-ON and AQP4-ON than MS-ON (84% v.82% v.23%), optic nerve 
head swelling was more common in MOG-ON (53% v.9% v.0%), chiasmal 
involvement was more common in AQP4-ON (5% v.64% v.15%), and bilateral optic 
tract involvement was more common in AQP4-ON (0% v.45% v.0%).  MOG-ON and 
AQP4-ON had longer lesion lengths than MS-ON.  The combination of two 
predictors, the absence of magnetic resonance imaging (MRI) brain abnormalities and 
a higher lesion extent score, showed a good ability to discriminate between an 
antibody-associated ON and MS.  When evaluating a cohort of 59 patients with 
relapsing MOG antibody-associated demyelination, the most common initial 
presentation was ON in 54% [BON 32%, unilateral ON (UON) 22%]. This was 
followed by acute disseminated encephalomyelitis (20%) in children. ON was also the 
dominant phenotype (BON 19%, UON 34%) throughout the disease course. Patients 
were steroid responsive but 70% of episodes treated with oral prednisone relapsed, 
especially at doses < 10 mg daily or within 2 months of cessation. Immunotherapy, 
including maintenance prednisone (P=0.0004), intravenous immunoglobulin (IVIg), 
rituximab, and mycophenolate, all reduced median ARRs on-treatment. Treatment 
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failure rates were lowest with maintenance prednisone (6%). Switching therapy in 
those who failed the first immunosuppressive agent reduced on-treatment ARR 
(P=0.03). 59% of patients experienced residual disability (average follow-up 60 
months, visual loss in 25%).  Three or more episodes were associated with sustained 
disability. 
 
Conclusions: MOG antibodies have a strong association with ON with optic disc 
swelling, in particular BON. MOG antibody-associated ON has distinct radiological 
characteristics including bilateral and longitudinally extensive optic nerve changes 
and anterior visual pathway involvement. Relapsing disease is steroid responsive but 
vulnerable to relapse on withdrawal of steroids, and is responsive to maintenance 
corticosteroids, IVIg, or immunosuppression. Increasing relapses result in sustained 
disability, highlighting the need for early recognition and institution of appropriate 
therapeutic regimes. We believe this condition warrants designation as a separate 
clinical entity from MS and NMOSD, and propose the terminology “MOG antibody-
associated demyelination” as a more accurate syndromic diagnosis.  
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1.1 SUMMARY OF CHAPTER 1 
 
Human immunity is a complex and highly evolved system with numerous facets that 
work in concordance to neutralise foreign pathogens. Antigens are molecules and 
proteins capable of inducing an immune response. Tolerance to self-antigens is a 
fundamental requirement of a healthy immune system, and failure to achieve this can 
result in immune activation against one’s self, or autoimmunity. Conditions that are 
the sequelae of this failure of self-tolerance are referred to as autoimmune disorders. 
 
Sections 1.2 and 1.3 of this chapter explore the mechanisms and interactions of 
various components of the human immune system and their role in autoimmunity. In 
particular, these sections focus on antibodies which are secreted proteins used by the 
immune system to eliminate foreign pathogens. The central nervous system (CNS) is 
made up of the brain and spinal cord and is a unique environment in a constant state 
of ‘immune surveillance’. This has implications on how immune responses may target 
components of the CNS to result in specific disorders. The role of the blood-brain 
barrier (BBB) in CNS autoimmunity is explored in Section 1.4, and is inclusive of 
work that has been published in Autoimmunity Reviews (Ramanathan et al 2016)1. 
 
Over the last decade there has been exponential research in the field of autoimmune 
encephalitis, an antibody-mediated disorder causing inflammation of the brain. 
Autoimmune encephalitis, discussed in Section 1.5, serves as an excellent model to 
demonstrate how using the appropriate methodology for the identification of 
biologically relevant antibodies has led to diagnostic biomarkers which enable us to 
unify subgroups of previously unclassified patients with specific clinical phenotypes, 
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understand pathogenic mechanisms of action, enable clinicians to appropriately target 
immunotherapy, and ultimately minimise disability in these patients. This section is 
inclusive of work that has been published in The Journal of Clinical Neuroscience 
(Ramanathan et al 2014)2. 
 
A similar approach to evaluating autoimmune encephalitis can be taken with 
antibody-associated CNS demyelination, where immune-mediated inflammation leads 
to damage of the insulating myelin around axons in the CNS. Section 1.6 provides an 
overview of demyelinating disorders and their potential to result in significant 
disability for patients. Section 1.7 summarises the evolution of myelin 
oligodendrocyte glycoprotein (MOG) as a candidate autoantigen in demyelination. 
These sections are inclusive of work that has been published in Autoimmunity 
Reviews (Ramanathan et al 2016)1.  
 
Section 1.8 outlines the aims and hypothesis of this thesis, which evaluates the 
clinical characterisation, radiological features, therapeutic responses, and outcomes in 
patients with MOG antibody-associated demyelination. 
 
1.2 INTRODUCTION 
 
The human immune system is a complex milieu with numerous pathways that 
orchestrate a response to potential infectious agents. While skin and other physical 
barriers pose the first defense against infection, higher mammals have additionally 
evolved to develop a complex and effective immune system, with both innate and 
adaptive immune mechanisms that provide an effective defense against external 
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pathogens. The role of the immune system is firstly to recognise an external pathogen 
as “non-self”, and secondly to launch an appropriate attack with a variety of 
components of the immune system acting in concert3, 4.  
 
1.3 OVERVIEW OF THE IMMUNE SYSTEM 
 
1.3.1 Innate and adaptive immunity 
 
The innate immune system is non-specific in its modes of action (Figure 1.1). It is 
activated almost immediately after the entry of a foreign pathogen into the body, and 
effector cells include macrophages, dendritic cells, natural killer (NK) cells, and 
neutrophils, as well as proteins such as complement and lysozyme3, 4. Antigen 
presenting cells (APCs) such as macrophages and dendritic cells express germ-line 
encoded pattern recognition receptors (PRRs) which recognise conserved, non-self 
molecular motifs. These motifs may be shared by microbes called pathogen-
associated molecular patterns (PAMPs)4. PAMPs can trigger PRR activation that in 
turn results in cytokine release, and a subsequent inflammatory cascade. Cytokines 
can induce recruitment of other immune cells including perforin and granzyme-
secreting NK cells, macrophages, neutrophils, and dendritic cells to the site of 
inflammation. Complement activation is also a key component of the inflammatory 
cascade. The end result of engulfing or lysing the offending pathogen will eliminate 
the foreign risk to the immune system. The innate immune system also serves to alert 
and initiate the adaptive immune system, as the former in isolation may not be 
sufficient to eliminate a foreign pathogen3. 
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Adaptive or acquired immunity is more evolved, is initiated later than the innate 
immune system, and serves to eliminate infectious agents through a targeted and 
specific response (Figure 1.1). Importantly, the concept of immunological memory is 
paramount, where repeated encounters with the same pathogen results in a more 
targeted and efficacious retaliation. The main effector cells of the adaptive immune 
system are T and B lymphocytes, and targets that they recognise and orchestrate a 
response to are called antigens4. 
 
 
Figure 1.1 The innate and adaptive immune responses The innate immune 
system is a non-specific but rapid mechanism to orchestrate elimination of a foreign 
pathogen, with key components including antigen presenting cells (macrophages, 
dendritic cells, NK cells) and the complement system. The adaptive immune system 
is slower to activate, but provides an antigen specific response, with contribution 
from both B and T lymphocytes (Abbas et al 2015)4. 
 
The adaptive immune system (Figure 1.2) is further divided. Firstly, there is a 
humoural component mediated by B cells, where antibodies play a major role in 
defending the self against soluble cell surface and extracellular antigens. Secondly, 
there is a cellular component mediated by T cells which mainly targets intracellular 
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antigens by activating macrophages to kill phagocytosed pathogens (T helper cells) or 
by directly killing cells infected with an intracellular pathogen such as viruses 
(cytotoxic T cells)4.  APCs play a major role in presenting antigens required to 
activate T cells. 
 
	
 
Figure 1.2 The components of adaptive immunity The role of B and T lymphocytes 
and their effector mechanisms in the adaptive immune system (Abbas et al 2015)4. 
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1.3.2 The role of B cells 
 
1.3.2.1 B cell development 
 
Lymphocytes arise from a common lymphoid progenitor, which in turn originates 
from haematopoietic pluripotent stem cells in the bone marrow5. Lymphocytes that 
undergo differentiation within the bone marrow become B lymphocytes, while those 
that undergo differentiation within the thymus become T lymphocytes. Pro-B cells are 
committed to the B cell lineage (Figure 1.3). Formation of the heavy and light chains, 
which make up the unique B cell receptor (BCR) of each B cell, occurs during the 
development and maturation of B lymphocytes in bone marrow, and requires a 
process called VDJ recombination (further discussed in Section 1.3.2.2 ).  
 
 
Figure 1.3 Stages of B cell maturation The stages of B cell maturation from a bone 
marrow stem cell to the development of a mature B cell with antigen specificity. 
(Abbas et al 2015)4. 
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Immature B cells that recognise self antigens may change their BCR specificities 
through a process called ‘receptor editing’ in order to allow the B cell to express an 
edited BCR that is not self-reactive4. If there is a failure of receptor editing, immature 
B cells which recognise self-antigens in the bone marrow or spleen may still be 
eliminated by apoptosis during development, through ‘negative selection’. These two 
mechanisms maintain B cell tolerance to self-antigens. Once B cells develop into 
mature B cells, further antigen recognition within the peripheral blood stream and 
secondary lymphoid organs stimulate proliferation and differentiation, as the main 
effector mechanism of humoural immunity, and permit an enhanced specific immune 
response4. Once the BCR of a mature B cell binds to its antigen in the periphery, the 
B cell will undergo clonal expansion and differentiate into memory or plasma B cells4, 
5. Memory B cells initiate an enhanced and specific immune response with future 
encounters with an antigen, and plasma cells produce and secrete soluble 
immunoglobulins4. BCRs are immunoglobulins which are bound in membranes of B 
cells, while secreted immunoglobulins are called antibodies. Antibodies have a 
number of mechanisms of action in humoural immunity (discussed in Section 
1.3.2.4). 
 
1.3.2.2   Immunoglobulin structure  
 
The basic structure of immunoglobulins includes four polypeptides which are made 
up of two identical heavy chains and two identical light chains linked by disulfide 
bonds (Figure 1.4). There are genetically different forms of the light chains known as 
κ (kappa) or λ (lambda), and of the heavy chains known as termed mu (µ), delta (δ), 
gamma (γ), epsilon (ε), and alpha (α). These variations are known as isotypes, as the 
subclass of immunoglobulin is determined by the isotype of the heavy chain5. 
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Figure 1.4 The structure of immunoglobulin The structure of immunglobulin 
when secreted (A) or membrane bound (B). (C) The structure of a human IgG 
molecule as seen with x-ray crystallography (heavy chains are blue and red, light 
chains are green, carbohydrates are gray). Immunoglobulins contain two identical 
heavy chains and two identical light chains. These chains are made up of two 
regions: the Fc (fragment crystallisable) or constant region, and the Fab (fragment 
antigen binding) or the variable region of the antibody. The Fc region binds to the 
effector cells, while the tip of the Fab region binds to the epitope of the antigen 
(Abbas et al 2015)4. 
 
Light chains have one variable domain (VL) and one constant domain (CL). Heavy 
chains have one variable domain (VH) and three (for α, δ, or γ isotypes) or four (for ε 
and µ isotypes) constant domains (CH). Variable regions are so termed for the 
variation in amino acid sequences between immunoglobulins produced by different B 
cells5. The ‘epitope-binding site’ or ‘antigen-binding site’ where the antibody binds a 
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specific region of an antigen is made up by the amino portion (N-terminus) of one 
heavy and one light chain (Figure 1.4). The variation between amino acid sequences 
of VL and VH domains as well as the random pairing of light and heavy chain that 
occurs between B cells results in a number of binding sites able to recognise and bind 
to a large number of different epitopes5,  which is referred to as antibody diversity3. 
 
The basic structure of different immunoglobulins share similar features, with three 
main units. Two of these units referred to as Fab (fragment antigen binding), are 
identical to each other, and are the regions of the antibody involved in binding to a 
particular epitope3. The third unit is referred to as the Fc component (fragment 
cyrstallisable), and is the region of the antibody which binds to the effector cells. The 
Fab domain has a hypervariable region which experiences a large number of point 
mutations due to a mechanism referred to as ‘somatic hypermutation’, which 
enhances the affinity of the antibody to its specific antigenic target or epitope4. 
 
“VDJ rearrangement or recombination” refers to the recombination of 
immunoglobulin genes and the random generation of antigen receptors which occurs 
in all B and T cells, through sequences of proliferation and gene rearrangement which 
confers a unique antigen specificity to each lymphocyte. The variable region is coded 
by 3 separate genes: V (variable), D (diversity), and J (joining)4.  The process of 
clonal expansion refers to the ability of a lymphocyte to be able to recognise an 
antigen and give rise to a large population of identical lymphocytes with that same 
specificity, upon re-exposure to the antigen4.  
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1.3.2.3  Immunoglobulin isotypes 
 
Immunoglobulin isotypes or classes are determined by the heavy chain isotypes, with 
µ, δ, γ, α, and ε subclasses of heavy chains respectively resulting in immunoglobulin 
classes IgM, IgD, IgG, IgA, and IgE respectively4. Humans synthesise all five 
isotypes, but most B cells will only express one particular heavy chain isotype. 
 
IgM exists as a monomer when expressed on the surface of a B cell, or as a pentamer 
(the combination of five monomers) when secreted as a soluble antibody. IgM is part 
of the initial immune response after antigenic stimulation, and is the first 
immunoglobulin to be secreted.  It has a low affinity but high avidity for antigen 
binding, with 10 effective binding sites. It can both immobilise the antigen by 
agglutination and activate the classical complement pathway. IgG is further divided 
into four subclasses (IgG1-4) and is present both as surface and secreted soluble 
molecules5. IgG accounts for the majority of immunoglobulin present in serum, and 
plays an essential role in the immune response to antigens, with a number of effector 
roles including opsonising pathogens, activating complement, and stimulating 
antibody-dependent cell-mediated cytotoxicity. The IgG response has a higher affinity 
to the antigen than the IgM response, with ‘isotype switching’ or the switch from IgM 
to IgG occurring at the B-cell level, to result in an increase of antibody to a particular 
antigen with time and re-exposure. 
 
The remaining Ig subclasses play less of a role in antibody-mediated CNS disorders. 
IgA, present as both a monomer in serum or a dimer in secretions, is secreted by 
epithelial cells and found in saliva, mucus, tracheobronchial and gastrointestinal 
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secretions. IgE is present on the surface of mast cells and basophils with minimal 
levels in the serum, and has a pathogenic role in hypersensitivity or allergic responses. 
IgD is a monomer present on the surface of B cells and its function is not yet clarified. 
 
1.3.2.4   Immunoglobulin function 
 
Antibodies serve an important role in firstly identifying antigens as foreign or ‘non-
self’ by binding to them (Figure 1.5)3. In some cases, this alone may be sufficient to 
immobilise or neutralise these foreign antigens. Alternatively, their binding to 
antigens may enhance phagocytosis of the pathogen by macrophages in a process 
called opsonisation. Upon crosslinking surface Ig with antigen, antibodies can activate 
B cells to synthesise a clonal population of the same antibody with specificity for the 
antigen in question. Antibody binding with an antigen can also initiate the classical 
pathway of the complement cascade. This activates a cascade of enzymes and proteins 
that are important in complement-mediated cytotoxicity, which in turn results in the 
development of a membrane attack complex (MAC) and accelerates microbial 
destruction5. The last mechanism of action is antibody-dependent cellular cytotoxicity 
(ADCC), whereby an effector cell of the immune system (such as NK cells, and to a 
lesser extent macrophages, neutrophils and eosinophils) can lyse a target cell by 
binding to antibodies bound to antigens on the membrane of the target cell.  
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Figure 1.5 Effector mechanisms of antibodies Antibodies may play a role in 
humoural immunity by neutralising toxins, opsonising them for phagocytosis, 
activating the complement cascade, or enabling antibody-dependent cellular 
cytotoxicity (Abbas et al 2015)4. 
 
 
1.3.3 Major histocompatibility complex (MHC) and their role in antigen  
presentation 
 
Major histocompatibility complex (MHC) or human leukocyte antigen (HLA) 
complex is located in chromosome 6 and includes genes which encode a number of 
molecules and enzymes which are essential for the function of the immune system5. 
MHC Class 1 molecules are present on the surfaces of all nucleated cells and can fold 
to result in a binding cleft that can bind to an eight to nine amino acid peptide. There 
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are three genetic loci (HLA-A, B and C) each of which may have multiple possible 
alleles for the same locus; consequently, based on structural variations, the binding 
cleft may bind better to particular peptides5. 
 
MHC class II molecules are present on the surface of APCs including dendrites, 
macrophages, B cells, and some activated T cells. They can bind to larger peptides of 
18-20 amino acids in length, and have three loci referred to as HLA-DP, DQ and DR 
regions5.  MHC plays an important role in the selection process of T cell development 
and activation. Some antigens enter cells by a process of phagocytosis where cells 
such as macrophages and dendritic cells ingest and enzymatically destroy the proteins, 
and present the peptides with MHC II. In contrast, pathogens such as viruses and 
some intracellular bacteria which do not enter cells by phagocytosis but rather by 
binding to the cell membrane and entering the host cytoplasm, are broken down and 
their peptides are presented by MHC I molecules. 
 
1.3.4      T cells 
 
1.3.4.1     T cell development 
 
Common lymphoid progenitor cells arise from the bone marrow and migrate through 
the thymus, while differentiating into mature T cells (Figure 1.6). 
Chapter	1:	Introduction	and	literature	review		
	 15	
 
Figure 1.6 Stages of T cell maturation The stages of T cell maturation from a bone 
marrow stem cell to the development of a mature and activated T cell in the peripheral 
circulation (Abbas et al 2015)4. 
 
T cell precursors, or prothymocytes, enter via the cortical region of the thymus, exit 
through postcapillary venules of the medullary region, and undergo a stringent 
selection process during their passage through the thymus5. Development of the T cell 
receptor (TCR), a membrane bound heterodimer structure, occurs during T cell 
maturation. It consists of two polypeptide chains (α and β), with the extracellular 
domain of each containing a variable (V) region and constant (C) region. The V 
regions of both the α and β constitute the antigen-binding site of a TCR, and diversity 
and unique antigenic specificity is created by VDJ recombination, as previously 
discussed in Section 1.3.2.24. There are certain molecules that are specific for 
different types of cells thus permitting immunophenotyping, which are referred to as 
‘cluster of differentiation’ or ‘cluster of designation’ (CD) molecules (Figure 1.7).  
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Figure 1.7 T cell maturation in the thymus Selection processes in the thymus 
eliminate self-reactive T cells, and promote survival of thymocytes whose T cell 
receptors do not bind self MHC molecules. Mature T cells which are phenotypically 
differentiated are released into the peripheral circulation (Abbas et al 2015)4. 
 
All thymocytes which initially traverse the thymic cortex are initially double negative 
as they do not express any CD4 or CD8 molecules. During their passage through the 
thymus, they begin to express CD4 and CD8 molecules (rendering them double 
positive) as well as CD3. These double positive thymocytes then undergo positive 
selection, where those unable to recognise and bind to MHC molecules expressed by 
cortical reticular cells are eliminated5. The thymocytes which bind to MHC I become 
single positive CD8+ cells, while those which bind to MHC II become single positive 
CD4+ cells. These single positive cells then undergo rigorous negative selection when 
they encounter other APCs. Thymocytes which bind to self-peptides are eliminated. 
The remaining surviving thymocytes, which have been selected for their ability to 
recognise but not react to self-antigens, egress the thymus and enter the peripheral 
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circulation as mature T cells. This selection process is essential to minimise 
autoimmunity5. 
 
1.3.4.2      T cell activation and function 
 
Primed CD4+ T cells are T helper (Th) cells. Undifferentiated Th cells (Th0) may 
respond to different cytokines. Th1 cells are important in cell mediated immune 
responses and activate phagocytic cells and cytotoxic T lymphocytes (CTLs), while 
Th2 lymphocytes are important in humoural immunity and activate B cells to 
differentiate into Ig secreting plasma cells5. Some CD4+ T cells become memory T 
cells expressing CD28. Activated CD8+ T cells may mature into CTLs. Granules 
within the CTLs contain perforin, which results in pore formation on the target cell 
membrane, osmotic swelling and lysis, activation of proteolytic enzymes called 
granzymes, and apoptosis of the target cell. Regulatory T cells (Tregs) suppress the 
activation and function of mature self-reactive lymphocytes, thus enabling self-
tolerance. Impairment of Tregs can result in lymphoproliferation, allergy, and 
autoimmunity. 
 
1.3.5 Autoimmunity 
 
Self-tolerance is a fundamental requirement of a normal immune system, and failure 
to achieve this tolerance results in autoimmunity. Genetic susceptibility, as well as 
environmental triggers such as infections and local tissue injury, can contribute to the 
development of an aberrant immune system, and the consequent development of 
autoimmunity4. 
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1.4 THE BLOOD BRAIN BARRIER (BBB) AND CNS AUTOIMMUNITY 
 
For many years the brain has been described as a site of ‘immune privilege’ that is 
separated from systemic immune responses by a critical interface referred to as the 
BBB6. The lack of efficacy of therapeutic agents such as certain antibiotics or 
chemotherapeutic treatments in gaining access to the cerebrospinal fluid (CSF) 
compartment, the absence of conventional lymphatic drainage from the brain, and the 
paucity of lymphocytes in the CSF surrounding the healthy brain and spinal cord, 
further substantiated the notion that the brain was isolated from systemic immune 
processes6.  However, it is now accepted that a low level of immune cells including T 
and B lymphocytes and APCs are indeed present in CSF and play a role in initiating 
immune responses. 
 
 A dense neurovascular network made up of arteries, capillaries, venules and venous 
sinuses provides a large surface area for interaction between the blood and the 
parenchyma of the brain (Figure 1.8)7. The BBB is made up of tight junctions 
between the endothelial cells on the luminal side of a blood vessel, and the foot 
processes of astrocytes on the abluminal side, with each of these components having a 
distinct basement membrane (Figure 1.8)7. These structures provide a relative size 
selective barrier to diffusion and transport of molecules across the BBB.  This barrier 
is not absolute, and there are mechanisms in place to selectively allow transport of 
soluble molecules, by a process referred to as transcytosis, where molecules bind to 
receptors on endothelial cells and subsequently pass through the cells7. However, by 
and large, active transport through the BBB is a highly selective process. The 
intervening perivascular space contains macrophages that function as APCs7. 
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Figure 1.8 Mechanisms of antibody entry into the CNS and components of the 
neurovascular network Breakdown of the integrity of the BBB may occur in 
relation with activation of CNS endothelial cells and perivascular macrophages, 
disruption of tight junctions, increased transcellular transport of soluble factors, and 
leucocyte adhesion amplifying inflammatory cytokines (Diamond et al 2013)7. 
 
 
Another possible interface between systemic and central nervous immunity is the 
blood-CSF barrier (Figure 1.9). In the absence of a direct lymphatic drainage 
mechanism, the brain does have leptomeningeal and ventricular systems in place 
which may serve a similar purpose7. These structures are encompassed in CSF 
generated by the choroid plexus, and are separated from the parenchyma of the brain 
by ependymal cells. Lymphocyte turn over between blood and CSF occur at least 
twice a day6. The absence of tight junctions in the endothelium as well as the presence 
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of immune cells in these specific regions provides a portal of entry for lymphocytes to 
migrate into the CNS, and initiate or perpetuate an immune response (Figure 1.9).  
 
 
Figure 1.9 Interfaces between the CNS and systemic immunity The 
neurovascular (BBB) and the cerebroventricular (circumventricular organs-CSF 
barrier) systems provide an interface between the peripheral and CNS immune 
systems (Diamond et al 2013)7. 
 
 
For an antibody to be pathogenic in human CNS autoimmune disorders, it either 
needs to be produced within the CNS, or to be permitted passage through the BBB 
from the periphery, into the CNS8. It is possible that a direct CNS infection could be 
associated with an inflammatory response, a break down of the BBB, and a 
subsequent leakage of CNS antigens into the peripheral circulation, where a 
peripheral immune response could be mounted against now accessible central 
antigens9.  
 
Alternatively, a peripheral initiator such as an infection could stimulate adaptive 
immune responses with activation of B and T cells, with the resultant inflammation 
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disrupting the BBB and allowing passage of circulating lymphocytes to the CNS with 
restimulation upon contact with the antigen, and subsequent clonal expansion within 
the CNS2, 9. There is the suggestion of an increased incidence of an infectious 
prodrome in some patients with antibody associated CNS disorders2.  
 
It is now becoming apparent that under resting healthy conditions, the brain is not 
‘immune privileged’ and devoid of immune and inflammatory cells as previously 
thought, but rather a site where there is continuous slow trafficking of immune cells, 
including memory T cells, resulting in an environment of ‘immune surveillance’ 10, 11. 
Leucocyte transendothelial migration, or diapedesis, occurs largely paracellularly at 
the endothelial cell borders, although some evidence points to transcellular migration 
as well through the endothelial cell body12. The long-standing view has been that the 
brain lacks a classic lymphatic system. However, CNS interstitial fluid drains via 
perivascular spaces into the CSF, as well as soluble CNS antigens accessing afferent 
lymphatics in the deep cervical lymph nodes, thus permitting APCs in the 
subarachnoid, meningeal, and lymphatic spaces access to CNS antigens10. Classic 
neuroimmunological concepts have been recently challenged by emerging research. 
Firstly, the identification of functional meningeal lymphatic vessels lining the dural 
sinuses of the brain suggests that there may be more accessibility of CNS antigens to 
the peripheral immune milieu than previously thought11. Secondly, novel pathways 
for migration of dendritic cells from the CNS to the cervical lymph nodes to present 
antigens to T cells have also been described13. Lastly, B cells from multiple sclerosis 
(MS) patients were shown to be able to traffic from and to the CNS and mature 
outside the CNS within the draining cervical lymph nodes14. It is as yet unclear how 
the process of CNS inflammation is initiated and propagated in many cases of 
Chapter	1:	Introduction	and	literature	review		
	 22	
antibody-associated CNS disorders, and further work is required to explore this 
important question. 
 
1.5 AUTOIMMUNE ENCEPHALITIS AS A MODEL FOR ANTIBODY-
MEDIATED CNS DISORDERS 
 
There has been a rapid advancement in the field of autoimmune encephalitis (immune 
mediated inflammation of the brain) with regards to our understanding of the 
methodology of antibody detection, disease aetiology, pathogenesis, and treatment, 
over the last decade. Autoimmune encephalitis thus serves as an excellent model of 
autoantibody-mediated disorders of the CNS.  
 
1.5.1 Limbic encephalitis 
 
Limbic encephalitis (LE) was first described in the 1960s and refers to the subacute 
onset of episodic memory loss, confusion, and agitation15. LE is frequently associated 
with hallucinations, seizures, sleep disturbance, and signal change in the medial 
temporal lobe and hippocampi on imaging. LE is classically described as being 
paraneoplastic15, where neurological sequelae are due to the body’s immune response 
to a malignancy, but not directly due to tumour cells themselves. Antibodies to 
onconeural intracellular antigens which are nuclear or cytoplasmic proteins such as 
Hu, Ma, and Ri are associated with certain malignancies such as lung cancer and 
testicular tumours15, 16. These antibodies are clearly demonstrated by standardised 
tests, associated with limited subtypes of malignancies, and have a variety of 
neurological manifestations16. The clinical course is usually monophasic and 
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relentlessly progressive with a guarded prognosis, and treatment is directed to the 
underlying malignancy17, 18. The antibodies targeting onconeural antigens are believed 
to be biomarkers of associated tumours rather than being directly pathogenic, and 
their detection should prompt investigation for an associated underlying malignancy16, 
18, 19. Previous studies including passive transfers or active vaccination with the 
antigen in animal models have failed to reproduce these clinical syndromes associated 
with onconeural antigens, and studies have largely shown that neuronal cell death was 
due to T-cell mediated cytotoxicity, lending further weight to the contention that this 
group of antibodies is not directly pathogenic16, 18. 
 
However, it became apparent that there were a group of patients with an immune-
mediated encephalitis who did not have antibodies to known intracellular antigens, 
who appeared to be partially or completely immunotherapy responsive. 
 
1.5.2 Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis: leading the 
field of autoimmune encephalitis 
 
In 2007, Dalmau et al20described a syndrome in young women who presented with a 
viral prodrome followed by psychiatric and cognitive disturbances as well as seizures 
early in the disease course, with dysautonomia, movement disorders, and central 
hypoventilation occurring at a later stage, suggesting an initial cortical pathology later 
giving way to a more subcortical process21. These patients often had an associated 
ovarian teratoma, and were found to have antibodies in their serum or CSF that 
targeted extracellular epitopes of the NR1 subunits of the NMDA receptor21, 22. 
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Since the initial descriptions, numerous studies have expanded the clinical phenotype 
of this syndrome. Using cell based assays (elaborated further in Chapter 2.2.4) to 
detect anti-NMDAR antibodies in patient serum and CSF, this condition is now 
recognised to be far more prevalent than initially thought and is in fact the most 
common cause of non-infectious encephalitis apart from acute disseminated 
encephalomyelitis (ADEM) in children23, 24. In the California Encephalitis Project the 
incidence of anti-NMDAR encephalitis exceeded that of viral aetiologies25.  
Importantly, anti-NMDAR encephalitis is not limited to women, with men also being 
affected 26, 27. Other malignancies including mediastinal and testicular teratomas, 
Hodgkin’s lymphoma, small cell lung carcinoma, and neuroblastomas have also been 
identified in association with anti-NMDAR encephalitis28, 29, although up to 80% of 
patients may have no associated malignancy. This syndrome has been widely reported 
in infants and children30-32, although the tumour association is less strong and the 
female over-representation is absent in young children16, 24, 29, 30, 33. Investigations may 
show inflammatory CSF changes including lymphocytic pleocytosis, elevated protein 
levels, and oligoclonal bands, although in a number of patients the CSF can be 
unremarkable. Magnetic resonance imaging (MRI) can be normal or demonstrate 
various abnormalities including medial temporal fluid attenuated inversion recovery 
(FLAIR) high signal or focal hyperintensities in the frontal or parietal cortex34, 35.  
 
There is accumulating evidence that the NMDAR antibodies play a pathogenic role in 
the disease process. Autoantibodies targeting the NMDAR have been shown to result 
in a reversible decrease in NMDAR synaptic localisation and surface density by 
mechanisms including antibody-mediated capping and internalisation of surface 
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NMDAR19, 36. A reversible process is mirrored clinically with complete recovery in a 
number of patients.  
 
Outcomes in anti-NMDAR encephalitis have been studied with many patients 
recovering or having mild sequelae22, 23. However, up to 45% of patients have 
incomplete recovery, and up to 30% may have a poor outcome with a mortality rate of 
approximately 4%23, 30. A comprehensive multicenter observational cohort study of 
577 patients with anti-NMDAR encephalitis demonstrated that only 53% responded to 
first-line therapy with steroids, intravenous immunoglobulin (IVIg), or plasma 
exchange24. Significant persistent cognitive impairment was observed in many 
patients in whom comprehensive cognitive assessments were performed, particularly 
in executive function and memory, where the role of NMDAR is pivotal37, 38. 
Predictors of a good outcome included early administration of immunotherapy24. 
Patients who did not improve with first-line therapy and underwent second-line 
therapy with maintenance immunosuppression and/or rituximab (a humanised 
monoclonal antibody which targets and depletes B cells), had a significantly better 
outcome and a reduced rate of relapse compared to those who did not receive any 
additional treatment24. 
 
Early diagnosis and immunotherapy at first presentation decreases the levels of 
circulating anti-NMDAR antibodies, reduces relapses, and improves neurological 
outcomes21, 39. Relapses are noted in 12-25% of patients, with risk factors including 
lack of immunotherapy at first episode and absence of a tumour diagnosis21, 24, 39. 
While relapses can be suggestive of tumour recurrence, they can occur independently 
of tumour activity, and up to 15 years after the initial presentation35, 40. 
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1.5.3 Neuronal surface antibody syndromes 
 
While anti-NMDAR encephalitis was identified as the diagnosis in many patients 
with autoimmune encephalitis, there remained a number of other patients who 
presented with overlapping features but were negative for NMDAR antibodies. The 
characterisation of anti-NMDAR encephalitis was a crucial step in identifying that the 
methodology of antibody detection is pivotal to identify new clinical syndromes with 
diagnostic and treatment implications in the field of CNS autoimmunity. Antigens in 
question, like NMDAR, are based on the surface of cells (neurons in this case). Using 
cell based assays (further elaborated on in Chapter 2.2.4), where antibodies from 
patients’ serum or CSF bind to the antigen in question transfected on the surface of 
specific cell lines, rather than enzyme linked immunosorbent assays (ELISAs) or 
Western blots where the proteins from the antigen are linearised or denatured, means 
that antibodies bind to antigens presented in their conformational state. This principle 
of surface antigen binding has been pivotal for the discovery of an increasing number 
of autoantibodies targeting neuronal cell surface antigenic epitopes following the 
discovery of anti-NMDAR encephalitis in 200716, 17, 41, 42. This group of antibodies are 
collectively referred to as “neuronal surface antibodies” (NSAbs), and the 
neurological manifestations associated with them as “neuronal surface antibody 
syndromes” (NSAS)19. 
 
Lancaster et al17 characterise NSAbs as demonstrating five features – the epitopes are 
extracellular, antibody binding is visible in cells transfected with the target antigen, 
the antibodies should alter the function or structure of the neural antigen, the 
downstream effects of the antibody are often reversible, and the clinical picture 
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corresponds with genetic or pharmacologic models in which the antigen is disrupted. 
These principles are useful to consider when evaluating all antibody-mediated 
disorders of the CNS. 
 
NSAS collectively appear to be far more prevalent than LE associated with 
onconeural antibodies, often have a relapsing course, have an overall better prognosis, 
and are less commonly paraneoplastic17, 18. The prevalence of an associated 
malignancy varies depending on the antibody in question, however, this is rarely more 
than 70%16. More detailed descriptions of some of the clinical and laboratory features 
of each of the syndromes associated with established and emerging NSAbs are 
outlined in Tables 1.1 and 1.2 respectively. A pathogenic role for the NSAbs as a 
group is clinically suggested by a positive response to immunomodulatory therapy, 
and in some patients, a correlation between antibody titres and patient outcomes16, 18, 
41,	 however ongoing basic science research is required to confirm pathogenic 
mechanisms of action. 
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Table 1.1 Clinical, laboratory & imaging characteristics associated with established neuronal surface antibody syndromes16, 17, 43-47 
Antigen NMDAR LGI1 Caspr2 AMPAR GABAbR Glycine R 
 
Age Infancy-elderly, 
frequently 2-40 
years 
Age 30-80 years  
(median 60 years) 
Age 45-80 years  
(median 60 years) 
Age 40-90 years  
(median 60 years) 
Age 25-75 years  
(median 60 years) 
Age 5-69 
years (median 
49 years) 
 
Neurological 
Manifestations 
Behavioural 
disturbance, 
psychosis, 
catatonia, seizures, 
aphasia, movement 
disorders including 
orolingual 
dyskinesias, central 
hypoventilation, 
dysautonomia 
 
Faciobrachial 
dystonic seizures, 
limbic encephalitis, 
epilepsy (often 
tonic seizures), 
myoclonus, rapidly 
progressive 
dementia (can 
mimic CJD), sleep 
disorders 
Peripheral nerve 
hyperexcitability or 
neuromyotonia 
(Isaac’s syndrome), 
Morvan’s syndrome, 
limbic encephalitis 
(less common), sleep 
disorders 
Limbic encephalitis, 
atypical psychosis, 
seizures, amnesia 
Limbic encephalitis, 
prominent seizures in 
up to 80% of patients 
Progressive 
encephalomyel
itis with 
rigidity, stiff 
person 
syndrome 
CSF 
abnormalities 
90% abnormal - 
CSF 
lymphocytosis, 
intrathecal 
oligoclonal bands 
and elevated 
protein 
40% abnormal 25% abnormal, often 
bland CSF 
90% abnormal, often 
intrathecal 
oligoclonal bands 
80-90% abnormal, 
often intrathecal 
oligoclonal bands 
Variable CSF 
elevated 
protein, 
lymphocytosis, 
and 
oligoclonal 
bands; can be 
normal 
Imaging Up to 50% 
abnormal; medial 
temporal lobe 
hyperintensity, 
focal cortical 
85% medial 
temporal lobe 
FLAIR high signal 
40% abnormal, medial 
temporal lobe FLAIR 
high signal 
90% abnormal, 
medial temporal lobe 
FLAIR high signal 
65% medial temporal 
lobe FLAIR high 
signal 
Frequently 
normal 
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Antigen NMDAR LGI1 Caspr2 AMPAR GABAbR Glycine R 
 
T2/FLAIR 
hyperintensity 
Tumour 
Frequency and 
Association 
Ovarian teratomas 
in women > 15 
years, can be other 
tumours 
(thymomas, 
mediastinal or 
testicular 
teratomas, Hodgkin 
lymphoma), 
significant portion 
non-paraneoplastic 
(particularly 
children and males) 
Rare, < 20% (lung, 
thymus) 
Thymomas in 20-40%, 
more frequently in 
patients with 
peripheral nerve 
hyperexcitability than 
LE 
Tumours in up to 
50% (small cell lung 
cancer, breast cancer, 
thymic, ovarian 
cancer)  
Tumours in 45-60% 
(small cell lung 
cancer) 
Reported lung 
cancer, 
Hodgkin 
lymphoma, 
thymoma; 
usually not 
paraneoplastic  
Other  Associated 
hyponatraemia 
   Can have 
GAD65-IgG  
Abs  
 
AMPAR α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; Caspr2 contactin-associated protein-like 2; CJD Creutzfeldt-Jakob 
Disease; GABAbR γ-aminobutyric acid b receptor; Glycine R glycine receptor; LGI1 leucine-rich glioma inactivated 1; NMDAR N-methyl-D-
aspartate receptor 
 
Adapted from Ramanathan et al 20142 
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Table 1.2. Clinical, laboratory & imaging characteristics associated with emerging neuronal surface antibody syndromes44, 48-57 
Antigen D2R DPPX mGluR5 GABAaR IgLON5 Neuraxin-3α  
Age 0.4-15 years; mean 
6.7 years 
45-76 years 15-46 years Median 40 (range 14-
62) 
50s-70s 23-50 years; 
median 44 
 
Clinical 
Manifestations 
Movement 
disorders (dystonia, 
parkinsonism, 
chorea, ocular 
flutter, motor tics), 
psychiatric features 
(agitation, 
depression, 
psychosis, 
emotional lability), 
and associated 
symptoms 
(encephalopathy, 
sleep disturbance, 
mutism, reduced 
consciousness) 
Protracted 
encephalitic 
illness 
characterised by 
agitation, 
myoclonus, 
tremor, seizures 
Ophelia syndrome 
– psychiatric 
symptoms, 
cognitive and 
memory 
impairments 
 
Associated with 
Hodgkin lymphoma 
Seizures (88%), 
altered cognition 
(including memory 
impairment) (67%), 
behaviour (46%), 
consciousness (42%), 
or abnormal 
movements (35%). 
Hallucinations and 
anxiety also described. 
 
Sleep disorders, 
central 
hypoventilation/ 
obstructive sleep 
apnoea, and 
neurological 
impairment including 
gait instability, 
dysarthria, dysphagia, 
ataxia, chorea, eye 
movement 
abnormalities, 
dysautonomia, and 
cognitive impairment 
prodromal fever, 
headache, or 
gastrointestinal 
symptoms, 
followed by 
confusion, 
seizures, and 
decreased level 
of 
consciousness. 
2/5 developed 
mild orofacial 
dyskinesias 
3/5 respiratory 
support 
4/5 had a 
propensity to 
autoimmunity 
 
CSF 
abnormalities 
Variable CSF 
lymphocytic 
CSF lymphocytic 
pleocytosis +/- 
CSF lymphocytic 
pleocytosis 
Abnormal CSF in 58% 
of patients, including 
Often normal CSF 
lymphocytic 
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Antigen D2R DPPX mGluR5 GABAaR IgLON5 Neuraxin-3α  
pleocytosis oligoclonal bands pleocytosis, increased 
protein concentration 
+/- oligoclonal bands  
pleocytosis 
1/5 elevated 
immunoglobulin 
G [IgG] index)  
Imaging 6/12 patients had 
abnormalities on 
MRI including 
basal ganglia 
enhancement 
acutely, and gliosis 
with chronicity 
MRI normal or 
nonspecific white 
matter disease, 
one patient had 
evidence of a new 
area of infarction 
without vasculitis 
MRI features vary - 
mesial temporal T2 
hyperintensity, 
cortical 
hyperintensity, and 
pontine 
hyperintensity and 
post-contrast 
enhancement have 
all been described 
Abnormal in 88% of 
patients – multifocal 
cortical/ subcortical T2 
and FLAIR 
abnormalities 
primarily involving the 
temporal and frontal 
lobes  
 
Often normal, in a few 
patients, some mild 
brainstem and 
cerebellar atrophy 
Brain MRI was 
normal in 4 of 5 
patients, and 1 
patient had 
increased fluid-
attenuated 
inversion 
recovery/T2 
signal in the 
medial temporal 
lobes.  
Relapse Rate 3/12 basal ganglia 
patients relapsed 
after initial 
improvement 
Unknown Unknown Unknown Monophasic 
neurodegenerative 
process rather than a 
neuroimmunological 
process, hence no 
relapses 
Unknown 
Other Significant 
proportion of 
patients (7/12) of 
non-Caucasian 
ethnicity 
A subunit of 
Kv4.2 potassium 
channels; 
prodromal 
diarrhea thought 
to be secondary to 
the expression of 
Improvement with 
antitumour therapy 
+/- steroids 
Associated in some 
children with a 
preceding viral 
infection (HSV1, 
HHV6) 
 
7/26 patients had 
More commonly a 
subacute/ chronic 
disease course, 
minimal/ no response 
to immunotherapy, 
hyperphosphorylated 
tauopathy on 
2/5 patients 
died, 3/5 had 
partial recovery 
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Antigen D2R DPPX mGluR5 GABAaR IgLON5 Neuraxin-3α  
DPPX in the 
myenteric plexus 
tumours (4 thymomas, 
1 small cell lung 
cancer, 1 rectal cancer 
in an HIV patient, 1 
multiple myeloma) in 
older population 
 
Treatment of tumours 
and immunotherapy 
led to improvement in 
86% of patients. 2 
deaths due to status 
epilepticus. 
histopathology, and 
60% mortality rate 
 
IgG4 antibodies 
predominant 
 
D2R dopamine 2 receptor; DPPX dipeptidyl-peptidase-like protein-6; GABAaR γ-aminobutyric acid a receptor; mGluR5; mGluR5 metabotropic 
glutamate receptor 
 
Adapted from Ramanathan et al 20142 
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1.5.4 Therapeutic implications in NSAS 
 
Although there are no definitive therapeutic guidelines for most of the NSAS, 
treatment is usually in the form of immunotherapy including pulsed steroids followed 
by high dose oral prednisone, and IVIg, and/or plasma exchange as first line therapy17, 
29.This can include, for example, simultaneous treatment with three to five days of 
pulsed IV methylprednisolone (30 mg/kg/day up to 1g/day) followed by high dose 
oral prednisone (1-2 mg/kg/day) and 2g/kg of IVIg administered over two to five 
doses. Failure to respond within one to two weeks should lead to consideration of 
three to five exchanges with plasma exchange, or commencement of second-line 
therapy such as cyclophosphamide or rituximab58. It is unclear whether rituximab, 
which depletes B cells, or cyclophosphamide, a broader immunosuppressant, is more 
efficacious59. Response to therapy is best judged by the patient’s clinical status, rather 
than by focusing on antibody titres in isolation, as the latter may not always directly 
correlate with clinical progress. 
 
The role of long-term steroid sparing agents such as mycophenolate or azathioprine 
on relapse rates is unclear, with their use being largely anecdotal at present29. Chronic 
immunosuppression with rituximab, monthly IVIg, or maintenance prednisone may 
also be considered60. Tumour surveillance both at initial presentation and during 
regular follow-up is also recommended17, 23. When there is a strong suspicion for an 
autoimmune process targeting cell surface antibodies, it would be reasonable to 
commence first line therapy as soon as infectious aetiologies have been excluded, 
while concurrently awaiting the results of antibody and tumour screening19. Opinions 
vary, but many groups advocate early treatment in patients where there is a high index 
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of suspicion of an NSAS even in the absence of specific autoantibodies, as this might 
improve patient outcomes61. NSAS patients tend to have better outcomes when they 
are treated with immunotherapy, when they are treated early in their disease course, 
and when those patients in whom first-line therapy fails are rapidly transited to 
second-line therapy60. 
 
1.5.5 The implications of autoimmune encephalitis on the broader field of CNS 
autoimmunity 
 
The exponential research in the field of autoimmune encephalitis and the 
identification of the various NSAS in the last decade has changed the landscape of 
CNS autoimmunity. Autoimmune encephalitis is an excellent model to demonstrate 
how using the appropriate methodology for the identification of antibodies, namely 
cell based assays, has led to the identification of increasing numbers of novel antibody 
biomarkers in serum and CSF which enable us to diagnose subgroups of previously 
unclassified or poorly characterised patients with specific clinical phenotypes. New 
antigen discovery and careful clinical characterisation has lead to our increased 
understanding of separate clinical entities in the broader field of autoimmune 
encephalitis. The identification of these antibodies and emerging understanding of 
their pathogenic mechanisms of action has enabled treating clinicians to institute early 
and appropriately targeted immunotherapy, and optimise their long-term outcomes in 
order to limit disability. A similar approach can be taken with CNS demyelination. 
 
 
 
Chapter	1:	Introduction	and	literature	review		
	 35	
1.6 AN OVERVIEW OF DEMYELINATION 
 
Neurons in the CNS white matter, inclusive of the brain, spinal cord, and optic nerves, 
are insulated by a lipid enriched layer referred to as myelin62. In the CNS, myelin is 
produced by oligodendrocytes, and the insulation it provides in white matter tracts 
plays a major role in optimising the speed and efficiency of neurotransmission via a 
process referred to as saltatory conduction, where action potentials are generated at 
nodes of Ranvier between internodal segments of axons insulated by compact 
myelin62, 63. Damage to the myelin sheath results in impaired neurotransmission, and 
this is referred to as demyelination.  
 
 
Figure 1.10 CNS myelination Oligodendrocytes produce myelin that forms 
an insulating layer around the axons of neurons in the CNS (Fields 2015)63. 
 
 
1.6.1 MS 
 
MS is an autoimmune CNS condition, and the most prevalent demyelinating disorder 
with an estimated 2.5 million patients with this diagnosis worldwide. The cost burden 
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of this condition in Australia alone is estimated to be over one billion dollars 
annually64. It is a major cause of disability in young adults, with up to 80% of MS 
patients going on to develop permanent deficits65. Patients with MS may have lesions 
in any part of the CNS including the cerebrum, optic nerves, cerebellum, brainstem, 
and spinal cord, with variable manifestations of disease such as weakness, sensory 
loss, visual loss, sphincter dysfunction, impaired balance, fatigue, and pain, depending 
on the pathways involved65. MRI is a critical tool used in the assessment of patients 
with possible demyelination (Figure 1.11). 
 
 
 
Figure 1.11 Representative MRI in a patient with relapsing remitting MS These 
axial images demonstrate multiple periventricular white matter lesions on a (A) T2 
weighted image (B) proton density weighted image (C) fluid attenuated inversion 
recovery (FLAIR) image and (D) a T1 weighted image with gadolinium 
enhancement (Trip et al 2005)66 
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Patients may be diagnosed with MS if they fulfil dissemination in space and 
dissemination in time definitions, as dictated by clinical and radiological criteria such 
as the 2010 revised McDonald criteria (Table 1.3)67. 
 
 
 
Table 1.3 2010 Revised McDonald Criteria for the diagnosis of MS Clinical and 
radiological criteria required to make a diagnosis of MS (Polman et al 2011)67. 
 
Environmental influences have a recognised role in the incidence of MS around the 
world with a higher incidence further from the equator, an earlier age at onset in 
higher latitude regions68, and migration studies suggesting that an individual adopts 
the incidence risk of a location they have migrated to in their childhood years65. Other 
proposed risk factors for an increased risk of developing MS include infections such 
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as Epstein Barr virus, and vitamin D deficiency69-73. Higher levels of 25-
hydroxyvitamin D has been associated with a lower risk of relapses in MS74. The 
search for alleles conferring genetic susceptibility for MS has been extensive, with 
DRB1*1501, DRB5*0101, DQA1*0102, and DQB2*0602, and single nucleotide 
polymorphic markers for the interleukin-2 and interleukin-7 receptor α chains being 
identified as increasing susceptibility, with a protective effect conferred by HLA-C5 
and HLA-DRB1*1175-82. The clinical course of MS may be influenced by genetic risk, 
with the contributions more likely to be polygenic83. Inflammation in MS has been 
largely ascribed to T cell mediated pathology, with the role of autoantibodies being 
less clear in adults65. To date, specific autoantibodies in isolation have not been 
identified as being pathogenic in MS. The current thinking regarding the 
aetiopathogenesis of MS involves a complex interaction between environmental 
factors, genetic susceptibility, and the immune system. 
 
1.6.2 Aquaporin-4 (AQP4) antibodies in Neuromyelitis Optica Spectrum 
Disorder (NMOSD): the precedent for antibody-associated demyelination 
 
1.6.2.1 Clinical presentations and treatment responses in NMOSD  
 
Neuromyelitis optica (NMO) is a CNS demyelinating disorder that selectively targets 
the optic nerves (resulting in optic neuritis or ON, and causing visual loss or 
blindness) and spinal cord (resulting in transverse myelitis or TM, and causing 
weakness, paralyisis, and/or sphincter dysfunction). The term “neuromyelitis optica” 
was first used by Eugene Devic, a French neurologist, in 1894 to describe this 
syndrome. Patients who presented with simultaneous ON and TM were classified as 
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having Devic disease84. In previous decades, these patients were thought of as being a 
subgroup of MS. However, in 2004, a circulating IgG antibody was discovered as 
being present in patients with NMO, but absent in patients with typical MS85. The 
target antigen was subsequently identified as the water channel aquaporin-4 
(AQP4)86. 
 
Patients with NMO were initially diagnosed based on having a history of presentation 
of both ON and TM, as well as two of three supportive criteria including MRI 
evidence of a contiguous spinal cord lesion spanning ≥ 3 segments referred to as 
longitudinally extensive TM (LETM), a brain MRI not typical of MS, and the 
presence of IgG antibodies against AQP487. It is now apparent that patients may 
present with definitive NMO that satisfies these initial diagnostic criteria, as well as 
presenting with limited forms such as isolated longitudinally extensive transverse 
myelitis (LETM) or isolated ON, while being seronegative for AQP4 antibodies. 
These limited presentations are now encompassed in the terminology NMO spectrum 
disorders (NMOSD), and revised diagnostic criteria have been established in 2015 
(Table 1.4). 
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Table 1.4 2015 NMOSD diagnostic criteria for adult patients. (Wingerchuk et al 
2015)88 
 
There is a higher incidence of patients of non-Caucasian extraction who fulfill 
diagnostic criteria for NMOSD, and women account for 85% of cases89. 3% of 
NMOSD patients have relatives with the disease but the underlying genetic 
susceptibility is unclear90-92. HLA associations with increased susceptibility have been 
identified, including DRB1*0301 in Caucasians, and DPB1*0501 in Asian patients93, 
94. 
 
An appropriate diagnosis and distinction of NMOSD from MS is essential as 
therapeutic approaches are significantly different. While MS is frequently treated with 
immunomodulatory or disease modifying therapy, some agents used in MS such as 
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interferon, natalizumab, and fingolimod, have been shown to not benefit, or in some 
cases, have a detrimental impact on outcome in AQP4 antibody-positive NMOSD95-97. 
In contrast, treatment with azathioprine, mycophenolate, and rituximab all reduce 
relapse rates in AQP4 antibody-positive NMOSD98-100. Treatment strategies in 
NMOSD are associated with immunosuppression, with acute episodes being treated 
with methylprednisolone and/or plasma exchange, and maintenance therapy often 
including a combination of corticosteroids and steroid sparing agents such as 
azathioprine, mycophenolate mofetil, cyclophosphamide, or rituximab101, 102. 
Treatment with rituximab has been shown to reduce relapse frequency, and stabilise 
or improve disability103. 
 
1.6.2.2 AQP4 antibodies and mechanisms of action 
 
The AQP4 water channel consists of 6 helical transmembrane domains and 2 shorter 
helical segments spanning an aqueous pore (Figure 1.12A). Tetramers of AQP4 
conglomerate to form a supramolecular assemble referred to as orthogonal arrays of 
particles (OAPs) (Figure 1.12B) which are the preferential binding site of most AQP4 
IgG102, 104, 105. AQP4 has two major isoforms – a long M1 isoform (translation 
initiation at Met-1) and a shorter M23 isoform (translation initiation at Met-23)102. 
The latter forms OAPs while the former does not form these OAPs in isolation106, 107. 
AQP4 IgG in the serum of patients with NMOSD preferentially binds to cells 
transfected with the M23 isoform compared to the M1 isoform, suggesting AQP4 IgG 
binds to OAPs108, 109. The subclass of immunoglobulin in NMOSD has been identified 
as IgG1102. Antibodies to the M23 isoform of AQP4 have been shown to identify 
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various epitopes on the extracellular loops of the conformational protein (Figure 
1.13)110. 
 
 
 
Figure 1.12 Aquaporin-4: an astrocyte water channel (A) crystal structure of 
human AQP4 with eight helical segments (M1-M8). (B) Freeze-fracture electron 
microscopy of AQP4 orthogonal arrays of particles in plasma membranes of Chinese 
hamster ovary cells transfected with AQP4 (Papadopoulous et al 2012)102.  
 
 
 
 
 
 
 
 
Figure	1.13	The	protein	sequence	of	the	M23	isoform	of	AQP4	Anti-AQP4-M23	 antibodies	 have	 been	 shown	 to	 recognise	 epitopes	 in	 various	extracellular	 locations	 in	 Loop	 A,	 C,	 and	 E,	 as	 well	 as	 some	 intracellular	locations	(Sinmaz	et	al	2016)110.		
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The main mechanism of cell death in NMOSD has been identified as complement-
mediated cytotoxicity (Figure 1.14)102, 111-113.  
 
 
 
 
Figure 1.14 AQP4 antibodies and complement mediated cytotoxicity (A) AQP4 
IgG antibodies are initially present in the serum. (B) These antibodies can bind to 
AQP4 on the foot process of astrocytes, leading to activation of the complement 
cascade, and deposition of membrane attack complexes. This results in the release 
of cytokines (such as IL-8, IL-17, and granulocyte colony stimulating factor), 
which in turn result in the recruitment of neutrophils and eosinophils to the site of 
inflammation. (C) Degranulation of the neutrophils can lead to astrocyte death, and 
subsequently, (D) to the death of oligodendrocytes. This results in axonal 
degeneration and neuronal death. (E) Infiltrating macrophages and microglia may 
phagocytose cellular and myelin debris. (F) Mature demyelinated lesions 
demonstrate pan-necrosis of the tissue and widespread macrophage infiltration 
(Papadopoulous et al 2012)102. 
 
Studies have shown that in the presence of complement and AQP4 IgG, various cell 
lines including HEK293 cells transfected with AQP4, mouse cortical astrocytes, and 
Chinese hamster ovary cells, all demonstrate plasma membrane deposition of the 
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complement MAC and consequent cytotoxicity. Examination of NMOSD lesions in 
humans demonstrate activated complement components, vasculocentric deposition of 
Ig, and granulocytes, with a relative paucity of T cells and NK cells, suggesting 
humoural and complement mediated immunity102, 111, 114, 115. Passive transfer 
experiments lend further weight to the notion that anti-AQP4 IgG antibodies are 
pathogenic, resulting in lesions similar to NMOSD in animal models113, 116, 117. These 
experiments suggest a pathogenic role for AQP4 antibodies in NMOSD, with much of 
the damage being carried out by complement-mediated cytotoxicity. Due to 
accumulating evidence for the pathogenicity of antibodies against AQP4 in this 
disorder, NMOSD is considered the prototypic antibody-mediated CNS disorder. 
 
 
1.7 MYELIN OLIODENDROCYTE GLYCOPROTEIN (MOG) AS A 
CANDIDATE AUTOANTIGEN IN DEMYELINATION 
 
1.7.1 An introduction to MOG 
 
MOG is a member of the immunoglobulin superfamily and a component of myelin, 
making up less than 0.05% of total myelin proteins118-121. Full-length human MOG is 
made up of 218 amino acids and is expressed exclusively in the CNS. Its relatively 
late expression in CNS development suggests it may serve as an important surface 
marker of oligodendrocyte maturation, as well as playing a role in myelin integrity, 
adhesion, and cell surface interactions121, 122. MOG has been studied as a target CNS 
autoantigen for both humoral and cell-mediated immune responses. The putative role 
of MOG and antibodies to MOG in CNS demyelination has been explored for 
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decades, with immunisation using MOG inducing experimental autoimmune 
encephalomyelitis (EAE), thought to be an important animal model of MS. MOG is 
sequestered to the external surface of myelin and the plasma membranes of 
oligodendrocytes119, with its highest antigen density in the outermost lamellae of 
myelin sheaths, thereby serving as a biologically plausible and accessible antigen 
target for the action of circulating autoantibodies (Figure 1.15)119, 123. 
 
 
Figure 1.15 Localisation of possible target antigens in the myelin sheath MOG 
is present on the outermost lamellae of the myelin sheath. Other suggested 
antigenic targets include myelin associated glycoprotein (MAG), proteolipid 
protein (PLP), and myelin basic protein (MBP) (Hemmer et al 2002)124. 
 
In order to evaluate MOG antibodies in the context of the extensive published 
literature on MOG and demyelination, several factors need to be considered, which 
will be elaborated on further in Section 1.7, and Chapter 2.2 and 2.3. Firstly, it has 
been animal studies, particularly the EAE model, which have led the way to identify 
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MOG as a candidate autoantigen. The EAE model is a complex system with a strong 
T cell driven component in which MOG antibodies are produced, but do not 
necessarily transfer disease. Secondly, it is important to note that while autoantibodies 
can bind to both linear and conformational epitopes, in the case of MOG antibodies, 
only those with conformation dependent binding have been shown to be pathogenic in 
animal studies. Thirdly, the translation of animal studies to humans should be 
evaluated carefully as autoantibody epitope binding sites can differ in rodents and 
humans. Lastly, although previous studies have focused on MS, the clinically relevant 
associations of MOG antibodies in human demyelination have only recently been 
explored. 
 
1.7.2 Rationale for the search for autoantibodies in MS 
 
Previous research largely focused on T cell mediated immune mechanisms in MS. 
However, findings such as elevated intrathecally synthesised immunoglobulins found 
in the CSF of MS patients125; the presence of B cells, Ig deposition, Ig associated 
receptor mediated phagoycytosis of myelin debris by macrophages, and complement 
activation in the vicinity of MS plaques126-129; as well as immunohistological evidence 
of autoantibodies binding to disintegrating myelin around axons of acute MS lesions 
and contributing to their destruction130, have all been compelling reasons to pursue a 
role for autoantibodies in the pathogenesis of demyelination in MS.   
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1.7.3 Animal studies: MOG and EAE 
 
EAE has been extensively used as a disease model that represents features of MS, and 
is induced by immunisation in animal models with CNS tissue or purified myelin 
components, and Freund’s complete adjuvant120, 131. The model is complex but has 
largely contributed to the understanding of the role of MOG as an autoantigen and 
autoantibody target131. MOG was originally identified as a minor CNS glycoprotein 
by the mouse IgG1 monoclonal antibody 8-18C5 (8-18C5 mAb) raised against rat 
cerebellar glycoproteins132. While animal models of demyelination and EAE were 
largely initiated by the transfer of activated encephalitogenic T cells, the identification 
of the 8-18C5 mAb permitted the evaluation of anti-MOG antibodies in CNS 
inflammation132. Passive transfer of the 8-18C5 mAb resulted in a hyperacute 
inflammatory response in animals with acute EAE, and in fatal relapses in those with 
chronic relapsing EAE, as well as the formation of extensive demyelinating plaques, 
suggesting that antibodies to MOG may amplify and modify CNS inflammation in 
EAE118, 123, 132. This effect was dependent on the weakening of the BBB by 
encephalitogenic T cells, thus indicating that both humoral and cell-mediated 
immunity might be at work in the MOG-directed autoimmune response.  
 
Early animal models of chronic relapsing EAE showed that MOG antibody titres as 
determined by ELISA correlated with in vivo demyelinating activity133, however there 
was no correlation between antibody titres and the course of clinical disease in murine 
models133, 134. 
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1.7.4 The antibody binding epitope in animal studies using linear MOG 
peptides 
 
Interestingly, MOG triggers both an encephalitogenic T cell response and an 
antibody-mediated demyelinating response in a synergistic way which renders it 
unique when compared to other potential target antigens in myelin that are more 
quantitatively present such as myelin basic protein (MBP), proteolipid protein (PLP), 
or neurofascin135, 136. Very early on, after immunisation of rodents with purified 
recombinant murine MOG, the encephalitogenic T cell response leading to acute 
demyelinating EAE was shown to target the Ig-like extracellular N-terminal domain 
(aa 1-125), especially MOG35-55135, 137. The immunodominant antibody epitope has 
been more challenging to decipher, and using ELISA, the dominant linear epitopes 
were shown to be to either MOG1-25, MOG35-55, or MOG202-218134, 135, 138. Therefore, 
while early animal studies certainly established MOG35-55 as a dominant immunogenic 
region in CNS demyelination, they were less clear on the importance of the B cell 
response in the disease. MOG antibodies were identified as being present in the sera 
and CSF of immunised animals133, 134. However, the role of MOG antibodies in the 
pathogenicity of EAE was unclear. For example, although titres in sera correlated 
with disease activity133, their presence alone was not sufficient to result in severe 
disease134. 
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1.7.5 The antibody binding epitope in animal studies using conformational 
MOG 
 
Major advances came from the recognition that experimental animals mount a 
complex antibody response to the extracellular Ig-like domain of MOG, and these 
antibodies are now known to target both linear epitopes of MOG, detected using 
ELISA and Western blot, as well as discontinuous conformational epitopes of MOG, 
which may not be detected using these techniques139. Animal studies have found that 
pathogenic demyelinating MOG-specific autoantibodies recognise only conformation-
dependent epitopes, while MOG peptide-specific autoantibodies were unable to 
recognise the native protein140-144. Crystallography of rat MOG revealed that a 
dominant component of the epitope binding site of the 8-18C5 mAb included amino 
acids 101-108 that comprises the FG loop, and protrudes from the top of the Ig 
domain of MOG as a hairpin loop143. The failure of linear peptides to replicate this 
loop structure may account for the inability of antibodies to MOG-specific linear 
peptides to detect this antigenic region (Figure 1.16)143. 
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Figure 1.16 Binding of the antigen-binding fragment of 8-18C5 to MOG This 
figure demonstrates the overall structure of the Fab-MOG complex, with the binding 
site of 8-18C5 coloured red. The heavy chain contributes significantly to the binding 
of MOG. FG loop residues of MOG are shown in yellow, and residues belonging to 
the strands F and G are shown in green (Breithaupt et al 2003)143. 
 
The same team subsequently identified His103 and Ser104 as the two central amino 
acids of the FG loop which form the antibody epitope139. Mutations of these two 
residues led to reduced binding of conformation-dependent monoclonal antibodies 
including 8-18C5, compared to the binding to wild-type MOG, suggesting that the 
pathogenic demyelinating anti-MOG antibody response targets this immunodominant 
region centred at the tip of the surface-exposed FG loop of MOG in rodents139. 
Interestingly, the correct folding of MOG does not only influence the B cell and 
antibody response, but also the T cell response. For example, rats immunised with 
correctly refolded recombinant human MOG developed severe acute EAE and had a 
higher amount of conformational MOG antibodies present in serum, as well as 
enhanced T cell responses against the encephalitogenic MOG91-108 peptide145. 
Antibodies to cell-membrane expressed MOG, which is native and glycosylated, were 
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associated with demyelination in rat EAE models and clinical severity, whereas 
antibodies to recombinant MOG detected by ELISA were not found to be associated 
with inflammation or demyelination146. Other EAE models, such as the non-human 
primate marmoset, also confirmed that conformation-dependent antibodies to MOG 
were associated with in vivo demyelinating activity, with IgG deposition, complement 
activation, and dissemination of white matter lesions occurring predominantly in the 
presence of conformational rather than linear peptide-recognising MOG antibodies142, 
144. 
 
As seen above, studies using linear and conformational MOG have yielded different 
results. Taken together, these findings suggest that MOG antibodies that are relevant 
to disease pathogenesis in animal models may target conformational MOG, rather 
than MOG that has been linearised or denatured. Given the inability of ELISA and 
Western blot to differentiate between autoantibodies to likely pathogenic 
conformational epitopes, and those targeting linear epitopes, the method of detection 
of MOG antibodies has been shown to be crucial147.  
 
1.7.6 Translation of animal studies to human demyelination 
 
While the predicted sequence of the mature MOG protein is highly conserved among 
mammalian species including humans, rats, mice, and bovine animals121, the 
applicability of animal models to human demyelination needs to be carefully 
evaluated. Marta et al found that a single amino acid substitution in human MOG at 
position 42 (huP42S) from proline (found in humans) to serine (found in rodents) 
changed the mechanism of encephalitogenicity from B cell dependent to 
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independent148. Although immunisation with rat, human, or huP42S all generated 
antibodies targeting recombinant mouse MOG which were detectable by ELISA, only 
the antibodies targeting human MOG were encephalitogenic in vivo, and bound to 
glycosylated MOG in immunoblots and to live rodent oligodendrocytes in culture. 
Thus, MOG antibodies may recognise different antigenic target epitopes on 
conformational MOG, which may account for variations in pathogenicity. For 
example, the human MOG-specific antibody repertoire was shown to target multiple 
epitopes in immunised C57BL/6 mice149. 
 
Figure 1.17 The structure of MOG Anti-MOG antibodies recognise amino acid 
epitopes at P42 and at H103/S104 within the immunoglobulin-like domain (Sinmaz 
et al 2016)110. 
 
Despite 90% sequence homology between recombinant rat and human extracellular 
MOG (aa 1-125), and a difference of only seven amino acids in length in two 
constructs of recombinant human MOG, Menge et al150 found that each of these 
isoforms had unique immunodominant epitopes recognised by a panel of monoclonal 
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antibodies, suggesting certain epitopes are length or species dependent. Mayer et al151 
also found that the majority of human anti-MOG antibodies did not recognise rodent 
MOG. Studies such as this further highlight the fact that translating the findings in 
animal models to human disease requires some consideration, even with the use of 
native conformational MOG. 
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1.8 PhD THESIS AIMS, HYPOTHESES, AND THESIS STRUCTURE 
 
While MS is the most prevalent demyelinating disorder, there remain a significant 
proportion of patients with demyelination who do not fulfill revised McDonald 
criteria for MS. These patients often have radiology and laboratory findings atypical 
for MS, and may be responsive to immunosuppression rather than immunomodulatory 
therapy, suggestive of an antibody-mediated aetiology. While a number of these 
patients fulfill criteria for NMOSD, between 12-30% of patients with NMOSD remain 
AQP4 antibody-negative152-154, suggesting that a subgroup of patients with presumed 
antibody-associated demyelination may have a target antigen that is not AQP4. It is 
paramount to differentiate patients who have demyelination due to specific antibodies, 
from those who have MS, as treatment modalities differ, and the lack of optimal 
therapy can lead to significant disability including permanent blindness and paralysis. 
The basic science research supporting the putative role of MOG as a candidate 
antigen in demyelination has been compelling, and the aim of this PhD was to explore 
the role of MOG antibodies as a biomarker in human CNS demyelination. Having 
identified a distinct group of patients with MOG antibody-associated demyelination, 
we subsequently sought to clinically and radiologically characterise this novel and 
important cohort of patients, and identify their treatment responses and outcomes. 
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1.8.1 Thesis outline 
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Introduction & Literature Review 
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MOG antibody-associated 
demyelination in adults 
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Chapter 3 
The radiological characterisation 
of optic neuritis due to MOG 
antibodies 
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Chapter 4 
The clinical course, therapeutic 
responses, and outcomes in 
relapsing MOG antibody-
associated demyelination 
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Chapter 5:  
Discussion, Future Directions, and 
Conclusions 
Aim:	to	evaluate	if	MOG	antibodies	are	present	in	adults	with	AQP4	antibody-negative	NMOSD	or	Japanese	opticospinal	MS	(OSMS)			
Hypothesis:	A	subgroup	of	patients	with	NMOSD	or	Japanese	OSMS	who	are	negative	for	AQP4	antibodies	will	have	antibodies	targeting	MOG,	and	a	characteristic	phenotype	suggestive	of	MOG	antibody-associated	demyelination	
Aim:	to	identify	radiological	characteristics	in	patients	with	first	episode	ON	that	may	assist	in	diagnosis		
Hypothesis:	patients	with	ON	due	to	MOG	antibodies,	AQP4	antibodies,	and	MS	have	differentiating	radiological	features	that	will	help	clinicians	identify	the	demyelinating	aetiology	
Aim:	to	evaluate	the	clinical	course,	treatment	responses,	and	outcomes	in	patients	with	relapsing	MOG	antibody-associated	demyelination		
Hypothesis:	Relapsing	MOG	antibody-associated	demyelination	has	an	expanding	clinical	spectrum,	is	immunotherapy	responsive,	and	has	the	potential	to	result	in	sustained	disability	if	not	treated	optimally.		
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2.1 SUMMARY OF CHAPTER 2 
 
In the last thirty years, MOG has been identified as an important candidate 
autoantigen in demyelination. Sections 2.2 and 2.3 review the relevance of antibody 
detection methodology and highlight the utility of the cell based assay in the 
identification of MOG antibodies as biomarkers in subgroups of patients with 
demyelination. These sections are inclusive of the work published in Autoimmunity 
Reviews (Ramanathan et al 2016)1. 
 
Using cell based assays, MOG antibodies were not detected in the majority of adult 
patients with MS. MOG antibodies have since been identified 20-40% of children 
presenting with ADEM, ON, and relapsing demyelinating disorders including 
NMOSD155-159. However, until 2013, the role of MOG antibodies in adults was less 
clear. We hypothesised that a subgroup of adults with AQP4 antibody-negative 
NMOSD would have MOG antibodies as a diagnostic biomarker, and would have a 
suggestive clinical phenotype. Our index adult patient was identified simultaneously 
at the time of publication of a case report of four other patients160, and was an 
important motivator to lead this study into the detailed characterisation of these 
adults. Section 2.4 outlines our work in evaluating one of the earliest MOG antibody-
positive adult cohorts internationally, and has been published in Neurology: 
Neuroimmunology and Neuroinflammation (Ramanathan et al 2014)161. This work 
identified that MOG antibodies are strongly associated with simultaneous bilateral 
and/or recurrent optic neuritis (BON) and optic disc swelling. 
 
Chapter	2:	The	clinical	characterisation	of	MOG	antibody-associated	demyelination	in	adults			
	 58	
Following these results, we postulated that some patients with Japanese opticospinal  
MS (OSMS) may also harbour MOG antibodies. Japanese OSMS is a demyelinating 
entity in Asians that shares some overlapping features with NMOSD including a 
predilection for optic nerve and spinal cord disease. We evaluated 50 patients with 
OSMS, but identified that MOG antibodies were uncommon in this group except for 
selected patients who had BON or LETM, once again highlighting the dominant 
clinical phenotype of MOG antibody-associated demyelination. This work is outlined 
in Section 2.5, and has been published in Multiple Sclerosis (Ramanathan et al 
2016)162. 
 
2.2 THE METHODOLOGY OF MOG ANTIBODY DETECTION 
 
2.2.1 MOG antibody detection in MS 
 
Given the interest in MOG antibody-associated demyelination in animal studies, the 
evaluation of MOG antibodies in patients with MS has been of interest for many 
years. Using Western blot and ELISA, a number of early studies found the presence 
of antibodies to recombinant human MOG or native full length mouse MOG in the 
serum and CSF of patients with clinically isolated syndromes or MS163-170. 
 
Using ELISA, MOG antibodies were found to be present in higher concentrations in 
the CNS parenchyma as derived from postmortem samples of MS lesions, compared 
with CSF and serum in MS patients, suggesting that local production of antibodies 
may play a role in CNS demyelination171. 
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While these results highlighted the importance of MOG in the immune response of 
patients with demyelination, other studies found a similar prevalence of seropositivity 
with MOG IgM and IgG antibodies in patients with other inflammatory neurological 
diseases as well as healthy controls 163-167, 170, 172-178. Additionally, varying results on 
whether IgG or IgM was the dominant Ig subtype, and the fact that MOG antibodies 
were found to have low affinity when detected at low titres further brought into 
question the true clinical implications of MOG antibody seropositivity150, 166, 172. 
Additionally, a comparative study in 72 patients with pathologically proven 
inflammatory demyelination showed that correlations between Western blot and 
ELISA results were poor, adding further concerns regarding the reproducibility of 
results obtained by these methods179. Overall, these studies (summarised in Appendix 
A) illustrated the technical difficulty in detecting MOG antibodies that are specific 
and disease relevant in humans using ELISA or Western blots. 
 
2.2.2 Identifying the antibody binding epitope in humans using linear MOG 
peptides 
 
The accurate detection of the antigenic target and epitope specificity of demyelinating 
MOG antibodies in patients with MS has long been of significant interest. Initial 
studies evaluating the binding epitopes to the extracellular immunoglobulin V-like 
domain of human MOG using ELISA yielded variable results. Using synthetic 
overlapping linear MOG peptides revealed that the B cell epitope specificity of 
purified antibodies from both seropositive MS patients and healthy controls varied 
between studies. Some groups found a heterogenous response with no association 
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between MS and any particular peptide specificity, and each donor often recognising 
multiple linear epitopes141, while other studies suggested the linear epitopes aa 37-48 
and aa 42-53 were immunodominant in relapsing remitting MS patients compared to 
healthy controls180. Furthermore, there was significant heterogeneity in the MOG 
antibody repertoires detected by different assay techniques181. 
 
2.2.3 Controversies in the methodology of antibody detection 
 
There are a number of possible explanations for the variation in findings of both the 
presence of MOG antibodies as well as the dominant binding epitopes between 
different study groups. Patient populations in many studies were heterogenous and 
groups evaluated different immunoglobulin isotypes. The discrepancies in results are 
now mainly thought to be due to technical differences in antigen preparation and 
antibody determination173. Some groups140, 168 used recombinant human MOG 
corresponding to the extracellular Ig domain, expressed in Escherichia coli. However, 
post-translational modification differs in prokaryotes and eukaryotes, hence the MOG 
protein produced could lack glycosylation and the correct membrane topology. Other 
groups translated native full length MOG but without glycosylation173. Glycosylated 
proteins conserve their tertiary structure better182. Nonspecific binding is also 
problematic in direct ELISA182. Finally, it could be hypothesised that MS is not the 
main demyelinating disorder associated with MOG antibodies, and that further work 
was required to evaluate the presence of MOG antibodies in other demyelinating 
conditions. 
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The methodology of antibody detection is important. Most early studies for MOG 
antibody detection and epitope recognition performed assays that utilised linearised or 
denatured MOG antigen, such as ELISA and Western blot, respectively (Appendix 
A). These assays potentially alter protein conformation and render the 
immunodominant epitopes that depend on the tertiary structure of the folded protein 
inaccessible. As discussed previously in Chapter 1.7.5, animal studies revealed that 
antibodies to conformational rather than linear or denatured MOG were shown to be 
more disease relevant. Therefore, an assay that detects antibodies targeting epitopes of 
native human MOG in its conformational state, taking into account the tertiary 
structure of folded MOG as it is expressed in vivo on myelin sheaths, is essential. The 
fact this was not the case in many early studies that used ELISA and Western blot for 
MOG antibody detection likely accounts for the low specificity of these antibodies in 
patient groups and controls, and variability in dominant epitope binding sites.  
 
2.2.4 The utility of cell based assays: MOG antibodies are uncommon in adults 
with MS 
 
In cell based assays (Figure 2.1), native human MOG is transfected or transduced in 
mammalian cell lines such as human embryonic kidney 293 (HEK293) cells. Surface 
MOG expressing cells are incubated with the sample to be tested, and then with a 
secondary anti-human IgG antibody, followed by microscopy or flow cytometry to 
qualitatively or quantitatively analyse the degree of antibody binding8. The MOG 
antigen is therefore presented to the autoantibody repertoire in its native state, with 
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positive antibodies identified using this methodology more likely to have disease 
relevance140, 141. 
A 
 
 
B 
 
Figure 2.1 Live cell based assays The antigen of interest is plasmid transfected or 
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lentivirus transduced into mammalian cells (such as HEK293 cells). The cells are 
incubated with human serum or CSF. Antibodies present in the serum or CSF that 
recognise the antigen of interest then bind to the antigen expressed on the cell surface. 
Cells are then incubated with a fluorochrome-conjugated secondary anti-human 
antibody. Samples are acquired using (A) flow cytometry or (B) fluorescence 
microscopy (Sinmaz et al 2015)8. 
  
Using cell based assays, although isolated studies identified increased serum IgG 
MOG antibodies in some patients with MS compared to controls183-185, the majority of 
studies confirmed that the prevalence of MOG antibody titres is low in the order of 0-
6% in Caucasian adult patients with MS157, 185, 186. Furthermore, MOG antibodies did 
not appear to have a prognostic or predictive value in adults with MS187. Additionally 
and in contrast to previous studies using ELISA, with the use of cell based assays 
MOG antibodies were not found in any healthy controls (0%), patients with viral 
encephalitis (0%), or other immune systemic diseases like type 1 diabetes mellitus 
(0%), and in only 2-7% of patients with other neurological diseases 155, 156, 185, 186, 188, 
189. 
 
2.3 THE FIRST IDENTIFICATION OF MOG ANTIBODY-ASSOCIATED 
DEMYELINATION IN HUMANS: CHILDREN WITH ADEM 
 
Using a MOG tetramer radioimmunoassay, O’Connor et al186 first identified the 
association of MOG antibodies in children presenting with ADEM. Using cell based 
assays, high-titre MOG antibodies were subsequently found to be more frequently 
positive in paediatric onset demyelination including ADEM and clinically isolated 
syndromes (CIS), with the presence of antibodies being correlated with a younger age 
of disease onset, and an initial presentation with ADEM155, 156, 185, 188-190. The high 
specificity (up to 97%) for demyelinating disease, and moderate sensitivity (40%) for 
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a diagnosis of ADEM was thought to be useful for distinguishing a presentation of 
paediatric monophasic ADEM from CIS which would later progress to fulfill criteria 
for MS191, thus guiding therapeutic decision-making which differs between these two 
entities. Probstel et al185 showed that the highest titres of MOG antibodies were 
associated with an initial presentation of ADEM, and that the majority of children 
with monophasic ADEM had a rapid decline of MOG antibody titres, with 63% 
reducing to undetectable levels within a year, which has been corroborated in further 
studies192. Paediatric ADEM patients with high titre MOG antibodies had MRIs 
characterised by large hazy bilateral cerebral lesions and/or LETM, compared to the 
seronegative ADEM children, and were more likely to have complete lesion 
resolution and a better outcome192. Corpus callosal lesions were more common in 
seronegative children with demyelination than seropositive children190. When 
reviewing paediatric patients with a first presentation of demyelination, MOG 
antibody-positive patients were less likely to go on to fulfill criteria for clinically 
definite MS than the seronegative patients193, 194. While some MOG antibody-positive 
children with relapsing demyelination do fulfill existing paediatric MS criteria, it is 
conceivable that they do not have typical MS, but rather, recurrent demyelination with 
ON and TM more suggestive of NMOSD.  
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2.4 ANTIBODIES TO MOG IN ADULTS WITH BILATERAL AND 
RECURRENT OPTIC NEURITIS 
 
2.4.1 Introduction 
 
Despite the refinement of detection methods, 12-30% of patients with NMOSD 
remain AQP4 antibody-negative152-154. Given the significant evidence supporting 
MOG as a candidate antigen in demyelination as discussed in Chapter 1.7 and 
Sections 2.2 and 2.3, as well as the fact that most adults with MS were not positive for 
MOG antibodies, we hypothesised that adults with AQP4 antibody-negative NMOSD 
would be an important subgroup to evaluate for the presence of MOG antibodies.  At 
the time of identification of our index MOG antibody-positive adult, Kitley et al160 
simultaneously reported four patients with NMOSD and MOG antibodies. We 
subsequently sought to perform detailed characterisation of the clinical phenotype and 
outcomes of adults with MOG antibody-positive NMOSD.  
 
2.4.2 Methods 
 
2.4.2.1 Patients and controls 
 
PATIENTS: We retrospectively investigated 23 patients who presented to 
neuroimmunology and neuro-ophthalmology clinics at four tertiary referral centers in 
Sydney, Australia (2004-2014) with AQP4 antibody-negative NMOSD (12 female; 
median age 38 years, range 17-59). These patients did not satisfy the 2010 McDonald 
diagnostic criteria for MS67. They presented with BON (n=11), LETM (n=10), or 
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sequential BON and LETM (n=2). All patients with LETM had longitudinally 
extensive disease, with spinal cord involvement greater than three vertebral segments 
in length on MRI.	The two patients with sequential BON and LETM satisfied both the 
2006 and 2015 diagnostic criteria for NMO/NMOSD87, 88, but were AQP4 antibody-
negative. Additionally, neither of these two patients had intrathcal oligoclonal bands. 
One of them had a normal MRI brain, and the second patient had an MRI brain with a 
left pontine and right cerebellar hyperintensity that did not fulfill radiological 2010 
revised McDonald criteria. 9/11 BON patients had simultaneous BON at least once 
+/- additional episodes of unilateral ON, while 2/11 had recurrent episodes of 
unilateral ON sequentially involving both eyes. In total, among the 11 BON patients, 
there were 30 ON episodes (18 unilateral and 12 simultaneous and bilateral). All 23 
patients were negative for NMO-IgG-antibodies tested by indirect 
immunofluorescence on monkey cerebrum, cerebellum, and stomach, and rat 
kidney85, 86 as well as for AQP4-antibodies by cell based assay using the M23 isoform 
(Euroimmun). 12/23 AQP4 antibody-negative NMOSD patients had a relapsing 
presentation (6/11 BON, 4/10 LETM, 2/2 sequential BON and LETM).  The relapses 
in the six BON patients were either recurrent unilateral ON or BON, while the four 
LETM patients only had spinal relapses. The two patients with sequential BON and 
LETM had relapses involving both the optic nerves and spinal cord.  
 
Stored acute serum (-80 C) taken during the first presentation (n=13), within one 
month of a relapse (n=5), or during remission (n=5) was tested. The serum of 16/23 
patients was collected on no treatment. Nine of these 16 patients on no treatment had 
samples obtained at initial presentation, three within a month of an acute relapse, and 
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four while in remission. At sample collection four patients had completed a course of 
pulsed steroids within the preceding three months, and three were experiencing 
relapses on long-term steroids and mycophenolate mofetil.  
 
This AQP4 antibody-negative NMOSD cohort was investigated for infectious, 
inflammatory, and autoimmune differential diagnoses (Tables 2.1 and 2.2). 3T MRI 
brain (n=21) and whole spine (n=17) scans were reviewed by neuroradiologists.  
Rapid steroid responsiveness was defined as a greater than 50% improvement in 
visual acuity or expanded disability status scale (EDSS) within 24 hours of 
commencing intravenous steroids, and a relapse on steroid cessation was defined as 
acute worsening within 48 hours of cessation of intravenous steroids. 
 
The sera of 76 patients with clinically definite MS as defined by the revised 
McDonald criteria67 was also tested (59 female, median age 43 years, range 22-71). 
These patients were classified as having relapsing remitting (n=68), secondary 
progressive (n=6), or primary progressive (n=2) MS.  Serum was collected 
pretreatment (n=23), or while on therapy including interferon beta-1a (n=12), 
interferon beta-1b (n=9), glatiramer acetate (n=5), natalizumab (n=15), fingolimod 
(n=11), or alemtuzumab (n=1). 
 
CONTROLS: 52 adult control patients (35 female, median age 55 years, range 24-79) 
were tested, including patients with other neurological diseases (epilepsy, Parkinson 
disease, and peripheral neuropathy; n=20), as well as healthy controls (n=32).  
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Table 2.1 Investigations in patients with AQP4 antibody-negative NMOSD 
 
Investigation Number elevated or positive/ 
number tested 
Erythrocyte sedimentation rate  11/17 
C-reactive protein 8/19 
Elevated anti-nuclear antibody titres  7/19 
Anti-neutrophil cytoplasmic antibodies 2/16 
Lupus related antibodies (double stranded DNA, 
anticardiolipin antibodies, lupus anticoagulant) 
5/19 
 
 
Table 2.2. Investigations in patients with BON 
 
Investigation Number positive/ number 
tested 
Toxoplasmosis serology 0/2 
Lyme disease serology 0/4 
Bartonella henselae serology 0/7 
Syphilis reactivity 0/7 
Quantiferon gold 0/4 
Human immunodeficiency virus serology 0/5 
Angiotensin converting enzyme level 1 /11 
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2.4.2.2 Visual outcomes  
 
All patients received a visual functional system score (VFSS) based on their visual 
acuity (rated from 0 to 6) during their acute presentation and at latest follow-up 
(median follow-up 24 months, mean 20 months, range 2-48 months). The VFSS was 
derived from the EDSS195 (Table 2.3). 
 
Table 2.3 VFSS  (Kurtzke et al 1983)195 
 
0 Normal 
1 Scotoma with visual acuity (corrected) better than 20/30 
2 Worse eye with scotoma with maximal visual acuity (corrected) of 20/30 
to 20/59 
3 Worse eye with large scotoma, or moderate decrease in fields, but with 
maximal visual acuity (corrected) of 20/60 to 20/99 
4 Worse eye with marked decrease of fields and maximal visual acuity 
(corrected) of 20/100 to 20/200; grade 3 plus maximal acuity of better eye 
of 20/60 or less 
5 Worse eye with maximal visual acuity (corrected) less than 20/200; grade 
4 plus maximal acuity of better eye of 20/60 or less 
6 Grade 5 plus maximal visual acuity of better eye of 20/60 or less 
 
Visual field sensitivity was assessed using the central 30-2 program on a Humphrey 
Visual Field Analyser (Carl Zeiss Meditec) at acute presentation and at latest follow-
up. The mean deviation (MD) was obtained as a measure of overall visual field 
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sensitivity. A negative MD corresponds to a loss in sensitivity, with normal values 
ranging from 0 to -3 dB196. As the visual field deficit increases, the MD value 
becomes progressively negative. We graded the sensitivity loss in each eye as mild 
(MD greater than -3.0 dB but less than –6.0 dB), moderate (MD greater than -6.0 dB 
but less than -20.0 dB), or severe (MD greater than -20.0 dB), as described in the 
Optic Neuritis Treatment Trial196. We assigned scores of 0 (normal), 1 (mild), 2 
(moderate), and 3 (severe) to sensitivity loss as determined by MD grades at acute 
presentation and follow-up (median follow-up 4 months, mean 5.4 months, range 1-13 
months). 
 
Optical coherence tomography (OCT) images of the peripapillary retinal nerve fiber 
layer (RNFL) were acquired using a Stratus OCT (Carl Zeiss Meditec, California 
USA; software version 6.00.599) using the Optic Disc Cube protocol. OCT performed 
at acute presentation and at latest follow-up (median follow-up 4 months, mean 4.2 
months, range 1.5-7 months) was evaluated for the average RNFL thickness for each 
eye and was compared to age appropriate normative data provided by the 
manufacturer. Values above this range reflect swelling, while values below this range 
reflect thinning of the RNFL197. OCT images were rejected if an individual eye had a 
signal strength less than 8, or if there was a difference of greater than 2 between the 
two eyes. All patients were imaged adequately using fixation with the fellow eye if 
needed. The fundus was well imaged from edge to edge within the imaging field. All 
OCT studies available adhered to these parameters. 
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2.4.2.3 Standard protocol approval, registrations, and patient consents 
 
Ethics approval for this study was granted by the Sydney Children’s Hospitals 
Network Human Ethics Committee (12/SCHN/395, SSA/13/WMEAD/53, 
SSA/13/CRGH/257, SSA/13/RPAH/599), and informed consent was obtained from 
all patients. 
 
2.4.2.4 Cloning and expression of human MOG 
 
Full-length human MOG cDNA was cloned from a human foetal brain RNA library 
(kind gift from Dr Monkol Lek).  Sequence-verified MOG cDNA was subcloned into 
pIRES2-ZsGreen1 lentivirus vector enabling both MOG and ZsGreen to be co-
expressed in cells (kind gift of Associate Professor Stuart Turville). We used 
published protocols to transduce and obtain MOG-expressing HEK293 cells 
(HEK293MOG+)198. Control cells (HEK293CTL) were obtained by transduction of 
particles with empty pIRES2-ZS Green lentiviral vectors. 
 
2.4.2.5 Cell based assay for the detection of serum antibodies to cell surface MOG  
 
We used fluorescence activated cell sorting (FACS) analysis to detect antibody 
binding of patient serum IgG to surface MOG transduced in HEK293 cells as we have 
previously described49, 199. Live cells were harvested using versene (Invitrogen) and 
washed in phosphate buffered saline (PBS) supplemented with 2% foetal bovine 
serum (FBS) (PBS/FBS). 50,000 cells were then incubated with serum at a 1:50 
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dilution in a 96 well V-bottom plate (Corning) for 30 minutes at room temperature as 
previously described49, 155, 199, 200. Cells were then washed three times with 200µl 
PBS/FBS, and incubated with Alexa Fluor 647-conjugated goat anti-human IgG 
secondary antibody (Life Technologies) for 30 minutes at room temperature. Cells 
were washed three times with PBS/FBS and then resuspended in 20µl PBS/FBS 
before analysis. A total of 10,000 events/well were recorded on a BD LSRII 
instrument equipped with a high-throughput sampler (BD Biosciences).  
 
Data analysis was performed using Flow Jo software (TreeStar, Ashland, OR, USA) 
and Excel. Binding was expressed as mean fluorescence intensity (MFI). Levels of 
antibody binding in ZsGreen-positive transfected cells were expressed as ΔMFI. 
ΔMFI was determined by the subtraction of MFI obtained with HEK293CTL cells from 
the MFI obtained with HEK293MOG+ cells (Figure 2.2).  
 
Figure 2.2 Analysis of live cell based assays for MOG antibodies using flow 
cytometry Representative examples of differences in mean fluorescence intensity 
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(MFI) between cells transduced with MOG (HEK293MOG+ cells) and control cells 
(HEK293CTL) in a MOG antibody-negative and a MOG antibody-positive patient, 
respectively. The degree of antibody binding, or ΔMFI, was determined by the 
subtraction of MFI obtained with HEK293CTL cells from the MFI obtained with 
HEK293MOG+ cells. 
 
A ΔMFI greater than the mean + 3x standard deviations of the control cohort was 
considered positive. Surface expression on transduced cells was analysed by flow 
cytometry after staining with mouse monoclonal anti-rat extracellular MOG (Clone 
818C5, kind gift of Professor Christopher Linington) in combination with an Alexa 
Fluor 647-conjugated appropriate secondary antibody (Life Technologies). Samples 
were considered positive if they were above threshold on at least two of three repeated 
experiments, and the intra-assay variation is summarised below (Table 2.4). 
 
Table 2.4 Intra-assay variation for flow cytometry live cell based assays used to 
test this cohort of AQP4 antibody-negative NMOSD patients for MOG 
antibodies 
 
 
Group 3 out of 3 
above mean + 
3SD threshold 
2 out of 3 
above mean + 
3SD threshold 
1 out of 3 
above mean + 
3SD threshold 
0 out of 3 
above mean + 
3SD threshold 
MOG antibody-
positive 
NMO/NMOSD 
(n=9) 
9 0 0 0 
MOG antibody-
negative 
NMO/NMOSD 
(n=14) 
0 0 3 11 
MS (n=76) 1 0 3 72 
Controls (n=52) 0 0 2 50 
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2.4.2.6 Statistical analysis 
 
The Chi-square test with Yates correction was used to compare MOG antibody 
positivity between patient and control groups, as well as binary clinical features 
between MOG antibody-positive and negative groups. No adjustment for multiple 
testing was performed. The Mann-Whitney test was used to compare continuous 
variables. Statistics and figures were generated using Prism software version 6.0 
(GraphPad Software).   
 
2.4.3 Results 
 
2.4.3.1 MOG antibodies and BON in adults 
 
We used FACS to detect antibody binding of patient IgG to surface MOG transduced 
in HEK293 cells. MFI was associated with antibody concentration (Figure 2.3A). 
Using the mean + 3x standard deviations of our control population to establish the 
threshold for positivity, MOG antibodies were detected in 9/23 AQP4 antibody-
negative NMOSD patients, compared to 1/76 MS patients and 0/52 controls (Figure 
2.3B-D; P<0.0001). 8/11 BON patients were MOG antibody-positive compared to 
0/10 LETM and 1/2 sequential BON and LETM patients (Figure 2.3E, Table 2.5). 
None of the MOG antibody-positive patients had a previous episode of ADEM.  
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Figure 2.3 MOG antibodies are associated with BON in adults (A) Antibody 
reactivity to MOG was determined by a flow cytometry live cell based assay and 
demonstrated increased IgG binding to MOG with an increasing MOG antibody 
concentration. (B and C) Representative examples of flow cytometry histograms for one 
MOG antibody-positive patient with an intermediate ΔMFI (B), and one with a very 
high ΔMFI (C). ΔMFI values are noted in the legend. (D) Human surface MOG IgG 
antibodies were detected in 9/23 AQP4 antibody-negative NMOSD patients compared 
to 1/76 MS patients and 0/52 controls.  The dotted line on the graph represents the 
threshold of positivity. MOG antibody positivity is shown between brackets. A 
representative experiment out of three is shown. (E) ΔMFI values for all subgroups of 
AQP4 antibody-negative NMOSD patients.  
HEK293MOG+ = HEK293 cells expressing MOG; HEK293CTL = control HEK293 cells 
 
 
None of the MOG antibody-positive patients demonstrated IgM reactivity (Figure 
2.4).  
Chapter	2:	The	clinical	characterisation	of	MOG	antibody-associated	demyelination	in	adults			
	 76	
 
Figure 2.4 MOG antibodies are not of the IgM isotype in adults with NMOSD 
Antibody reactivity to MOG was determined by a flow cytometry live cell based 
assay and none of the patients demonstrated IgM reactivity. The dotted line on the 
graph represents the threshold of positivity. MOG antibody positivity is shown 
between brackets. A representative experiment out of three experiments is shown.  
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Table 2.5: Clinical comparison of MOG antibody-positive and negative patients 
 
Clinical and investigation 
findings 
 
MOG antibody-
positive (n=9) 
(number/total  
tested) (%) 
MOG antibody-
negative (n=14) 
(number/total 
tested) (%) 
 
P value1 
 
Gender (female) 6/9 (67%) 6/14 (43%) 0.492 
 
Age at onset (median; range) 
 
36 (22-52) 43 (17-59) 0.3602 
 
Caucasian ethnicity 6/9 (67%) 10/14 (71%) 0.809 
 
Infectious prodrome 6/9 (67%) 4/14 (29%) 0.171 
 
Clinical presentation 
      BON 
      LETM 
      BON and LETM 
 
8/9 (89%) 
0/9 (0%) 
1/9 (11%) 
 
3/14 (21.5%) 
10/14 (71.5%) 
1/14 (7%) 
 
0.006 
0.003 
0.742 
Relapsing disorder 6/9 (67%) 6/14 (43%) 0.492 
 
Number of episodes (median; 
range) 
 
2 (1-5) 1 (1-8) 0.2842 
 
Personal or family history of 
autoimmunity 
 
2/9 (22%) 2/14 (14%) 0.624 
CSF lymphocytosis 
 
2/9 (22%) 7/14 (50%) 0.371 
Presence of intrathecal CSF 
oligoclonal bands 
 
1/9 (11%) 1/14 (7%) 
 
0.742 
MRI fulfilling revised 
McDonald criteria 
 
0/9 (0%) 0/14 (0%) NA 
Rapid steroid response3 6/9 (67%) 2/14 (14%) 
 
0.034 
Relapse with steroid cessation4 
 
4/9 (44%) 0/14 (0%) 0.029 
 
1P values determined using Chi square test with Yates correction unless otherwise 
specified 
2P values calculated using Mann-Whitney test 
3Rapid steroid response defined as a greater than 50% improvement in visual acuity or  
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EDSS within 24 hours of commencing intravenous steroids 
4Relapse with steroid cessation was defined as acute worsening within 48 hours of 
cessation of intravenous steroids 
 
2.4.3.2 Clinical phenotyping of MOG antibody-positive patients 
 
MOG antibody-positive patients were more often female, younger, had a preceding 
infectious prodrome, and more likely to relapse than MOG antibody-negative patients 
(Table 2.5).  
 
The AQP4 antibody-negative NMOSD cohort as a whole frequently had elevated 
markers of inflammation or autoimmunity (Table 2.1) but there were no significant 
differences between the MOG antibody-positive and negative patients. The presence 
of oligoclonal bands in the CSF was uncommon and patients did not fulfill revised 
McDonald criteria67 for MS in either group. All MOG antibody-positive patients had 
brain MRIs that did not fulfill revised McDonald criteria. Of these, seven had MRIs 
performed during acute presentation with optic nerve gadolinium enhancement. One 
MOG antibody-positive patient had large enhancing cerebral lesions that resolved 
rapidly with steroids. This patient’s imaging (featured in Chapter 3, Figure 3.4A) also 
did not fulfill revised McDonald criteria.  
 
8/9 MOG antibody-positive patients had BON (Table 2.6). 6/9 had a relapsing course 
(median episodes 2, range 1-5), although this was not a statistically significant 
difference compared to the seronegative group. All nine MOG antibody-positive 
patients had prominent optic disc swelling, defined as papillitis or optic nerve head 
swelling visible on fundoscopy at acute presentation (Figure 2.5A). In 6/9, this disc 
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swelling rapidly resolved with steroid therapy. The ninth patient demonstrated 
sequential BON and LETM (Figure 2.3E, Figure 2.5B). MOG antibody-positive 
patients were more likely to be rapidly steroid responsive, and relapse on steroid 
cessation, compared to MOG antibody-negative patients (Table 2.5, P=0.034, 
P=0.029, respectively). The treatment of all MOG antibody-positive patients is 
outlined in Table 2.6. The median follow-up was 28 months (range 6-120). One of 76 
MS patients was MOG antibody-positive. This patient was a 55-year-old Caucasian 
female with clinical and radiological findings consistent with relapsing remitting MS 
and no previous ADEM or ON episodes. Notably, she had a strongly positive anti-
nuclear antibody titre of 1:2,560. 
 
 
 
Figure	 2.5	 Representative	
examples	 of	 clinical	 and	
radiological	 findings	 in	
MOG	 antibody-positive	
NMOSD		(A)	 MOG	 antibody-positive	patients	 with	 BON	 had	bilateral	 optic	 disc	 swelling	visible	 on	 fundoscopy	 at	acute	 presentation	 (B)	Radiological	 appearance	 of	LETM	 spanning	 numerous	segments	of	the	cervical	and	thoracic	spinal	cord	on	MRI.	This	 is	 a	 representative	sagittal	 image	 from	 the	MRI	spine	 of	 the	 single	 MOG	antibody-positive	 patient	 in	this	 cohort	 who	 presented	with	 simultaneous	BON	and	LETM.	
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Table 2.6 Clinical characterisation of MOG antibody-positive patients 
 
 
 Age at 
first 
episode 
& 
gender 
Clinical 
events 
Visual 
Functional 
System 
Score at 
onset 
Spinal symptoms 
in absence of 
spinal lesion on 
imaging 
Number of 
optic neuritis 
episodes:  
total 
(unilateral/ 
bilateral) 
Treatment regime Rapid 
steroid 
response 
Relapse 
on 
steroid 
cessation 
Disease 
duration 
and 
follow-up 
(months)3 
Visual 
Functio
nal 
System 
Score at 
latest 
follow-
up 
Patient 1 26 F BON 2 Lhermitte’s 
phenomenon 
2 (1/1) IV MP x 2 courses, oral 
prednisone 
Yes Yes 52 0  
Patient 2 
 
32 M BON 
 
5 No 2 (0/2) IV MP x 2 courses, oral 
prednisone  
Yes Yes 7 0  
Patient 3 
 
52 F BON 2 Lhermitte’s 
phenomenon, 
limb paraesthesia 
4 (4/0) of which 
2 left ON and 2 
right ON 
IV MP x 2 courses Yes No 120 2  
Patient 4 
 
29 M BON & 
LETM 
2 NA as patient had 
LETM 
1 (0/1) 
1 LETM 
IV MP x 2 courses, PE, 
maintenance MMF and oral 
prednisone 
No No 9 1  
Patient 5 
 
45 F BON 6 No 3 (2/1) IV MP x 3 courses, glatiramer 
acetate 
Yes Yes 28 2  
Patient 6 36 F BON 6 No 1 (0/1) IV MP Yes No 6 2  
Patient 71 
 
22 M BON 6 Bladder 
symptoms and 
lower limb 
paraesthesia 
5 (5/0) of which 
3 right ON and 
2 left ON 
IFN, latest episode IV MP, 
maintenance MMF and oral 
prednisone, rituximab 
No No 58 5  
Patient 8 
 
51 F BON 5 Sphincter 
dysfunction and 
lower limb 
paraesthesia 
1 (0/1) No treatment  NA NA 24 2  
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 Age at 
first 
episode 
& 
gender 
Clinical 
events 
Visual 
Functional 
System 
Score at 
onset 
Spinal symptoms 
in absence of 
spinal lesion on 
imaging 
Number of 
optic neuritis 
episodes:  
total 
(unilateral/ 
bilateral) 
Treatment regime Rapid 
steroid 
response 
Relapse 
on 
steroid 
cessation 
Disease 
duration 
and 
follow-up 
(months)3 
Visual 
Functio
nal 
System 
Score at 
latest 
follow-
up 
Patient 92 
 
38 F BON 5 Lower limb 
paraesthesia 
1 (0/1) IV MP x 2, PE, maintenance 
MMF and oral prednisone 
Yes Yes 29 2  
Group 
Summary 
Median 
(range) 
36  
(22-52) 
BON 8/9 
BON & 
LETM 
1/9 
Median 
(range) 
5 (2-6) 
5/8 with isolated 
BON 
Median total 
episodes (range) 
2 (1-5) 
IV MP                   8/9 
Oral prednisone    5/9 
PE                         2/9 
MMF                    3/9 
Rituximab            1/9 
6/9 4/9 Median 
(range) 
28 (6-
120) 
Median 
(range) 
2 (0-5) 
 
1 Personal history of Henoch-Schonlein purpura 
2 Two first degree relatives with type 1 diabetes, one first degree relative with lymphocytic colitis 
3All patients had clinical follow-up from the time of disease onset.  
F = female gender; IFN = β-interferon therapy; IV MP = intravenous methylprednisolone; M = male gender; MMF = mycophenolate mofetil; 
NA = not applicable; PE = plasma exchange. 
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2.4.3.3 Serial dilutions in MOG antibody-positive patients 
 
We determined the maximum serum dilution required for a sample to still have a 
ΔMFI above the threshold. Seven MOG antibody-positive patients were tested at 
serum dilutions ranging from 1:50 to 1:2,000. 6/7 remained positive at 1:100, 5/7 at 
1:200, and 4/7 at 1:400. Only one patient remained positive at dilutions of 1:1,000 and 
1:2,000. MOG antibody-positive patients can have variably high titres (Figure 2.6).  
 
 
 
Figure 2.6 Serial dilutions in MOG antibody-positive patients Serial dilutions of 
MOG antibody-positive samples show differing IgG binding. The end point dilution 
where a sample remained above the positive threshold (dotted line) ranged from 
1:50 to 1:2,000. For clarity, only three representative patients are shown.  
 
 
2.4.3.4 Classification of evidence 
 
This study provides Class II evidence that MOG antibodies are associated with BON 
(sensitivity 69%, 95% CI 42 to 87%; specificity 99%, 95% CI 93.7 to 99.8%). The 
study is Class II because of the case control design. Sensitivity was calculated from 
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the proportion of BON patients with positive MOG assays (9/13). Specificity was 
calculated from the proportion of non-BON autoimmune patients (MS and isolated 
LETM patients) without MOG antibodies (85/86). 
 
2.4.3.5 Visual outcomes in MOG antibody-positive and MOG antibody-negative  
patients 
 
 
A selection of both MOG antibody-positive (total n=9; BON n=8, simultaneous BON 
and LETM n=1) and MOG antibody-negative (total n=4; BON n=3, simultaneous 
BON and LETM n=1) patients had visual acuity scores (9/9; 4/4) visual field testing 
(5/9; 2/4) and RNFL thickness (3/9; 1/4) available both at acute presentation and at 
long term follow-up (Tables 2.7-2.9).  
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Table 2.7 Visual acuity scores in MOG antibody-positive and antibody-negative  
     patients. 
 
 MOG antibody-positive (n=9) MOG antibody-negative (n=4) 
 Acute Follow-up Acute Follow-up 
VFSS     
0 0 2 0 2 
1 0 1 1 0 
2 3 5 0 1 
3 0 0 0 1 
4 0 0 1 0 
5 3 1 2 0 
6 3 0 0 0 
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Table 2.8 Visual field deficit scores in MOG antibody-positive and antibody-   
                 negative patients 
 
 
 MOG antibody-positive (n=10 
affected eyes)1 
MOG antibody-negative (n=4 
affected eyes)1 
 Acute Follow-up Acute Follow-up 
Visual Field 
Deficit Score 
    
Normal 1 4 1 3 
Mild 2 4 0 1 
Moderate 4 2 2 0 
Severe 3 0 1 0 
 
1 n=5 MOG antibody-positive and n=2 MOG antibody-negative patients had both 
acute and follow-up visual field testing done, hence only these ten and four affected 
eyes respectively are included in this table. 
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Table 2.9 Retinal nerve fibre layer thickness in MOG antibody-positive and   
                 antibody-negative patients 
 
 
 Retinal nerve fiber layer 
thickness at acute presentation1 
Retinal nerve fiber layer 
thickness at follow-up1 
MOG 
antibody-
positive (n=3) 
OD OS OD OS 
Patient 2 146 µm 223 µm 77 µm 71 µm 
Patient 4 119 µm 122 µm 113 µm 111 µm 
Patient 6 185 µm 248 µm 119 µm 115 µm 
MOG 
antibody-
negative (n=1) 
100 µm 109 µm 70 µm 71 µm 
 
 
1n=3 MOG antibody-positive and n=1 MOG antibody-negative patient had both acute 
and follow-up optical coherence tomography performed, so only these patients are 
included in this table. The three MOG antibody-positive patients included are patients 
2, 4, and 6 on Table 2.6. 
 
Both patients who were MOG antibody-positive and negative from this cohort of 
AQP4 antibody-negative NMOSD patients had the potential for sustained visual 
impairment.  
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2.4.3.6 MOG antibody-associated BON and visual outcomes 
 
Most MOG antibody-positive patients had significant visual impairment during the 
acute episode, with 6/9 (67%) having a VFSS of 5 or 6 (Figure 2.7A). While 8/9 
patients had good visual acuity at follow-up with a VFSS of 0 to 2, one patient 
(patient 7, Table 2.6) had a significant residual deficit with a VFSS of 5 (Figure 2.7A) 
(median follow-up interval 24 months, mean 20 months, range 2-48 months).  
 
Visual fields were assessed in five MOG antibody-positive patients (ten eyes) at acute 
presentation and follow-up (median follow-up 4 months, range 1-13 months) (Figure 
2.7B and C). 7/10 eyes had a moderate or severe visual field deficit at acute 
presentation. Follow-up demonstrated an improvement in all eyes with the MD 
approaching the normal range (Figure 2.7B), and visual field deficits scoring as 
normal or mildly affected in 8/10 eyes (Figure 2.7C).  
 
We reviewed RNFL thickness as measured by OCT during an acute episode of ON 
and at follow-up. While acute ON can result in increased peripapillary RNFL 
thickness (Figure 2.7D-F), with clinical resolution, RNFL thickness returns towards 
the normal range (Figure 2.7D). Three patients demonstrated evidence of RNFL 
thinning (Figure 2.7E and G) suggesting axonal loss and irreversible damage.  
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Figure 2.7 MOG antibody-associated BON has the potential to result in long-
term visual impairment (A) Visual functional system score for MOG antibody-
positive patients taken at the time of acute presentation and at latest follow-up 
demonstrate that the majority of patients experienced an improvement in visual acuity 
at follow-up. (B) Visual field deficits in five patients in both left (OS) and right (OD) 
eyes as measured by the mean deviation also demonstrate improvement at latest 
follow-up and approach the normal range (shaded region 0 to -3 dB) (C) The majority 
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of affected eyes had a moderate to severe visual field deficit at onset, but experienced 
an improvement in these scores. However, two affected eyes had a moderate residual 
deficit at latest follow-up. (D-F) OCT allowed for estimation of average peripapillary 
RNFL thickness. During an acute episode of ON, swelling results in increased RNFL 
thickness (F). With resolution of the attack, RNFL thickness can either return towards 
the normal range (shaded region) (D) or result in RNFL thinning (E and G). Avg 
RNFL thickness = average retinal nerve fibre layer thickness; dB = decibels; OD = 
oculus dexter (right eye); OS = oculus sinister (left eye) 
 
Patient 7 (Table 2.6) experienced five relapses in a four-year period. He is a 22 year-
old man who experienced five relapses since disease onset four years prior. Early 
treatment with injectable β-interferon reflected a provisional diagnosis of MS. 
Subsequent relapses led to referral to a tertiary center, and revision of diagnosis and 
management. At this stage his VFSS was already poor with a score of 5. His latest 
relapse (44 months post disease onset) resulted in a VFSS of 6, and was managed 
aggressively with pulsed steroids, followed by maintenance immunosuppression with 
oral prednisone and mycophenolate mofetil, and subsequently rituximab. Despite this, 
the best VFSS at last follow-up remained at 5. OCT performed at 40 months post 
disease onset revealed significant RNFL atrophy with measures of 57 µm (OD) and 
79 µm (OS). Delayed diagnosis and initiation of immunotherapy were possible 
contributors to a poor follow-up VFSS and significant RNFL thinning in this patient. 
In conjunction, these findings suggest that visual acuity, visual field deficits and 
RNFL thickness improve in the majority of patients with MOG antibody-associated 
BON, however some patients exhibit sustained visual impairment, which may be 
contributed to by delayed immunosuppressive treatment. 
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2.4.3.7 Final diagnoses in all patients with BON and/or LETM presenting to 
participating institutions from 2004-2014  
 
A total of 38 patients presented with BON to the participating centers during the 
recruitment period for patients considered for this study, 2004-2014. Of these, eleven 
patients had a diagnosis of AQP4 antibody-positive NMOSD, nine had confirmed 
MOG antibody-positive NMOSD, four were double seronegative and had a 
monophasic illness, six went on to fulfill diagnostic criteria for MS, one patient was 
diagnosed with ADEM, one with vasculitis, and six patients were lost to follow-up. 
Within this time frame, a total of 34 patients presented with LETM (2 with sequential 
LETM and BON, 13 with LETM and unilateral ON, and 19 with isolated LETM). Of 
these, seventeen patients were AQP4 antibody-positive NMOSD, one had MOG 
antibody-positive NMOSD, eleven were double seronegative, one had a diagnosis of 
Japanese OSMS, one was post-vaccination, and three were unclassified. 
 
2.4.4 Discussion 
 
Using a flow cytometry live cell based assay, we found that antibodies targeting 
native human full-length surface MOG may be a clinical biomarker in adults with 
BON. We provide clinical characterisation of this condition as a relapsing disorder 
frequently associated with prominent disc swelling. While early recognition and 
institution of therapy can result in a favourable outcome, MOG-antibody-associated 
BON has the potential to result in long-term visual impairment. 
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We describe that surface MOG IgG antibodies have a strong association with BON in 
adults. The fact that 39% of AQP4 antibody-negative NMOSD patients in our cohort 
were positive for MOG antibodies renders this a potentially useful biomarker. We 
detected an IgG rather than IgM antibody response, implying this is not an acute 
immunological response to injury but rather a more mature response. 7/9 MOG 
antibody-positive patients had one or more episodes of simultaneous BON with two 
having additional episodes of unilateral ON. 2/9 MOG antibody-positive patients had 
recurrent episodes of unilateral ON affecting both eyes. Our group recently described 
MOG antibodies in paediatric patients with BON, further strengthening this clinical 
association201. A similar association with MOG antibody-positivity and ON was 
recently reported202. MOG antibodies should be a diagnostic consideration in any 
patient with recurrent ON, whether they present unilaterally or bilaterally. We 
additionally found that prominent optic disc swelling was noted in all nine MOG 
antibody-positive patients acutely, and should prompt testing for MOG antibodies as 
this appearance is not typical of ON related to MS201, 203. Interestingly, chronic 
relapsing inflammatory optic neuropathy (CRION) describes a group of patients with 
recurrent optic neuropathy who are largely AQP4 antibody-negative204, 205. The 
diagnostic criteria for CRION includes relapsing disease, loss of visual function, 
NMO-IgG seronegativity, optic nerve contrast enhancement, and response to 
immunosuppressive therapy and relapse on withdrawal of therapy205. This description 
is largely similar to the clinical characteristics of our MOG antibody-positive cohort, 
and it is possible that a subset of patients labeled as CRION may indeed have MOG 
antibody-associated BON.  
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Keeping the MOG antibody association with ON this study revealed in mind, one can 
look back at previous animal studies that yield interesting supporting evidence. MOG 
induced EAE in murine models demonstrated that the most common pattern of 
demyelination in 39% of rats resulted in the visual pathyway (optic nerves, chiasm 
and tract) and spinal cord, reminiscient of NMOSD206. In one study, more than 30% 
of MOG-specific T cell receptor (TCR) transgenic mice spontaneously develop 
isolated ON in the absence of EAE either clinically or histologically207. MOG was 
found to have a higher expression in the optic nerve than the spinal cord of these 
transgenic mice, suggesting increased autoantigen expression in the optic nerves as a 
reason for their predilection to spontaneous ON histologically207. Prevalent ON in 
mice immunised with MOG peptides has also been shown208. Both active and 
adoptive transfer of disease by immunisation with encephalitogenic MOG peptides or 
transfer of MOG-specific T cells into naïve B6 mice respectively, resulted in ON both 
with and without concurrent EAE in mouse models, with ON frequently being 
bilateral209. These results are of interest given the strong association with MOG 
antibodies and BON that we demonstrated in this study. 
 
One MOG antibody-positive patient in this cohort had LETM in the context of a 
preceding attack of BON. This fulminant presentation of sequential BON and LETM 
is uncommon in AQP4 antibody-positive NMOSD and reminiscent of the original 
descriptions of Devic disease160. A recent study described nine patients with MOG 
antibodies, the majority of whom had transverse myelitis210. All our MOG antibody-
positive patients had both brain and spine MRIs performed. In our cohort, none of the 
radiologically defined isolated LETM patients had MOG antibodies. Notably, five of 
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our patients with MOG antibody-associated BON did have symptoms suggestive of 
spinal involvement including Lhermitte’s phenomenon, limb paraesthesia, and 
sphincter dysfunction, despite a normal MRI spine. This suggests cord involvement 
may occur without clinical or radiological evidence of myelitis. The use of full-length 
human MOG in our cell based assay as opposed to C-terminal truncated human MOG 
used by other groups210, 211 may account for some differences in findings. 
Additionally, 14/23 AQP4 antibody-negative NMOSD patients in our cohort were 
also MOG antibody-negative, suggesting there may well be other antigenic targets. 
 
Our cohort of MOG antibody-positive patients was predominantly Caucasian.  This is 
in keeping with recent findings, and serves to highlight the relatively high prevalence 
of AQP4 antibody-positivity in patients who are of African and Afro-Caribbean 
descent 153, 154, 212. A recent report of 16 MOG antibody-positive patients of a similar 
median age found that most patients were male202. We did not find a statistically 
significant association with gender, age at onset, and MOG antibody status. In our 
cohort, the 9 MOG antibody-positive patients did not have intrathecal oligoclonal 
bands or radiology consistent with MS.   
 
The majority of MOG antibody-positive patients in our cohort had a propensity to 
relapse. This is an important finding in adults as previously published cohorts have 
suggested that MOG antibody-positivity is associated with a monophasic illness202, 210. 
The presence of relapses has been observed in paediatric patients with MOG 
antibodies and LETM or recurrent or bilateral ON158, 185. Notably, a number of our 
MOG antibody-positive patients had previous treatment with short courses of pulsed 
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steroids alone, and had a propensity to relapse. This phenomenon of steroid 
responsiveness and steroid dependency is elaborated on further in Chapter 4.5.4 and 
4.5.6. This may indicate that early and sustained immunotherapy with multiple agents 
including steroid sparing maintenance immunosuppression may be more effective in 
maintaining disease remission.  
 
Conventional measures of disability such as the EDSS195 or modified Rankin Scale 
may not be an appropriate outcome measure in patients with BON, as visual 
impairment alone does not rate highly on such scales despite causing major functional 
disability. Previous studies highlight the favourable clinical outcomes of patients with 
MOG antibody-positive NMOSD160, 210. The majority of our MOG antibody-positive 
patients did indeed demonstrate an improvement of visual acuity and visual field 
deficits with early immunotherapy suggesting this condition may be treatable, 
however this was not universal. A minority of our seropositive patients did have 
significant residual deficits in terms of visual acuity, visual field loss, and RNFL 
thinning. Although most patients had preserved visual acuity, some had evidence of 
concomitant RNFL thinning, which may represent a vulnerability to sustained visual 
impairment in the context of relapses. In addition to visual dysfunction, spinal cord 
related disability may also persist as in our one patient with sequential BON and 
LETM. These results highlight the fact that MOG antibody-associated demyelination 
may not always have a favourable outcome. 
 
Due to the retrospective study design, most samples were obtained pre-treatment, 
however some patients had received steroids or other immunosuppressive therapy at 
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the time of sample collection. Despite this, the strong association of MOG antibody 
positivity with the clinical phenotype of relapsing BON with prominent optic disc 
swelling is novel and an important contribution to the field. Evaluation of visual fields 
was retrospective, and only half of the antibody-positive patients had both acute and 
convalescent OCT results. Nonetheless, our study comprises the first attempt to 
objectively define visual acuity, visual field deficits, and RNFL in MOG antibody-
positive patients, and provide important insights on disease mechanisms.  
 
Taken together, our findings suggest that MOG antibody-associated BON may be a 
distinct immunological entity with a characteristic clinical profile. Detection of MOG 
antibodies may assist with the early differentiation of this condition from AQP4 
antibody-positive NMOSD and MS, and prove to be an essential biomarker with 
diagnostic and therapeutic implications. 
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2.5 EXPLORING THE PRESENCE OF MOG ANTIBODIES IN 
JAPANESE OPTICOPSINAL MS (OSMS) 
 
2.5.1 Introduction 
 
MS in a subgroup of individuals of Asian ethnicity has significant differences to 
conventional MS (CMS) in Caucasians. The predilection for selective optic nerve and 
spinal cord involvement in Japanese patients has been established213, 214. In patients 
with lesions confined to the optic nerve and spinal cord with minor brainstem lesions, 
no clinical evidence of cerebellar or cerebral involvement, and at least one relapse, 
this entity is referred to as OSMS213, 214. OSMS is characterised by later age of onset, 
female predominance, more relapses, severe disability, LETM, and negative 
intrathecal oligoclonal bands compared to CMS214. 
 
Given the similarities between NMOSD and OSMS, it was postulated that they were 
the same entity85. Studies evaluating AQP4 antibody-positivity in OSMS quoted 
seroprevalence rates of 27-63%, compared to only 6-15% in patients with CMS85, 215-
218. AQP4 antibody-positive OSMS patients were more likely to have LETM, 
increased relapses, and severe ON compared to the seronegative patients215-217. 
 
Given our results identifying MOG antibodies in patients with BON and LETM 
(Section 2.4), we postulated that that some patients with AQP4 antibody-negative 
OSMS may be positive for MOG antibodies.  
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2.5.2 Materials and Methods 
 
2.5.2.1 Patients and controls 
 
PATIENTS: As a consequence of our collaboration with Professor Jun-Ichi Kira and 
his team at Kyushu University, Fukuoka, Japan, we were provided with serum 
samples from fifty Japanese patients in their database who fulfilled criteria for OSMS 
(42 female; median age at onset 30.5 years, mean 31.94, range 9-60) and were AQP4 
antibody-negative. The median disease duration was 7 years (mean 11.7, range 0.8-36 
years). Twenty patients had magnetic resonance imaging (MRI) studies that satisfied 
the 2010 revised McDonald criteria for MS67. All patients clinically demonstrated 
features of selective optic nerve and/or spinal cord involvement in keeping with their 
diagnosis of OSMS.  
 
The median number of relapses was 4 (mean 5, range 1-18), and the median annual 
relapse rate was 0.47 (mean 0.56, range 0.08-1.67). Data regarding the exact nature of 
all clinical episodes were available in 31/50 OSMS patients. Of these 31, 17 had 
unilateral ON (median number of episodes 1, range 0-3), 4 had simultaneous BON 
(median 0, range 0-1), all 31 had short segment myelitis (median 3, range 1-11), and 
only one patient had LETM (median 0, range 0-1). Of the fifty OSMS patients, 
samples were collected during the initial attack (n=4), relapse (n=13), remission 
(n=21), or during progressive disease (n=1). Data regarding the disease phase during 
sample collection was not available in eleven patients. The median interval between 
disease onset and serum collection was 4.5 years (mean 8.56, range 0-36).  
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29 patients were on no disease modifying therapies at latest clinical follow-up, while 
21 were on treatment including interferon beta-1b (n=10), low dose oral prednisolone 
(n=5), interferon beta-1a (n=4), or fingolimod (n=2). The median EDSS score at latest 
follow-up was 2 (mean 2.56, range 0-7.5).  
 
CONTROLS: Forty Japanese controls were also tested (20 females, median age 51 
years, mean 49, range 24-69). Twenty were healthy controls, and twenty had other 
neurological diseases (Parkinson disease, amyotrophic lateral sclerosis, 
spinocerebellar degeneration, or epilepsy). 
 
Our research team was initially blinded to all clinical information, and provided only 
with 90 coded samples incorporating the 50 Japanese OSMS patients and 40 Japanese 
controls detailed above. 
  
2.5.2.2 Standard protocol approval, registrations, statistical analysis, and detection 
of MOG antibodies 
 
Ethics approval and statistical analysis was carried out as detailed in Sections 2.4.2.3 
and 2.4.2.6 above.  One control was eliminated from the statistical analysis as it was 
detected as a significant outlier in an otherwise normally distributed population, using 
Grubbs’ test. 
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Detection of MOG antibodies was carried out as detailed in Sections 2.4.2.4 and 
2.4.2.5. Following identification of MOG antibody serostatus, the samples were 
unblinded and clinical information was subsequently provided. 
 
2.5.3 Results 
 
2.5.3.1 MOG antibodies in Japanese OSMS 
 
We used FACS to detect antibody binding of patient IgG to surface human MOG in 
transduced HEK293 cells. The MFI was associated with antibody concentration 
(Figure 2.8A). Using the mean + 3x standard deviations of our Japanese control 
population to establish the threshold for positivity, IgG MOG antibodies were 
detected in 2/50 patients with OSMS, compared to 0/39 controls (Figure 2.8B). One 
of these MOG IgG-positive patients also demonstrated IgM reactivity (Figure 2.8C).  
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Figure 2.8 MOG antibodies are uncommon in patients with Japanese OSMS (A) 
Antibody reactivity to human full-length MOG was determined by a flow cytometry 
live cell based assay and revealed increased IgG binding to MOG was associated with 
an increasing MOG antibody concentration. (B) Human surface MOG IgG antibodies 
were detected in 2/50 patients with Japanese OSMS compared to 0/39 Japanese 
controls. The dotted line on the graph represents the threshold of positivity (mean + 3 
x standard deviations of control population). MOG antibody positivity is shown in 
brackets. A representative experiment out of three is shown. (C) One MOG IgG 
antibody-positive OSMS patient also demonstrated IgM reactivity.  
 
2.5.3.2 Clinical phenotyping of MOG antibody-positive patients 
 
Patient 1 
The first MOG antibody-positive OSMS patient (62 year old male) developed left ON 
at the age of 40. He subsequently experienced a further episode of unilateral ON, as 
well as one episode of simultaneous BON. He also had short segment myelitis. A 
vasculitic screen was negative. CSF analyses during remission revealed 11 
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mononuclear cells/µl (normal range 0-5), and elevated protein 60.5 mg/dL (normal 
range 15-45). An MRI brain fulfilled revised McDonald criteria67. This patient had 
been on no therapy, and was in remission at sample collection. He has normal visual 
acuity at latest follow-up, and an EDSS of 1. 
 
Patient 2 
The second MOG antibody-positive (40 year old female) developed sensory loss 
below the neck at the age of 39, following a viral illness. She went on to have one 
episode of confirmed LETM, and one episode of short segment myelitis. A vasculitic 
screen was positive for antinuclear antibodies and SS-A antibodies. CSF analyses 
during the initial episode revealed 179 mononuclear cells/µl, elevated protein at 53 
mg/dL, and no intrathecal oligoclonal bands. An MRI brain did not fulfill revised 
McDonald criteria67. She is on no therapy and was in remission at sample collection. 
Latest follow-up revealed normal visual acuity and an EDSS of 2. 
 
2.5.4 Discussion  
 
We found that antibodies targeting native human surface full-length MOG are 
uncommon in patients with Japanese OSMS. As outlined in Section 2.4.3.1, we had 
previously found MOG antibodies were rare in Australian patients with CMS with 
only 1.3% (1/76) being seropositive. Despite the fact that OSMS patients have 
dominant ON, we found similarly low rates of MOG antibody-positivity in Japanese 
OSMS (2/50, 4%). Another study looking at a small number of Japanese patients with 
demyelination also concurred that MOG antibody-positivity was uncommon219. 
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Interestingly, one of the two MOG antibody-positive patients in this Japanese OSMS 
cohort had recurrent episodes of unilateral ON as well as one episode of BON. This 
patient was one of only four patients in this cohort with BON. This suggests the 
presence of BON, which is not common in CMS or OSMS, should raise suspicion for 
MOG antibody-associated demyelination. MOG antibody-associated LETM has been 
described in recent cohorts202, 210. Of note, the second MOG antibody-positive patient 
was the only patient in this OSMS cohort with LETM, once again suggesting that this 
clinical phenotype should prompt testing for MOG antibodies. 
 
The two MOG antibody-positive OSMS patients also exhibited relapses. Interestingly, 
both had a favourable outcome in terms of EDSS and normal follow-up visual acuity 
despite no therapy, in keeping with previous findings that while a minority of MOG 
antibody-positive patients had sustained impairment, the majority had good 
outcomes202, 210. Steroid therapy alone or in combination with intravenous 
immunoglobulin, plasma exchange, or other maintenance immunosuppression may 
improve outcomes in patients with MOG antibody-associated demyelination rather 
than using disease-modifying therapies as in CMS. Recognition of this condition thus 
has therapeutic implications. 
 
This is the first study to use a flow cytometry live cell based assay to evaluate the 
prevalence of MOG antibodies in Japanese patients with OSMS. While only a 
minority of patients with OSMS appear to be seropositive for MOG antibodies, the 
clinical phenotype of BON and/or LETM should raise clinical suspicion for the 
possibility of MOG antibody-associated demyelination. 
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1. Radiological differentiation of optic neuritis with myelin oligodendrocyte 
glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis.  
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RC. 
 
Multiple Sclerosis 2016; 22(4):470-482 
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Chapter	3:	Radiological	characterisation	of	optic	neuritis	due	to	MOG	antibodies		
	 104	
3.1 SUMMARY OF CHAPTER 3 
 
Having established the association of MOG antibodies with ON, and in particular 
BON as outlined in Chapter 2, we postulated that there would be specific radiological 
features associated with MOG antibody-associated ON. It is crucial to differentiate a 
patient who has ON due to MS from one with ON due to antibody-associated 
demyelination (either AQP4 or MOG antibodies), as therapeutic pathways and 
outcomes may differ. The duration for a result from antibody testing for AQP4 or 
MOG antibodies may vary depending on the availability of serological testing in 
different centres. In contrast, MRI is widely available and early radiological clues 
regarding a more likely demyelinating aetiology would be valuable in providing 
guidance for the treating clinician. We designed a study to directly perform blinded 
neuroradiological assessment of first episode ON associated with MOG antibodies, 
AQP4 antibodies, and MS, and identify differentiating radiological features of ON 
according to diagnosis. The work covered in this chapter was published in Multiple 
Sclerosis (Ramanathan et al 2016)220. 
 
3.2 INTRODUCTION 
 
ON is characterised by visual loss and pain with eye movement due to inflammation 
of the optic nerve, and occurs as the presenting symptom in 25%, or during the 
disease course in up to 70%, of patients diagnosed with multiple sclerosis (MS)65, 221.	
AQP4 antibody-positive NMOSD selectively targets the spinal cord and optic nerves, 
resulting in TM and ON, and is often associated with severe disability85, 86. Our group 
demonstrated a strong association between MOG antibody-positivity and 
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simultaneous bilateral and recurrent optic neuritis in children201 and adults (as detailed 
in Chapter 2). Early distinction of the cause of ON is important, due to the varied 
pathogenesis, therapy, and prognosis of these three demyelinating conditions. 
 
MRI of the brain and spinal cord plays an essential role in the diagnosis and 
management of patients with suspected demyelination. While MRI brain 
abnormalities in patients with NMOSD have been described222-224, only a few 
previous studies have assessed the radiological features of ON in NMOSD versus MS, 
and these results were limited by small sample size, the lack of gadolinium 
administration, and/or the lack of dedicated orbital imaging225-227. These studies 
showed that AQP4 antibody-positive patients had a tendency to have bilateral and 
longitudinally extensive optic neuritis with chiasmal involvement225-227. Akaishi et 
al228 studied Japanese patients (n=19 MOG antibody-positive ON affected eyes, and 
n=9 AQP4 antibody-positive ON affected eyes) and demonstrated severe and 
extensive inflammatory changes in the optic nerves of MOG antibody positive 
patients that typically spared the chiasm, while A QP4 antibody positive patients had 
chiasmal swelling. Ours is the first study to directly compare the radiological 
characteristics of first episode ON associated with MOG antibodies (MOG-ON), 
AQP4 antibodies (AQP4-ON), and MS (MS-ON). Herein, we demonstrate 
differentiating features of ON according to diagnosis.  
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3.3 MATERIALS AND METHODS 
 
3.3.1 Patient and control recruitment and clinical characterisation 
 
We retrospectively assessed 55 patients who had MRI during a first presentation of 
ON, and who were assessed at nine tertiary referral MS/neuroimmunology centers in 
Australia and the United States from January 2001 to September 2014. Inclusion 
criteria were a presentation consistent with the first episode of clinical ON227; MR 
imaging within four weeks of symptom onset whereby acute radiological features 
including contrast enhancement may persist225; and access to clinical follow up. 
Patients were excluded if there was a lack of dedicated orbital imaging, lack of 
clinical follow up, symptom resolution in less than 24 hours, or an alternate diagnosis. 
Five patients were excluded from further analysis due to the lack of dedicated MRI 
orbital imaging.  In total, fifty patients (41 female, mean age at onset 24 years, median 
15 years, range 3 to 58 years) had dedicated orbital and brain imaging with a 3T 
(n=32) or 1.5T (n=18) MRI scanner.  
 
Prior to study commencement, a diagnosis of MOG antibody-positive ON had been 
made in nineteen patients, using a live cell based assay analysed by flow cytometry to 
detect antibody binding of patient serum IgG to surface full-length human MOG as 
described in Chapter 2.4.2.5. A diagnosis of AQP4 or NMO IgG antibody-positive 
ON had been made in eleven patients. NMO IgG antibodies were tested by indirect 
immunofluorescence on monkey cerebrum, cerebellum and stomach, and rat kidney85, 
86. AQP4 antibodies were tested by cell based assays using the M23 isoform 
(Euroimmun, Lübeck, Germany).  Thirteen patients with MS-ON served as the 
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control group, and were recruited from three MS referral centers in Sydney. We 
reviewed files of MS patients from 2001 to 2013 presenting with first episode ON, 
and included only patients where MRI brain and dedicated orbital imaging was 
available. These patients were diagnosed with MS as defined by revised 2010 
McDonald criteria67. Of these, 2/13 MS patients fulfilled McDonald radiological 
criteria at their first presentation of ON. 8/13 had subsequent clinical relapses, while 
3/13 fulfilled revised McDonald criteria on follow-up due to radiological evidence of 
dissemination in space and time. Finally, seven patients were seronegative for both 
MOG and AQP4 antibodies and did not fulfill diagnostic criteria for MS, were 
defined as ‘unclassified’, and were not included in the statistical analyses due to their 
likely heterogenous aetiologies. Clinical data on these seven patients is provided in 
Table 3.1. Patients were tested for MOG antibodies (n=19/19 MOG-ON patients, n= 
2/11 AQP4-ON patients, n= 9/13 MS-ON patients, n=7/7 unclassified ON patients) 
and AQP4 antibodies (n=17/19 MOG-ON patients, n=11/11 AQP4-ON patients, 
n=6/13 MS-ON patients, n=4/7 unclassified ON patients) depending on the 
availability of serum from the patient during their index episode of ON.  28 patients in 
this cohort were tested for both MOG and AQP4 antibodies and none were 
seropositive for both antibodies. A retrospective review of clinical information was 
performed.  
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Table 3.1 The clinical characteristics of ON acutely and at follow up in patients with unclassified ON 
 
 
Clinical variable 
assessed 
Unclassified 
ON 1 
Unclassified 
ON 2 
Unclassified 
ON 3 
Unclassified 
ON 4 
Unclassified 
ON 5 
Unclassified 
ON 6 
Unclassified 
ON 7 
Gender  female female female male male female female 
Age at onset (years) 57 52 12 13 14 15 7 
Was the ON episode 
the first 
demyelinating event? 
Yes Yes Yes Yes Yes Yes Yes 
Worst VFSS during 
acute episode of ON 
5 5 5 4 6 5 5 
Presence of optic 
nerve head swelling 
on fundoscopy 
Yes No Yes Yes No Yes No 
Presence of 
intrathecal oligoclonal 
bands when CSF 
analysed 
Not done Negative Negative Negative Negative Negative Negative 
Clinical follow-up 
duration (months) 
13 3 36 6 1.5 26 20 
Presence of any 
clinical demyelinating 
relapses 
No No Yes Yes No No Yes 
Total number of 
clinical demyelinating 
episodes  
1 1 3 2 1 1 3 
Subsequent number 
of ON episodes 
0 0 2 1 0 0 2 
Chapter	3:	Radiological	characterisation	of	optic	neuritis	due	to	MOG	antibodies		
	 109	
Length of VFSS 
follow-up after first 
ON episode (months)  
2 3 34 6 1.25 24 18 
Final VFSS at follow-
up 
2 2 2 5 5 2 3 
 
 
 
 
 
 
 
 
 
 
 
Chapter	3:	Radiological	characterisation	of	optic	neuritis	due	to	MOG	antibodies		
	 110	
Following the first episode of ON, most patients commenced de novo therapy (MOG-
ON n=17, AQP4-ON n=7, MS-ON n=10) while those who had previous non ON 
demyelinating episodes switched therapy (MOG-ON n=1, AQP4-ON n=4, MS-ON 
n=3) (Table 3.2).  
 
The nature of the clinical phenotypes of all demyelinating episodes, and treatment 
courses in all the recruited patients are outlined in Table 3.2 below. One MOG-ON 
patient declined therapy. Eight patients (MOG-ON n=1, AQP4-ON n=4, MS-ON n=3) 
had previous demyelinating episodes such as TM, preceding their first episode of ON. 
As detailed in Table 3.2, the one MOG-ON patient had previous treatment with 
pulsed steroids, weaning oral prednisone, and monthly IVIg. The four AQP4-ON 
patients had previous treatment including pulsed steroids (n=4), rituximab (n=4), 
weaning oral prednisone (n=3), plasma exchange (n=3), maintenance mycophenolate 
mofetil (n=3), and maintenance oral steroids (n=2). The three MS patients had pulsed 
steroids (n=2), fingolimod (n=2), dimethyl fumarate (n=1), and glatiramer acetate 
(n=1).  
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Table 3.2 Clinical episodes of demyelination and treatment in ON patients 
 
 
Patient Preceding 
episodes 
Concurrent 
episodes 
with first 
ON episode 
Subsequent 
episodes after 
first ON episode 
Total 
number 
of 
demyelin-
ating 
episodes 
Therapeutic regime 
MOG-ON 1 - - ON (n=4) 5 Acute episodes IV MP, IFN, later changed to RTX with maintenance 
MMF and po prednisone 
MOG-ON 2 - - - 1 First episode IV MP, no ongoing therapy 
MOG-ON 3 - - ON (n=2) 3 Acute episodes IV MP, then weaning po prednisone, no ongoing 
therapy 
MOG-ON 4 - - - 1 Acute episodes IV MP and PE, maintenance with MMF and po 
prednisone 
MOG-ON 5 - - - 1 Acute episode IV MP followed by PE, no ongoing therapy 
MOG-ON 6 - - - 1 No therapy 
MOG-ON 7 - - ON (n=1) 2 Acute episodes IV MP, then weaning po prednisone, no ongoing 
therapy 
MOG-ON 8 - TM (n=1) ON (n=2) 3 Acute episodes IV MP and PE; maintenance with MMF and po  
prednisone 
MOG-ON 9 - - - 1 Acute episode IV MP, then weaning po prednisone, no ongoing 
therapy 
MOG-ON 10 - - - 1 Acute episode IV MP, then weaning po prednisone, no ongoing 
therapy 
MOG-ON 11 - - - 1 Acute episode IV MP, no ongoing therapy 
MOG-ON 12 - - - 1 Acute episode IV MP, then weaning po prednisone, no ongoing 
therapy 
Chapter	3:	Radiological	characterisation	of	optic	neuritis	due	to	MOG	antibodies		
	 112	
Patient Preceding 
episodes 
Concurrent 
episodes 
with first 
ON episode 
Subsequent 
episodes after 
first ON episode 
Total 
number 
of 
demyelin-
ating 
episodes 
Therapeutic regime 
MOG-ON 13 - - - 1 Acute episode IV MP, weaning po prednisone, and IVIg, no ongoing 
therapy 
MOG-ON 14 - - - 1 Acute episode IV MP, then weaning po prednisone, no ongoing 
therapy 
MOG-ON 15 1 TM 
1 ADEM + 
TM 
- - 3 First episode treated with IV MP, weaning po prednisone and IVIg; 
second episode treated with monthly IVIg and weaning po prednisone; 
third episode treated with IV MP and maintenance MMF and po 
prednisone for 2 years, no ongoing therapy currently 
MOG-ON 16 - ADEM (n=1) - 1 Acute episode IV MP, then weaning po prednisone, no ongoing 
therapy 
MOG-ON 17 - - - 1 Acute episode IV MP, then weaning po prednisone, no ongoing 
therapy 
MOG-ON 18 - - ON (n=4) 5 First four episodes treated with IV MP and weaning po prednisone, 
commenced maintenance with MMF and po prednisone after fourth 
episode, MMF ceased as not tolerated; fifth episode treated with IVIg, 
ongoing therapy with po prednisone 
MOG-ON 19 - TM (n=1) - 1 Acute episode IV MP, then weaning po prednisone, maintenance with 
monthly PE 
AQP4-ON 1 - - ON (n=2) 3 Acute episodes IV MP and PE, maintenance with AZT later changed to 
MMF, RTX x 2, maintenance with po prednisone 
AQP4-ON 2 - - ON (n=2) 3 Acute episodes IV MP and PE, maintenance trialed with AZT, RTX, 
maintenance with monthly PE and po prednisone 
AQP4-ON 3 - - ON (n=1) 7 Acute episodes treated with IV or po prednisone +/- PE, AZT trialed as 
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Patient Preceding 
episodes 
Concurrent 
episodes 
with first 
ON episode 
Subsequent 
episodes after 
first ON episode 
Total 
number 
of 
demyelin-
ating 
episodes 
Therapeutic regime 
TM (n=3) 
Brainstem (n=2) 
maintenance and ceased due to pancreatitis, Initial two ON episodes 
treated with po prednisone, then AZT ceased due to pancreatitis, RTX 
x 3, maintenance with MMF and monthly IVIg  
AQP4-ON 4 TM (n=4) - ON (n=1) 6 Acute episodes IV MP +/- PE, RTX x 3, maintenance MMF and po 
prednisone 
AQP4-ON 5 - - ON (n=3) 4 First episode IV MP and PE with maintenance po prednisone and 
monthly IVIg plus MMF; second episode pulsed IV MP added, third 
episode ceased MMF and RTX x 5 with weaning of po prednisone 
AQP4-ON 6 - TM (n=1) TM (n=2) 
Brainstem (n=2) 
5 First episode IV MP and PE, maintenance po prednisone and MMF, 
subsequent TM episode commenced IV MP and RTX x 1, maintenance 
with AZT and po prednisone, lost to follow-up 
AQP4-ON 7 - - TM (n=2) 
TM + ON + 
Brainstem (n=1) 
4 Acute episode IV MP and weaning po prednisone, maintenance with 
monthly IVIg, then RTX x 4   
AQP4-ON 8 - TM (n=1) TM + ON (n=1) 
Brainstem (n=1) 
3 Acute episodes IV MP, weaning po prednisone and IVIg; RTX x 4 
AQP4-ON 9 TM (n=1) - TM (n=1) 3 Acute episodes IV MP and weaning po prednisone plus PE, RTX x 3 
AQP4-ON 10 TM (n=2) - ON (n=2) 
TM (n=3) 
8 Acute episodes IV MP +/- weaning po prednisone and IVIg, 
maintenance with AZT changed to MMF due to leucopenia, RTX x 5 
AQP4-ON 11 TM (n=1) - ON (n=3) 
TM (n=5) 
10 Acute episodes IV MP and weaning po prednisone +/- PE, 
maintenance with po prednisone and AZT later changed to MMF, RTX 
x 3  
MS-ON 1 - - - 1 IFN 
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Patient Preceding 
episodes 
Concurrent 
episodes 
with first 
ON episode 
Subsequent 
episodes after 
first ON episode 
Total 
number 
of 
demyelin-
ating 
episodes 
Therapeutic regime 
MS-ON 2 TM (n=1) - - 2 Acute episode IV MP, then fingolimod 
MS-ON 3 TM (n=1) 
Sensory 
cortical (n=1) 
- - 3 Fingolimod switched to dimethyl fumarate 
MS-ON 4 - - ON (n=2) 
TM (n=1) 
4 Acute episode IV MP, ongoing therapy with IFN changed to 
natalizumab  
MS-ON 5 - - - 1 Acute episode IV MP, maintenance with IFN 
MS-ON 6 - - TM (n=1) 2 IFN 
MS-ON 7 - - ON (n=1) 2 Acute episodes IV MP and weaning po prednisone, no maintenance 
therapy 
MS-ON 8 TM (n=1) - TM (n=1) 3 Acute episodes IV MP,  then glatiramer acetate 
 
 
MS-ON 9   Sensory cortical 
(n=2) 
3 IFN for 17 months, changed to glatiramer acetate for 12 months due to 
liver function derangement, then changed to fingolimod due to 
injection site reactions  
MS-ON 10 - TM + 
brainstem 
(n=1) 
ON (n=3) 
TM (n=2) 
6 Acute episodes IV MP and weaning po prednisone, on third episode 
given IVIg and started on IFN, changed to fingolimod after 10 months 
MS-ON 11 - - - 1 Acute episode IV MP and weaning po prednisone, IVIg, no 
maintenance therapy 
MS-ON 12 - - ON (n=3) 
Brainstem (n=1) 
5 Acute episodes IV MP and weaning po prednisone, trialed IFN (2 
months) and glatiramer acetate (6 months) but did not tolerate, ongoing 
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Patient Preceding 
episodes 
Concurrent 
episodes 
with first 
ON episode 
Subsequent 
episodes after 
first ON episode 
Total 
number 
of 
demyelin-
ating 
episodes 
Therapeutic regime 
therapy with fingolimod 
MS-ON 13 - - - 1 Acute episode IV MP and weaning po prednisone, no maintenance 
therapy 
Unclassified ON 1 - - - 1 Acute episode IV MP, no maintenance therapy 
Unclassified ON 2 - - - 1 Acute episode IV MP, no maintenance therapy 
Unclassified ON 3 - - ON (n=2) 3 Acute episodes IV MP and weaning po prednisone, no maintenance 
therapy 
Unclassified ON 4 - - ON (n=1) 2 Weaning po prednisone 
Unclassified ON 5 - - - 1 Acute episode IV MP and IVIg, weaning po prednisone 
Unclassified ON 6 - - - 1 Acute episode IV MP then weaning po prednisone, no maintenance 
therapy 
Unclassified ON 7 - - ON (n=2) 3 First episode no treatment, second episode weaning po prednisone, 
third episode weaning po prednisone and maintenance  
 
 
AZT: azathioprine; IFN: interferon; IVIg: intravenous immunoglobulin; IV MP: pulsed intravenous methylprednisolone; MMF: mycophenolate 
mofetil; PE: plasma exchange; po prednisone: oral prednisone; RTX: rituximab 
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All patients received a VFSS based on their visual acuity (rated from 0-6) during their 
initial presentation with ON and at latest follow-up.  
 
3.3.2 Radiological characterisation 
 
Neuroradiology assessment was carried out by a neuroradiologist (KP) blinded to 
diagnoses, and the scans were presented in a random order. The neuroradiology 
assessment proforma we used is outlined in Appendix B. All patients had standardised 
imaging including axial T2 weighted and/or fluid attenuated inversion recovery 
(FLAIR) sequences, coronal T2 or FLAIR sequences of the whole brain, and coronal 
sequences with or without axial T2 fat suppressed (FS) sequences. In the majority of 
the patients (47/50), coronal and/or axial T1 weighted FS sequences were performed 
following gadolinium administration. The following radiological parameters were 
assessed with some being incorporated or adapted from previous studies225-227.  
 
1. The assessment of MRI brain abnormalities 
2. The laterality of optic pathway abnormalities (whether optic nerve changes 
including T2 hyperintensity, optic nerve swelling, and/or contrast     
enhancement were unilateral, bilateral, or absent) 
3. The presence of optic nerve T2 hyperintensity (none versus any) 
4. The degree of optic nerve T2 hyperintensity ipsilateral to the maximally 
       affected eye (none, mild, moderate, or severe) as previously described225.  
       Examples of this rating system are outlined in Figure 3.1A-D. 
5. The presence of optic nerve enhancement with gadolinium (none versus any) 
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6. The degree of optic nerve enhancement ipsilateral to the maximally affected    
eye. This was graded using the level of extraocular muscle (EOM) 
enhancement as a reference, as previously described225: 0 none, 1 subtle, 2 
definite but < EOM, 3 definite and ≥ EOM. Examples of this rating system are 
outlined in Figure 3.1E-H. 
7. The presence of optic nerve swelling (when compared to the contralateral 
normal optic nerve in unilateral ON, or an ipsilateral unaffected segment of  
optic nerve in bilateral ON)225 
8. The presence of radiologically visible optic nerve head swelling (that is, optic 
nerve head elevation)  
9. The presence of optic chiasmal involvement 
10. The presence of optic tract involvement 
11. The most affected segment of the optic nerve (retrobulbar, canalicular or 
intracranial) 
12. The extent of optic nerve involvement classified as none, focal, or 
longitudinal. Longitudinal was defined as involving two or more contiguous  
optic nerve segments, with segments comprising anterior orbital, posterior  
orbital, canalicular, or intracranial227. (Figure 3.1I) 
13. The lesion length in the maximally affected eye, measured in millimeters 
(mm). This was calculated by multiplying the slice thickness plus inter-slice  
interval (10% of slice thickness) by the number of coronal sections through 
which the optic nerve changes were visible. 
14.  The lesion extent score out of 12 as adapted from a previous study226. The 
visual pathway was divided into 12 segments (anterior orbital, posterior 
orbital, canalicular, intracranial, chiasmal, and tract segments for each of the 
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left and right optic pathways). The number of segments involved (as 
determined by T2 hyperintensity, optic nerve swelling and/or contrast 
enhancement) were summated. A score of 1 was given for each segment 
affected, such that a maximum lesion extent score of 12 could be reached  
(Figure 3.1I).  
 
Figures were generated using Prism software version 6.0 (GraphPad Software, La 
Jolla, CA) and Adobe Illustrator CS6 (Adobe Systems Incorporated, San Jose, CA). 
 
Figure 3.1 Examples of rating scales used in the neuroradiological assessment of 
ON  
Degree of T2 hyperintensity (A-D) (A) Normal MRI with no T2 hyperintensity (Cor 
T2 FS) (B) Mild T2 hyperintensity on the right optic nerve, and moderate T2 
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hyperintensity on the left optic nerve (arrows) (Cor T2 FS) (C) Moderate T2 
hyperintensity bilaterally (arrows) (Cor T2 FS) (D) Severe T2 hyperintensity 
bilaterally (arrows) (Cor T2 FS TSE)  
Degree of optic nerve enhancement (E-H) (E) Normal MRI with no optic nerve 
enhancement (Cor T1 FS + C) (F) Subtle optic nerve enhancement particularly noted 
on the left optic nerve (arrow) – Grade 1 (Cor T1 FS + C) (G) Optic nerve 
enhancement less than that of extraocular muscles bilaterally (arrows) – Grade 2 (Cor 
T1 FS SE + C) (H) Optic nerve enhancement equal or greater than that of extraocular 
muscles bilaterally (arrows), particularly notable on right – Grade 3 (Cor T1 FS SE + 
C). (I) The division of the visual pathway into 12 segments to permit calculation of 
the lesion extent score.  
Cor: coronal; FS: fat suppressed; SE: spin echo; TSE: turbo spin echo; + C: with 
gadolinium contrast 
 
 
 
3.3.3 Standard protocol approval and patient consent 
 
Ethics approval for this study was granted by the Sydney Children’s Network and 
Westmead Hospital Human Ethics Committees (12/SCHN/395, 
SSA/13/WMEAD/53), as well as the ethics committees for participating hospitals. 
Informed consent was obtained from all patients and the research protocol was 
approved as per local committee requirements. 
 
3.3.4 Statistical analyses 
 
Statistical analyses were performed using SAS 9.3. Chi-square and Kruskal-Wallis 
tests were used to compare clinical characteristics between diagnostic groups. All 
categorical radiological variables were described by frequencies and percentages 
overall and within diagnostic groups, and compared between diagnostic groups using 
exact chi squared tests calculated using Monte Carlo estimates. Continuous 
radiological variables were described by median and interquartile ranges overall and 
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within diagnostic groups, and compared between diagnostic groups using Kruskal-
Wallis tests.  
 
P-values are presented without adjustment for multiple statistical comparisons. This is 
a descriptive study and no pre-specified significance level has been set for hypothesis 
testing. Due to the large number of tests performed the significance level used 
to categorise any individual p-value as “significant” or not should be 0.002 using a 
Bonferroni correction to maintain an overall type I error rate of 5%. 
 
A further analysis categorised patients as either antibody-positive (MOG and AQ4 
antibody-positive) or MS patients. Univariable chi-square analyses and Kruskal-
Wallis tests compared each radiological predictor between these two groups. 
Predictors with P values < 0.1 were included in a multivariable logistic regression 
using backward variable selection to identify independent predictors of an antibody-
positive diagnosis. 
 
3.4 RESULTS 
 
3.4.1 Clinical comparison 
 
The clinical comparison in ON due to all three diagnoses is summarised in Table 3.3.  
The age at onset between diagnostic groups was similar with the mean age of onset in 
the third decade of life, reflecting recruitment from both paediatric and adult 
neuroimmunology referral clinics. Previous demyelinating episodes occurred in 1/19 
MOG-ON patients, 5/11 AQP4-ON, and 3/13 MS-ON patients. Previous, concurrent, 
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and subsequent clinical associations are described in Table 3.2. MOG-ON and AQP4-
ON patients were more likely to have severe visual impairment at acute presentation 
with some patients scoring a maximum VFSS of 6 (MOG-ON n=8, AQP4-ON n=6) 
(Figure 3.2). In contrast, only 1 MS patient had a VFSS of 6 acutely. The majority of 
MOG-ON patients (15/19, 79%) had optic nerve head swelling visible on fundoscopy 
while this was only present in a minority of AQP4-ON and MS-ON patients. While 
6/8 (75%) of MS-ON patients tested had intrathecal oligoclonal bands, this was less 
common in the antibody-associated patients (Table 3.3). All AQP4-ON patients had 
relapses, and a larger number of total clinical demyelinating episodes compared to 
MOG-ON and MS-ON patients. 
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Table 3.3 The clinical comparison of ON acutely and at follow up in patients with   
                 MOG-ON, AQP4-ON, and MS-ON.  
 
Clinical variable 
assessed 
MOG-ON 
(n=19) 
AQP4-ON 
(n=11) 
MS-ON 
(n=13) 
P value1 
Gender  
number of females 
(%) 
15/19 (79%) 
(57-91%)2 
9/11 (82%) 
(52-95%) 
12/13 (92%) 
(67-99%) 
P=0.59 
Age at onset  
mean; median 
(range) in years 
20; 14 (3-55) 
(13-28) 
23; 14 (8-58) 
(11-35) 
29; 29 (12-45) 
(21-37) 
P=0.11 
Number of patients 
for whom the ON 
episode was the first 
demyelinating event 
number (%) 
18/19 (95%) 
(75-99%) 
6/11 (55%) 
(28-79%) 
10/13 (77%) 
(50-92%) 
P=0.033 
Worst VFSS during 
acute episode of ON 
mean; median 
(range) 
4.8; 5 (2-6) 
(4.2-5.5) 
5.4; 6 (4-6) 
(4.8-5.9) 
3.7; 4 (2-6) 
(2.9-4.5) 
P=0.0054 
Presence of optic 
nerve head swelling 
on fundoscopy 
number (%) 
15/19 (79%) 
(57-91%) 
3/11 (27%) 
(10-57%) 
2/13 (15%) 
(4-42%) 
P=0.0006 
Presence of 
intrathecal 
oligoclonal bands 
when CSF analysed 
number (%) 
1/15 (7%) 
(1-30%) 
3/8 (38%) 
(14-69%) 
6/8 (75%) 
(41-93%) 
P=0.018 
Clinical follow-up 
duration (months) 
mean; median 
(range) 
30; 18 (0.17-
75) 
(18-42) 
37; 32 (5-102) 
(19-56) 
51; 44 (13-
156) 
(29-72) 
P=0.13 
Presence of any 
clinical 
demyelinating 
relapses 
number (%) 
6/19 (32%) 
(15-54%) 
11/11 (100%) 
(74-100%) 
9/13 (69%) 
(42-87%) 
P=0.0008 
Total number of 
clinical 
demyelinating 
episodes  
mean; median 
(range) 
1.8; 1 (1-5) 
(1.1-2.4) 
5; 4 (3-10) 
(3.5-6.7) 
2.6; 2 (1-6) 
(1.6-3.6) 
P=0.0002 
Subsequent number 
of ON episodes 
mean; median 
(range) 
0.68; 0 (0-4) 
(0.04-1.33) 
1.45; 1 (0-3) 
(0.76-2.15) 
0.69; 0 (0-3) 
(0-1.41) 
P=0.042 
Length of VFSS 
follow-up after first 
19; 9 (0.13-
75) 
37; 26 (12-102) 
(19-55) 
36; 31 (6-120) 
(16-55) 
P=0.015 
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ON episode 
(months) 
mean; median 
(range)  
(8-30) 
Final VFSS at 
follow-up 
mean; median 
(range) 
1.4; 1 (0-5) 
(0.6-2.1) 
2.2; 1 (0-6) 
(0.4-4.0) 
0.6; 0 (0-2) 
(0.03-1.2) 
P=0.25 
 
1 The P values for all categorical variables were determined using chi squared 
tests. The P values for all continuous variables were determined using 
Kruskal-Wallis tests. 
 
2 The 95% confidence intervals for all categorical variables and the 95% 
confidence limits for all continuous variables are listed in each cell within 
brackets and italicised 
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Figure 3.2 VFSS at acute presentation and at latest clinical follow-up in patients 
with MOG-ON, AQP4-ON and MS-ON (A) VFSS during acute presentation for 
MOG-ON patients (B) VFSS at latest clinical follow-up for MOG-ON patients (C) 
VFSS during acute presentation for AQP4-ON patients (D) VFSS at latest clinical 
follow-up for AQP4-ON. Three AQP4-ON patients have severe and sustained visual 
impairment with a VFSS of 6. (E) VFSS during acute presentation for MS-ON 
patients (F) VFSS at latest clinical follow-up for MS-ON patients. All thirteen MS-
ON patients had a follow-up VFSS of 0 or 1, demonstrating an excellent recovery 
from their initial episode of ON.  
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3.4.2 Blinded neuroradiological review 
 
Examples of characteristic radiological findings in ON due to all three diagnoses are 
depicted in Figures 3.3, 3.4 and 3.5, and these comparisons are highlighted in Table 
3.4 and Figure 3.6.  
 
Table 3.4   The radiological comparison of ON in patients with MOG-ON,  
AQP4-ON, and MS-ON.  
 
Radiological variable 
assessed 
MOG-ON 
(n=19) 
AQP4-ON 
(n=11) 
MS-ON 
(n=13) 
P value1 
Presence of brain 
abnormalities on MRI 
number (%) 
7/19 (37%) 
(19-59%)2 
9/11 (82%) 
(52-95%) 
12/13 
(92%) 
(67-99%) 
P=0.0019 
Presence of radiological 
bilateral ON 
number (%) 
16/19 
(84%) 
(62-94%) 
9/11 (82%) 
(52-95%) 
3/13 (23%) 
(8-50%) 
P=0.00123 
Presence of T2 
hyperintensity  
number (%) 
19/19 
(100%) 
(83-100%) 
11/11 
(100%) 
(74-100%) 
8/13 (62%) 
(36-82%) 
P=0.0023 
Degree of 
optic nerve 
T2 
hyperintensity 
in maximally 
affected eye4 
number (%) 
None 0/19 (0%) 
(0-17%) 
0/11 (0%) 
(0-26%) 
5/13 (38%) 
(18-64%) 
P=0.0044 
Mild 5/19 (26%) 
(12-49%) 
2/11 (18%) 
(5-48%) 
5/13 (38%) 
(18-64%) 
Moderate 12/19 
(63%) 
(41-81%) 
6/11 (55%) 
(28-79%) 
2/13 (15%) 
(4-42%) 
Severe 2/19 (11%) 
(3-31%) 
3/11 (27%) 
(10-57%) 
1/13 (8%) 
(1-33%) 
Presence of optic nerve 
gadolinium enhancement 
(number; %) 
17/18 
(94%) 
(74-99%) 
10/10 
(100%) 
(72-100%) 
9/12 (75%) 
(47-91%) 
P=0.14 
Degree of 
optic nerve 
enhancement 
in maximally 
affected eye5 
number (%) 
None 1/18 (6%) 
(1-26%) 
0/10 (0%) 
(0-28%) 
3/12 (25%) 
(9-53%) 
P=0.13 
Grade 1 3/18 (17%) 
(6-39%) 
0/10 (0%) 
(0-28%) 
2/12 (17%) 
(5-45%) 
Grade 2 3/18 (17%) 
(6-39%) 
2/10 (20%) 
(6-51%) 
4/12 (33%) 
(14-61%) 
Grade 3 11/18 
(61%) 
(39-80%) 
8/10 (80%) 
(49-94%) 
3/12 (25%) 
(9-53%) 
Presence of optic nerve 
swelling 
number (%) 
17/19; 89% 
(69-97%) 
11/11; 
100% 
(74-100%) 
9/13; 69% 
(42-87%) 
P=0.077 
Presence of radiological 10/19 1/11 (9%) 0/13 (0%) P=0.0003 
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Radiological variable 
assessed 
MOG-ON 
(n=19) 
AQP4-ON 
(n=11) 
MS-ON 
(n=13) 
P value1 
optic nerve head swelling 
number (%) 
(53%) 
(32-73%) 
(2-38%) (0-23%) 
Chiasmal involvement 
number (%) 
1/19; 5% 
(1-25%) 
7/11; 64% 
(35-85%) 
2/13; 15% 
(4-42%) 
P=0.0009 
Presence of bilateral optic 
tract involvement 
number (%) 
0/19 (0%) 
(0-17%) 
5/11; 45% 
(21-72%) 
0/13; 0% 
(0-23%) 
P=0.00053 
The most 
affected 
segment of 
the optic 
nerve 
number (%) 
None 0/19 (0%) 
(0-17%) 
0/11 (0%) 
(0-26%) 
3/13 (23%) 
8-50%) 
P=0.0078 
Retrobulbar 10/19 
(53%) 
(32-73%) 
3/11 (27%) 
(10-57%) 
3/13 (23%) 
(8-50%) 
Canalicular 3/19 (16%) 
(6-38%) 
1/11 (9%) 
(2-38%) 
5/13 (38%) 
(18-64%) 
Intracranial 6/19 (32%) 
(15-54%) 
7/11 (64%) 
(35-85%) 
2/13 (15%) 
(4-42%) 
Presence of 
focal vs 
longitudinal 
optic nerve 
involvement 
number (%) 
No 
involvement 
0/19 (0%) 
(0-17%) 
0/11 (0%) 
(0-26%) 
3/13 (23%) 
(8-50%) 
P=0.0077 
Focal 1/19 (5%) 
(1-25%) 
0/11 (0%) 
(0-26%) 
3/13 (23%) 
(8-50%) 
Longitudinal 18/19 
(95%) 
(75-99%) 
11/11 
(100%) 
(74-100%) 
7/13 (54%) 
(29-77%) 
Optic nerve lesion length 
(mm) in maximally affected 
eye  
(median, interquartile range) 
Median 
23.1 
Interquartile 
range  
18-33 
(20-29) 
 
Median 
23.1 
Interquartile 
range  
16.5-26.5  
(18-29) 
 
Median 9.9 
Interquartile 
range  
6.6-19.8 
(6-21) 
 
P=0.016 
Lesion extent score out of 12 
(median, interquartile range) 
Median 4 
Interquartile 
range 3-7 
(3.6-5.9) 
 
Median 6 
Interquartile 
range 4-9 
(4.7-8.6) 
 
Median 2 
Interquartile 
range 1-3 
(1.1-3.5) 
 
P=0.0008 
 
1 The P values for all categorical variables were determined using exact chi 
squared tests. The P values for all continuous variables were determined using 
Kruskal-Wallis tests. 
2 The 95% confidence intervals for all categorical variables and the 95% 
confidence limits for all continuous variables are listed in each cell within 
brackets and italicised 
3 P value is derived from chi squared test of a 3x3 table 
(none/unilateral/bilateral involvement versus diagnostic groups) 
4 The degree of optic nerve T2 hyperintensity ipsilateral to the maximally 
affected eye (none, mild, moderate, or severe); elaborated on in Section 3.3.2 
5 The degree of optic nerve enhancement ipsilateral to the maximally affected 
eye was graded using the level of EOM enhancement as a reference. 0 none, 1 
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subtle, 2 definite but < EOM, 3 definite and ≥ EOM; elaborated on in Section 
3.3.2 
 
 
Figure 3.3 Examples of radiological characteristics in ON associated with MOG 
antibodies, AQP4 antibodies, and MS  
Presence of MRI brain abnormalities: (A-D) (A) Normal MRI (Ax T2 TSE) (B) No 
brain changes in a MOG-ON patient (Ax T2 TSE) (C) Bilateral thalamic and 
hypothalamic (arrow) changes in an AQP4-ON patient (Ax T2) (D) Typical white 
matter periventricular hyperintensities in an MS-ON patient (Ax T2 FLAIR)   
T2 hyperintensity and laterality: (E-H) (E) Normal optic nerves (arrows) (Cor T2 
FS) (F) Bilateral optic nerve T2 hyperintensity (arrows) in a MOG-ON patient (Cor 
T2 FS TSE) (G) Bilateral optic nerve T2 hyperintensity (arrows) in an AQP4-ON 
patient (Cor T2 FS) (H) Unilateral right optic nerve T2 hyperintensity (arrow) in an 
MS-ON patient (Cor T2 FS)  
Optic nerve enhancement: (I-L) (I) Normal optic nerves (arrows) (Cor T1 FS + C) 
(J) Bilateral retrobulbar optic nerve enhancement and swelling (arrows) in a MOG-
ON patient (Cor T1 FS + C) (K) Bilateral intracanalicular optic nerve enhancement 
(arrows) in an AQP4-ON patient (Cor T1 FS + C) (L) Unilateral retrobulbar left optic 
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nerve enhancement (arrow) in an MS-ON patient (Cor T1 FS + C)  
Optic nerve swelling: (M-P) (M) Normal optic nerves (arrows) (Cor T2 FS) (N) 
Bilateral optic nerve swelling (arrows) in a MOG-ON patient (Cor T2 FS) (O) 
Bilateral optic nerve swelling (arrows) in an AQP4-ON patient (Cor T2 FS) (P) 
Unilateral left optic nerve swelling (arrow) in an MS-ON patient (Cor T2 FS). 
Ax: axial; Cor: coronal; FLAIR: fluid attenuated inversion recovery; FS: fat 
suppressed; TSE: turbo spin echo; + C: with gadolinium contrast 
 
Brain lesions were present in a minority of MOG-ON patients but in the majority of 
AQP4-ON and MS-ON patients (Table 3.4, Figure 3.3A-D). The brain changes in 
MOG-ON patients were not typical of those seen in MS-ON, with some patients 
exhibiting large enhancing tumefactive lesions, or multiple areas of cortical and 
subcortical T2 hyperintensity (Figure 3.4A-C). Hypothalamic involvement was more 
common in AQP4-ON patients (3/11, 27%) compared to MOG-ON (2/19, 11%) or 
MS-ON patients (1/13, 8%) (Figure 3.3C, Figure 3.4D-F). At the time of first episode 
ON, brain MRIs fulfilled revised McDonald criteria67 with radiological evidence of 
dissemination in space and time in 2/19 (11%) MOG-ON patients, 0/11 (0%) AQP4-
ON patients, and 2/13 (15%) MS-ON patients. 
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Figure 3.4 MRI brain abnormalities in patients with ON due to MOG antibodies, 
AQP4 antibodies, and MS (A-C) MRI brain abnormalities in three patients with 
MOG-ON (A) large tumefactive lesions (Ax T2 FLAIR FS) which also demonstrated 
gadolinium enhancement (B) Multiple regions of cortical and subcortical T2 
hyperintensity (Cor T2 FLAIR) (C) Left globus pallidus and right external 
capsule/claustrum T2 hyperintensity (Ax T2) (D-F) MRI brain abnormalities in three 
patients with AQP4-ON (D) T2 hyperintensity involving the hypothalamus and optic 
tracts (Ax T2 FLAIR) (E) T2 hyperintensity involving the thalami bilaterally 
(arrows), as well as the hypothalamus and periaqueductal regions (Ax T2) (F) T2 
hyperintensity involving periventricular regions bilaterally (AX T2 FLAIR) (G-I) 
MRI brain abnormalities in three patients with MS-ON (G) T2 hyperintensity 
involving the cortical and subcortical regions as well as corpus callosum, typical of 
MS (Sag T2 FLAIR) (H) Multiple areas of periventricular T2 white matter 
hyperintensity, typical of MS (Ax T2 FLAIR) (I) T2 white matter hyperintensity 
involving the corpus callosum and cerebellum, typical of MS (Sag T2 FLAIR).  
Ax: axial; Cor: coronal; FLAIR: fluid attenuated inversion recovery; FS: fat 
suppressed; Sag: sagittal 
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Radiological bilateral ON was present in the majority of patients with MOG-ON and 
AQP4-ON compared to a minority of patients with MS-ON (Table 3.4, Figure 3.3E-
H). The majority of MS patients had unilateral ON. There were no radiological optic 
nerve changes in three MS patients, despite clinically unilateral ON. 
 
Optic nerve T2 hyperintensity was present in all patients with MOG-ON and AQP4-
ON, and in 8/12 (62%) of patients with MS-ON (Table 3.4, Figure 3.3E-H). The 
degree of optic nerve T2 hyperintensity in the maximally affected eye was moderate 
in most patients with MOG-ON and AQP4-ON, but in most MS-ON patients was 
either absent or mild (Table 3.4, methodology described in Section 3.3.2). There was 
no association between the presence and degree of optic nerve enhancement, or the 
presence of optic nerve swelling between diagnostic groups (Table 3.4, Figure 3.3I-
P). 
 
Optic nerve head swelling was radiologically visible in over half of the MOG-ON 
patients, whereas only one AQP4-ON patient and none of the MS-ON patients had 
optic nerve head swelling (Table 3.4, Figure 3.5A-D). APQ4-ON patients were more 
likely to show involvement of the optic chiasm compared to the other diagnostic 
groups (Table 3.4, Figure 3.5E-H). Bilateral optic tract involvement was noted in 
almost half the AQP4-ON patients, and in none of the MOG-ON or MS-ON patients 
(Table 3.4, Figure 3.5I-L). 
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Figure 3.5 Further examples of radiological characteristics in ON associated with 
MOG antibodies, AQP4 antibodies, and MS  
Optic nerve head swelling: (A-D) (A) normal MRI (Ax T2 FS) (B) Bilateral optic 
nerve head swelling (black arrows) visible in a MOG-ON patient (Ax T2 FS) (C) 
Absent optic nerve head swelling in an AQP4-ON patient (Ax T2) (D) Absent optic 
nerve head swelling in an MS-ON patient (Ax T2 FS)  
Optic chiasmal involvement: (E-H) (E) Normal MRI (Cor T2 FS) (F) No chiasmal 
involvement in a MOG-ON patient (Cor T2 FS TSE) (G) Chiasmal involvement 
(arrow) in an AQP4-ON patient (Cor T2 FS)  (H) No chiasmal involvement in an MS-
ON patient (Cor T2 FS)  
Optic tract involvement: (I-L) (I) Normal MRI (Cor T2 FS) (J) No optic tract 
changes in a MOG-ON patient (Cor T2 FS) (K) Bilateral optic tract involvement with 
T2 hyperintensity (arrows) in an AQP4-ON patient (Cor T2 FS) (L) No optic tract 
changes in an MS-ON patient (Cor T2 FS)  
Extent of optic nerve involvement: (M-P) (M) Normal MRI (Ax T2 FS) (N) 
Bilateral longitudinally extensive optic nerve involvement (arrows) in a MOG-ON 
patient (Ax T2 FS TSE) (O) Bilateral longitudinally extensive optic nerve 
involvement (arrows) in an AQP4-ON patient (Ax T2 FS) (P) Unilateral focal 
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involvement (arrow) in an MS-ON patient with focal enhancement of the 
intracanalicular portion of the left optic nerve visible (Ax T1 FS + C).  
Ax: axial; Cor: coronal; FS: fat suppressed; TSE: turbo spin echo; + C: with 
gadolinium contrast 
 
When assessing the most affected segment of the optic nerve, more than half of the 
MOG-ON patients had retrobulbar ON. In contrast, the majority of AQP4-ON 
patients had involvement of the intracranial portion of the optic nerve (Table 3.4).  
 
The majority of MOG-ON and AQP4-ON patients exhibited longitudinally extensive 
ON, compared to about half of the MS-ON patients (Table 3.4, Figure 3.5M-P). When 
looking specifically at lesion length, both MOG-ON and AQP4-ON patients had 
longer segment involvement of the optic nerve than MS-ON patients (Table 3.4). 
Likewise, the lesion extent score out of 12 was longer in MOG-ON and AQP4-ON 
patients when compared to MS-ON patients (Table 3.4). None of the MS-ON patients 
had a lesion extent score greater than 6, while this was noted frequently in the MOG-
ON (n=6/19, 32%) and AQP4-ON (n=5/11, 45%) patients. The main radiological 
differences between the diagnostic groups are presented in Figure 3.6. 
 
Using multivariable logistical regression analysis to compare autoantibody-associated 
ON (MOG or AQP4) with MS-ON, backward selection removed all predictors with 
the exception of brain abnormalities on MRI (OR 0.013, 95% CI <0.001-0.306), and 
the lesion extent score (OR 2.8, 95% CI 1.37-5.65 per unit increase in lesion extent 
score). The resulting model had an area under the ROC curve of 0.94 (95% CI: 0.88 – 
1.0) indicating that the combination of these two predictors showed a good ability to 
discriminate between antibody-associated ON and MS-ON. 
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Figure 3.6 The radiological characteristics and visual outcomes of ON 
associated with MOG antibodies, AQP4 antibodies, and MS (A) The majority of 
patients with AQP4-ON and MS-ON exhibited MRI brain changes compared to a 
minority of patients with MOG-ON. (B) Both MOG-ON and AQP4-ON was 
bilateral in the majority of patients, while most MS-ON patients had unilateral ON. 
(C) Optic nerve head swelling was seen in over half the MOG-ON patients, was rare 
in AQP4-ON patients, and absent in MS-ON. (D) Chiasmal involvement was seen in 
the majority of AQP4-ON patients and infrequent in MOG-ON and MS-ON patients. 
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(E) Bilateral optic tract involvement was exclusively seen in the AQP4-ON group. 
(F) While most patients with MOG-ON had retrobulbar ON, the intracranial portion 
of the optic nerve was more frequently affected in AQP4-ON patients. (G) The 
majority of MOG-ON and all of the AQP4-ON patients had longitudinal optic nerve 
involvement. (H) VFSS for MOG-ON patients at the time of acute presentation and 
at latest follow-up demonstrate that most patients experienced an improvement in 
visual acuity at follow-up, with only one patient having a follow-up VFSS of greater 
than or equal to 5. (I) VFSS for AQP4-ON patients at the time of acute presentation 
and at latest follow-up show that while many patients experienced an improvement 
in visual acuity, 3/11 still had sustained severe visual impairment with a VFSS of 6. 
(J) VFSS for MS-ON patients at the time of acute presentation and at latest follow-
up demonstrate that all 13 patients had a good visual outcome with a follow-up score 
of less than or equal to 1.  
 
3.4.3 Unclassified ON patients 
 
The radiological characterisation of the 7 unclassified ON patients are outlined in 
Table 3.5. They were not included in the statistical comparisons as it was felt their 
clinical and radiological phenotype was heterogenous, and likely reflected diverse 
aetiologies. 
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Table 3.5 The radiological characterisation of patients with unclassified ON 
 
 
Radiological 
variable assessed 
Unclassified 
ON 1 
Unclassified 
ON 2 
Unclassified 
ON 3 
Unclassified 
ON 4 
Unclassified 
ON 5 
Unclassified 
ON 6 
Unclassified 
ON 7 
Presence of brain 
abnormalities on MRI 
Normal Abnormal Normal Normal Normal Normal Normal 
Presence of 
radiological bilateral 
ON 
Bilateral Unilateral Unilateral Unilateral Bilateral Bilateral Bilateral 
Presence of T2 
hyperintensity 
Not done Present Present Present Present Present Absent 
Degree of optic nerve 
T2 hyperintensity in 
maximally affected 
eye 
Not done Moderate Severe Mild Moderate Moderate None 
Presence of optic 
nerve gadolinium 
enhancement 
Present Present Present Absent Present Absent Absent 
Degree of optic nerve 
enhancement in 
maximally affected 
eye 
Grade 3 Grade 3 Grade 3 None Grade 1 None None 
Presence of optic 
nerve swelling 
Present Present Present Absent Present Present Absent 
Presence of 
radiological optic 
nerve head swelling 
Present Absent Present Absent Absent Present Absent 
Chiasmal No No No No Yes No No 
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involvement 
Presence of bilateral 
optic tract 
involvement 
No No No No Yes No No 
The most affected 
segment of the optic 
nerve 
Retrobulbar Canalicular Intracranial Canalicular Retrobulbar Retrobulbar Retrobulbar 
Presence of focal vs 
longitudinal optic 
nerve involvement 
Longitudinal Longitudinal Longitudinal Focal Longitudinal Longitudinal None 
Optic nerve lesion 
length (mm) in 
maximally affected 
eye 
29.7 23.1 29.7 6.6 33 33 None 
Lesion extent score 
out of 12 
5 3 4 1 12 6 0 
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3.4.4 Subsequent course and outcome 
 
At latest clinical follow up, patients with AQP4-ON were more likely to have clinical 
relapses, more total demyelinating episodes, and more subsequent ON episodes, 
compared to MOG-ON or MS-ON patients (Table 3.3). While 9/13 MS-ON patients 
had clinical relapses, the remainder of the MS-ON patients had radiological relapses 
during their subsequent follow-up. The presence of severe and sustained visual 
impairment was mainly evident in the AQP4-ON group, with 3/11 patients still 
scoring a VFSS of 6 on follow up (Figure 3.2). In contrast, none of the MOG-ON or 
MS-ON patients had a VFSS of 6 on follow-up. In fact, 100% of MS-ON patients 
(13/13) had a VFSS of 0 or 1, revealing an excellent visual outcome in this group 
compared to the antibody-associated ON patients (Figure 3.6H-J and Figure 3.2). 
 
3.5 DISCUSSION 
 
With blinded neuroradiology assessment, we found that specific radiological 
parameters in ON were more suggestive of particular demyelinating entities. In 
particular, MOG-ON and AQP4-ON were strongly associated with bilateral and 
longitudinally extensive ON, in contrast to MS-ON, which was more frequently 
unilateral with shorter segment optic nerve involvement. While some overlap does 
exist, the majority of patients with MOG-ON had more anterior optic pathway 
involvement with significant optic nerve head swelling visible both clinically on 
fundoscopy, and radiologically, and the retrobulbar segment of the optic nerve most 
commonly affected. The presence of radiological optic nerve head swelling in 
particular was significant and highly suggestive of MOG-ON. Although fundoscopy 
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and OCT are more standard ways to evaluate the optic nerve head, this radiological 
feature should be reported when present. In contrast, the majority of patients with 
AQP4-ON had posterior optic pathway involvement with the intracranial segment of 
the optic nerve most affected, in addition to chiasmal and optic tract involvement. 
Posterior optic pathway involvement should thus raise clinical suspicion for AQP4-
ON. The combination of two radiological predictors, the absence of MRI brain 
abnormalities, and a higher lesion extent score, showed a good ability to predict an 
antibody-positive diagnosis compared to a diagnosis of MS. 
 
While the retrospective design of this study, the potential treatment effect of steroids, 
the relatively small number of MS patients as a control group due to the stringent 
inclusion criteria, and the caveats associated with multivariate logistic regression 
when the sample number is less than 100 are limitations, this is the first attempt to 
define and compare the radiological characterisation of first episode ON in patients 
with MOG antibodies, AQP4 antibodies, and MS. Further studies are required to 
determine if our observations are reproducible. These findings would be important to 
expedite clinical diagnosis and guide the implementation of the appropriate 
therapeutic regimes. It would be of interest for future studies to evaluate the impact of 
previous immunotherapy on the radiological findings of ON we describe.  
 
In addition, early differentiation between the aetiologies of demyelinating ON may 
have prognostic significance. While broader disability scores such as the EDSS were 
outside the scope of this study, evaluation of visual outcomes between the diagnostic 
groups in this study showed that AQP4-ON patients had a tendency to more relapses 
including ON episodes, as well as more severe and sustained visual impairment at 
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latest clinical follow-up than MOG-ON and MS-ON patients. This may suggest 
differences in pathogenic mechanisms. Studies demonstrating MOG antibody 
pathogenicity are limited and while there is evidence of both complement-mediated 
and cell-mediated mechanisms, a few have suggested that more reversible 
mechanisms may be associated with MOG antibodies compared to AQP4 
antibodies229.  Long-term outcomes and prognoses in relapsing MOG antibody-
positive patients are explored further in Chapter 4.	
 
Taken together, our findings demonstrate discriminating radiological findings, with 
MOG and AQP4 antibody-associated ON more frequently resulting in bilateral and 
longitudinally extensive ON. MOG antibodies are more likely to be associated with 
anterior visual pathway involvement, while AQP4 antibodies are more commonly 
associated with posterior visual pathway involvement. This radiological 
characterisation may assist with an expedited diagnosis, appropriate institution of 
immunotherapy, and have prognostic implications on visual outcomes. 
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Riney K, Rodriguez-Casero V, Ryan MM, Scheffer IE, Shuey N, Spooner CG, 
Subramanian GM, Tea F, Thomas T, Thompson J, Troedson C, Ware TL, 
Webster RI, Yiannikas C, Yiu EM, Zou A. 
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4.1 SUMMARY OF CHAPTER 4 
 
As outlined in chapters 2 and 3, MOG antibodies are strongly associated with ON, 
and have distinct radiological characteristics distinguishing this clinical condition 
from other demyelinating aetiologies including MS and AQP4 antibody-positive 
NMOSD. Based on the referral of samples to our research group, we identified that a 
significant proportion of patients with MOG antibodies had a relapsing clinical 
course.  While the steroid sensitivity of these patients was noted in our initial study 
(Chapter 2.4.3.2), we identified this warranted closer scrutiny with larger patient 
numbers. Additionally, the response of MOG antibody-positive patients to other 
immunosuppressive therapeutic agents was unknown and long-term follow up data on 
these patients was not available. The work covered in this chapter is inclusive of a 
publication (Ramanathan et al 2017) currently submitted and under review, and 
explores the clinical course, therapeutic responses, and outcomes in a cohort of 
paediatric and adult patients with relapsing MOG antibody-associated demyelination. 
 
4.2 ESTABLISHMENT OF THE AUSTRALASIAN AND NEW ZEALAND 
MOG STUDY GROUP  
 
Our research team, the Brain Autoimmunity Group based at the Institute For 
Neuroscience and Muscle Research at The Children’s Hospital at Westmead, was 
previously dedicated to testing and researching paediatric patients for CNS antibody-
mediated disorders. Subsequent to patient recruitment for the study outlined in 
Chapter 2.4, I initiated a service provided by our research team as the sole provider 
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for flow cytometry live cell based assays to detect MOG antibodies in adults with 
demyelination in Australasia. Since this development in 2013, we have received over 
1500 adult serum and CSF samples and diagnosed over 150 MOG antibody-positive 
adults. Our research team has additionally identified over 150 MOG antibody-positive 
children, and receives in total over 1000 samples (both paediatric and adult) for 
testing each year. In accordance with our increasing service provision, and identifying 
that the opportunity existed for a unique collaborative platform, in 2016 I established 
and now lead the Australasian and New Zealand MOG Study Group. This includes 
over 100 paediatric and adult neurologists from 46 centres throughout Australasia and 
New Zealand [New South Wales (n=18), Queensland (n=8), Victoria (n=5), South 
Australia (n=3), Australian Capital Territory (n=2), Western Australia (n=2), 
Tasmania (n=2), Northern Territory (n=1)], New Zealand (n=3), and Singapore 
(n=2)]. The serum and CSF samples provided on patients with a suspected antibody-
mediated demyelination syndrome are biobanked and constitute a powerful resource 
for further research incorporating this cohort of patients, and exploring pathogenic 
mechanisms of action of these antibodies.  
 
The work outlined in this chapter and currently under review is the first publication 
based on the collaborative efforts of some of the participating centres of the 
Australasian and New Zealand MOG Study Group. 
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4.3 INTRODUCTION 
 
Accurate diagnosis of the demyelinating aetiology is essential as treatment options 
vary between MS and NMOSD. While MS may be treated with disease modifying 
therapy, some agents used in MS such as interferon, natalizumab, and fingolimod, 
have been shown to have possible detrimental impacts on outcome in AQP4 antibody-
positive disease95-97. 
 
AQP4 antibody-positive demyelination, in contrast to MS, is often treated with 
immunotherapy including intravenous and/or oral steroids, IVIg, and/or plasma 
exchange; chronic immunosuppressive therapy such as mycophenolate or 
azathioprine; or rituximab or cyclophosphamide97. Treatment with azathioprine, 
mycophenolate, and rituximab have all been shown to reduce relapse rate in AQP4 
antibody-positive NMOSD, but azathioprine was shown to have a higher failure rate, 
and rituximab was identified as being effective in reducing severe relapses98, 100, with 
switching therapy and/or escalation of therapy in the presence of treatment failure also 
shown to improve outcomes98, 99. The efficacy of relapse prevention with rituximab in 
NMOSD has been demonstrated in both children and adults98, 100, 230. 
 
While some early studies identifying MOG antibody-positive demyelination 
suggested this is predominantly a monophasic disease202, 210, 231, other centers158, 232 
including ours share the experience that there is a definite relapsing subgroup. 
Patients with MOG antibodies have been identified as having a more favorable 
prognosis to AQP4 antibody-positive NMOSD202, 210, 231, 233, 234, however, we have 
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increasingly recognised that a subset of patients with MOG antibodies may have 
significant residual deficits, highlighting the importance of early recognition, and 
appropriate institution of immunotherapy. At present, the efficacy of specific 
immunosuppressive agents in MOG antibody-associated demyelination has not been 
systematically studied and therapeutic data is lacking. Herein, we provide the first 
study to evaluate the response to specific immunotherapies in the largest cohort of 
patients with relapsing MOG antibody-associated demyelination to date. 
 
4.4 METHODS 
 
4.4.1 Study design, patient recruitment, and MOG antibody testing 
 
Patients were classified as paediatric (≤16) or adult (>16) based on age at disease 
onset. All serum samples were tested for MOG antibodies in a single center using a 
flow cytometry live cell based assay as previously described (Chapter 2.4.2.5). We 
identified 61 patients with relapsing demyelination (≥2 episodes) for whom detailed 
clinical information was available, from neurology, neuroimmunology, and neuro-
ophthalmology clinics in 25 centers in Australasia (Australia n=22, New Zealand n=2, 
Singapore n=1). An acute episode was defined as a new neurological deficit lasting at 
least 24 hours99. A relapse was any new CNS symptom or sign lasting > 24 hours in 
the absence of other causes, and supported clinically or radiologically98. This included 
neurological symptoms/signs that occurred during the course of treatment weaning, 
but were distinct from the initial presentation and separated by a period of recovery or 
improvement. Two paediatric patients were excluded due to being lost to follow-up. 
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In total, 59 patients (paediatric n=33, adult n=26) were included. Data was 
retrospectively collected by SRa (adult) and RCD (paediatric) through telephone 
interviews with each patient’s neurologist, using a structured questionnaire created for 
this study (Appendix C).  
 
4.4.2 Therapeutic efficacy 
 
We calculated annualised relapse rates (ARRs) for each patient as the number of 
relapses/year pre-treatment and on-treatment230, 235. Pre-treatment ARRs were 
calculated after excluding the index episode, to avoid an inaccurately high value230, 
235. All ARRs were calculated only if the period of time being assessed was ≥6 
months. We calculated the cumulative cohort ARR for each treatment (total number 
of relapses in cohort/ total patient-years on each treatment). Patients were included in 
calculations of ARR if they fulfilled the following criteria for each treatment agent. 
 
Corticosteroids: Pulsed intravenous (IV) methylprednisolone (dose 20-30 mg/kg/day 
for children, 500 mg–1g/day for adults, over 3-5 days), and/or a taper of oral 
prednisone (starting dose 1-2 mg/kg/day in children and 1 mg/kg in adults) with 
variable tapering durations. Patients were on ‘maintenance corticosteroids’ if they 
were given oral corticosteroids after second or further demyelinating episodes at daily 
doses >10 mg for patients >40 kg in weight, and >5 mg for patients <40 kg in weight.  
IVIg: An induction course dose of 2g/kg, and subsequent monthly doses of 1 
g/kg/infusion (children) and 0.4-1g/kg/infusion (adults).  
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Steroid-sparing immunosuppression: Treatment with mycophenolate, azathioprine, or 
methotrexate at adequate doses based on weight as previously described98. 
 
Rituximab: ARR was calculated for 6 months after rituximab infusion. Rituximab 
failure was defined as a relapse occurring between 2 weeks and 6 months after 
treatment. A “repopulation relapse” was a relapse associated with B cell repopulation 
(CD19 count ≥10 x 106 cells/L)230. 
 
4.4.3 Outcomes 
 
Patient outcomes were characterised using EDSS195. Recovery from each 
demyelinating episode was also classified as complete, partial, or no recovery. 
Residual deficits were categorised to include visual impairment (with reduced visual 
acuity), sensory, motor, cognitive, and/or sphincter dysfunction, and epilepsy. 
 
4.4.4 Standard protocol approval and patient consent 
 
Ethics and research protocol approval (NEAF 12/SCHN/395) was granted by the 
individual ethics committees for all participating hospitals. Informed consent was 
obtained from all patients. 
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4.4.5 Statistical analyses 
 
Patient and clinical characteristics were described by frequencies and percentages for 
categorical variables; and by mean, median, and range for continuous variables. 
Patient-level characteristics were compared using chi-square tests and described using 
odds ratios (OR) and 95% confidence intervals. ARRs were tested using the Wilcoxon 
signed-rank test to examine whether ARRs decreased during treatment. Figures were 
generated using Prism Software version 6.0 (GraphPad Software, La Jolla, CA) and 
Adobe Illustrator CS6 (Adobe Systems Incorporated, San Jose, CA). 
 
4.5 RESULTS 
 
4.5.1 Clinical characterisation  
 
We identified 59 patients (40 female, 19 male) with relapsing MOG antibody-
associated demyelination, with a total of 216 episodes. Patients were followed up for 
an average of 60 months (median 45, range 1-288). Detailed information regarding 
each patient are included in Table 4.1, and a summary of the demographics, clinical 
phenotypes, and CSF analysis and a comparison between adult and paediatric patients 
in this cohort are highlighted in Table 4.2.  
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Table	4.1.	Demographic,	clinical,	laboratory,	and	outcome	data	of	patients	with	relapsing	MOG	antibody-associated		
								demyelination		
Patient 
Number 
Age 
at 
onset
/sex 
Ethnic 
group  
Prior 
infect-
ious 
prodr
ome 
Other 
clinical 
history of 
note 
Number of 
episodes - total 
(phenotype)  
EDSS at 
acute 
present-
ation 
Fulfills 
2007 
NMO 
criteria 
Fulfills 
2015 
NMOSD 
criteria 
Optic 
disc 
swelling 
(if ON 
present) 
CSF 
white 
cell 
count 
(106/L) 
CSF 
protein 
(g/L) 
CSF 
OCB 
Follow 
up 
duration 
(months) 
EDSS 
at latest 
clinical 
follow 
up 
Patient 1 
 
 
1/F Cauca-
sian 
Yes  3 (ADEM n=1, 
ADEM + 
cerebellar 
/brainstem n=1, 
ADEM + 
cerebellar n=1) 
8 No No Not 
recorded  
5 
eosinop
hils, 0 
PMNs, 
16 
monos 
0.25  Not 
done 
25 0 
Patient 2  
 
1/M Cauca-
sian 
Yes 
(adeno
virus) 
 2 (ADEM n=1, 
BON n=1) 
5.5 No No Yes, 
bilateral 
15 
PMNs, 
8 monos 
0.20 Neg 85 0 
Patient 3 
 
2/F Cauca-
sian 
Yes Fevers with 
relapses 
5 acute 
demyelination 
syndromes 
(brainstem/cerebe
llar n=5, L 
hemiplegia n=1) 
Not 
availabl
e  
No No No No cells 0.30 Neg 74 2 
Patient 4 
 
3/F Cauca-
sian 
No Seizures at 
first 
presentatio
n 
4 (ADEM n=3, 
brainstem n=1) 
3  No No NA No cells 0.14  Neg 35 1 
Patient 5 
 
4/F Cauca-
sian 
Yes Mother has 
ITP, 
paternal 
aunt has 
coeliac 
2 (ADEM + 
LETM n=2) 
9.5 No No NA 1 PMN, 
14 
monos 
0.22  Neg 32 2 
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Patient 
Number 
Age 
at 
onset
/sex 
Ethnic 
group  
Prior 
infect-
ious 
prodr
ome 
Other 
clinical 
history of 
note 
Number of 
episodes - total 
(phenotype)  
EDSS at 
acute 
present-
ation 
Fulfills 
2007 
NMO 
criteria 
Fulfills 
2015 
NMOSD 
criteria 
Optic 
disc 
swelling 
(if ON 
present) 
CSF 
white 
cell 
count 
(106/L) 
CSF 
protein 
(g/L) 
CSF 
OCB 
Follow 
up 
duration 
(months) 
EDSS 
at latest 
clinical 
follow 
up 
disease 
Patient 6 
 
4/M Indian 
 
 
 
Yes Initially 
diagnosed 
as relapsing 
remitting 
MS 
5 (ADEM n=1, 
cerebellar n=1. 
UON n=3) 
6.5 No No Yes 5 
PMNs, 
3 
monos, 
0.29  Neg 64 1 
Patient 7 
 
4/M Cauca-
sian 
Yes 
(croup 
1 week 
prior) 
 2 (ADEM n=1, 
BON n=1) 
5.5 No No Not 
recorded  
25 
PMNs, 
25 
monos 
0.64  Neg 10 0 
Patient 8 
 
5/F Cauca-
sian 
No Initially 
diagnosed 
as  CRION 
5 (UON n=3, 
BON n=2) 
4  No No Yes, 
bilateral 
0 
PMNs, 
2 monos 
0.24  Neg 68 1 
Patient 9 
 
5/F Aborig-
inal 
Yes Fevers with 
no 
infectious 
origin in 3 
relapses, 
developed 
chicken 
pox 
between 
first two 
episodes 
8 (BON n=1, 
ADEM + LETM 
n=1, UON n=5, 
LETM n=1) 
8 Yes Yes Yes, 
bilateral 
28 
PMNs, 
42 
monos 
0.34  Neg 194 2 
Patient 10 
 
5/F Aborig-
inal/ 
Cauca-
No initially 
diagnosed 
with MS; 
5 (ADEM n=1, 
UON n=3, seizure 
n=1) 
6 No No Not 
recorded  
No cells 0.23  Neg 63 1 
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Patient 
Number 
Age 
at 
onset
/sex 
Ethnic 
group  
Prior 
infect-
ious 
prodr
ome 
Other 
clinical 
history of 
note 
Number of 
episodes - total 
(phenotype)  
EDSS at 
acute 
present-
ation 
Fulfills 
2007 
NMO 
criteria 
Fulfills 
2015 
NMOSD 
criteria 
Optic 
disc 
swelling 
(if ON 
present) 
CSF 
white 
cell 
count 
(106/L) 
CSF 
protein 
(g/L) 
CSF 
OCB 
Follow 
up 
duration 
(months) 
EDSS 
at latest 
clinical 
follow 
up 
sian treated with 
β-IFN for 4 
years 
following 
E4 
Patient 11 
 
5/M Cauca-
sian 
Yes  3 (ADEM n=1, 
ADEM + LETM 
n=1, non-
encephalitic ADS 
n=1) 
5 No No NA 8 
PMNs, 
40 
monos,  
0.23  Neg 16 2 
Patient 12 
 
5/F Cauca-
sian 
Yes maternal 
cousin with 
ON, 
unexplaine
d visual 
loss in 
maternal 
grandmothe
r in her 40s 
2 (BON n=1, 
short TM n=1) 
5  No No Yes,  
bilateral 
4 cells 
(differen
tials not 
provide
d) 
0.28 Neg 2 1 
Patient 13 
 
5/F Chinese Yes Mother 
with IgA 
nephropath
y 
3 (ADEM n=1, 
UON n=2) 
5 No No Yes, 
unilatera
l 
39 cells 
(differen
tials not 
provide
d) 
1.00 Not 
done 
105 0 
Patient 14 
 
5/F Middle 
Eastern 
No  4 (BON n=4) 5 No No Not 
recorded  
3 
PMNs, 
5 monos 
<0.10  Neg 97 2 
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Patient 
Number 
Age 
at 
onset
/sex 
Ethnic 
group  
Prior 
infect-
ious 
prodr
ome 
Other 
clinical 
history of 
note 
Number of 
episodes - total 
(phenotype)  
EDSS at 
acute 
present-
ation 
Fulfills 
2007 
NMO 
criteria 
Fulfills 
2015 
NMOSD 
criteria 
Optic 
disc 
swelling 
(if ON 
present) 
CSF 
white 
cell 
count 
(106/L) 
CSF 
protein 
(g/L) 
CSF 
OCB 
Follow 
up 
duration 
(months) 
EDSS 
at latest 
clinical 
follow 
up 
Patient 15 
 
5/M Cauca-
sian 
Yes Diagnosed 
as MS, 
treated with  
β-IFN for 5 
years after 
E3 
4 (ADEM with 
seizures n=1, 
ADEM + UON 
n=2, ADEM + 
cerebellar n=1) 
6 No No Not 
recorded  
64 
PMNs, 
9 monos 
0.45  Not 
done 
151 1 
Patient 16 
 
5/M Cauca-
sian 
Yes  3 (ADEM n=2, 
cerebellar n=1) 
6 No No NA 0 
PMNs, 
24 
monos,  
0.43  Neg 46 1 
Patient 17 
 
6/F Cauca-
sian 
No Paternal 
grandmothe
r with Type 
1 DM 
2 (BON + LETM 
n=1, BON n=1) 
6 Yes Yes Yes, 
bilateral 
0 
PMNs, 
28 
monos 
0.90 Neg 16 0 
Patient 18 
 
6/F Cauca-
sian 
No  3 (L UON n=1, 
seizure + 
encephalopathy 
n=1, L UON + 
dyscognitive 
seizures n=1) 
Not 
availabl
e for E1 
or E2, 5 
for E3 
No No Not 
recorded  
Not 
availabl
e 
Not 
availabl
e 
Neg 23 2 
Patient 19 
 
7/F Cauca-
sian 
No  2 (BON n=1, 
LETM n=1) 
5 Yes Yes Yes 3 
PMNs, 
90 
monos,  
0.47  Neg 22 1 
Patient 20 
 
7/F Cauca-
sian 
No  5 (seizures + 
encephalopathy 
n=2, UON n=2, 
5 No No Not 
recorded  
14 
PMNs, 
28 
0.31  Neg 85 2 
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Patient 
Number 
Age 
at 
onset
/sex 
Ethnic 
group  
Prior 
infect-
ious 
prodr
ome 
Other 
clinical 
history of 
note 
Number of 
episodes - total 
(phenotype)  
EDSS at 
acute 
present-
ation 
Fulfills 
2007 
NMO 
criteria 
Fulfills 
2015 
NMOSD 
criteria 
Optic 
disc 
swelling 
(if ON 
present) 
CSF 
white 
cell 
count 
(106/L) 
CSF 
protein 
(g/L) 
CSF 
OCB 
Follow 
up 
duration 
(months) 
EDSS 
at latest 
clinical 
follow 
up 
ADEM (with 
seizures) + BON 
n=1) 
monos 
Patient 21 
 
7/F Cauca-
sian 
Yes  5 (ADEM n=2, 
brainstem n=3) 
8 No No NA 10 
PMNs, 
18 
monos 
0.44  Pos 21 0 
Patient 22 
 
7/F Cauca-
sian 
No Past history 
of Type 1 
DM and 
Hashimo-
to’s 
thyroiditis, 
father with 
Hashimo-
to’s 
thyroiditis 
2 (BON n=2) 5 No No Not 
recorded  
0 
PMNs, 
2 monos 
0.21  Neg 206 1 
Patient 23 
 
7/M Cauca-
sian 
No Elevated 
CSF 
opening 
pressure 
(49 cm 
H20) 
prompted 
initial 
therapy 
with 
3 (BON n=2, 
UON n=1) 
5.5 No No Not 
recorded 
1 PMN, 
22 
monos 
0.50 Neg 13 0 
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Patient 
Number 
Age 
at 
onset
/sex 
Ethnic 
group  
Prior 
infect-
ious 
prodr
ome 
Other 
clinical 
history of 
note 
Number of 
episodes - total 
(phenotype)  
EDSS at 
acute 
present-
ation 
Fulfills 
2007 
NMO 
criteria 
Fulfills 
2015 
NMOSD 
criteria 
Optic 
disc 
swelling 
(if ON 
present) 
CSF 
white 
cell 
count 
(106/L) 
CSF 
protein 
(g/L) 
CSF 
OCB 
Follow 
up 
duration 
(months) 
EDSS 
at latest 
clinical 
follow 
up 
acetazola-
mide  
Patient 24 
 
7/M Chinese Yes  2 (LETM + UON 
n=1, UON n=1) 
2  Yes Yes Yes 341 
cells 
(differen
tials not 
provide
d) 
1.00 Neg 17 0 
Patient 25  9/F Cauca-
sian 
No Mother 
with 
psoriasis, 
personal 
history of 
nausea and 
vomiting 
which 
abated with 
steroids 
3 (UON n=3) 4  No No No No CSF analysis done 15 1 
Patient 26 
 
9/M Chinese No  2 (ADEM n=1, 
ADEM + LETM 
n=1) 
9.5 No No NA 23 
monos 
0.32 Neg 26 3.5 
Patient 27 
 
10/F Pacific 
Islander 
No Rheumatic 
fever 2 
years prior 
to E1 
4 (UON n=2,  
seizures n=2 with 
one episode being 
epilepsia partialis 
continua) 
Not 
availabl
e for E1, 
5 for E2 
No No Not 
recorded 
0 
PMNs, 
1 mono 
0.30 Neg 74 2 
Patient 28 11/F Cauca- Yes Fever at 3 (LETM + 4  Yes Yes Not 4 0.20  Neg 49 2 
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Patient 
Number 
Age 
at 
onset
/sex 
Ethnic 
group  
Prior 
infect-
ious 
prodr
ome 
Other 
clinical 
history of 
note 
Number of 
episodes - total 
(phenotype)  
EDSS at 
acute 
present-
ation 
Fulfills 
2007 
NMO 
criteria 
Fulfills 
2015 
NMOSD 
criteria 
Optic 
disc 
swelling 
(if ON 
present) 
CSF 
white 
cell 
count 
(106/L) 
CSF 
protein 
(g/L) 
CSF 
OCB 
Follow 
up 
duration 
(months) 
EDSS 
at latest 
clinical 
follow 
up 
 sian onset brainstem + 
cerebellar n=1, R 
UON n=1, 
ADEM + LETM 
+ brainstem n=1) 
recorded PMNs, 
32 
monos 
Patient 29 
 
11/F Cauca-
sian 
No Diagnosed 
as MS 
following 
E3, treated 
for 9 
months 
with β-IFN, 
elevated 
anti 
thyroglob-
ulin and 
thyroid 
peroxide-
ase 
antibodies 
4 (BON n=2, 
aphasia/ R 
hemiplegia/ raised 
ICP  (normal 
MRI) n=1, seizure 
+ ADS (aphasia, 
R hemiplegia) 
n=1 
Not 
availabl
e 
No No Not 
recorded 
24 
PMNs, 
15 
monos 
0.69  Pos 76 2 
Patient 30 
 
12/F Cauca-
sian 
Yes   2 (UON n=2) 3  No No Not 
recorded 
Not available 120 0 
Patient 31 
 
12/M Cauca-
sian 
No Treated 
with 
glatiramer 
acetate for 
5 years 
3 (UON n=2, 
ADEM n=1) 
Not 
availabl
e for E1 
or E2, 5 
at E3 
No No Not 
recorded 
Not 
availabl
e 
0.60  Neg 186 2 
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Patient 
Number 
Age 
at 
onset
/sex 
Ethnic 
group  
Prior 
infect-
ious 
prodr
ome 
Other 
clinical 
history of 
note 
Number of 
episodes - total 
(phenotype)  
EDSS at 
acute 
present-
ation 
Fulfills 
2007 
NMO 
criteria 
Fulfills 
2015 
NMOSD 
criteria 
Optic 
disc 
swelling 
(if ON 
present) 
CSF 
white 
cell 
count 
(106/L) 
CSF 
protein 
(g/L) 
CSF 
OCB 
Follow 
up 
duration 
(months) 
EDSS 
at latest 
clinical 
follow 
up 
after E2 
Patient 32 
 
14/F Pacific 
Islander 
No  3 (LETM n=1, 
brainstem + 
cerebellar  n=1, 
UON n=1) 
8 No Yes Not 
recorded 
1 PMN, 
2 monos 
0.23  Neg 76 0 
Patient 33  16/M Cauca-
sian 
Yes  2 (BON n=1, 
LETM n=1) 
Not 
availabl
e for E1, 
6 at E2 
Yes Yes Not 
recorded 
39 
PMNs, 
100 
monos 
0.4 Not 
done 
81 0 
Patient 34 
 
18/M Cauca-
sian 
Yes Henoch 
Schonlein 
Purpura 
aged 2 
5 (UON n=5) 5.5 No No Yes 0 
PMNs, 
6 monos 
0.31  Pos 92 5.5 
Patient 35 
 
26/F Cauca-
sian 
No  2 (Sensory non 
spinal n=1, 
cerebellar n=1) 
2  No No NA 1 PMN, 
34 
monos 
0.53  Pos 19 1.5 
Patient 36 
 
26/F Cauca-
sian 
Yes  10 (BON n=4, 
UON, n=5, short 
TM n=1) 
2 No No Yes No cells Normal 
protein 
(value 
not 
noted) 
Neg 84 1 
Patient 37 
 
28/F Pacific 
Islander 
No Vaccine 3 
weeks 
before 
episode 
2 (BON n=1, 
UON n=1) 
3 No No Yes, 
bilateral 
0 
PMNs, 
30 
monos 
0.41  Neg 32 0 
Patient 38 
 
29/M Indian Yes Fevers with 
no 
4 (BON n=1, 
LETM n=1, UON 
8 Yes Yes Yes, 
bilateral 
360 
PMNs, 
1.87  Neg 40  4.5 
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Patient 
Number 
Age 
at 
onset
/sex 
Ethnic 
group  
Prior 
infect-
ious 
prodr
ome 
Other 
clinical 
history of 
note 
Number of 
episodes - total 
(phenotype)  
EDSS at 
acute 
present-
ation 
Fulfills 
2007 
NMO 
criteria 
Fulfills 
2015 
NMOSD 
criteria 
Optic 
disc 
swelling 
(if ON 
present) 
CSF 
white 
cell 
count 
(106/L) 
CSF 
protein 
(g/L) 
CSF 
OCB 
Follow 
up 
duration 
(months) 
EDSS 
at latest 
clinical 
follow 
up 
infectious 
origin 
during  
episodes 
n=1, brainstem 
n=1) 
0 monos 
Patient 39 
 
31/M Cauca-
sian 
Yes Pertussis 
vaccina-
tion two 
weeks prior 
to first 
episode 
10 (BON n=2, 
UON n=3, 
ADEM n=2, 
ADEM + UON 
n=1, cerebellar 
n=1, brainstem 
n=1) 
3  No Yes Yes. 
bilateral 
5 
PMNs, 
41 
monos 
0.58  Pos 55 2 
Patient 40 
 
32/M Cauca-
sian 
No  2 (BON n=2) 4 No No Yes. 
bilateral 
0 
PMNs, 
16 
monos 
0.26  Neg 36.8 1 
Patient 41 
 
32/M Cauca-
sian 
No  3 (UON n=3) 5 No No Yes, 
unilatera
l 
Not available 20 1 
Patient 42 
 
33/F Indian Yes ulcerative 
colitis in 
mother 
2 (UON n=2) 1 No No Yes, 
unilatera
l 
No CSF analysis done 10 0 
Patient 43 
 
33/M Cauca-
sian 
Yes No 2 (BON n=1, 
UON n=1) 
5.5 No No Yes, 
unilatera
l 
0 
PMNs, 
1 mono 
0.43  Neg 6 2 
Patient 44 
 
35/F Cauca-
sian 
Not 
record
ed 
E9 while 
pregnant, 
E10 
10 (short TM 
n=8, brainstem 
n=1, UON n=1) 
3  No No No 0 
PMNs, 
2 monos 
0.45  Neg 97 2 
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Patient 
Number 
Age 
at 
onset
/sex 
Ethnic 
group  
Prior 
infect-
ious 
prodr
ome 
Other 
clinical 
history of 
note 
Number of 
episodes - total 
(phenotype)  
EDSS at 
acute 
present-
ation 
Fulfills 
2007 
NMO 
criteria 
Fulfills 
2015 
NMOSD 
criteria 
Optic 
disc 
swelling 
(if ON 
present) 
CSF 
white 
cell 
count 
(106/L) 
CSF 
protein 
(g/L) 
CSF 
OCB 
Follow 
up 
duration 
(months) 
EDSS 
at latest 
clinical 
follow 
up 
occurred 1 
week post 
partum 
Patient 45 
 
35/M Indian Not 
record
ed 
 2 (UON n=2) Not 
availabl
e  
No No Not 
recorded 
No CSF analysis done 8 0 
Patient 46 
 
36/F Cauca-
sian 
No E1 
occurred 4 
months 
post partum 
4 (BON n=3, 
sensory (non 
spinal) n=1) 
4 No No Yes, 
bilateral 
No cells 0.16  Neg 60 1.5 
Patient 47 
 
37/F Indones-
ian 
No E1 
occurred 2 
months 
post partum 
2 (BON n=1, R 
UON n=1) 
5 No No Yes, 
bilateral 
2 
PMNs, 
1 mono 
0.30 Neg 5 0 
Patient 48 
 
38/F Cauca-
sian 
No  2 (UON + short 
TM + brainstem 
n=1), R UON n=1 
7 No Yes Yes, 
unilatera
l 
14 
monos, 
Normal 
protein 
(value 
not 
noted) 
Neg 1 1, 
Patient 49 
 
40/F Cauca-
sian 
No On β-IFN 
for 13 years 
5 (UON + TM 
n=1, UON + 
LETM n=1, BON 
+ LETM n=2, 
UON n=1) 
8.5 Yes Yes Not 
recorded 
No cells Normal 
protein 
(value 
not 
noted) 
Not 
done 
288 3 
Patient 50 
 
44/F Leban-
ese 
No Was on β-
IFN and 
glatiramer 
5 (short TM n=1, 
LETM n=4) 
6  No No NA 0 
PMNs, 
3 monos 
1.61 g/L  Neg 39 3.5 
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Patient 
Number 
Age 
at 
onset
/sex 
Ethnic 
group  
Prior 
infect-
ious 
prodr
ome 
Other 
clinical 
history of 
note 
Number of 
episodes - total 
(phenotype)  
EDSS at 
acute 
present-
ation 
Fulfills 
2007 
NMO 
criteria 
Fulfills 
2015 
NMOSD 
criteria 
Optic 
disc 
swelling 
(if ON 
present) 
CSF 
white 
cell 
count 
(106/L) 
CSF 
protein 
(g/L) 
CSF 
OCB 
Follow 
up 
duration 
(months) 
EDSS 
at latest 
clinical 
follow 
up 
acetate 
during 
early part 
of disease 
course 
when 
thought to 
have MS  
Patient 51 
 
45/F Sri 
Lankan 
Yes Was on β-
IFN for 3 
months, 
then 
glatiramer 
acetate 
3 (UON n=1, 
BON n=2) with 
one ON episode 
including a 
symptomatic 
cerebral 
syndrome 
5.5 No Yes Not 
recorded 
1 PMN, 
0 monos 
0.25 g/L Neg 59 1 
Patient 52 
 
47/F Cauca-
sian 
No Previous 
diagnosis 
of LGI1 Ab 
positive 
autoimmun
e 
encephalitis 
2 (UON n=2) 4 No No Yes, 
unilatera
l 
No CSF analysis done 36 
months 
following 
UON (60 
months 
following 
autoimmu
ne 
encephalit
is) 
2 
Patient 53 
 
49/F Cauca-
sian 
No  6 (UON n=3, 
short TM n=1, 
3 No No Yes, 
unilatera
0 
PMNs, 
Not 
availabl
Neg 147 2 
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Patient 
Number 
Age 
at 
onset
/sex 
Ethnic 
group  
Prior 
infect-
ious 
prodr
ome 
Other 
clinical 
history of 
note 
Number of 
episodes - total 
(phenotype)  
EDSS at 
acute 
present-
ation 
Fulfills 
2007 
NMO 
criteria 
Fulfills 
2015 
NMOSD 
criteria 
Optic 
disc 
swelling 
(if ON 
present) 
CSF 
white 
cell 
count 
(106/L) 
CSF 
protein 
(g/L) 
CSF 
OCB 
Follow 
up 
duration 
(months) 
EDSS 
at latest 
clinical 
follow 
up 
sensory non-
spinal n=1, UON 
and sensory non-
spinal n=1) 
l 21 
monos 
e 
Patient 54 
 
51/F Cauca-
sian 
Yes  2 (BON n=1, 
sensory non-
spinal n=1) 
2 No No Yes, 
unilatera
l (on 
left) 
No CSF analysis done 56 0 
Patient 55 
 
51/M Cauca-
sian 
Yes  2 (UON n=2) 4 No No Yes, 
unilatera
l 
No CSF analysis done 16.5 2 
Patient 56  52/F Cauca-
sian 
Yes Fevers with 
presentatio
n 
3 (LETM n=1, 
UON n=2) 
8.5 Yes Yes Not 
recorded 
0 
PMNs, 
68 
monos 
0.47  Not 
done 
49 4 
Patient 57 
 
53/F Cauca-
sian 
No Cognitive 
deterioratio
n as 
presentatio
n in two 
episodes 
with 
improveme
nt 
following 
immunothe
rapy 
6 (BON n=4, 
cognitive decline 
n=2) 
3 No Yes Yes, 
bilateral 
0 
PMNs, 
1 mono 
0.63  Neg 45 2 
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Patient 
Number 
Age 
at 
onset
/sex 
Ethnic 
group  
Prior 
infect-
ious 
prodr
ome 
Other 
clinical 
history of 
note 
Number of 
episodes - total 
(phenotype)  
EDSS at 
acute 
present-
ation 
Fulfills 
2007 
NMO 
criteria 
Fulfills 
2015 
NMOSD 
criteria 
Optic 
disc 
swelling 
(if ON 
present) 
CSF 
white 
cell 
count 
(106/L) 
CSF 
protein 
(g/L) 
CSF 
OCB 
Follow 
up 
duration 
(months) 
EDSS 
at latest 
clinical 
follow 
up 
Patient 58  58/F Cauca-
sian 
No Diagnosed 
as CRION 
5 (BON n=1, 
UON n=4) 
Not 
availabl
e 
No No Yes, 
bilateral 
2 monos 0.53 Neg 39 0 
Patient 59 
 
74/F Cauca-
sian 
No  4 (UON n=3, 
brainstem n=1) 
3 No Yes Not 
recorded 
0 
PMNs, 
40 
monos 
0.35  Neg 12.5 0 
	ADS	acute	demyelinating	syndrome;	CRION	chronic	relapsing	inflammatory	optic	neuropathy;	DM	diabetes	mellitus;	ICP	intracranial	pressure;	ITP	idiopathic	thrombocytopenic	purpura;	LGI1	Ab	leucine	rich	glioma-inactivated	1;	M	male;	OCB	oligoclonal	band;	PMN	polymorphonuclear	cell	
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Table 4.2 Cohort summary of relapsing paediatric and adult MOG 
antibody-positive patients: clinical and laboratory characteristics 
 
Clinical and 
laboratory 
characteristics 
Total cohort (n=59) 
 
Paediatric patients 
(n=33) 
Adult patients  
(n=26) 
Age at onset  
Mean; median 
(range) 
 
21; 12 (1-74) 
 
7; 6 (1-16) 
 
40; 37 (18-74) 
Gender  
F: M (% female) 
40: 19 (68%) 
 
22: 11 (67%) 18:8 (69%) 
Ethnicity Caucasian 43/59 (73%) 
South Asian 5/59 (8.5%) 
East Asian 4/59 (6.7%) 
Pacific Islander 3/59 
(5%) 
Middle Eastern 2/59 
(3.4%) 
Aboriginal 2/59 (3.4%) 
Caucasian 24/33 (73%) 
South Asian 1/33 (3%) 
East Asian 3/33 (9%) 
Pacific Islander 2/33 
(6%) 
Middle Eastern 1/33 
(3%) 
Aboriginal 2/33 (6%) 
Caucasian 19/26 (73%) 
South Asian 4/26 (15%) 
East Asian 1/26 (4%) 
Pacific Islander 1/26 
(4%) 
Middle Eastern 1/26 
(4%) 
Aboriginal 0/26 (0%) 
Presence of a 
preceding 
infectious 
prodrome 
27/57 (47%) 
 
17/33 (52%) 10/24 (42%) 
EDSS at initial 
presentation 
Mean; median 
(range) 
5.1; 5 (1-9.5) 5.6; 5 (2-9.5)  4.4; 4 (1-8.5) 
CSF 
lymphocytic 
pleocytosis at 
initial 
presentation 
27/46 (59%) 
 
18/26 (69%) 9/20 (45%) 
CSF protein 
elevation at 
initial 
presentation 
18/49 (37%) 
 
11/30 (37%) 7/19 (37%) 
Presence of 
intrathecal 
oligoclonal 
bands at initial 
presentation 
5/45 (11%) 
 
2/27 (7%) 3/18 (17%) 
Relapsing 
Syndromic 
Classification1  
Relapsing ON 17/59 
(29%) 
NMOSD 15/59 (25%) 
ADEM-ON 4/59 (7%) 
ADEM-LETM 2/59 (3%) 
ADEM-ON-cerebellar 
2/59 (3%) 
Relapsing ON 6/33 
(18%) 
NMOSD 7/33 (21%)                 
ADEM-ON 4/33 (12%) 
ADEM-LETM 2/33 (6%) 
ADEM-ON-cerebellar 
2/33 (6%) 
Relapsing ON 11/26 
(42%) 
NMOSD  8/26 (31%) 
Other relapsing 
presentations 7/26 (27%) 
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ADEM-brainstem 
2/59 (3%) 
UON- short TM 2/59 
(3%) 
Other relapsing 
presentations 15/59 
(25%)  
ADEM-brainstem 2/33 
(6%) 
Other relapsing 
presentations 10/33 
(30%) 
Fulfills 2015 
NMOSD criteria 
15/59 (25%) 7/33 (21%) 8/26 (31%) 
Fulfill Revised 
McDonald 
criteria for MS 
9/59 (15%) 6/33 (18%) 3/26 (12%) 
Follow up 
duration 
(months) 
Mean; median 
(range) 
60; 45 (1-288) 
 
 
 
 
66; 63 (2–206) 
 
 
 
 
52; 39 (1-288) 
 
 
 
 
EDSS a latest 
clinical follow 
up 
Mean; median 
(range) 
 
1.29; 1 (0-5.5) 
 
1.08; 1 (0-3.5) 
 
1.56; 1.25 (0-5.5) 
 
1 Breakdown of “Other relapsing presentations” in Total Cohort: ADEM-cerebellar 1/59 
(2%), ADEM-brainstem-cerebellar 1/59 (2%), Relapsing TM 1/59 (2%), ON-TM-brainstem 
1/59 (2%), Other 11/59 (19%); Paediatric Cohort: ON-TM 1/33 (3%), ADEM-cerebellar 1/33 
(3%), ADEM-brainstem-cerebellar 1/33 (3%), Other 7/33 (21%); Adult Cohort: ON-TM 1/26 
(4%), Relapsing TM 1/26 (4%), ON-TM-brainstem 1/26 (4%), Other 4/26 (15%). A detailed 
description of “other” presentations is supplied in Tables 4.3 and 4.4. 
 
The median age of onset for the total cohort was 12 years (mean 21 range 1-74), in 
children 6 years (mean 7, range 1-16), and in adults 37 years (mean 40, range 18-74). 
43/59 (73%) patients were Caucasian. 47% had an infectious prodrome in the month 
prior to their first episode. Two patients had a vaccination within three weeks prior to 
an episode. Three patients had their first presentation (n=2) or relapse (n=1) ≤4 
months post-partum. Four patients had coexistent autoimmunity (type 1 diabetes 
mellitus and Hashimoto’s thyroiditis, elevated thyroid antibodies, Henoch Schonlein 
Purpura, and prior LGI1 antibody-positive encephalitis). 22/59 patients had 2 
demyelinating episodes, and 37/59 had ≥3 (Figure 4.1). 
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Figure 4.1 Relapse numbers. The	number	of	demyelinating	episodes	experienced	by	the	59	patients	in	this	study.	
 
There was a difference in clinical phenotypes on first presentation between children 
and adults (P=0.007). The most common presenting phenotype in the total cohort was 
ON (54%) [bilateral ON (BON) 32%, unilateral ON (UON) 22%] (Figure 4.2A). 
ADEM (2013 criteria)236 was the most common presentation in children (36%), 
followed by BON (24%) and UON (15%) (Table 4.3). Adults presented primarily 
with ON 73% (BON 42%, UON 31%) (Table 4.3). TM was less common. Isolated 
seizures with mild encephalopathy and subtle inflammatory changes in CSF or 
radiology, but in the absence of clinical and radiological features of ADEM236, were 
present in 2 children.  
 
When evaluating the clinical phenotype of all 216 episodes in the cohort, ON 
remained dominant (Figure 4.2B). UON (34%) was most common, followed by BON 
(19%). ADEM was common in children (15%), but rare in adults (2%) (Table 4.4). 
TM (both short TM and LETM) was less common (11%), and more prevalent in 
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adults (Table 4.4).  Mixed presentations were common. 7/59 patients (5 adults and 2 
children) had simultaneous ON+LETM consistent with the classical description of 
Devic disease, however the majority of patients in this cohort did not have this 
phenotype. 
 
Relapsing ON was the main relapsing clinical syndrome in the total cohort (29%), 
followed by NMOSD (2015 criteria)88 (25%) (Table 4.2). 51/59 patients had one or 
more episodes involving ON. Fundoscopy results were available in 30/51 patients and 
27/30 (90%) had visible optic nerve head swelling with the ON [9/11 (82%) children 
and 18/19 (95%) adults]. Various phenotypes including ADEM  (such as relapsing 
ADEM, ADEM-ON, ADEM-LETM, etc) were present in 36% of children.  
 
This study identified some uncommon clinical phenotypes associated with MOG 
antibodies. Some patients presented with steroid sensitive sensory symptoms (lower 
limb paraesthesia), in the absence of radiological myelitis. One adult with BON 
presented with recurrent subacute cognitive decline that was reversible with steroids 
and immunotherapy. It is conceivable that she had concurrent autoimmune 
encephalitis, however testing for neuronal cell surface antibodies was negative, and 
radiology was not consistent with encephalitis. During her episodes of BON, there 
were expected optic nerve radiological changes but no brain lesions. When she 
presented with cognitive decline, she had two large peritrigonal T2 hyperintense 
lesions up to 1 cm in diameter each, and multiple smaller lesions consistent with 
demyelination, but not fulfilling revised 2010 McDonald criteria. Progress MRIs 
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demonstrated resolution of the peritrigonal lesions, but residual scattered smaller 
white matter lesions.  
 
 
Figure 4.2 The clinical phenotype in relapsing MOG antibody-associated 
demyelination (A) Illustration of the clinical phenotype at first presentation of all 
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patients in the cohort, with a breakdown reflecting the distribution of each clinical 
phenotype in the paediatric age group (0-16 years at disease onset), and adult age 
group (>16 years at disease onset). (B) Illustration of the clinical phenotype at all 
presentations (n=216, initial presentation plus relapses) in the cohort, with a 
breakdown reflecting the distribution of each clinical phenotype in the paediatric and 
adult groups.  
	
	
Table	4.3	 	Clinical	phenotype	at	initial	presentation	
	
		
Clinical	
Phenotype	
Total	Cohort	(n=59)	 Paediatric	patients	(n=33)	 Adult	patients	(n=26)	BON	 19/59	(32%)	 8/33	(24%)	 11/26	(42%)	UON	 13/59	(22%)	 5/33	(15%)	 8/26	(31%)	ADEM	 12/59	(20%)	 12/33	(36%)	 0/26	(0%)	Mixed	 7/59	(12%)	 4/33	(12%)		
1	episode	each	of	
ADEM	+	LETM,	
BON	+	LETM,		
UON	+	LETM,	
LETM	+	brainstem	
+	cerebellar	
3/26	(12%)		
1	episode	each	of	
UON	+	LETM,	UON	
+	short	TM	+	
brainstem,	UON	+	
sensory	(non-
spinal)	Short	TM	 2/59	(3%)	 0/33	(0%)	 2/26	(8%)	LETM	 2/59	(3%)	 1/33	(3%)	 1/26	(4%)	Seizures	 2/59	(3%)	 2/33	(6%)	 0/26	(0%)	Other	 2/59	(3%)	 1/33	(3%)		
non	encephalitic	
acute	
demyelinating	
syndrome		
1/26	(4%)		
sensory	(non-
spinal)	
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Table	4.4	 Clinical	phenotype	of	all	episodes	through	the	disease	course	
	
	
Clinical	
Phenotype	
Total	Cohort	(n=216)	 Paediatric	patients	(n=111)	 Adult	patients	(n=105)	UON	 74/216	(34%)	 31/111	(28%)	 43/105	(41%)	BON	 42/216	(19%)	 19/111	(17%)	 23/105	(22%)	Mixed	 26/216	(12%)	 18/111	(16%)		
5	episodes	of	ADEM	
+LETM,	2	episodes	of	
ADEM	+	UON,	2	
episodes	of	ADEM	+	
cerebellar,	1	episode	
of	each	of	the	
following:	ADEM	+	
BON,	ADEM	+	LETM	+	
brainstem,	ADEM	+	
cerebellar	+	
brainstem,	BON	+	
LETM,	UON	+	LETM,	
UON	+	seizures,	LETM	
+	brainstem,	LETM	+	
brainstem	+	
cerebellar,	brainstem	
+	cerebellar	
8/105	(8%)		
3	episodes	of	BON	
+	LETM,	2	episodes	
of	UON	+	LETM,	1	
episode	of	each	of	
the	following:	
ADEM	+	UON,	UON	
+	short	TM	+	
brainstem,	UON	+	
sensory	non	spinal	
ADEM	 19/216	(9%)	 17/111	(15%)	 2/105	(2%)	Short	TM	 12/216	(6%)	 1/111	(1%)	 11/105	(10%)	LETM	 10/216	(5%)	 4/111	(4%)	 6/105	(6%)	Brainstem	 8/216	(4%)	 4/111	(4%)	 4/105	(4%)	Seizures	 6/216	(3%)	 6/111	(5%)	 0/105	(0%)	Cerebellar	 4/216	(2%)	 2/111	(2%)	 2/105	(2%)	Other	 15/216	(7%)	 9/111	(8%)	
8	episodes	of	non-
encephalitic	acute	
demyelinating	
syndromes	(5	with	
brainstem	and	
cerebellar,	1	with	
tremor,	1	with	left	
hemiplegia,	1	with	
aphasia	and	right	
hemiplegia),	1	with	
seizures	+	acute	
demyelinating	
syndrome	
6/105	(6%)	
4	episodes	of	
sensory	(non-
spinal),	2	episodes	
of	cognitive	
impairment	
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4.5.2 CSF analysis  
 
CSF at initial presentation was available in 49/59 patients. 28/49 (57%) had a 
mononuclear lymphocytic pleocytosis (≥5 mononuclear cells x 106/L) but only 15/49 
(31%) had an elevated protein level (>0.40 g/L for children, >0.45 g/L for adults). 
45/49 patients were tested for intrathecal oligoclonal bands and only 5/45 (11%) were 
positive (Table 4.2). 14/49 patients had normal CSF. 
 
4.5.3 MRI findings 
 
MRI brain scans were reviewed to confirm whether they fulfilled revised McDonald 
criteria67. 129 MRIs were performed within one month of a demyelinating episode, 
and 56/129 (43%) of these demonstrated no brain lesions. 52/56 of normal brain scans 
were performed during isolated ON and/or TM. Only 11/129 brain MRIs fulfilled 
McDonald criteria in seven patients.  
 
95 brain MRIs were performed during an asymptomatic recovery period (≥3 months 
following presentation). 51/95 (54%) of asymptomatic MRIs had no brain lesions. 
37/95 (39%) had residual changes, and only 7/95 (7%) had new asymptomatic lesions. 
These seven MRIs belonged to six patients, and only 1/6 patients fulfilled revised 
McDonald criteria for MS. 2/6 patients had follow-up scans which showed no new 
lesions and partial (n=1) or complete (n=1) resolution of previous lesions. 4/6 patients 
are yet to have further follow-up radiology and have been clinically asymptomatic. 
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4.5.4 Acute corticosteroid usage and risk of relapse 
 
Treatment data was available for 189/216 episodes. 179/189 episodes were treated 
with corticosteroids. 35/179 episodes were treated with IV methylprednisolone alone 
and 144/179 episodes were treated with oral steroids (following IV 
methylprednisolone, n=115; or solely as an oral taper, n=29). The median duration of 
the oral taper was 1.75 months. Following the 144 episodes treated with oral 
prednisolone taper, there were 101 subsequent episodes, most of which occurred 
towards the end of the taper (n=40 episodes; mean dose of oral prednisone at relapse 
11.5 mg, median 10 mg, range 1.25-60 mg), or shortly after prednisone cessation 
(n=61 episodes; median duration after prednisone cessation 2 months, range 0-62) 
(Figure 4.3). The median length of a planned steroid taper was 1.5 months (mean 3, 
range 0.25-24) for all episodes followed by a relapse, compared to 5 months (mean 
6.6, range 0.75-26) for all episodes not followed by a relapse.  
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Figure 4.3 Steroid dependency in MOG antibody-associated demyelination An 
illustration of the number of relapses that occurred during tapering oral prednisone 
(and the dose of prednisone at which these relapses occurred), or following the 
cessation of an oral prednisone taper (and the time frame at which these relapses 
occurred). 
 
27/35 (74%) of episodes treated with IV methylprednisolone alone and no oral taper 
were similarly followed by a relapse after a median of 2 months (range 0.3-19). 
30/179 (17%) episodes treated with intravenous and/or oral steroids had concurrent 
immunotherapy (mycophenolate n=7, IVIg n=6, methotrexate n=4, azathioprine n=3, 
plasma exchange n=2, rituximab n=1, cyclophosphamide n=1, β-interferon n=1, and 
various combinations of these agents n=5). 
 
4.5.5 Therapeutic regimes trialed in cohort 
Details regarding the therapeutic agents utilised in each patient in this cohort is 
outlined in Table 4.5.  
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Table	4.5	 Treatment	courses	in	patients	with	relapsing	MOG	antibody-associated	demyelination		 	
   First line immune therapy Second line immunotherapy  Third line immunotherapy  
Patient  Number 
of 
episodes 
No 
Imm
Tx 
IV MP Tapering oral 
prednisone 
IVIg PLEX AZT MMF MTX 
 
Rituximab Cyclophospha
mide or 
mitoxantrone 
Patient 1 
 
3 - 3 courses 
(IV dex 
with E1, 
IV MP 30 
mg/kg x 5 
for E2 
and E3) 
Taper over 1.5 
months for E1, 
from 12.5 mg 
over 6 months 
for E2, from 
15 mg over 14 
months and 
ongoing from 
E3 
- - - - - - - 
Patient 2 
 
2 - 2 courses 
(30 mg/kg 
x 3 for E1 
and x 5 
for E2) 
Taper over 4 
weeks for E1, 
from 
2mg/kg/day 
over 5 months 
for E2  
- - - - - - - 
Patient 3 
 
6 E1-
E4 
- Taper over 20 
months from 2 
mg/kg to 5 mg 
alt days for 
E5, taper from 
2 mg/kg/day to 
5 mg alt days 
ongoing for E6  
- - - - - - - 
Patient 4 
 
4 E1 3 courses 
(30 mg/kg 
x 5 for E2 
Taper over 6 
weeks from  2 
mg/kg/day for 
- - - For 20 
months 
(200 mg 
- - - 
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   First line immune therapy Second line immunotherapy  Third line immunotherapy  
Patient  Number 
of 
episodes 
No 
Imm
Tx 
IV MP Tapering oral 
prednisone 
IVIg PLEX AZT MMF MTX 
 
Rituximab Cyclophospha
mide or 
mitoxantrone 
and x 3 
for E3 
and E4) 
E1,  taper over 
7 months from 
2mg/kg for E2, 
taper over 12 
months and 
ongoing from 
60 mg 
once/week to 
20 mg 
twice/week 
maintenance )   
bd then 
300 mg 
bd 
ongoing
) 
followin
g E2 
Patient 5 
 
2 - 2 courses 
(15 mg/kg 
x 5 for E1 
and x 4  
for E2) 
Taper over 4 
weeks for E1, 
and from 20 
mg/day over 8 
months for E2 
- - - - - - - 
Patient 6 
 
5 - All five 
episodes 
treated 
with 30 
mg/kg x 3 
Taper from 1 
mg/kg/day 
over 6 weeks 
(E1), 3 months 
(E2), 3 weeks 
(E3 and E4), 
and 25 days 
(E5) 
- - - - - - - 
Patient 7 
 
2 - 2 courses 
(30 mg/kg 
x3 for E1 
and E2) 
Taper from 
2mg/kg/day 
over 3 months 
with E1, from 
1g/kg/day 
once a 
month for 
two 
- - - - - - 
Chapter	4:	Clinical	course,	therapy,	and	outcomes	in	relapsing	MOG	antibody-associated	demyelination			
	 173	
   First line immune therapy Second line immunotherapy  Third line immunotherapy  
Patient  Number 
of 
episodes 
No 
Imm
Tx 
IV MP Tapering oral 
prednisone 
IVIg PLEX AZT MMF MTX 
 
Rituximab Cyclophospha
mide or 
mitoxantrone 
2mg/kg/day 
over 2.5 
months with 
E2 
months 
after E2 
Patient 8 
 
5 - 3 courses 
(30 mg/kg 
x 3 for 
E2, E3 
and E5) 
Taper over 3 
months for E1 
and E2, and 
over 13 
months and 
ongoing from 
E3 to present 
(currently 20  
mg alternate 
days)  
1g/kg 
(45g)/ 
month 
started 
after E5, 
now 
ongoing 
for 8 
months 
- - For 6 
months 
followin
g E3 
(500 mg 
bd then 
750 mg 
bd), 
with 2 
breakthr
ough 
relapses 
prompti
ng 
switch 
to  
monthly 
IVIg 
- - - 
Patient 9 
 
8 - 8 courses 
(500 mg x 
5 for 
E1/E2 
/E4/E5/E6
/E7/E8, x 
Taper from 25 
mg od over 3 
weeks for E2, 
from 25 mg od 
over 1 week 
for E3 and E4, 
Induction 
IVIg and 
monthly 
0..4g/kg 
maintenan
ce over 
- - - - - - 
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   First line immune therapy Second line immunotherapy  Third line immunotherapy  
Patient  Number 
of 
episodes 
No 
Imm
Tx 
IV MP Tapering oral 
prednisone 
IVIg PLEX AZT MMF MTX 
 
Rituximab Cyclophospha
mide or 
mitoxantrone 
7 for E3) from 37.5 mg 
od over 6 
months for E5 
and E6, from 
25 mg od over 
5 weeks for E7 
and E8   
 
 
 
 
189 
months 
starting 
after E5 - 
2 attempts 
at 
cessation 
leading to 
relapse 
within 6 
and 3 
months 
respective
ly (E6 and 
E7) 
Patient 
10 
 
5 (on 
beta-
interferon 
from E4 
on for 4 
years) 
E3 4 courses 
(20mg/kg/
day x 3 
for E1, 
E2, E4, 
E5) 
Taper over 3 
weeks for E1, 
E2, E4, E5 
- - - - - - - 
Patient 
11 
 
3 - 2 courses 
(15 mg/kg 
x 5 for E1 
and E2)   
Taper over 1 
month from 
2mg/kg/day 
for E1, taper 
over 4 months 
from 2 
mg/kg/day to 
- - - - - - - 
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   First line immune therapy Second line immunotherapy  Third line immunotherapy  
Patient  Number 
of 
episodes 
No 
Imm
Tx 
IV MP Tapering oral 
prednisone 
IVIg PLEX AZT MMF MTX 
 
Rituximab Cyclophospha
mide or 
mitoxantrone 
alternate day 
10 mg when 
relapsed for 
E2, taper over 
2.5 months 
from 2 
mg/kg/day for 
E3 
Patient 
12 
 
2 - 15 
mg/kg/da
y x 3 for 
E1 and x 
5 for E2 
Taper over 7 
weeks from 20 
mg od for E1  
- - - - - - - 
Patient 
13 
 
3 - IV MP 
dose and 
duration 
uncertain 
for E1, 20 
mg/kg/da
y x 3 for 
E3 
Tapering over 
18 months in 
total from 10 
mg od 
(attempts to 
wean below 3 
mg and 2 mg 
resulting in E2 
and E3 
relapses) 
Following 
E3, 2g/kg 
for first 
dose, then 
1g/kg/mo
nth for 8 
months, 
then 
every 
second 
month for 
4 months 
- - - - - - 
Patient 
14 
 
4 - 4 courses 
(30mg/kg 
x 3 for all 
Taper over 4 
weeks from 30 
mg od for E1, 
- - - Followi
ng E4, 1 
g bd for 
- - - 
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   First line immune therapy Second line immunotherapy  Third line immunotherapy  
Patient  Number 
of 
episodes 
No 
Imm
Tx 
IV MP Tapering oral 
prednisone 
IVIg PLEX AZT MMF MTX 
 
Rituximab Cyclophospha
mide or 
mitoxantrone 
E1-E4) then following 
E3 taper over 
21 months 
starting 30 mg 
od when 
relapsed at 8 
months (E4) at 
dose of 10 mg 
alt days which 
led to increase 
to 50 mg od 
and further 
taper for 
another 13 
months before 
cessation 
9 
months 
and 
ongoing 
Patient 
15 
 
4 - 3 courses 
(30 
mg/kg/da
y x 3 for 
E2-E4) 
Taper over 6 
weeks from 40 
mg od (E1), 
over 8 weeks 
each from 20 
mg od (E2 and 
E3), and over 
26 months 
from 40 mg alt 
days (E4) 
Monthly 
IVIg for 
26 
months 
after E4 
6g (0.5 
g/kg) 
- - - - - - 
Patient 
16 
3 - 3 courses 
(30 mg/kg 
Taper from 
2mg/kg/day 
2g/kg x 2 
days  
- - For 15 
months 
- - - 
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   First line immune therapy Second line immunotherapy  Third line immunotherapy  
Patient  Number 
of 
episodes 
No 
Imm
Tx 
IV MP Tapering oral 
prednisone 
IVIg PLEX AZT MMF MTX 
 
Rituximab Cyclophospha
mide or 
mitoxantrone 
 x 3 for 
E1-E3) 
over 7 weeks 
for E1, 6 
months for E2, 
then ongoing 
maintenance 
after E3, 
currently at 7.5 
mg alt days 23 
months after 
E3 
 
(500 mg 
od then 
360 mg 
bd) after 
E2, then 
ceased  
Patient 
17 
 
2 - 30mg/kg 
x 5 for E1 
and x 3 
for E2 
Taper over 16 
months from 
onset (E2 
occurred when 
down to 2.5 
mg alt days 
prompting 
increasing 
dose), 
currently on 
10 mg alt days 
2g/kg 
induction 
dose with 
E1 then 
1g/kg 
monthly 
for 16 
months 
- - - - - - 
Patient 
18 
 
3 E2 
(only 
treate
d 
with 
antie
30 
mg/kg/da
y x 3 for 
E1 and x 
5 for E3 
Taper over 5 
weeks from 40 
mg od for E1, 
from 30 mg od 
now ongoing 
taper at 1.5 
2g/kg 
dose after 
E3  
- - - - - - 
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   First line immune therapy Second line immunotherapy  Third line immunotherapy  
Patient  Number 
of 
episodes 
No 
Imm
Tx 
IV MP Tapering oral 
prednisone 
IVIg PLEX AZT MMF MTX 
 
Rituximab Cyclophospha
mide or 
mitoxantrone 
pilep
tics)  
months post 
E3 
Patient 
19 
 
2 - 15 mg/kg 
x 5 for E1 
and E2 
Taper over 2 
weeks for E1, 
taper from 1 
mg/kg/day 
over 5 months 
for E2 
- - - - - - - 
Patient 
20 
 
5 E1 
and 
E2 
only 
treate
d 
with 
antie
pilep
tics 
1g/day x 
3 for E3-5 
Taper over 10 
weeks from 40 
mg od for E3 
and E4, taper 
over 4 months 
from 60 mg od 
for E5 
 
 
Monthly 
IVIg for 
last 4 
months  
- - - - - - 
Patient 
21 
 
5 - 20 mg/kg 
x 3 for 
E1, 30 
mg/kg x 5 
for E2 
and E3 
Taper over 4 
weeks from 
2mg/kg (40 
mg od) for E1, 
taper over 8 
weeks for E2, 
then ongoing 
for 15 months  
2 g/kg for 
2 days for 
E2 and E3 
- - After 
E4, 500 
mg bd 
then 
increase
d to 600 
mg bd 
(15 
months 
and 
- - - 
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   First line immune therapy Second line immunotherapy  Third line immunotherapy  
Patient  Number 
of 
episodes 
No 
Imm
Tx 
IV MP Tapering oral 
prednisone 
IVIg PLEX AZT MMF MTX 
 
Rituximab Cyclophospha
mide or 
mitoxantrone 
ongoing
) 
Patient 
22 
 
2 - 500 mg x 
5 for E1, 
x 3 for E2 
Taper over 4 
weeks from 2 
mg/kg for E1, 
taper over 4 
months for E2, 
taper over 10 
weeks for E3 
- - - - - - - 
Patient 
23 
 
3  30mg/kg 
x 3 for 
E1, 1 g 
single 
dose for 
E3 
Taper over 7 
weeks from 60 
mg od for E1. 
For E2, started 
at 60 mg od, 
with slow 
wean and 
relapse 
prompting 
increase and 
continuation of 
slow taper 
(now 11 
months 
ongoing at 20 
mg on 
alternate days) 
- - - - - - - 
Patient 
24 
2 - 30 
mg/kg/da
Taper over 3 
weeks from 15 
- - - 500 mg 
od for 
- - - 
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   First line immune therapy Second line immunotherapy  Third line immunotherapy  
Patient  Number 
of 
episodes 
No 
Imm
Tx 
IV MP Tapering oral 
prednisone 
IVIg PLEX AZT MMF MTX 
 
Rituximab Cyclophospha
mide or 
mitoxantrone 
 y x 5 for 
E1 and E2 
mg od for E1, 
taper over 14 
months from 
18 mg od for 
E2 
15 
months 
and 
ongoing  
Patient 
25 
 
3 E1 x 3 days 
each for 
E2 and E3 
Taper over 5 
months from 
25 mg od for 
E2, ongoing at 
4 months for 
E3 
- - - - - - - 
Patient 
26 
 
2 - 30 mg/kg 
x 5 for E1 
and E2, 
with 
second 3 
day 
course for 
E2 
Taper over 3 
weeks from 40 
mg od for E1, 
taper over 1 
year from 60 
mg od for E2 
2g/kg 
over 2 
days for 
E2 
- - 1 g 
mane 
750 mg 
nocte 
for 25 
months 
and 
ongoing 
- - - 
Patient 
27 
 
4 E1, 
E4 
(only 
anti-
epile
ptics) 
1g x 3 for 
E1 and E2 
Taper over 3 
weeks from 50 
mg od for E2 
 
- - - - - - - 
Patient 
28 
 
3 - 30mg/kg 
x 3 for all 
three 
Taper over 5 
weeks for E1 
and E2, and 
1g/kg on 
one 
occasion 
- - - - redosed 4 
times with B 
cell 
- 
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   First line immune therapy Second line immunotherapy  Third line immunotherapy  
Patient  Number 
of 
episodes 
No 
Imm
Tx 
IV MP Tapering oral 
prednisone 
IVIg PLEX AZT MMF MTX 
 
Rituximab Cyclophospha
mide or 
mitoxantrone 
episodes over 6 weeks 
for E3 from 50 
mg od  
for E2, 
then 
induction 
2g/kg and 
monthly 
for 27 
months  
repopulation; 
375 mg/m2 x 
4 infusions 
for fist two 
courses, and 
single 
infusions of 
700 mg (as 
per weight) 
for third and 
fourth doses   
Patient 
29 
 
4 + 2 
episo
des 
(E3 
and 
E4 – 
latter 
treate
d 
with 
β-
IFN   
30 mg/kg 
IV MP x 
3 for E1,  
Initial planned 
taper over 2 
weeks from 50 
mg od, but 
relapse leading 
to an increase 
back to 50 mg 
od and a 5 
week taper  
- - - - - - - 
Patient 
30 
 
2 - 30 mg/kg 
3 for E1 
and E2 
Taper over 6 
weeks from 50 
mg od for E2 
- - - - - - - 
Patient 
31  
3 E2  1g/day x 
3 for E3 
Taper over 2 
weeks from 25 
- - - - - 1000 mg 2x 
7 months 
- 
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   First line immune therapy Second line immunotherapy  Third line immunotherapy  
Patient  Number 
of 
episodes 
No 
Imm
Tx 
IV MP Tapering oral 
prednisone 
IVIg PLEX AZT MMF MTX 
 
Rituximab Cyclophospha
mide or 
mitoxantrone 
mg od for E1, 
taper over 5 
weeks from 50 
mg od for E3 
after E3 
following 
MOG 
antibody 
positive 
result 
Patient 
32 
 
3  3 day 
course 
with each 
of three 
episodes  
Taper over 6 
weeks with 
E1, over 3 
months with 
E2, and over 6 
months with 
E3 (all starting 
from 60 mg 
od) 
2g/kg 
with E1, 
monthly 
1g/kg 
over 3 
months 
with E2 
- - +1 g bd 
for 18 
months 
- - - 
Patient 
33  
2 E1 1g/day x 
3 
Taper over 12 
months from 
60 mg od for 
E2 
 6 
exchang
es 
followin
g E2 
12 
months 
of 150 
mg od 
followin
g cyclo 
- - - 12 months of 
100 mg od of 
cyclophospha
mide 
following E2 
(concurrent 
with steroids) 
Patient 
34 
 
5 E1 
and 
E2 
1 g/day x 
5 E1-E3 
one short taper 
(over 1 
month), and 
then 37 
months of 
tapered 
- monthly 
for 10 
months 
after E4, 
and then 
again 
- 1 g bd 
for 37 
months 
- + 3 courses 
over 24 
months (first 
course 1 g x 
2 infusions, 
second 
- 
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   First line immune therapy Second line immunotherapy  Third line immunotherapy  
Patient  Number 
of 
episodes 
No 
Imm
Tx 
IV MP Tapering oral 
prednisone 
IVIg PLEX AZT MMF MTX 
 
Rituximab Cyclophospha
mide or 
mitoxantrone 
steroids (from 
80 mg down to 
7.5 mg od) 
for 14 
months 
after E5 
course 1 g 
resulting in 
anaphylaxis 
thus 
treatment 
ceased, third 
course 1g 
following 
desensitisatio
n protocol) 
Patient 
35 
 
2  E1 1g/day x3 
for E2 
- - - - - - - - 
Patient 
36 
 
10 E4-
E7 
+ 1 
course of 
IV MP 
1g/day x 
5 for E1  
Taper over 2 
weeks from 
100 mg (E1), 
and 5 episodes 
of oral taper 
from 50 mg to 
cessation over 
1-2 months 
each 
- - - - - - - 
Patient 
37 
 
2 - 1 g x3 for 
E1 and E2 
- - - - 
 
 
- - - - 
Patient 
38 
 
4 - 1g x 3 E1, 
x 5 days 
for E2 
Taper over 
10.5 months 
from 70 mg to 
 - 5 
exchang
es for 
 500 mg 
bd after 
E2, 
- commenced 
after E4, 2 
doses 2 
- 
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   First line immune therapy Second line immunotherapy  Third line immunotherapy  
Patient  Number 
of 
episodes 
No 
Imm
Tx 
IV MP Tapering oral 
prednisone 
IVIg PLEX AZT MMF MTX 
 
Rituximab Cyclophospha
mide or 
mitoxantrone 
and E4 10 mg for E2; 
then increased 
to 75 mg and 
weaned to 7.5 
mg over 2.8 
months for E3 
and continued 
for 3.5 
months, then 
increased to 25 
mg and 
weaned to 
cessation over 
10 months 
following E4 
E2 increase
d to 1 g 
bd in 5 
days, 
continue
d for 
16.2 m 
until 
RTX 
started  
weeks apart, 
relapse free 
for 21 
months to 
date 
Patient 
39 
 
10  E1 + 6 
courses of 
1g/day x 
3 days 
maintenance 
prednisone for  
55 months 
- - for 14 
months 
(ceased 
seconda
ry to 
rash and 
breakthr
ough 
relapses
) 
for 10 
months 
(ongoin
g) 
for 12 
months 
(ceased 
secondary 
to 
intoleranc
e and 
ongoing 
relapses) 
- - 
Patient 
40 
 
2 - 1g/day x 
5 for E1 
and E2 
- - - - - - - - 
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   First line immune therapy Second line immunotherapy  Third line immunotherapy  
Patient  Number 
of 
episodes 
No 
Imm
Tx 
IV MP Tapering oral 
prednisone 
IVIg PLEX AZT MMF MTX 
 
Rituximab Cyclophospha
mide or 
mitoxantrone 
Patient 
41 
 
3 - 1g x 3 for 
E1-E3 
Taper over 20 
months from 
70 mg od to 5 
mg od with 
increased 
doses at 
relapses 
- - - - - - - 
Patient 
42 
 
2 E1 - Taper over 3 
weeks from 50 
mg od for E2 
- - - - - - - 
Patient 
43 
 
2 - 1g/day x 
3 for E1 
Taper over 3.5 
months from 
50 mg od with 
relapse at 5 mg 
od prompting 
increase to 
10mg od and 
commencing 
AZT 
- - 25 mg 
bd and 
increasi
ng to 
2mg/kg 
in 
divided 
daily 
doses 
(TPMT 
heterozy
gote) 
- - - - 
Patient 
44 
 
10 E1-3 
and 
E8 
1g/day x5 
(E5) and 
x 3 (E6, 
E8, E10) 
Taper over 6 
weeks from 25 
mg od  
- - - - - + 1000 mg 
and 500 mg 
IV 2 weeks 
apart with 
10th episode 
- 
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   First line immune therapy Second line immunotherapy  Third line immunotherapy  
Patient  Number 
of 
episodes 
No 
Imm
Tx 
IV MP Tapering oral 
prednisone 
IVIg PLEX AZT MMF MTX 
 
Rituximab Cyclophospha
mide or 
mitoxantrone 
Patient 
45 
 
2 E1 
and 
E2 
- - - - - - - - - 
Patient 
46 
 
4 1 + 2 
courses x 
3 days 
each (E1 
and E2) 
Taper over 3 
months from 
75 mg od then  
slow wean 
over 6 months 
after E3 
- + 5 
exchang
es in 
one 
week for 
E3 
Comme
nced 
after E3, 
ceased 
seconda
ry to 
intolera
nce and 
started 
MMF 
instead 
1 g bd 
for 33 
months 
(ceased 
as 
relapse 
free and 
planning 
pregnan
cy) 
- - - 
Patient 
47 
 
2 - 1g/day x 
3 days E1 
and E2 
Taper over one 
month from 60 
mg for E1, 
taper over 5 
months from 
60 mg for E2 
- - - - - - - 
Patient 
48 
 
2 - 3 day 
course 
after E1 
and E2 
Taper over 6 
weeks from 50 
mg od for E1, 
on 10 mg od 
following E2 
- 5 
exchang
es after 
E1 
started 
on 50 
mg bd 
after E2 
- - - - 
Patient 
49 
 
5 - 1g/day x 
5 (thrice 
following 
Taper over 2 
weeks from 50 
mg for E 1,2,3 
- - - - - - 125 mg qid IV 
for 12 days, 
then single 
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   First line immune therapy Second line immunotherapy  Third line immunotherapy  
Patient  Number 
of 
episodes 
No 
Imm
Tx 
IV MP Tapering oral 
prednisone 
IVIg PLEX AZT MMF MTX 
 
Rituximab Cyclophospha
mide or 
mitoxantrone 
E3, and 
once/ 
episode 
for E4 
and E5) 
infusion 1.25 
months later 
(for E3 and 
E4) 
Patient 
50 
 
5 - 1g/day x 
3 (E2-4) 
40 mg od 
tapered to 
maintenance 
12.5 mg (25 
months and 
ongoing) 
- - - 1 g bd 
since 
after E4  
- 3 doses 500 
mg – 1 g 
each in 14 
months 
- 
Patient 
51 
3 - 1g/day x 
3 (E1-E3) 
- - - - - - - - 
Patient 
52 
 
2 - 1g/day x 
5 (E1 and 
E2) 
_ + 6 
weekly 
IVIg 
(27.5 
g/month) 
increased 
in 
frequency 
to 4 
weekly on 
second 
episode of 
UON 
(over 60 
months as 
- - - - - - 
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   First line immune therapy Second line immunotherapy  Third line immunotherapy  
Patient  Number 
of 
episodes 
No 
Imm
Tx 
IV MP Tapering oral 
prednisone 
IVIg PLEX AZT MMF MTX 
 
Rituximab Cyclophospha
mide or 
mitoxantrone 
treated for 
pre-
existing 
autoimmu
ne 
encephalit
is; 36 
months 
for ON) 
Patient 
53 
 
6 E1 
and 
E2 
 
1g/day x 
3 (E4-6) 
Taper over one 
month from 75 
mg od (E3,5, 
and 6), and 
over 5 days for 
E4  
 
 
- - - - - - - 
Patient 
54 
 
2 E1 
and 
E2 
- - - - - - - - - 
Patient 
55 
2  1g/day x 
3 for E1 
and E2 
Taper over  
10 days from 
50 md od for 
E1; E2 treated 
with 50 mg od 
with slow 
taper over 15.5 
months and 
- - - - - - - 
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   First line immune therapy Second line immunotherapy  Third line immunotherapy  
Patient  Number 
of 
episodes 
No 
Imm
Tx 
IV MP Tapering oral 
prednisone 
IVIg PLEX AZT MMF MTX 
 
Rituximab Cyclophospha
mide or 
mitoxantrone 
maintenance 3 
mg  po od 
Patient 
56 
 
3 - 1g/day x 
5 for E1, 
x 3 for 
E2, and 
pulsed 
with 
mitoxantr
one once 
a month 
for 3 
months 
after E3 
- - - 100 mg 
od 
started 
after E3 
(ongoin
g 
therapy 
for 47 
months) 
- - - 20 mg IV 
mitoxantrone 
monthly for 3 
months (with 
pulsed IV MP) 
after E3 
Patient 
57 
 
6 - 1g/day x 
5 (E1-3); 
then for 
40 
months 
had a 
monthly 
IV pulse 
(300g to 
1g/month) 
2 relapses on 
attempts to 
taper oral 
prednisone so 
continued with 
slow taper for 
10 months 
prior to 
cessation 
- 5 
exchang
es with 
E2 
200 mg 
od 
(reduced 
to 150 
mg od 
due to 
nausea) 
for 34 
months, 
then 
changed 
to MMF 
due to 
ongoing 
500 mg 
bd 
mainten
ance 6 
months 
and 
ongoing 
 
- - 5 pulses over 9 
months; month 
1 500 mg/m2, 
month 2 750 
mg/m2, month 
3/6/9 1g/m2 
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   First line immune therapy Second line immunotherapy  Third line immunotherapy  
Patient  Number 
of 
episodes 
No 
Imm
Tx 
IV MP Tapering oral 
prednisone 
IVIg PLEX AZT MMF MTX 
 
Rituximab Cyclophospha
mide or 
mitoxantrone 
relapses 
Patient 
58  
5 - 1g/day x 
3 E1-E5 
Taper over 3 
months from 
60 mg od for 
E1, taper over 
6 months from 
60 mg od to 10 
mg od for E2, 
maintained at 
10 mg od over 
9 months until 
E5, then 
increased to 25 
mg od 
following E5 
and 
maintained on 
this for last 5 
months 
- - - 500 mg 
bd 
commen
ced after 
E5, 
increase
d to 
1500 
mg bd 
and 
maintain
ed on 
this for 
last 4 
months 
10 mg 
weekly 
commend
ed after 
E2, and 
continued 
for 6 
months 
with 2 
further 
relapses 
prompting 
switch to 
RTX  
1000 mg x 2 
infusions 
after E4, 
with further 
relapse  8 
months later  
- 
Patient 
59 
 
4 E2 1g/day x 
3 days for 
E1, E3, 
and E4 
Taper over 2 
weeks from 50 
mg for E1 and 
E3, and one 
slow oral wean 
over 6 months 
for E4 
- - - 500  mg 
bd 
commen
ced after 
E4 and 
ongoing 
now for 
6 
months 
- - - 
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    AZT azathioprine; ImmTx immunotherapy; IVIg intravenous immunoglobulin; IV MP intravenous methylprednisolone; MMF mycophenolate mofetil;  
    MTX methotrexate; PLEX plasma exchange 
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4.5.6 Efficacy of maintenance immunosuppression 
 
The ARR pre-, on-, and post-treatment, cumulative cohort ARR, and failure rates for 
each therapeutic agent are summarised in Table 4.6.  
 
17 patients received maintenance oral prednisone for ≥6 months and were included in 
ARR calculations (Figure 4.4A). 1/17 (6%) experienced treatment failure. 
 
7/14 patients treated with IVIg fulfilled inclusion criteria for maintenance therapy 
(Figure 4.4B). Three patients had six relapses while on adequate treatment with IVIg. 
3/7 (43%) experienced treatment failure. Three relapses in two patients occurred 
while weaning IVIg doses (n=2) or increasing dosing intervals (n=1).  
 
15/16 patients given mycophenolate fulfilled inclusion criteria for maintenance 
therapy (Figure 4.4C) with a median duration of treatment of 15 months (range 6-37 
months). Eight patients experienced ten relapses. 7/15 (47%) experienced treatment 
failure. 4/10 relapses occurred during concomitant prednisone taper.  7/10 relapses 
occurred within the first year of mycophenolate treatment. One patient relapsed one 
month following mycophenolate cessation. 
 
5/7 patients given rituximab fulfilled inclusion criteria (Figure 4.4D). 3/5 patients 
were redosed (4 courses in 1 patient, and 3 courses each for 2 patients). Treatment 
failure occurred in 1/5 (20%) patients with 2 relapses (1 and 3 months after dosing) 
despite B cell depletion. Three patients had B cell repopulation relapses more than 6 
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months after treatment and were redosed with rituximab. 1/5 patients remained 
relapse free following the first infusion of rituximab and has not been retreated.  
 
Seven patients were treated with azathioprine. Three patients experienced intolerance 
with prominent nausea, prompting cessation. Four patients received azathioprine for 
≥6 months and 2/4 were treatment failures (Figure 4.4E).  
 
Two patients were treated with methotrexate. 1/2 patients reported nausea and fatigue 
but continued treatment. Both patients experienced breakthrough relapses despite 
adequate dose and duration of treatment. Another 2 patients were treated with 
cyclophosphamide, with 1 experiencing treatment failure during ongoing treatment. 
6/59 patients received plasma exchange during treatment, with 5 patients receiving 5 
exchanges following a single demyelinating episode. Only 1 patient (patient 34) 
received monthly plasma exchange over a 24 month period, but has required 
concomitant steroids, mycophenolate and rituximab to control disease activity.  
 
7/59 patients switched maintenance immunosuppression treatment (Figure 4.4F) due 
to concerns of cumulative dose toxicity in one (cyclophosphamide), intolerable side 
effects of nausea and vomiting in one (azathioprine), and treatment failure of the 
initial agent in five (mycophenolate n=2, methotrexate n=2, azathioprine n=1) 
patients. Two patients experienced a relapse following a switch in treatment, with 1/7 
(14%) experiencing treatment failure.  
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As summarised in Table 4.6, all treatments were associated with a reduction in ARR 
on-treatment, with maintenance prednisone having the lowest treatment failure rate. 
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Table 4.6. Evaluation of pre- and on- treatment annualised relapse rates for the main treatment modalities 
 
Treat
ment 
moda-
lity 
Num-
ber of 
patie-
nts  
on 
treat-
ment 
for > 
6m 
Disease 
duration 
(months) 
at time 
of 
comme-
ncement 
of 
therapy 
median 
(range) 
Duration 
of 
therapy 
(months) 
median 
(range) 
Pre 
treatm-
ent 
ARR1 
exclud-
ing first 
episode 
median 
(range) 
ARR1 on 
treatment 
median 
(range) 
Concurrent 
treatment 
Cumulative  
cohort ARR 
on-
treatment 
for all 
patients 
with a 
particular 
treatment 
modality  
(episodes/ 
months) 
Change 
from pre-
treatment 
to ARR 
on 
treatment 
(%) 
excludi-
ing first 
episode  
median 
(range) 
Wilc-
oxon 
P-
value2 
Post-
treat-
ment 
ARR1  
median 
(range)3 
Failure 
rate (%  
of 
patients) 
Main-
tenan-
ce oral 
predn-
isone 
17 12 (1-78) 10 (6-53) 2 (0.5-
6) 
0 (0-1.57) MFM (n=10), 
IVIg (n=4), 
AZT (n=3), 
RTX (n=2), 
PLEX (n=1), 
MTX (n=1), 
cyclo (n=1), 
beta-IFN 
(n=1) 
9/271 = 
ARR of 
0.40 
100 
(-87.5 to 
100) 
0.000
4 
0 (0-
0.6) 
1/17 
(6%) 
MMF 15 9 (1-76) 15 (6-37) 1.83  
(0.47-
6.00) 
0.32  
(0-4.00) 
Steroids 
(n=15), RTX 
(n=3), Beta-
IFN (n=1) 
10/253 = 
ARR of 
0.47 
83  
(-700 to 
100) 
0.074 0 (0-
0.48) 
7/15 
(47%) 
IVIg  7 12 (0-60) 16  2 (0.8- 0  (0-0.75) Steroids 6/326 = 100 0.250 0 (0-0) 3/7 
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(8-189) 2) (n=6, RTX 
n=1, beta-
IFN n=1) 
ARR of 
0.22 
(100-
100) 
(43%) 
Ritux-
imab 
5 18 (3-54) 18 (6-24) 1.65  
(0.67-
2) 
0 (0-1.33) Steroids 
(n=5), 
monthly IVIg 
(n=1), 
monthly 
PLEX (n=1), 
MFM (n=1), 
beta-IFN 
(n=1) 
2/74 = ARR 
of 0.32 
100 (34-
100) 
0.125 0 (0-
1.71) 
1/5 
(20%) 
Swit-
ched 
treat-
ment 
7 27  
(7-60) 
8 (6-33) 1.42   
(0.8-
2.13) 
0   (0-1.2) Steroids 
(n=6), RTX 
(n=1) 
2/81 = ARR 
of 0.30 
100 (44-
100) 
0.031 0 (0-2) 1/7 
(14%) 
 
1 all ARRs only calculated if time period included with a particular treatment modality was >/ 6 months 
2 The Wilcoxon signed-rank test was used to identify the presence of difference between the pre-treatment and on-treatment ARR, but does 
not represent the size of this change 
3 post treatment ARR calculated only in patients in whom modality of treatment in question has been ceased 
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Figure 4.4 Disease activity of MOG antibody-positive patients on immunosuppressive 
therapy  (A) Depictions of the clinical course and disease activity in patients who underwent 
therapy with maintenance prednisone. In patients who had more than two courses of 
maintenance prednisone lasting ≥ 6 months each, the green lines depict the duration of each 
course of maintenance corticosteroid therapy. Depictions of the clinical course and disease 
activity in patients who underwent therapy with monthly IVIG (B), mycophenolate (C), 
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rituximab (D), and azathioprine (E). (F) Illustration of response to switched therapy in the 
event of side effects (patient 46 azathioprine to mycophenolate), treatment failure of the 
initial agent (patient 38 mycophenolate to rituximab, patient 58 methotrexate to rituximab, 
patient 39 methotrexate to mycophenolate, patient 8 mycophenolate to monthly IVIg, and 
patient 57 azathioprine to mycophenolate), or after exceeding the maximum recommended 
cumulative dose of the first agent (patient 33 cyclophosphamide to azathioprine). All therapy 
(or switched therapy) commenced at time point 0. The magenta lines represent a 
demyelinating episode. The purple squares represent time of treatment cessation. The orange 
circles represent time of latest clinical follow-up. The blue arrows represent timing of 
rituximab dosing.  
 
 
4.5.7 Risk factors for poor outcomes and residual disability  
 
The average EDSS at initial presentation was 5 (median 5, range 1-9.5) and at latest 
follow-up was 1.3 (median 1, range 0-5.5) (Table 4.7).  
 
Table	4.7		 EDSS	during	sequential	episodes	and	at	recovery	from	each		
episode		Episode	Number	 Number	of	patients	with	EDSS	available	
	Mean	 Median	 Range	 Interquartile	Range	
Episode	1	nadir	 44	 5		 5	 1-9.5	 3-6	Episode	1	recovery	 42	 0.9		 0	 0-4	 0-1.1	Episode	2	nadir	 51	 4.3	 4	 1-8	 3-5.5	Episode	2	recovery	 49	 1.1	 1	 0-5	 0-2	Episode	3	nadir	 30	 4.1	 5	 1-7	 3-5	Episode	3	recovery	 30	 1.5	 1	 0-5	 0-2	Episode	4	nadir	 22	 4.1	 5	 1-8.5	 2-5.5	
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Episode	4	recovery	 19	 1.6	 1	 0-5	 0-3.1	Episode	5	nadir	 11	 3.7	 3	 1-7.5	 3-4.5	Episode	5	recovery	 14	 1.8	 1.5	 0-5.5	 0.75-3	Episode	6	nadir	 4	 3	 3	 3-3	 3-3	Episode	6	recovery	 5	 1.4	 2	 0-2	 0.5-2	Episode	7	nadir	 2	 3.8	 3.8	 3.5-4	 3.5-4	Episode	7	recovery	 2	 2.5	 2.5	 2-3	 2-3	Episode	8	nadir	 5	 2.6	 2	 2-4	 2-3.5	Episode	8	recovery	 5	 1.6	 1	 1-3	 1-2.5	Episode	9	nadir	 3	 2.3	 2	 2-3	 2-3	Episode	9	recovery	 3	 1.3	 1	 1-2	 1-2	Episode	10	nadir	 3	 3.5	 3	 2-5.5	 2-5.5	Episode	10	recovery	 3	 1.7	 2	 1-2	 1-2		EDSS	expanded	disability	status	scale	
 
 
The median EDSS at recovery for later episodes was higher than the median EDSS at 
recovery for earlier episodes (Figure 4.5A). None of the patients who experienced ≥7 
episodes returned to an EDSS of 0, suggesting cumulative disability.  
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Figure 4.5 Recovery and outcomes in relapsing MOG antibody-associated demyelination 
(A) Median EDSS and range of the cohort at the nadir and at recovery after each 
demyelinating episode. (B) Percentage of patients with residual disability in a particular 
domain. (C) Recovery status of all clinical episodes based on clinical phenotype.  
E: episode 
 
Patients with ≥3 episodes in total were more likely to have a final follow-up EDSS of 
≥2 (P=0.019) (Table 4.8). None of the other risk factors assessed were associated with 
a final follow-up EDSS of ≥2, although the presence of TM approached significance 
(P=0.096).  
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Table 4.8 Risk factors associated with EDSS ≥ 2 at final follow up 
 
Risk Factor Frequency of a residual deficit1 at final 
follow up 
Odds Ratio 
(OR) 
95% Confidence Interval  
(95% CI) 
P value 
Older age of onset Paediatric patients 12/33 (36%) 
Adult patients 13/26 (50%) 
1.75 0.61-4.98 0.293 
Female gender Males 7/19 (37%) 
Females 18/40 (45%) 
1.40 0.46-4.30 0.554 
Any ON Patient without ON 6/10 (60%) 
Patients with ON 19/49 (39%) 
0.42 0.11-1.69 0.216 
Any TM Patients without TM 14/40 (35%) 
Patients with TM 11/19 (58%) 
2.55 0.83-7.82 0.096 
Delayed treatment Patients with early treatment initiation 16/43 
(37%) 
Patients with delayed treatment initiation 
9/16 (56%) 
2.17 0.68-6.96 0.188 
Number of relapses Patients with 1 relapse (2 episodes in total) 
5/22 (22%) 
Patients with ≥2 relapses (≥3 episodes in 
total) 20/37 (54%) 
4.00 1.22-13.13 0.019 
 
1 a ‘residual deficit at final follow up’ was defined as an EDSS of ≥2 at latest clinical follow up 
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41% (24/59) of patients had no residual disability (Figure 4.5B). The most common 
deficit was visual acuity loss (15/59, 25%). A further 8/59 had optic disc pallor on 
fundoscopy, without visual acuity reduction. Other disability including sensory (9/59, 
15%), motor (8/59, 14%), cognitive (7/59, 12%), and sphincter (6/59, 10%) 
dysfunction was also present. Epilepsy was rare (2/49, 3%) and limited to 2 children 
who had seizures as a prominent part of their early presentation. Recovery status was 
available in 188/216 episodes (Figure 4.5C). The proportion of episodes with 
complete recovery was higher when the presenting phenotype was ADEM, BON, and 
UON, and lower with TM (Table 4.9).  
 
Table	4.9	 Recovery	status	based	on	clinical	phenotype		
	
	
	 Complete	
Recovery	(CR)	
	
Partial	Recovery	
(PR)	
No	Recovery	
(NR)	ADEM	 7/16	(44%)	 9/16	(56%)	 0/16	(0%)	BON	 21/37	(57%)	 16/37	(43%)	 0/37	(0%)	UON	 33/67	(49%)	 30/67	(45%)	 4/67	(6%)	LETM	 1/10	(10%)	 9/10	(90%)	 0/10	(0%)	Short	TM	 2/12	(17%)	 10/12	(83%)	 0/12	(0%)	Brainstem	 4/7	(57%)	 3/7	(43%)	 0/7	(0%)	Cerebellar	 1/4	(25%)	 3/4	(75%)	 0/4	(0%)	Seizures	 2/3	(67%)	 1/3	(33%)	 0/3	(0%)	Mixed	 7/22	(32%)	 14/22	(63%)	 1/22	(5%)	Other	 3/10	(30%)	 7/10(70%)	 0/10	(0%)	
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4.5.8 Serial MOG antibody testing in relapsing patients 
 
We evaluated the clinical course and treatment response in 12 patients with serial 
serum samples tested for MOG antibody positivity (representated in Figures 4.6 and 
4.7). The steroid sensitivity and tendency to relapse on cessation of short courses of 
IV or oral steroids is clearly illustrated. Overall, there does not appear to be a close 
correlation with the degree of MOG antibody binding as demonstrated by ΔMFI, and 
disease activity or relapse status. While the presence of antibodies or the quantitative 
degree of antibody binding as determined by the ΔMFI is useful, this does not equate 
to antibody concentration, titre, or mechanisms of pathogenicity. While one patient 
who had been in clinical remission for an extended period of time (Figure 4.6A) 
became MOG antibody seronegative, patients with ongoing relapses remained 
seropositive but did not always demonstrate a rise in MFI at relapse (Figure 4.6B and 
C, Figure 4.7). 11/12 relapsing patients remained seropositive, even during remission. 
Figure 4.6A represents a subgroup of MOG antibody-positive patients who, after an 
initial period of prominent disease activity, achieve clinical remission even in the 
absence of therapy. The patient represented in Figure 4.6C is interesting as she was 
strongly MOG antibody-positive in serum collected 2 years prior to her first 
demyelinating episode, when she presented with an LGI1 antibody-positive 
autoimmune encephalitis, once again highlighting a lack of correlation between 
demyelinating disease activity and the degree of MOG antibody binding.  Despite 
recurrent relapses, many patients with ON predominant disease appear to have milder 
residual disability as measured by EDSS (Figure 4.6), while patients with TM are left 
with more severe functional impairment (Figure 4.7). 
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Figure	 4.6	 Serial	 samples	 in	 patients	 with	 relapsing	 MOG	 antibody-
associated	demyelination	Clinical	episodes	of	demyelination,	and	the	nature	and	 duration	 of	 immunotherapy	 are	 indicated.	 Mean	 fluorescence	 intensity	(MFI)	tested	on	serial	serum	samples	represented	on	left	y-axis	(magenta)	with	the	dotted	black	line	representing	the	positive	threshold.	EDSS	represented	on	the	right	y-axis	(blue).	
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Figure	 4.7	 Serial	 samples	 in	 two	 patients	 with	 relapsing	 MOG	 antibody-
associated	 demyelination	 characterised	 by	 LETM	 Clinical	 episodes	 of	demyelination,	 and	 the	 nature	 and	 duration	 of	 immunotherapy	 are	 indicated.	Mean	 fluorescence	 intensity	 (MFI)	 tested	on	 serial	 serum	samples	 represented	on	 left	 y-axis	 (magenta)	 with	 the	 dotted	 black	 line	 representing	 the	 positive	threshold.	 EDSS	 represented	 on	 the	 right	 y-axis	 (blue).	 Both	 patients	 had	
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significant	residual	disability	from	their	transverse	myelitis,	at	long-term	clinical	follow	up.	
 
4.6 DISCUSSION 
 
This study systematically evaluates the responses to various therapies in a large cohort 
of patients with relapsing MOG antibody-associated demyelination. We highlight the 
strong clinical association with ON and the steroid responsiveness of this condition, 
and the fact that increasing numbers of relapses can worsen long-term outcomes. 
Immunotherapy, particularly low dose steroids, IVIg, and rituximab reduce relapse 
rates.  
 
This study identified a female predominance, and over 70% of patients in this 
Australasian cohort were Caucasian. Coexistent autoimmunity in this cohort was 
lower than reported for AQP4 antibody-positive patients. Demyelinating episodes in 
almost half the patients were preceded by an infectious prodrome. BON was the most 
common initial presentation and UON was the most frequent phenotype throughout 
the disease course. Optic disc swelling was common as we have previously reported 
(Chapters 2.4 and 3.4.2). ADEM was prominent in children192, while TM was more 
common in adults. It is additionally likely that a proportion of children previously 
classified as multiphasic DEM (MDEM) have MOG antibodies237, 238. Brainstem 
presentations classically recognised in AQP4 antibody-positive disease239, were 
present in some patients and have also been recently reported240. MOG antibody-
associated seizures have been described in a few adults241 and we identified two such 
children.  
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A large proportion of patient MRIs showed no brain lesions, and only a small 
percentage fulfilled revised McDonald criteria. This contrasts with MS radiology, and 
may be helpful diagnostically. Recent publications have found similar predictors of 
MS versus antibody-associated demyelination based on specific MRI brain 
characteristics242, 243. 
 
This study identified that patients with relapsing MOG antibody-associated 
demyelination are steroid responsive, but frequently relapse at daily prednisone doses 
<10 mg, within the first two months of steroid cessation, and with a rapid taper. This 
data provides further detail to corroborate previous reports on post-steroid relapses by 
our group (outlined in Chapter 2.4.3.2) as well as a European cohort232. A number of 
patients had an extremely rapid return to baseline within 48 hours following steroid 
initiation (personal observation). Some patients on maintenance low dose prednisone 
alone had a relapse free course, suggesting this is effective in sustaining remission, 
but the long-term metabolic and bone related side effects warrant caution. Despite the 
relatively recent recognition of MOG antibody-associated demyelination, the practical 
use of steroids for this condition has rapidly deviated from normal practice in MS to 
include steroid use for more prolonged periods with a slower weaning process, 
indicating that neurologists have observed this steroid dependence in their 
accumulating experience.  
 
This study identified improvement in ARRs with most immunotherapy evaluated. 
Treatment failure rates were lowest with maintenance oral prednisone and rituximab. 
Weaning doses of IVIg and prednisone as well as B cell repopulation after rituximab 
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frequently resulted in relapses, further emphasising the effect of immune therapy in 
relapse prevention in this condition. In relapsing MOG antibody-positive patients 
needing rituximab, regular CD19 monitoring and proactively redosing a brittle patient 
in the event of B cell repopulation might reduce the incidence of repopulation 
relapses, as demonstrated in NMOSD244, 245. Mycophenolate also appeared to have 
effect, but treatment failure rates were higher and relapses were often associated with 
steroid taper suggesting the steroid was producing the benefit in these patients. The 
majority of mycophenolate relapses occurred within the first 12 months of treatment, 
suggesting perhaps continuing mycophenolate therapy for over a year before weaning 
off concurrent steroid therapy may be more likely to induce remission. Interestingly, 
studies in myasthenia gravis similarly support the finding that in the short term, 
mycophenolate is not superior to placebo in reducing relapses246, 247. Switching 
maintenance immunotherapy following treatment failure on the initial agent 
significantly reduced relapse rates, supporting the need for flexibility in management. 
 
MOG antibody-associated demyelination has been suggested to have a more favorable 
prognosis compared to AQP4 antibody-associated disease202, 210, 231, 234. The median 
EDSS at acute presentation in this relapsing cohort was 5 and at latest clinical follow-
up was 1, suggesting that the most patients did have a good outcome. We showed that 
the severity of the first episode appeared to be worse than relapses – this could be due 
to either patients presenting earlier or being on immunotherapy at the time of relapse, 
or potentially due to the nature of the disease process. However, patients with more 
relapses and/or TM did have the potential for marked disability with EDSS up to 5.5. 
We showed only 41% of patients had no residual disability, suggesting that EDSS 
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measures may underestimate non-motor deficits. Residual disability including visual 
acuity loss, sensory deficits, and/or sphincter dysfunction, in addition to potential  
weakness was present in the majority of our cohort. A recent study by Jarius et al232 
similarly highlights the potential for serious disability in these patients. We 
additionally observed some MOG antibody-positive patients remained relapse free for 
a long time after initial treatment with steroids, and had a relapse many years later.  
 
Our data suggests that in relapsing MOG antibody-positive patients, a prolonged 
steroid taper may reduce the chance of early relapses and provide a good maintenance 
option, with close monitoring during and after steroid cessation. Having a relapse plan 
with readily accessible steroids for typical symptoms has also been used locally in 
some patients. In the event of a relapse, after acute treatment, prophylaxis with low 
dose prednisone or monthly IVIg would be reasonable, with mycophenolate or 
rituximab as a next step. In the event of a patient having TM, more aggressive 
immunosuppressive therapy such as rituximab from an early stage would be indicated 
if the patient is not showing early improvement with steroids.  Second line agents 
such as mycophenolate may take months to reach full efficacy, thus corticosteroids 
should not be rapidly weaned when adding or switching therapeutic agents. 
 
Serial samples from a selection of MOG antibody-positive patients in our cohort 
demonstrated the majority remained seropositive. While we did not identify an 
association with absolute MFI values and disease activity, this must be tempered with 
the fact that we did not examine titres in these patients. All sera were assayed at a 1 to 
50 dilution and are therefore not representative of a MOG antibody titre, which in fact 
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could vary with treatment. A recent study248 has identified that median MOG Ig-G 
titres were significantly higher (median titre 1:2560) in samples taken during an acute 
episode or temporally close to a relapse, compared to those taken in remission more 
than 3 months after a clinical episode of demyelination (median titre 1:320), although 
there was a wide range between individual samples. 
 
Limitations of our study include the retrospective design, the small number of patients 
in some treatment groups, and the fact that some patients were on multiple therapeutic 
agents simultaneously. Some regression to the mean with ARRs cannot be excluded. 
Additionally, indication bias, which is inherently present in observational studies, is 
acknowledged. Future studies with accumulated larger cohorts should identify clinical 
and radiological characteristics that may confound treatment assignment and combine 
them into a propensity score for use in multivariable models in order to mitigate some 
of the effects of indication bias. Nevertheless, this study systematically evaluates 
treatment responses in the largest reported cohort of relapsing MOG antibody-positive 
patients with extensive clinical follow-up, and provides important information on 
disease course, therapeutic efficacy, and outcomes.  
 
In conclusion, ON is the dominant manifestation of MOG antibody-associated 
demyelination, but there is a wide clinical spectrum. Relapsing patients are often 
steroid responsive, but vulnerable to relapses on tapering or withdrawal. 
Consideration should be given to early secondary prevention treatment strategies that 
may include maintenance corticosteroids, IVIg, or immunosuppression with 
mycophenolate or rituximab.  
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5.1 SUMMARY OF THESIS 
 
This thesis encompasses work undertaken to detail the clinical phenotypes, 
radiological characterisation, therapeutic responses, and outcomes of patients with 
MOG antibody-associated demyelination.  
 
MOG has been a putative candidate antigen in demyelination for over three decades, 
based on experimental data in animal models as highlighted in Chapter 1. With the 
evolution and refinement of antibody detection methods and the advent of the cell 
based assay detailed in Chapter 2, MOG antibodies were initially identified as an 
important biomarker in children with demyelination, particularly in those presenting 
with ADEM. At the start of my PhD candidature, the role of MOG antibodies in 
adults was less clear, apart from the growing consensus that they were not present in 
most adults with MS. Our published work outlined in Chapter 2.4 detailed one of the 
earliest cohorts internationally to identify that MOG antibodies were present in a 
subgroup of adults with AQP4 antibody-negative NMOSD. This publication was 
critical in highlighting the strong association of MOG antibodies with ON, and in 
particular BON, often accompanied by optic disc swelling. This work also identified 
that some patients may have other features of the NMOSD spectrum including 
LETM, and had the potential to experience residual disability. We additionally 
showed that most patients with Japanese OSMS, another demyelinating syndrome 
with a predilection for spinal cord and optic nerve involvement, were negative for 
MOG antibodies, as discussed in Chapter 2.5. 
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ON is a common overlapping clinical phenotype in MS, MOG and AQP4 antibody-
associated demyelination. Given MRI is a critical and widely available investigation 
in evaluating patients with demyelination, we explored whether there were any 
characteristic radiological findings of the optic nerve on a first presentation of ON 
that could help differentiate between these three aetiologies. As hypothesised, this 
publication detailed in Chapter 3, identified that bilateral optic nerve involvement was 
more common in the two antibody-associated demyelination syndromes than in MS, 
and that patients with MOG and AQP4 antibodies more frequently had longitudinally 
extensive involvement of the optic nerve compared with the more focal involvement 
seen in MS. MOG antibody-positive patients had more anterior visual pathway 
involvement, with optic nerve head swelling as well as prominent involvement of the 
retrobulbar section of the optic nerve.  In contrast, patients with AQP4 antibodies had 
more posterior visual pathway changes with prominent intracranial optic nerve, optic 
chiasmal, and tract involvement. Patients with AQP4 antibodies had more severe and 
sustained visual impairment, but a subgroup of MOG antibody positive patients also 
had significant and irreversible visual acuity loss. 
 
A significant proportion of MOG antibody-positive patients we diagnosed were 
identified as having a relapsing course, and provided an opportunity to evaluate their 
associated clinical phenotypes, treatment responses, and outcomes, as explored in 
Chapter 4.  Evaluating 216 demyelinating episodes from 59 patients (33 paediatric 
and 26 adults) revealed that the most common presenting phenotype was ON (BON 
being more common on first presentation than UON), in both adults and children, 
followed by ADEM in children. Throughout the disease course, ON remained the 
dominant phenotype with UON more common during relapses than BON. Almost half 
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the patients had no brain lesions on MRI, most with lesions had resolution of lesions 
with clinical remission, and only a minority of patients fulfilled revised McDonald 
criteria for MS, suggesting that these patients have a very different radiological 
profile to those with clinically definite MS. Patients were largely steroid responsive, 
but 70% of episodes treated with steroids relapsed, primarily with attempts to wean 
the prednisone dose, within the first 2 months of cessation of an oral taper of steroids, 
and with a rapid taper. Maintenance prednisone, intravenous immunoglobulin, 
mycophenolate mofetil, and rituximab all reduced ARRs on-treatment, with 
maintenance prednisone having the lowest treatment failure rate. After an average 
follow-up of 60 months, 59% of patients experienced some form of residual disability 
(including visual acuity loss in 25%). Patients who had 3 or more episodes of clinical 
demyelination were more likely to have residual disability at long-term follow-up. 
 
The work encompassed in my thesis has served to better define the clinical and 
radiological phenotype of patients with MOG antibody-associated demyelination, and 
provide early data on treatment efficacy and outcomes in these patients. This final 
chapter will evaluate international findings which expand on our understanding of 
MOG antibody-associated demyelination, discuss a proposed algorithm to investigate 
and manage patients with a first presentation of ON, expand on future directions in 
this rapidly evolving field, and conclude with recommendations regarding 
nomenclature and diagnostic testing in this recently described but increasingly 
recognised clinical entity. This chapter is inclusive of work that has been published in 
Autoimmunity Reviews (Ramanathan et al 2016)1 as well as a publication that is 
currently under review (Ramanathan et al 2017). 
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5.2 EVALUATING OUR FINDINGS IN THE CONTEXT OF THE 
EMERGING LITERATURE ON MOG ANTIBODY-ASSOCIATED 
DEMYELINATION 
 
5.2.1 Clinical phenotype and disease course 
 
Since our initial publication outlined in Chapter 2.4, there have been advances made 
in the international literature that enhance our understanding of MOG antibody-
associated demyelination. Studies using cell based assays to detect MOG antibodies 
are detailed in Appendix D, and the main findings they highlight that are relevant to 
this thesis will be discussed in Section 5.2. 
 
In keeping with our findings, MOG antibody-positive patients have been shown to 
exhibit less of a female preponderance and to have a higher Caucasian representation 
than AQP4 antibody-positive patients202, 210, 231, 232, 249-251. Our finding of infections, 
vaccinations, or childbirth preceding the first episode of demyelination in some 
patients in our relapsing cohort have been similarly identified in a European cohort232, 
suggesting a potential trigger for BBB breakdown and access of peripheral 
autoantibodies to the CNS in these cases.   
 
The association of MOG antibodies with ON, and particularly BON, highlighted in 
our work has been corroborated by multiple other groups248, 252. While LETM is 
present, we have shown in our relapsing cohort and other groups have also identified 
that many myelitis episodes are short TM232, 253. In patients with first episode LETM, 
those who were MOG antibody-positive were more likely to have further episodes of 
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ON compared to those who were seronegative234. More MOG antibody-positive 
patients appear to present with simultaneous or immediately sequential ON and TM as 
classically described in Devic disease than AQP4 antibody-positive patients232, 250, 251, 
253. 
 
The clinical spectrum associated with MOG antibodies is expanding. MOG antibodies 
have now been identified in children with multiphasic DEM (MDEM)238 who had two 
or more episodes of ADEM. While the association of brainstem involvement in AQP4 
antibody-positive NMOSD is well established, this has now been identified in patients 
with MOG antibodies240, 254, and certainly was present in a few patients in our 
relapsing cohort. These patients with brainstem lesions may manifest with respiratory 
insufficiency, intractable nausea and vomiting, hiccups, dysphagia, and/or dysarthria, 
and this presentation may occur with concomitant myelitis and/or ON or in 
isolation240. We identified two children in our relapsing cohort who presented with 
seizures but who did not fulfill clinical or radiological criteria for ADEM, and only 
later went on to develop demyelinating episodes. A recent study has identified a small 
group of MOG antibody-positive adults who similarly present with seizures and have 
radiological and clinical features supporting a unilateral cortical encephalitis241. 
 
Of much interest given a general concordance that MOG antibody-positive patients 
are largely phenotypically and radiologically distinct from MS, a recent study 
identified a few patients with MOG antibodies who had clinically definite MS and 
were McDonald positive, with positive intrathecal oligoclonal bands and supporting 
radiology255. These patients had brainstem and spinal cord involvement with a severe 
disease course, numerous relapses, failure of immunomodulatory therapy, and a 
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favourable response to plasma exchange in some. This finding emphasises that there 
remains some overlap in clinical phenotype and antibody serostatus in patients with 
clinically definite MS and antibody-associated demyelination, and that clinical 
responses to therapy rather than serological findings should guide management. 
 
Interestingly, there have been recent reports of MOG antibodies being associated with 
other immune mediated CNS presentations. For example, demyelination preceding, 
concurrent with, or following autoimmune encephalitis has been described, in patients 
with anti-NMDAR antibody-associated encephalitis who also have AQP4 or MOG 
antibodies256, 257. Indeed, this was replicated in our experience where some of the 
patients we have diagnosed with MOG antibody-associated demyelination have had 
previously confirmed antibody-positive autoimmune encephalitis (two patients with 
NMDAR encephalitis not previously discussed in this thesis, and one patient with 
LGI1 antibody-positive encephalitis). 
 
While MOG antibody-associated demyelination was initially described as more 
frequently being monophasic compared to AQP4 antibody-positive NMOSD202, 210, 250, 
251, 253, 258, our group and others who have studied larger cohorts of patients with a 
longer follow-up period have identified that a substantial proportion of MOG 
antibody-positive patients have a relapsing disease course231, 232, 259, 260. 
 
5.2.2 Serum and CSF MOG antibody status 
 
Cases of patients being seropositive for both AQP4 and MOG antibodies were 
reported when anti-MOG antibodies were detected by ELISA261 but are in reality 
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extremely rare when using cell based assays157, 202, 210, 219, 231, 233, 248, 258, 260, 262. Even 
using cell based assays, numerous factors influence the sensitivity and specificity for 
MOG antibody detection. C-terminal truncation of the human MOG antigen resulting 
in short length (SL) MOG, as compared to full length (FL) MOG has been found to 
reduce the sensitivity of the cell based assay263. Given the extracellular domains are 
identical in SL- and FL-MOG with the only difference being the former is shorter by 
73 cytosolic amino acids at the intracellular C-terminus than the latter, the differences 
in assay sensitivity may be secondary to surface expression of the construct, or the 
ability to multimerise263. Waters et al identified low specificity with the use of FL-
MOG that they attributed to cross-reactivity of the anti-human IgG antibody with the 
IgM antibody263. They found the specificity increased significantly with the use of an 
IgG1-specific antibody. Additional studies have identified the MOG antibody is of the 
IgG1 isotype, which is associated with complement activation248. In our hands, we 
find that IgG antibodies targeting FL-MOG have a high specificity and sensitivity 
when analysed using flow cytometry, and low cross-reactivity with IgM. The low 
sensitivity with the use of SL-MOG implies it should not be used in diagnostic 
assays263, therefore previous publications describing an association between SL-MOG 
antibody and clinical features in patients would need confirmation with FL-MOG 
antibody. 
 
In our experience and corroborated by other groups, only a small proportion of MOG 
antibody-positive patients have intrathecal oligoclonal bands189, 194, 232. MOG antibody 
detection has been found to be more sensitive in serum when compared to CSF. One 
study found that in MOG IgG seronegative patients, the corresponding CSF samples 
were negative; at the low titre range MOG antibodies were only present in the serum 
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but not in the CSF; but in patients with serum titre values greater than or equal to 
1:640, there was detectable reactivity to MOG in the CSF, suggesting a peripheral 
production of MOG specific autoantibodies189. Similarly in other studies, patients 
positive for serum MOG antibodies were shown to be negative for CSF MOG 
antibodies, or have a reduced MOG-specific antibody index which allows 
quantification of antigen-specific intrathecal antibody synthesis, which could either 
represent a lack of sensitivity of the assay or, more likely, a lack of intrathecal 
immunoglobulin production231, 248. This is similar to the finding that AQP4 IgG 
autoantibodies often have a much higher serum than CSF concentration, consistent 
with peripheral production of antibodies264. Interestingly, the EAE animal model of 
demyelination is similarly peripherally stimulated, with peripheral injection and 
immunisation with myelin peptides and Freund’s complete adjuvant resulting in an 
encephalitogenic trigger, which in the context of a breached BBB, results in 
encephalomyelitis131. 
 
5.2.3 Radiology                                                               
                                                                                                                                                                                                                                                    
We have found that cerebral imaging is abnormal in about a third of MOG antibody-
positive patients, and numerous other studies have identified a variety of lesions 
including blurred hazy large lesions, widespread cortical lesions, deep grey matter 
involvement such as bilateral thalamic and basal ganglia lesions, and cerebellar and 
brainstem changes 158, 159, 210, 253, 265. In our experience, there has been rapid resolution 
of radiological cerebral changes, particularly following steroid therapy, and this has 
been corroborated210, 253. A recent study performed a detailed analysis of radiological 
features in MS, MOG and AQP4 antibody-positive patients and identified that the 
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lesions most suggestive of MS included ovoid lesions adjacent to the body of the 
lateral ventricles, the presence of Dawson’s finger-type lesions, and T1 hypointense 
lesions; while the presence of ‘fluffy’ lesions and having three or fewer lesions was 
most predictive of MOG antibody-associated demyelination242, 243. These findings are 
predictive at distinguishing MS from either of the two antibody-associated 
demyelination syndromes, however are not able to reliably differentiate between 
MOG and AQP4 antibody-associated demyelination, highlighting the radiological 
overlap in cerebral changes that may exist243. 
 
Complementing our findings of radiological changes of the optic nerve, Kim et al258 
identified that perineural enhancement extending to the soft tissue around the optic 
nerves was present in a third of MOG antibody-patients and this has been confirmed 
by other groups232. Spinal imaging shows more involvement of the conus and 
thoracolumbar region in MOG antibody-positive patients, compared to 
cervicothoracic involvement in AQP4 antibody-positive patients202, 210, 253. 
 
5.2.4 OCT 
 
OCT suggests that MOG antibody-positive patients have severe optic nerve swelling, 
but experience less retinal neuronal loss than AQP4 antibody-positive patients228. 
Several studies have demonstrated the reduction in peripapillary RNFL thickness in 
MOG antibody-positive patients that we identified, and expanded on this with some 
centres finding no difference in peripapillary RNFL thickness or ganglion cell and 
inner plexiform layer volume on OCT between MOG and AQP4 antibody-positive 
patients266, and other centres finding more thinning in MOG267, or AQP4 antibody-
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positive268 patients. There is no consensus at present and further studies clarifying this 
are required. 
 
5.2.5 Therapeutic responses 
 
We found that MOG antibody-positive patients appear to have a rapid response to 
steroids, although they also exhibit a tendency to relapse rapidly on steroid 
withdrawal or cessation necessitating maintenance immunosuppression in some 
patients. This steroid dependence has now been corroborated in numerous studies160, 
201, 232, 259. Data on response to agents such as azathioprine and methotrexate is limited 
by small patient numbers232, and while multiple studies include patients treated with 
mycophenolate and rituximab, patient numbers are too small to extrapolate on 
treatment efficacy. Interestingly, Jarius et al232 identified that some MOG antibody-
positive patients treated with interferons for a presumed diagnosis of MS had ongoing 
or increased disease activity, once again highlighting the need to accurately diagnose 
these patients and commence appropriate immunotherapy. 
 
5.2.6 Outcomes and prognosis 
 
Visual and motor outcomes have been reported as being more favorable in MOG 
antibody-associated demyelination compared to AQP4 antibody-positive NMOSD159, 
160, 202, 210, 231, 234, 250-252. However, we have identified a distinct subgroup of MOG 
seropositive patients who have poor outcomes with serious sequelae including 
blindness due to recurrent ON and/or paraplegia due to spinal disease, indicating that 
the failure to recognise and appropriately treat this condition can result in sustained 
Chapter	5:	Discussion,	Future	Directions,	and	Conclusions			
	 223	
disability. The potential for poor outcomes, in particular, in relapsing patients, has 
now been confirmed internationally190, 232, 258. 
 
5.3 A PROPOSED ALGORITHM FOR THE EVALUATION OF FIRST 
EPISODE ON 
 
Given the growing consensus that ON is the main phenotype in MOG antibody-
associated demyelination, and based on our data on the laboratory, clinical, and 
radiological features associated with this condition, we propose the following 
algorithm for the evaluation of a patient presenting with a first episode of ON.  We 
acknowledge that many clinicians may test for both AQP4 and MOG antibodies 
simultaneously if they suspect an ‘antibody-associated ON’, however, this proposed 
algorithm provides a stratified approach to antibody testing. 
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Figure 5.1 An algorithm for the investigation and diagnosis of first 
episode ON  A proposed algorithm for investigating the aetiology of first  
episode ON based on clinical, laboratory, and radiological features. 
(Ramanathan et al 2016)1 
Abs antibodies; CIS clinically isolated syndrome 
 
 
5.4 FUTURE DIRECTIONS 
 
It is yet to be established whether MOG antibodies have a pathogenic role in 
demyelinating disease, or whether their presence is an epiphenomenon secondary to 
destruction of myelin. There is a paucity of histopathological data in this condition, 
possibly associated with the relatively recent description of this disorder in adults as 
well as the availability of serum and CSF diagnostic testing which may preclude the 
need for a brain biopsy. MOG IgG from paediatric patients with demyelination has 
been shown to induce NK mediated killing of surface MOG expressing cells 
suggesting a cytotoxic effect, as well as showing a correlation between the antibody 
titre and extent of antibody-dependent cellular cytotoxicity155. The presence of 
complement in mediating demyelination due to MOG antibodies has been suggested 
in both in vitro and in vivo animal studies269, 270. The majority of MOG antibodies 
identified in patients have been of the IgG1 isotype156, which would be able to fix 
complement and bind to Fc receptors. Mader et al157 identified that high titre MOG 
antibodies from seropositive patients were able to activate the complement cascade in 
vitro with complement-mediated lysis of MOG transfected cells, while low titre MOG 
antibodies and MOG antibody-negative samples could not, further suggesting a role 
for complement mediated cytotoxicity. Additionally, purified MOG IgG from 
seropositive patients has been shown to result in a loss of organisation of the thin 
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filaments and the architecture of the microtubule cytoskeleton of oligodendroctyes but 
not increased cell death201. While there is early evidence regarding the effect of MOG 
antibodies on effector cells, major criteria to establish pathogenicity including 
antibody transfer of disease in humans, and transfer of disease to animal models using 
human autoantibodies is lacking271. This has to be additionally considered in the 
context that recognition of murine MOG epitopes in paediatric patients with MOG 
antibodies has been shown to be reduced151. Why MOG antibody-associated 
demyelination has a propensity for ON and papillitis is not yet understood. Research 
evaluating whether the concentration or localisation of MOG in the optic nerve differs 
from MOG elsewhere in the CNS would be of interest. Future studies should expand 
on potential pathogenic mechanisms of action in MOG antibody-associated 
demyelination. Our research team is currently evaluating the epitope binding 
specificity of MOG antibodies in paediatric and adult patients, and I am undertaking a 
study exploring the contribution of T cell activation in patients who are MOG 
antibody-positive. 
 
The relative incidence and prevalence of MOG antibody-associated demyelination has 
not been studied to date. While MS is the most common cause of demyelination 
globally, based on our experience as the sole testing centre for MOG antibodies 
detected by live cell based assays in Australasia, we believe that MOG antibody-
associated demyelination is relatively more common than AQP4 antibody-positive 
NMOSD. Indeed, our anecdotal experience from three tertiary referral metropolitan 
hospitals is in keeping with this, with twelve patients with a first clinical episode of 
demyelination being diagnosed with MOG antibodies over a 12 month period, 
compared to two patients with AQP4 antibodies. It is important to identify the true 
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incidence of MOG antibody-associated demyelination as there is a possibility its 
presence is underestimated, and such patients may be misdiagnosed as MS. As 
treatment modalities between these two entities differ, accurate diagnosis is critical. 
With this in mind, we are undertaking a multicenter study utilising the collaborative 
platform of the Australasian and New Zealand MOG Study Group to evaluate the 
incidence of MOG antibodies, AQP4 antibodies, and MS in patients presenting with a 
first clinical episode of demyelination with prospective recruitment over a two year 
period. 
 
While our work evaluating the therapeutic responses of patients to steroids has been 
important, our early data suggests a response to other immunotherapeutic agents 
including IVIg, mycophenolate, and rituximab. However, this study evaluating a 
retrospective cohort of patients with relapsing MOG antibodies was not adequately 
powered to provide definitive results regarding therapeutic efficacy of individual 
agents and generate treatment guidelines for this condition. We are commencing a 
large multicenter study with prospectively recruited patients who will be necessary to 
complement our findings, and provide evidence-based guidelines in treatment. Future 
prospectively recruited randomised control trials will be crucial to guide management 
of these patients. 
 
Finally, based on the referral of patients to our diagnostic service, it is clear that there 
are a number of patients reviewed in MS and neuroimmunology clinics who are 
suspected to have an “antibody-mediated” demyelination syndrome. These patients do 
not have radiology consistent with MS, may be responsive to immunosuppressive 
therapy, and may have clinical features more in keeping with NMOSD than MS. 
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However, some of these patients are negative for both AQP4 and MOG antibodies. It 
is likely that there are other novel antigenic targets in antibody-associated 
demyelination, and future work needs to address this. 
 
5.5 CONCLUDING STATEMENTS 
 
Given the high pre-test probability of MOG antibody-positivity in children, we 
believe that it is reasonable to test for MOG antibodies in all childhood-onset 
demyelination, particularly if relapsing. In adults, we recommend that MOG 
antibody-testing could be reasonably restricted to patients with a clinical and 
radiological phenotype atypical for MS. We additionally recommend that all patients 
being investigated for first episode demyelination have a gadolinium enhanced MRI 
brain and spine and dedicated orbital views, to enable detailed radiological 
phenotyping. 
 
At present there is no clear consensus on the nomenclature for demyelination 
associated with MOG antibodies. Many patients have been classified in the literature 
as having NMOSD, but we have shown that clinical phenotypes such as UON and 
short TM are frequently present in MOG antibody-positive patients, as well as the 
BON and LETM more classically associated with NMOSD.  In fact, only a quarter of 
patients in our relapsing cohort fulfilled 2015 revised NMOSD criteria. Additionally, 
the inclusion of paediatric patients with MOG antibodies who have a prominence of 
ADEM further complicates the classification of patients with MOG antibodies as a 
diagnostic biomarker for NMOSD. AQP4 antibody-associated disease is an 
astrocytopathy with a distinct histological and immunopathological profile, while 
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MOG antibody-associated disease targets oligodendrocytes262, 272. Increasingly, there 
is an awareness of differences in epidemiology, clinical associations, radiological 
characterisation, therapeutic responses, and prognoses of these two antibody-
associated disorders, which indicate that the underlying disease pathophysiology is 
likely to be divergent, and that they are separate biological entities. As such, we 
believe this condition warrants designation as a separate clinical entity from MS and 
NMOSD. We propose the terminology “MOG antibody-associated demyelination” as 
a more accurate syndromic diagnosis to encompass these patients.  
 
In conclusion, for more than three decades, MOG has been identified as being a 
potentially important antigen in demyelination. Optimisation of the methodology of 
antigen preparation and antibody detection has enabled the identification of MOG 
antibodies as a diagnostic biomarker in demyelination. ON (often with associated 
optic disc swelling) in all age groups, and ADEM in children, are dominant 
manifestations of MOG antibody-associated demyelination, but there is an expanding 
clinical spectrum and suggestive radiological findings. Relapsing patients are often 
steroid responsive, but vulnerable to relapses on tapering or withdrawal. 
Consideration should be given to early secondary prevention treatment strategies that 
may include maintenance corticosteroids, IVIg, or immunosuppression with 
mycophenolate or rituximab, as these agents appear to be effective in reducing disease 
activity. Early recognition and diagnosis is critical to distinguish these patients from 
those with MS and AQP4 antibody-positive NMOSD as treatment pathways can 
differ in both the acute and chronic setting, with significant prognostic implications. 
Institution of appropriate immunotherapy in selected patients with MOG antibody-
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associated demyelination may reduce the risk of relapses and improve long-term 
outcomes and quality of life in this vulnerable group of patients. 
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Appendix	A:	 	 Comparison	of	the	prevalence	of	MOG	antibodies	in	patients	with	demyelination	using	ELISA	and	Western	blot	
	
	
Reference Description 
of Cohort 
Sample Detection 
Method 
Antigen 
characteristics 
Analysis approach Prevalence of MOG antibody positivity Concordance 
for MOG 
antibodies 
between CSF 
and serum 
Longitudinal 
evaluation of 
seropositivity 
Xiao et 
al273 
J 
Neuroimm
unol 1991 
Adults with 
clinically 
definite MS 
n=30 
 
OND n=30 
Tension 
headache 
n=30 
Plasma 
and CSF 
ELISA 
 
Antibody 
specificity 
confirmed 
with 
Western 
blot 
MOG from human 
brain white matter 
Mean value of OD at 
405  nm + 3sd; upper 
reference limit for 
CSF 0.076 and for 
plasma 0.243 
Anti-MOG IgG antibodies detected in CSF 
only 
 
MS 7/30 (23%) 
OND 2/30 (7%) 
Tension headache 1/30 (3%) 
with higher titres in MS compared to 
controls 
 
Antibodies only 
detected in 
CSF, not 
plasma 
Not assessed 
Lindert et 
al165 
Brain  
1999 
MS n=37 
 
(CIS n=5, 
RRMS n=12, 
SPMS n=10, 
PPMS n=10) 
Plasma Western 
blot 
Recombinant human 
extracellular MOG 
expressed in E coli 
A serum sample was 
considered to be 
positive if the 
immunoreactivity 
was ≥ control 
samples 
Anti MOG antibodies in: 
 
PPMS 2/10 (20%) 
SPMS 5/10 (50%) 
RRMS 8/12 (67%) 
CIS 5/5 (100%) 
 
HC 10/37 (27%) 
Not applicable Not assessed 
Reindl et 
al163 
Brain  
1999 
MS n=130 
 
(CIS n=42, 
RRMS n=50, 
SPMS n=38) 
 
OIND n=32 
ONND n=30 
RA n=10 
Paired 
serum 
and CSF 
Presence of 
MOG Ig 
specific 
IgG 
identified 
by Western 
blots, and 
end-point 
titres 
determined 
by ELISA 
Recombinant human 
extracellular Ig domain 
of MOG expressed in E 
coli 
 
(102 aa long N-
terminal MOG peptide 
aa 28-130) 
 
 
A serum sample was 
considered to be 
positive if the 
immunoreactivity 
was ≥ control 
samples 
 
IgG MOG antibodies  
Serum; CSF  
 
MS  
49/130 (38%); 43/130 (33%) 
OIND  
17/32 (53%); 17/32 (53%) 
ONND  
1/30 (3%); 0/30 (0%) 
RA 
1/10 (10%); not done 
Very close 
concordance 
MOG antibodies 
persisted in MS 
but not in OIND 
on longitudinal 
analysis; serum 
anti MOG-Ig 
titres as 
determined by 
ELISA did not 
correlate with 
disease severity 
Karni et 
al164 
MS n=33 
OND n=31 
CSF and 
serum 
ELISA Recombinant human 
MOG Ig domain 
considered positive if 
mean OD reading 
Anti-MOG antibodies in Serum; CSF 
MS 
Higher 
proportion of 
Not assessed 
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Reference Description 
of Cohort 
Sample Detection 
Method 
Antigen 
characteristics 
Analysis approach Prevalence of MOG antibody positivity Concordance 
for MOG 
antibodies 
between CSF 
and serum 
Longitudinal 
evaluation of 
seropositivity 
Arch 
Neurol  
1999 
HC  n=31 was greater than 
mean OD405 +2 SD of 
controls 
2/33 (6%); 10/31 (32%) 
OND 
0/28 (0%); 12/31 (39%) 
Healthy controls 
1/31 (3%); 1/28 (4%) 
patients 
positive in CSF 
than serum 
Egg et al166 
Mult Scler  
2001 
MS n=261 Serum Western 
blot 
Recombinant human 
extracellular Ig domain 
of MOG 
A serum sample was 
considered to be 
positive if the 
immunoreactivity 
was ≥ control 
samples 
IgM MOG Abs: 146/261 (56%) 
IgG MOG Abs: 91/261 (35%) 
IgA MOG Abs 66/261 (25%) 
Not applicable IVIg and IFN 
beta treatment 
reduced IgG3 
responses 
Haase et 
al141 
J 
Neuroimm
unol 
2001 
MS n=17 
HC n=9 
Serum ELISA 
 
 
 
 
 
 
Cell based 
assay 
Synthetic human MOG 
peptides 
 
 
 
 
 
Human MOG 
transfected LTK3 cells 
A serum sample was 
considered to be 
positive if the 
immunoreactivity 
was ≥ control 
samples 
 
Flow cytometry 
By ELISA: antibodies to anti-MOG 
peptides in all patients and controls; 
heterogenous epitope specificity of 
purified antibodies 
 
 
 
Only one MS patient positive by FACS 
Not applicable Not assessed 
Haase et 
al274 
Neurosci 
Lett  
2001 
NMO n=4 Serum Western 
blots 
 
 
 
 
 
ELISA for 
epitope 
specificity 
analysis 
Extracellular Ig domain 
of MOG expressed in E 
coli system and 
purified 
 
 
A serum sample was 
considered to be 
positive if the 
immunoreactivity 
was ≥ control 
samples 
 
OD at 490 nm; Cut-
off = OD three-times 
beyond background, 
at least surpassing 0.1 
OD units and a titer 
of > 1:800 for MOG 
IgG MOG Abs 4/4 
IgM MOG Abs 3/4 
Not applicable Not assessed 
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Reference Description 
of Cohort 
Sample Detection 
Method 
Antigen 
characteristics 
Analysis approach Prevalence of MOG antibody positivity Concordance 
for MOG 
antibodies 
between CSF 
and serum 
Longitudinal 
evaluation of 
seropositivity 
Lutterotti 
et al172 
J 
Neuroimm
unol 2002 
sMS n=41 
fMS n=24 
AR of fMS 
n=33  
HC n=65  
Serum Western 
blot 
Recombinant human 
extracellular Ig domain 
of MOG 
 
A serum sample was 
considered to be 
positive if the 
immunoreactivity 
was ≥ control 
samples 
 
 
IgG anti-MOG antibodies 
sMS 16/41 (39%) 
fMS 6/24 (25%) 
AR of fMS 17/33 (52%) 
Healthy controls 14/65 (22%) 
 
IgM anti-MOG antibodies 
sMS 24/41 (59%) 
fMS 19/24 (79%) 
AR of fMS 23/33 (70%) 
Healthy controls 22/65 (34%) 
 
IgA anti-MOG antibodies 
sMS 8/41 (20%) 
fMS 8/24 (33%) 
AR of fMS 10/33 (30%) 
Healthy controls 6/65 (9%) 
 
Not applicable Not assessed 
Markovic 
et al167 
J Neurol 
Sci  
2003 
MS n=44 
OIND n=11 
ONND n=40 
CSF ELISA Recombinant human 
extracellular Ig domain 
of MOG 
 
OD at 490 nm, 
positive when 
adjusted OD reading 
> background value 
+/- 2 SD 
MS 13/44 (30%) 
OIND 6/11 (55%) 
ONND 3/40 (8%) 
Not applicable Not assessed 
Berger et 
al168 
N Engl J 
Med 
2003 
CIS n=103  Serum  Western 
blot 
Recombinant human 
MOG Ig domain 
expressed in E coli 
A serum sample 
considered to be 
positive if the 
immunoreactivity 
was >/ control sample 
Only IgM anti-MOG antibodies identified 
 
22/103 (21%) positive for anti-MOG and 
anti-MBP antibodies, of which 21/22 
relapsed 
42/103 (41%) positive for anti-MOG 
antibodies only, of which 35/52 relapsed   
39/103 seronegative, of which 9/39 
relapsed 
 
Increased risk of CDMS in patients with 
Not applicable Not assessed 
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Reference Description 
of Cohort 
Sample Detection 
Method 
Antigen 
characteristics 
Analysis approach Prevalence of MOG antibody positivity Concordance 
for MOG 
antibodies 
between CSF 
and serum 
Longitudinal 
evaluation of 
seropositivity 
MOG antibodies 
Lampason
a et al173 
Neurology  
2004 
MS  n=87  
encephalomy
elitis n=12  
HC n=47  
Serum Liquid 
phase 
radiobindin
g assay and 
Western 
blot 
analysis 
Recombinant human 
MOG (full length non-
glycosylated) 
Positive threshold for 
anti-MOG IgG/IgM = 
mean + 2 SD HC  
IgG anti-MOG antibody  
MS 5.7% 
Encephalomyelitis 0% 
HC 4.1% 
 
IgM anti-MOG antibody  
MS with samples at onset 7.5% 
Encephalomyelitis 8.3% 
HC 6.2% 
 
Not applicable Not assessed 
Gaertner et 
al169 
Neurology  
2004 
Adult MS 
patients 
 
CIS n=9  
RRMS 
during 
relapse n=19 
RRMS 
during 
remission 
n=20 
SPMS n=36 
HC n=20 
Serum ELISA Native glycosylated 
full length mouse 
MOG transfected Ag8 
cells 
OD at 405 nm, 
presented as a ratio of 
geometric means of 
patient’s duplicates 
and geometric mean 
of standard serum 
duplicates 
Mean ratio IgG against MOG 
CIS 1.62  
Relapsing RRMS 1.86 
Remitting RRMS 1.27 
SPMS 1.65 
HC 1.22 
 
Mean ratio IgM against MOG 
CIS 1.43 
Relapsing RRMS 0.98 
Remitting RRMS 1.15 
SPMS 0.99 
HC 0.86 
Not applicable Not assessed 
O’Connor 
et al171 
J Immunol  
2005 
postmortem 
cases of MS 
n=14 
controls n=7 
purified 
IgG 
from MS 
lesions, 
serum 
and CSF  
ELISA 
 
 
 
 
 
 
Solution 
phase 
radioimmu
Refolded extracellular 
domain of human 
MOG expressed in E 
coli 
 
 
 
In vitro translated 
human MOG 
IgG concentration in 
each sample was 
determined by 
relating the OD to 
that of the human IgG 
standard 
 
Quantification of 
immunoprecipitated 
MOG 
Autoantibodies recognizing MOG are 
present in substantially higher 
concentrations in purified IgG from MS 
lesions compared with CSF and serum in 
subjects with MS; CNS tissue 7/14 
positive for MOG IgG (50%) compared to 
1/7 controls 
 
 
 
Anti-MOG 
autoantibodies 
were generally 
not found in the 
CSF or serum 
of MS patients; 
the few that 
were positive 
had marginal 
binding 
Not assessed 
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Reference Description 
of Cohort 
Sample Detection 
Method 
Antigen 
characteristics 
Analysis approach Prevalence of MOG antibody positivity Concordance 
for MOG 
antibodies 
between CSF 
and serum 
Longitudinal 
evaluation of 
seropositivity 
noassay  
 
 
Lim et al174 
Mult Scler  
2005 
CIS n=47  Serum Western 
blot 
Recombinant human 
extracellular Ig domain 
of MOG 
 
A serum sample was 
considered to be 
positive if the 
immunoreactivity 
was ≥ control 
samples 
 
Antibodies to: 
Anti-MOG and anti-MBP: 13/47 (28%) 
Anti-MOG: 13/47 (28%) 
Anti-MBP: 11/47 (23%) 
Seronegative: 10/47 (21%) 
 
Anti-MOG antibody status in CIS patients 
did not predict conversion to CIS 
Not applicable Not assessed 
Rauer et 
al175 
J Neurol 
Neurosurg 
Psychiatry 
2006 
CIS n=45  
HC n=56  
Serum Western 
blot, 
immunoblo
ts 
Recombinant human 
MOG Ig domain 
A serum sample was 
considered to be 
positive if the 
immunoreactivity 
was ≥ control 
samples 
Anti-MOG IgM Abs: 
23/45 CIS (51%) 
12/56 HC (21%) 
Not applicable Not assessed 
Kuhle et 
al170 
J Neurol  
2007 
CIS n=133  Serum Western 
blot 
Recombinant human 
MOG Ig domain 
expressed in E coli 
A serum sample was 
considered to be 
positive if the 
immunoreactivity 
was ≥ control 
samples 
IgG MOG antibodies in 92/133 (69.2%) 
 
MOG antibody seropositivity did not 
indicate an increased risk of conversion to 
CDMS 
Not applicable Not assessed 
Kuhle et 
al176 
N Engl J 
Med  
2007 
CIS n=462  Serum Western 
blot 
Recombinant human 
MOG Ig domain 
expressed in E coli 
A serum sample was 
considered to be 
positive if the 
immunoreactivity 
was ≥ control 
samples 
No significant increase in IgG or IgM 
MOG antibodies in the CIS patients who 
went on to develop CDMS 
Not applicable Not assessed 
Pelayo et 
al177 
N Engl J 
Med  
2007 
CIS n=114  Serum Western 
blot 
Recombinant human 
extracellular Ig domain 
of MOG expressed in E 
coli 
A serum sample was 
considered to be 
positive if the 
immunoreactivity 
was ≥ control 
Anti-MOG antibodies  
 
62/114 (54%) 
 
No association of anti-myelin antibodies 
Not applicable  Not assessed 
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Reference Description 
of Cohort 
Sample Detection 
Method 
Antigen 
characteristics 
Analysis approach Prevalence of MOG antibody positivity Concordance 
for MOG 
antibodies 
between CSF 
and serum 
Longitudinal 
evaluation of 
seropositivity 
samples with rate of conversion to CDMS 
Pittock et 
al179 
Mult Scler  
2007 
MS patients 
with biopsy 
proven 
inflammatory 
demyelinatio
n n=72 
Serum Western 
blot 
 
 
 
 
 
 
ELISA 
 
Recombinant human 
extracellular Ig domain 
of MOG 
 
 
 
 
 
Recombinant human 
MOG-Ig expressed in 
E. coli and purified 
A serum sample was 
considered to be 
positive if the 
immunoreactivity 
was ≥ control 
samples 
 
 
OD at 492 nm, cut off 
determined by values 
from 188 age and sex 
matched controls 
Anti MOG antibody-positive by Western 
blot: 
IgM 38/72 (53%) 
IgG 19/72 (26%) 
 
 
 
 
Anti MOG antibody-positive by ELISA: 
IgM 4/72 (6%) 
IgG 16/72 (22%) 
Not applicable Not assessed 
Tomassini 
et al275 
Mult Scler  
2007 
CIS n=51 Serum Western 
blots for 
MOG IgM 
antibodies 
 
 
 
ELISA for 
MOG IgG 
antibodies 
Recombinant human 
extracellular Ig domain 
of MOG 
A serum sample was 
considered to be 
positive if the 
immunoreactivity 
was ≥ control 
samples 
 
OD at 492 nm, “Cut 
off” determined by 
values from 188 age 
and sex matched 
controls 
 
Anti-MOG antibody positive for 
IgM 21/51 (41%) 
IgG 3/51 (6%) 
 
Anti-myelin (anti-MOG and anti-MBP) 
antibodies predicted conversion to MS 
using Poser’s but not McDonald’s criteria. 
Seropositive patients had a shorter interval 
to relapse compared to seronegative 
patients 
Not applicable Not assessed 
Greeve et 
al276 
Acta 
Neurol 
Scand 
2007 
CIS n=39 Serum Western 
blot 
Recombinant human 
MOG Ig domain 
A serum sample was 
considered to be 
positive if the 
immunoreactivity 
was ≥ control 
samples 
Anti-MOG IgM antibodies 
30/39 (77%)  
 
Anti-myelin antibody positive patients 
more likely to progress to CDMS 
Not applicable Not assessed 
Wang et MS n=126  Serum ELISA Recombinant human A cutoff value of 0.6 MOG antibody-positive Not applicable Among patients 
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Reference Description 
of Cohort 
Sample Detection 
Method 
Antigen 
characteristics 
Analysis approach Prevalence of MOG antibody positivity Concordance 
for MOG 
antibodies 
between CSF 
and serum 
Longitudinal 
evaluation of 
seropositivity 
al178 
Neurology  
2008 
Controls 
n=252  
MOG Ig expressed in 
E. coli  
OD units for anti-
MOG IgG and 1.3 
OD units for IgM was 
set, (values derived 
from a pool of 
external reference 
samples from healthy 
individuals) 
 
IgG 
MS: 45/126 (36%) 
Controls: 70/252 (28%) 
 
IgM  
MS: 28/126 (22%) 
Controls: 44/252 (17%) 
 
 
who developed 
MS, positivity to 
IgG anti-MOG 
before MS onset 
did not change 
over time, but 
was lower in 
samples collected 
after MS. 
Positivity to IgM 
anti-MOG did not 
change from the 
earliest to the 
most recent 
sample before 
MS onset or post-
onset sample. 
Klawiter et 
al277 
Arch 
Neurol  
2010 
MS n=35 
(RRMS 
n=22, SPMS 
n=5, PPMS 
n=98) 
 
OND n=26 
Serum 
and CSF 
ELISA Recombinant human 
extracellular MOG 
expressed in insect 
cells 
Serum sample 
considered positive if 
there was a dilution 
effect, and 
absorbance was >/0.1 
 
CSF – rMOG index 
was calculated 
rMOG index was elevated in MS subjects 
compared to controls (P=0.012), PPMS 
patients exhibited elevated rMOG indices 
compared to RRMS patients 
No statistical 
differences 
existed between 
controls and 
MS subjects for 
serum rMOG 
Abs or CSF 
rMOG Ab 
 
Not assessed 
Gori et 
al278 
J 
Neuroimm
unol 2011 
Adult 
patients 
MS n=49 
HC n=71 
OND n=17 
RA n=31 
Serum 
and CSF 
Solid phase 
ELISA 
Recombinant rat 
extracellular MOG 
expressed in E coli, 
refolded 
Absorbance read at 
405 nm; cut off 
determined by mean 
+ 3 SD of HC 
 
Positive if IgM 
absorbance >1.81 and 
IgG absorbance 
Serum MOG IgM antibodies positive 
MS n=0/49 (0%) 
HC n=1/71(1%) 
OND n=2/17 (12%) 
RA n=4/31 (13%) 
 
Serum MOG IgG antibodies positive 
MS n=4/49 (8%) 
No positive 
results in CSF 
Not assessed 
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Reference Description 
of Cohort 
Sample Detection 
Method 
Antigen 
characteristics 
Analysis approach Prevalence of MOG antibody positivity Concordance 
for MOG 
antibodies 
between CSF 
and serum 
Longitudinal 
evaluation of 
seropositivity 
>0.77 HC n=2/71 (3%) 
OND n=1/17 (6%) 
 
 
. 
Menge et 
al150 
J 
Neuroinfla
mmation 
2011 
MS n=325 
CIS n=69 
HC n=164 
Serum Quantitativ
e high 
throughput 
ELISA 
1. recombinant 
human MOG 
(extracellular 
domain 
spanning aa 1-
125): 
rhMOG125 
2. recombinant 
human MOG 
aa1-118: 
rhMOG118 
3. recombinant 
rat MOG (aa 
1-135): 
ratMOG125 
OD at 405 nm; 
BR = OD 
signal/background 
- Anti-MOG IgG concentrations below 5.0 
µg/mL were over-represented, resulting in 
a skewed distribution 
 
- Anti-rhMOG125 reactivity was 
significantly elevated in the CIS patient 
group compared to MS and HC (p < 0.05), 
and anti-rat- MOG125 significantly higher 
in MS compared to HC (p < 0.05); 
however, extensive overlap between 
groups was observed and the clinical 
relevance of this finding remains unclear 
 
- 8.2% of all HC, CIS and MS samples 
were identified as high-titer reactive; 
differences between groups were not 
statistically significant 
Not applicable Not assessed 
Kezuka et 
al261 
J 
Neuroopht
hal  
2012 
ON n=23 Serum ELISA Anti-human  
MOG1–125 IgG   
MOG antibody 
concentration was 
calculated by 4-
parameter logistic 
curve fit based on the 
average absorbance 
values; A serum 
MOG-Ab 
concentration > 4 SD 
Anti MOG antibodies in 8/23 (34%) 
patients 
 
Note 6/23 patients (26%) positive for 
MOG antibodies (measured by ELISA) 
and AQP4 antibodies (measured by a cell 
based assay) 
Not applicable Not assessed 
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Reference Description 
of Cohort 
Sample Detection 
Method 
Antigen 
characteristics 
Analysis approach Prevalence of MOG antibody positivity Concordance 
for MOG 
antibodies 
between CSF 
and serum 
Longitudinal 
evaluation of 
seropositivity 
of the mean 
concentration in HC 
considered positive 
			
	
aa amino acids, AR asymptomatic relatives, BR binding ratio, CIS clinically isolated syndrome, E Coli Escherichia coli, fMS familial MS, HC healthy 
controls, OD optical density, OIND other inflammatory neurological diseases, OND other neurological diseases, ONND other non-inflammatory 
neurological diseases, PPMS primary progressive multiple sclerosis, RA rheumatoid arthritis, RRMS relapsing remitting multiple sclerosis, SD 
standard deviations, sMS sporadic MS, SPMS secondary progressive multiple sclerosis 		
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Appendix B: Neuroradiology assessment proforma for optic neuritis radiological 
characterisation study 
 
Patient details		
Name:     DOB:    Date of study: 
 
Age at event:    Male Female 
 
MRI brain abnormal    MRI brain normal 
 
MRI optic pathway abnormal MRI optic pathway normal 
 
 
Radiological characterisation 
 
 
Laterality  Left  Right 
 
Characteristic Left Right 
SEQUENCES   
3 or 1.5 Tesla   
Orbital views   
T2   
FLAIR   
T1   
T2 fat suppressed   
Contrast   
   
Optic nerve enhancement   
   
Degree of enhancement   
-none   
-subtle   
-definite (<extraocular muscles)   
-definite (>extraocular muscles)   
   
Presence of optic nerve thickening   
   
Presence of T2 hyperintensity   
Degree of hyperintensity (0-3, none-
marked) 
  
Extent of optic nerve involvement, 0-
none; 1-up to one-third; 2-one-third to 
two-third; 3-two-third or greater 
 
  
Optic nerve head swelling   
Segment of nerve most affected 
(retrobulbar, canalicular, intracranial) 
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Chiasmal involvement   
   
Optic tract involvement   
   
T2 hyperintensity or contrast (Graves et 
al): 
  
-not present   
-focal   
-longitudinal (2 or more contiguous optic 
nerve segments, anterior orbital, posterior 
orbital, canalicular, or cisternal) 
  
   
 
Number of slices involved:  Right    Left 
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Clinical characterisation 
 
Demyelination event number for this episode of ON (and duration after 1st): 
 
First event if this is not the first event: 
 
Bilateral optic neuritis  Yes  No 
 
Unilateral optic neuritis  Left Right 
 
Timing of MRI relative to onset of visual symptoms: 
 
Pain    Yes No 
 
Worst Visual acuity  Left 
 
Worst Visual acuity  Right 
 
VF plotted formally  Yes No 
 
Afferent papillary defect Yes No 
 
Papillitis, swelling  Yes No 
 
 
 
Outcome data 
 
Length of follow-up: 
 
Visual acuity   Left 
 
Visual acuity   Right 
 
Relapse 1 (type and time after previous attack): 
 
Relapse 2 (type and time after previous attack):  
 
Relapse 3 (type and time after previous attack):  
 
Total number of events: 
 
Outcome diagnosis: 
 
Most recent MRI (duration after first attack): 
 
MRI optic nerve outcome: 
 
MRI brain outcome:  
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Appendix C: Clinical dataset for relapsing MOG antibody-associated demyelination 
therapy and outcomes study 
 
 
Date of completion of form: 
Name and email address of person completing form: 
Treating physician: 
Treating physician’s email address and contact details: 
Hospital: 
Date of sample collection:  first presentation   ☐          relapse   ☐        remission  ☐ 
Treatment at time of sample collection: 
Latest clinical follow-up date: 
 
Patient Demographics  
Name:           
MOG antibody status (specify serum or CSF):  Positive ☐    Negative ☐    Unknown ☐  
AQP4 antibody status (specify serum or CSF):  Positive ☐    Negative ☐    Unknown ☐  
Centre and date where AQP4 antibody status was tested: 
DOB:           
Age: 
Gender: 
Ethnicity: 
Weight: 
Personal or family history of autoimmunity: 
Preceding infectious prodrome: 
Time of preceding illness (time before neurological onset): 
Any additional relevant history or comorbidities: 
 
Clinical Details 
 
Current diagnosis:  
Is this the first demyelinating event?   Yes ☐ No ☐ 
Were there previous demyelinating events?   Yes ☐ No ☐ 
Total number of demyelinating events including current and previous episodes: 
If more than five total demyelinating events, please print out as many extra copies of page 6 
as needed to provide information for each episode. 
 
Investigations 
 
• Cerebrospinal fluid analysis (if more than one, please provide details of all) 
o Date: 
o Cells (provide count):  
o Protein (provide value): 
o Oligoclonal bands (mirrored or CSF only): 
 
• Erythrocyte sedimentation rate (ESR) (provide value): 
 
• Any other observations or investigations of note (eg presence of neuroretinitis,  
                        unusual features for optic neuritis, investigations for sarcoidosis etc) 
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Clinical Episodes 
• First demyelinating event  date/month/year:                                    
BON    ☐   UON   ☐  short TM   ☐       LETM  ☐   
ADEM   ☐  Other   ☐  Describe: 
PRESENTING SYMPTOM/S: 
 
o Therapy 
Agent Date 
started 
Date 
ceased 
Dose Other details 
(taper, etc) 
Response 
IV steroids      
Oral 
prednisone 
     
IVIg 
 
     
Plasma 
exchange 
     
Steroid 
sparing agent 
(specify) 
 
 
     
Rituximab 
 
     
Other  
 
    
 
o Improvement with treatment?   Yes ☐ No ☐ 
o If ON  Visual acuity at worst   L  R  Date: 
Visual acuity at best at follow-up L  R  Date: 
Visual fields available?  Yes ☐ No ☐ Date/s: 
OCT available?   Yes ☐ No ☐ Date/s: 
Optic disc swelling present on examination?:                        radiology?: 
o If TM  EDSS1 at worst   Date:  
EDSS at best at follow-up  Date: 
Spinal region/s involved Cervical ☐ Thoracic ☐ Lumbar ☐ Conus ☐ 
Sphincter dysfunction?   Bladder  ☐  Bowel     ☐   
o If ADEM  isolated ☐ coexistent ON ☐ coexistent TM ☐ 
EDSS1 at worst   Date:  
EDSS at best at follow-up  Date: 
o If other demyelinating event 
Brainstem  ☐ Cerebellar   ☐ Primarily motor (non spinal) ☐   
Primarily sensory (non spinal)     ☐ Other (please specify) ☐ 
EDSS1 at worst   Date:  
EDSS at best at follow-up  Date: 
o MRI brain   Date or nd:   Normal   ☐ Abnormal   ☐   
o MRI spine   Date or nd:  Normal   ☐ Abnormal   ☐   # vertebral 
segments:  
o MRI meeting 2010 McDonald’s criteria2?   Yes    ☐    No    ☐   Unknown    ☐ 
Please describe MRI abnormalities if present 
ASYMPTOMATIC (FOLLOW-UP) MRI: Date: 
normal ☐ residual ☐ new lesions ☐			NO	new lesions ☐ 
  RESIDUAL PROBLEMS: Yes  ☐ No ☐……………………………………………. 
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• Second demyelinating event   date/month/year:                                    
BON    ☐   UON   ☐  short TM   ☐       LETM  ☐   
ADEM   ☐  Other   ☐  Describe: 
PRESENTING SYMPTOM/S: 
CURRENT THERAPY AT EVENT: 
 
o Therapy 
Agent Date 
started 
Date 
ceased 
Dose Other details 
(taper, etc) 
Response 
IV steroids      
Oral 
prednisone 
     
IVIg 
 
     
Plasma 
exchange 
     
Steroid 
sparing agent 
(specify) 
 
 
     
Rituximab 
 
     
Other  
 
    
 
o Improvement with treatment?   Yes ☐ No ☐ 
o If ON  Visual acuity at worst   L  R  Date: 
Visual acuity at best at follow-up L  R  Date: 
Visual fields available?  Yes ☐ No ☐ Date/s: 
OCT available?   Yes ☐ No ☐ Date/s: 
Optic disc swelling present on examination?:                        radiology?: 
o If TM  EDSS1 at worst   Date:  
EDSS at best at follow-up  Date: 
Spinal region/s involved Cervical ☐ Thoracic ☐ Lumbar ☐ Conus ☐ 
Sphincter dysfunction?   Bladder  ☐  Bowel     ☐ 
o If ADEM  isolated ☐ coexistent ON ☐ coexistent TM ☐ 
EDSS1 at worst   Date:  
EDSS at best at follow-up  Date: 
o If other demyelinating event 
Brainstem  ☐ Cerebellar   ☐ Primarily motor (non spinal) ☐   
Primarily sensory (non spinal)     ☐ Other (please specify) ☐ 
EDSS1 at worst   Date:  
EDSS at best at follow-up  Date: 
o MRI brain   Date:   Normal   ☐ Abnormal   ☐   
o MRI spine   Date:  Normal   ☐ Abnormal   ☐   # vertebral 
segments:  
o MRI meeting 2010 McDonald’s criteria2?   Yes ☐     No   ☐  Unknown    ☐ 
Please describe MRI abnormalities if present 
ASYMPTOMATIC (FOLLOW-UP) MRI: Date: 
normal ☐ residual ☐ new lesions ☐  NO new lesions ☐ 
RESIDUAL PROBLEMS: Yes  ☐ No ☐……………………………………………. 
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• Third demyelinating event   date/month/year:                                    
BON    ☐   UON   ☐  short TM   ☐       LETM  ☐   
ADEM   ☐  Other   ☐  Describe: 
PRESENTING SYMPTOM/S: 
CURRENT THERAPY AT EVENT: 
 
o Therapy 
Agent Date 
started 
Date 
ceased 
Dose Other details 
(taper, etc) 
Response 
IV steroids      
Oral 
prednisone 
     
IVIg 
 
     
Plasma 
exchange 
     
Steroid 
sparing agent 
(specify) 
 
 
     
Rituximab 
 
     
Other  
 
    
 
o Improvement with treatment?   Yes ☐ No ☐ 
o If ON  Visual acuity at worst   L  R  Date: 
Visual acuity at best at follow-up L  R  Date: 
Visual fields available?  Yes ☐ No ☐ Date/s: 
OCT available?   Yes ☐ No ☐ Date/s: 
Optic disc swelling present on examination?:                        radiology?: 
o If TM  EDSS1 at worst   Date:  
EDSS at best at follow-up  Date: 
Spinal region/s involved  Cervical ☐ Thoracic ☐ Lumbar ☐ Conus ☐ 
Sphincter dysfunction?    Bladder  ☐  Bowel     ☐ 
o If ADEM  isolated ☐ coexistent ON ☐ coexistent TM ☐ 
EDSS1 at worst   Date:  
EDSS at best at follow-up  Date: 
o If other demyelinating event 
Brainstem  ☐ Cerebellar   ☐ Primarily motor (non spinal) ☐   
Primarily sensory (non spinal)     ☐ Other (please specify) ☐ 
EDSS1 at worst   Date:  
EDSS at best at follow-up  Date: 
o MRI brain   Date:   Normal   ☐ Abnormal   ☐   
o MRI spine   Date:  Normal   ☐ Abnormal   ☐   # vertebral 
segments:  
o MRI meeting 2010 McDonald’s criteria2?   Yes ☐    No    ☐ Unknown ☐ 
Please describe MRI abnormalities if present 
ASYMPTOMATIC (FOLLOW-UP) MRI: Date: 
normal ☐ residual ☐ new lesions ☐ NO new lesions ☐ 
  RESIDUAL PROBLEMS: Yes  ☐ No ☐……………………………………………. 
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• Fourth demyelinating event   date/month/year:                                    
BON    ☐   UON   ☐  short TM   ☐       LETM  ☐   
ADEM   ☐  Other   ☐  Describe: 
PRESENTING SYMPTOM/S: 
CURRENT THERAPY AT EVENT: 
 
o Therapy 
Agent Date 
started 
Date 
ceased 
Dose Other details 
(taper, etc) 
Response 
IV steroids      
Oral 
prednisone 
     
IVIg 
 
     
Plasma 
exchange 
     
Steroid 
sparing agent 
(specify) 
 
 
     
Rituximab 
 
     
Other  
 
    
 
o Improvement with treatment?   Yes ☐ No ☐ 
o If ON  Visual acuity at worst   L  R  Date: 
Visual acuity at best at follow-up L  R  Date: 
Visual fields available?  Yes ☐ No ☐ Date/s: 
OCT available?   Yes ☐ No ☐ Date/s: 
Optic disc swelling present on examination?:                        radiology?: 
o If TM  EDSS1 at worst   Date:  
EDSS at best at follow-up  Date: 
Spinal region/s involved  Cervical ☐ Thoracic ☐ Lumbar ☐ Conus ☐ 
Sphincter dysfunction?    Bladder  ☐  Bowel     ☐ 
o If ADEM  isolated ☐ coexistent ON ☐ coexistent TM ☐ 
EDSS1 at worst   Date:  
EDSS at best at follow-up  Date: 
o If other demyelinating event 
Brainstem  ☐ Cerebellar   ☐ Primarily motor (non spinal) ☐   
Primarily sensory (non spinal)     ☐ Other (please specify) ☐ 
EDSS1 at worst   Date:  
EDSS at best at follow-up  Date: 
o MRI brain   Date:   Normal   ☐ Abnormal   ☐   
o MRI spine   Date:  Normal   ☐ Abnormal   ☐   # vertebral 
segments:  
o MRI meeting 2010 McDonald’s criteria2?   Yes ☐    No     ☐ Unknown ☐ 
Please describe MRI abnormalities if present 
ASYMPTOMATIC (FOLLOW-UP) MRI: Date: 
normal ☐ residual ☐ new lesions ☐ NO new lesions ☐ 
  RESIDUAL PROBLEMS: Yes  ☐ No ☐……………………………………………. 
Appendix	C			
	 248	
• Fifth demyelinating event   date/month/year:                                    
BON    ☐   UON   ☐  short TM   ☐       LETM  ☐   
ADEM   ☐  Other   ☐  Describe: 
PRESENTING SYMPTOM/S: 
CURRENT THERAPY AT EVENT: 
 
o Therapy 
Agent Date 
started 
Date 
ceased 
Dose Other details 
(taper, etc) 
Response 
IV steroids      
Oral 
prednisone 
     
IVIg 
 
     
Plasma 
exchange 
     
Steroid 
sparing agent 
(specify) 
 
 
     
Rituximab 
 
     
Other  
 
    
 
o Improvement with treatment?   Yes ☐ No ☐ 
o If ON  Visual acuity at worst   L  R  Date: 
Visual acuity at best at follow-up L  R  Date: 
Visual fields available?  Yes ☐ No ☐ Date/s: 
OCT available?   Yes ☐ No ☐ Date/s: 
Optic disc swelling present on examination?:                        radiology?: 
o If TM  EDSS1 at worst   Date:  
EDSS at best at follow-up  Date: 
Spinal region/s involved  Cervical ☐ Thoracic ☐ Lumbar ☐ Conus ☐ 
Sphincter dysfunction?    Bladder  ☐  Bowel     ☐ 
o If ADEM  isolated ☐ coexistent ON ☐ coexistent TM ☐ 
EDSS1 at worst   Date:  
EDSS at best at follow-up  Date: 
o If other demyelinating event 
Brainstem  ☐ Cerebellar   ☐ Primarily motor (non spinal) ☐   
Primarily sensory (non spinal)     ☐ Other (please specify) ☐ 
EDSS1 at worst   Date:  
EDSS at best at follow-up  Date: 
o MRI brain   Date:   Normal   ☐ Abnormal   ☐   
o MRI spine   Date:  Normal   ☐ Abnormal   ☐   # vertebral 
segments:  
o MRI meeting 2010 McDonald’s criteria2?   Yes     No      Unknown  
Please describe MRI abnormalities if present 
ASYMPTOMATIC (FOLLOW-UP) MRI: Date: 
normal  residual  new lesions  NO new lesions  
  RESIDUAL PROBLEMS: Yes   No ……………………………………………. 
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MOST RECENT STATUS: 
 
Date: 
  
Current drugs: 
 
Current EDSS: 
 
Current clinical diagnosis: 
 
Current clinical comments on course: 
 
 
 
Current clinical problems: 
 
Motor     yes  no   
 
Cognition    yes  no   
 
Vision     yes  no   
 
Sphincter    yes  no   
 
Sensory    yes  no   
 
Epilepsy    yes  no   
 
 
Therapeutic summary:  
 
 
 
Current MRI: normal  residual   
 
CURRENT MRI McDonald yes  no   
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1Kurtzke’s Expanded Disability Status Scale (EDSS)195 
 
 
0: normal 
1: no disability, minimal signs in one functional system 
1.5: no disability, minimal signs on two functional systems 
2: minimal disability in one functional system 
2.5: minimal disability in two functional systems 
3: moderate disability in one functional system or mild disability in 3 or 4 functional 
systems, although fully ambulatory 
3.5: fully ambulatory but with moderate disability in one functional system and mild 
disability in one or two functional systems; or moderate disability in two functional 
systems; or mild disability in five functional systems 
4: fully ambulatory without aid, self-sufficient, despite severe disability in one 
functional system, able to walk without aid or rest 500 m 
4.5: fully ambulatory without aid, up for much of the day and able to work a full day, 
may have some limitations of full activity or require minimal assistance. Relatively 
severe disability. Able to walk without aid or rest for 300 meters. 
5: ambulatory without aid or rest for 200 m, impaired ability to carry out full daily 
activities 
5.5: ambulatory without aid or rest for 100 m, disability precludes full daily activities 
6: intermittent or unilateral constant assistance (walking aid like a cane/crutch/brace) to 
walk 100 m with or without resting 
6.5: constant bilateral support (cane, crutch or braces) required to walk 20 meters without 
resting 
7: unable to walk beyond 5 m even with aid, restricted to wheelchair but self-sufficient 
with this up to 12 hours a day 
7.5: unable to take more than a few steps, restricted to wheelchair, may need aid to 
transfer; wheels self, but may require motorised chair for full day’s activities 
8: restricted to bed or wheelchair, effective use of arms, able to self-care, may be out of 
bed for much of the day 
8.5 essentially restricted to bed for much of the day, some effective use of arms, retains 
some self care abilities 
9: bedbound, can communicate and eat 
9.5: bedbound, unable to communicate effectively or eat 
10: death due to MS. 
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2The 2010 Revised McDonald Criteria for Diagnosis of MS67 
 
 
Clinical Presentation Additional Data Needed for MS Diagnosis 
>/ 2 attacks; objective clinical 
evidence of >/2 lesions or objective 
clinical evidence of 1 lesion with 
reasonable historical evidence of a 
prior attack  
None 
>/2 attacks; objective clinical 
evidence of 1 lesions 
Dissemination in space (DIS), demonstrated by: 
 
>/ T2 lesion in at least 2 of 4 MS-typical regions of 
the CNS (periventricular, juxtacortical, infratentorial, 
or spinal cord); or await a further clinical attack 
implicating a different CNS site. 
 
1 attack; objective clinical evidence 
of >/2 lesions 
Dissemination in time (DIT); demonstrated by:  
 
Simultaneous presence of asymptomatic gadolinium-
enhancing and nonenhancing lesions at any times; or 
a new T2 and/or gadolinium-enhancing lesion(s) on 
follow-up MRI, irrespective of its timing with 
reference to a baseline scan; or await a second 
clinical attack 
 
1 attack; objective clinical evidence 
of 1 lesion (clinically isolated 
syndrome) 
Dissemination in space and time, demonstrated by: 
 
For DIS: >/ T2 lesion in at least 2 of 4 MS-typical 
regions of the CNS (periventricular, juxtacortical, 
infratentorial, or spinal cord); or await a further 
clinical attack implicating a different CNS site; and 
 
For DIT: Simultaneous presence of asymptomatic 
gadolinium-enhancing and nonenhancing lesions at 
any times; or a new T2 and/or gadolinium-enhancing 
lesion(s) on follow-up MRI, irrespective of its timing 
with reference to a baseline scan; or await a second 
clinical attack 
Insidious neurological progression 
suggestive of MS (PPMS) 
1 year of disease progression (retrospectively or 
prospectively determined) plus 2 of 3 of the 
following criteria: 
1. evidence for DIS in the brain based on >/ 1 
T2 lesions in the MS characteristic 
(periventricular, juxtacortical, or 
infratentorial) regions 
2. Evidence of DIS in the spinal cord based on 
>/ 2 T2 lesions in the cord 
3. Positive CSF (isoelectric focusing evidence of 
oligoclonal bands and/or elevated IgG index) 
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Appendix D: Comparison of prevalence of MOG antibodies in patients with demyelination using cell based assays  	
Reference Description of  
Cohort 
Sample Antigen 
characteristics 
Detection  Analysis 
approach 
Prevalence of MOG 
antibody positivity 
Concordance for 
MOG antibodies 
between CSF and 
serum 
Longitudinal 
evaluation of 
seropositivity 
Lalive et 
al183 
Proc Natl 
Acad Sci 
USA 
2006 
Adults 
CIS n=36 
RRMS n=35 
SPMS n=33 
PPMS n=24 
HC n=37 
Serum Full length 
human MOG 
transfected 
CHO cells 
Flow 
cytometry on 
live cells  
 
BR = Gmean 
value of IgG 
binding to MOG 
transfected CHO 
cells/ IgG binding 
to nontransfected 
CHO cells, 
normalised to the 
value of a positive 
control 
 
MOG IgG titres compared 
with HC were significantly 
increased in CIS (P<0.001), 
RRMS (P<0.01) and SPMS 
(P<0.05) 
  
Not assessed Not assessed 
Zhou et 
al184 
Proc Natl 
Acad Sci 
USA 
2006 
OIND n=47 
Adult MS n=47 
HC n=140 
RRMS n=54 
SPMS n=80 
PPMS n=29 
Serum Full length 
human MOG 
transduced 
human 
glioblastoma 
cell line LN18 
Flow 
cytometry on 
live cells 
MFI LN18MOG- 
MFI LN18Ctr, 
positive if over 
positive threshold 
(mean + 2SD of 
HC or OIND)  
MOG IgG positive: 
OIND 2/47 (4%) 
MS 15/47 (32%) 
 
HC 6/140 (4%) 
RRMS 12/54 (22%) 
SPMS 20/80 (25%) 
PPMS 12/29 (41%) 
Not assessed Not assessed 
O’Connor 
et al186 
Nat Med 
2007 
 
ADEM n=69 
Paediatric MS n=19 
Asian MS n=12 
RRMS n=76 
SPMS n=17 
PPMS n=16 
CIS n=32 
VE n=58 
HC n=75 
Serum 
and CSF 
First method: 
folded human 
MOG tetramer 
(extracellular 
domain of 
human MOG, 
CD2, and 
streptavidin 
complex) 
 
Second method: 
Full length 
human MOG-
Tetramer 
radioimmuno
assay 
 
 
 
 
 
 
 
Flow 
cytometry on 
live cells1 
Samples that 
precipitated >10% 
of the MOG 
tetramer were 
positive. This 
threshold for 
positivity was 
equal to 4 SD 
above the mean of 
HC 
 
 
 
MOG Ab positive 
IgG; IgM 
 
ADEM 13/69 (19%); 1/29 
(3%) 
Paediatric MS 1/19 (5%); 0/4 
(0%) 
Asian MS 1/12 (8%); nd 
RRMS 1/76 (1%); 0/12 (0%) 
SPMS 0/17 (0%); nd 
PPMS 0/16 (0%); nd 
CIS 0/32 (0%); 0/28 (0%) 
VE 0/58 (0%); 0/20 (0%) 
Concordance in 
presence of MOG 
antibodies in serum and 
CSF in 8 ADEM 
patients 
Not assessed 
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Reference Description of  
Cohort 
Sample Antigen 
characteristics 
Detection  Analysis 
approach 
Prevalence of MOG 
antibody positivity 
Concordance for 
MOG antibodies 
between CSF and 
serum 
Longitudinal 
evaluation of 
seropositivity 
GFP transfected 
Jurkat cells; 
HC 1/75 (1%); 0/32 (0%) 
McLaughli
n et al156 
J Immunol 
2009 
Paediatric patients 
MS n=131 
OND n=34 
Non neurological 
controls n=37 
Juvenile DM n=28 
 
Adult patients 
MS n=254 
Controls n=86 
CIS n=30 
NMO n=13 
VE n=29 
Serum 
and CSF 
Full length 
human MOG-
GFP transfected 
Jurkat cells 
Flow 
cytometry on 
live cells1  
BR = MFI of 
MOG: GFP clone, 
BR>5 considered 
positive 
MOG IgG positive: 
 
Paediatric 
MS: 28/131 (21%) 
OND: 2/34 (6%) 
Non neurological 
controls: 0/37 (0%) 
Juvenile DM: 0/28 (0%) 
 
Adult 
MS 11/254 (4%) 
Controls 4/86 (4.7%) 
CIS 2/30 (7%) 
NMO 0/13 (0%) 
Viral encephalitis 0/29 (0%) 
13 patients had CSF 
testing, of whom 3 
were serum MOG Ab 
positive. Of these 3, 1 
patient had MOG 
antibodies detected in 
both serum and CSF 
(latter with a lower 
BR). 
Not assessed  
Brilot et 
al155 
Ann 
Neurol 
2009 
Paediatric 
 
ADEM n=19 
CIS n=28 
(ON n=7, hemispheric 
n=6, brainstem n=2, 
cerebellar n=2, TM 
n=1, multifocal  n=10) 
 
OND n=29 
type 1 DM n=15 
HC n=30 
 
Adult MS n=54 
Serum 
and CSF 
Full length 
human MOG 
transduced 
human 
glioblastoma 
cell line LN18 
Flow 
cytometry on 
live cells 
ΔMFI = MFI 
LN18-MOG - 
MFI controls; cut 
off determined as 
median +95% of 
HC and OND 
groups 
 
MOG IgG positive: 
DEM 22/47 (46.8%) (both 
ADEM and CIS) 
OND 2/29 (6.9%) 
Not found in HC, type 1 DM, 
or adult MS cohorts 
 
MOG IgM positive: 
3/47 DEM (all ADEM) 
Not found in other groups 
 
Paired samples in 5 
paediatric CIS and 3 
ADEM patients, with 
serum and CSF both 
positive for MOG Abs 
in all patients; Ab titre 
higher in serum in all 
ADEM patients, and 
higher in CSF in 3/5 
CIS patients 
Not assessed 
Lalive et 
al188 
Mult Scler 
2011 
Paediatric 
ADEM n=11 
Paediatric MS n=22 
VE n=7 
Serum Recombinant 
human MOG 1-
125 
extracellular Ig 
ELISA and  
LiPhELIA 
(liquid phase 
assay based 
BR=OD against 
MOG/OD 
background 
 
MOG IgG (% positive) 
 
By ELISA: 
ADEM 55% 
Not assessed Not assessed 
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Reference Description of  
Cohort 
Sample Antigen 
characteristics 
Detection  Analysis 
approach 
Prevalence of MOG 
antibody positivity 
Concordance for 
MOG antibodies 
between CSF and 
serum 
Longitudinal 
evaluation of 
seropositivity 
HC n=13 domain 
expressed by E 
coli 
 
 
Human full 
length MOG 
transfected 
CHO cells 
on 
biotinylation 
of rMOG) 
 
 
Flow 
cytometry on 
live cells 
 
 
 
 
 
BR = MFI of 
MOG transfected 
cells/ MFI of 
control cells; 
considered 
positive if 
individual’s BR > 
mean +2 SD of 
controls 
 
 
Paediatric MS 14% 
HC 0% 
 
By LiPhELIA: 
ADEM 0% 
Paediatric MS 0% 
HC 0% 
 
By flow cytometry: 
ADEM 27% 
Paediatric MS 5% 
HC 0% 
 
Di Pauli et 
al189 
Clin 
Immunol 
2011 
 
ADEM n=34 (27 
paediatric, 7 adult) 
CIS n=38 (18 
paediatric, 20 adult) 
MS n=89 (18 
paediatric, 71 adult) 
OND n=58 (15 
paediatric, 43 adult) 
HC n=47 (all adult) 
Serum  
 
 
 
CSF in 
33 
patients 
(ADEM 
n=8, CIS 
n=13, 
MS 
n=12) 
Full length 
human MOG-
GFP transiently 
transfected 
HEK293A cells 
 
 
 
 
 
 
 
 
Recombinant 
human MOG 1-
125 
extracellular Ig 
domain 
expressed by E 
Microscopy 
on live cells 
 
 
 
 
 
 
 
 
 
 
 
 ELISA 
Visual scoring  
 
 
 
 
 
 
 
 
 
 
 
 
OD at 492 nm, cut 
off determined by 
values from age 
and sex matched 
controls 
Cut off value of high titre 
MOG IgG identified as 1:160 
and present in serum in: 
 
ADEM 15/34 (44%) 
CIS 3/38 (8%) 
MS 2/89 (2%) 
OND 1/58 (2%) 
HC 0/47 (0%) 
 
 
CSF 12/33 positive 
 
Non-specific results with 
serum anti-MOG antibodies 
by ELISA in: 
ADEM 5/21 (24%) 
CIS 3/36 (8%) 
MS 13/89 (15%) 
In anti-MOG IgG 
seronegative patients, 
the corresponding CSF 
samples were negative 
 
In the low titer range, 
anti-MOG antibodies 
were only present in 
serum, but not in the 
CSF.  
 
All patients with higher 
titer values (>/1:640) in 
serum showed 
detectable reactivity to 
MOG in the CSF 
 
Correlation between 
disease severity or 
relapse and anti-
MOG Ab titre in 
ADEM patients 
(n=10), but not clear 
in the other groups 
(CIS n=4, MS n=9, 
OND n=2) 
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Reference Description of  
Cohort 
Sample Antigen 
characteristics 
Detection  Analysis 
approach 
Prevalence of MOG 
antibody positivity 
Concordance for 
MOG antibodies 
between CSF and 
serum 
Longitudinal 
evaluation of 
seropositivity 
Coli 
 
 
OND 6/54 (11%) 
HC 2/47 (4%) 
Mader et 
al157 
J 
Neuroinfla
mmation 
2011 
Paediatric and adult 
NMO n=45 
HR-NMO n=53 (28 
mLETM, 13 rLETM, 
12 rON) 
ADEM n=33 
CIS n=32 
MS n=71 (44 RRMS, 
19 SPMS, 8 PPMS) 
Controls n=101 (24 
OND, 27 SLE, 50 HC) 
Serum Full length 
human MOG –
GFP2 transiently 
transfected 
HEK293A cells 
Microscopy 
on live cells 
Visual scoring 
 
 
 
 
 
High titre (>/1:160) MOG IgG 
positive: 
 
NMO 3/45 (7%) 
HR-NMO 7/53 (3%)  
ADEM 14/33 (42%) 
CIS 2/32 (6%) 
MS 2/71 (3%) 
Controls 3/101 (3%) 
Not assessed Not assessed 
Probstel et 
al185 
Neurology 
2011 
 
Paediatric: 
MS n=65 
ADEM n=54 
CIS n=7 
Controls n=35 
 
Adult: 
MS n=62 
Controls n=28 
Serum Full length 
human MOG 
transfected 
human 
rhabdomyosarco
ma cell line (TE 
671) 
Flow 
cytometry on 
live cells  
Geometric MCF 
of transfected cell 
line/untransfected 
cell line for each 
patient; cut off 4 
SD above mean of 
paediatric controls 
(geometric MCF 
ratio=1.45) 
MOG IgG positive: 
 
Paediatric 
MS 10/65 (15%) 
ADEM 19/54 (35%)  
CIS 2/7 (29%) 
Controls 0/35 (0%) 
 
Adult 
MS 4/62 (6%) 
Controls 0/28 (0%) 
 
None positive for MOG IgM 
Not assessed Anti-MOG antibodies 
rapidly and 
continuously declined 
in monophasic 
ADEM 
 
MOG antibodies 
persisted in the 
majority of children 
who went on to be 
diagnosed with 
childhood MS 
Kitley et 
al160 
Neurology  
2012 
Adults 
 
AQP4 Ab-negative 
NMO/NMOSD n=27 
 
AQP4 Ab-positive 
NMO/NMOSD n=44 
 
Serum 
 
Human C-
terminal 
truncated MOG 
transfected 
HEK293 cells 
Microscopy 
on live cells 
Visual scoring  MOG Ab-positive3: 
 
AQP4 Ab-negative 
NMO/NMOSD 4/27 (15%) 
 
none of the other groups 
Not assessed Not assessed 
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Reference Description of  
Cohort 
Sample Antigen 
characteristics 
Detection  Analysis 
approach 
Prevalence of MOG 
antibody positivity 
Concordance for 
MOG antibodies 
between CSF and 
serum 
Longitudinal 
evaluation of 
seropositivity 
Adult MS n=75 
HC n=47 
Rostasy et 
al158 
Arch  
Neurol 
2012 
 
Paediatric ON n=37 
 
Serum  Full length 
human MOG-
GRP transfected 
HEK293A cells 
Microscopy 
on live cells 
Visual scoring  MOG IgG positive: 
12/15 rON (80%) 
2/10 mON (20%) 
3/12 CIS (25%) 
 
Not assessed Not assessed 
Rostasy et 
al159 
Mult Scler  
2013 
Paediatric 
demyelination n=106 
(NMO n=8, mON 
n=14, rON n=3, TM 
n=6, ADEM n=29, CIS 
n=32, MS n=11, 
cerebellitis n=3) 
 
OND n=20 
Serum Full length 
human MOG-
GFP transfected 
HEK293A cells 
Microscopy 
on live cells 
Visual scoring MOG IgG positive: 
3/8 NMO (38%) 
2/14 mON (14%) 
2/3 rON (67%) 
0/6 TM (0%) 
13/29 ADEM (45%) 
1/32 CIS (3%) 
1/11 MS (9%) 
0/3 cerebellitis (0%) 
0/20 OND (0%) 
Not assessed Persistent high titre 
MOG Ab 
seropositivity 
identified in 
longitudinal samples 
of MOG Ab positive 
NMO patients  
Kitley et 
al210 
JAMA 
Neurol 
2014 
1st episode CNS 
demyelination positive 
for MOG or AQP4 Abs 
from 2010-2013, 
n=46 
Serum Human C-
terminal 
truncated MOG 
transfected 
HEK293 cells 
Microscopy 
on live cells 
Visual scoring  MOG IgG positive: 
9/46 (20%) 
 
Not assessed Not assessed 
Baumann 
et al192 
JNNP 
2015 
Paediatric ADEM  
n=33 
Serum Full length 
human MOG-
GFP transfected 
HEK293A cells 
Microscopy 
on live cells 
Visual scoring  High-titre (>/1:160) MOG IgG 
positive: 19/33 patients (58%) 
Not assessed Persistent MOG Ab 
persistence in 4/19 
MOG Ab-positive 
patients with 
relapsing disease 
Dale et 
al201 
Neurol 
Neuroimm
unol 
Neuroinfla
mm 2014 
Paediatric 
demyelination n=73 
(ADEM n=28, TM 
n=15, ON n=15, other 
CIS n=15) 
OND n=24 
Serum 
(and 
paired 
CSF in 
22 
samples) 
Full length 
human MOG-
ZsGreen+ 
lentivirus 
transduced 
HEK293 
cells 
Flow 
cytometry on 
live cells 
Positive threshold 
defined as mean 
ΔMFI + 3 SD of 
controls 
MOG IgG positive: 
 
Demyelination 31/73 (42%) 
ADEM 11/24 (46%) 
ON 6/7 (86%) 
rON 3/4 (75%) 
TM 4/13 (31%) 
22 patients had CSF 
tested, of whom 5 were 
serum MOG Ab-
positive. 3 CSF 
samples were MOG Ab 
positive (2 who were 
serum MOG Ab-
Persistent 
seronegativity in two 
patients treated with 
mycophenolate 
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Reference Description of  
Cohort 
Sample Antigen 
characteristics 
Detection  Analysis 
approach 
Prevalence of MOG 
antibody positivity 
Concordance for 
MOG antibodies 
between CSF and 
serum 
Longitudinal 
evaluation of 
seropositivity 
CIS 0/10 (0%) 
MS 7/15 (47%) 
OND 0/24 (0%) 
positive and 1 who was 
serum MOG Ab-
negative) 
Sato et 
al202 
Neurology 
2014 
Paediatric and adults 
NMO/NMOSD n=215 
Serum Full length 
human MOG 
transiently 
transfected 
HEK293 cells 
Microscopy 
on live cells  
Visual scoring  MOG IgG positive: 16/215 
(7.4%) 
 
Of these 16: 
ON + TM 1/16 
LETM 5/16 
rON 5/16 
BON 5/16 
 
Not assessed Persistent 
seropositivity in 
seven patients 
Ramanatha
n  et al161 
Neurol 
Neuroimm
unol 
Neuroinfla
mm 
2014 
23 adults with AQP4 
Ab-negative 
NMO/NMOSD 
including: 
BON n=11 
LETM n=10 
BON and LETM n=2 
 
Adult MS n=76 
OND n=20 
HC  n=32 
Serum Full length 
human MOG-
ZsGreen4 
lentivirus 
transduced 
HEK293 
cells 
Flow 
cytometry on 
live cells 
Positive threshold 
defined as mean 
ΔMFI + 3 SDs of 
controls 
MOG IgG positive: 
9/23 (39%) of which BON 
(n=8) and BON and LETM 
(n=1) 
 
Adult MS 1/76 (1%) 
OND 0/20 (0%) 
HC 0/32 (0%) 
Not assessed Persistent 
seropositivity (albeit 
with reduced ΔMFI) 
despite clinical 
recovery and 
treatment in 2 
patients, ΔMFI 
increasing with 
relapses in 1 patient, 
and return to normal 
in 1 patient in whom 
serial samples were 
obtained 
Tanaka et 
al219 
J 
Neuroimm
unol 
2014 
 
Japanese adults 
 
AQP4 Ab-negative TM 
or ON n=48 
 
AQP4 Ab-positive 
NMO/NMOSD n=14 
Serum Full length 
human MOG 
transfected 
HEK293 cells 
Microscopy 
on fixed cells 
Visual scoring MOG IgG1 positive:  4/48 
(8%) AQP4 Ab-negative 
patients only 
 
 
Not assessed Not assessed 
Martinez 
Hernandez 
et al233 
Isolated ON n=51 (36 
adults, 15 paediatric) 
 
Serum  
 
Paired 
Full length 
human MOG-
GFP2 transfected 
Microscopy 
on live cells 
Visual scoring MOG IgG positive: 
 
10/51 (20%) ON patients, and 
MOG Ab positive in 
serum and CSF for one 
patient; MOG and 
Not assessed 
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Reference Description of  
Cohort 
Sample Antigen 
characteristics 
Detection  Analysis 
approach 
Prevalence of MOG 
antibody positivity 
Concordance for 
MOG antibodies 
between CSF and 
serum 
Longitudinal 
evaluation of 
seropositivity 
JAMA 
Neurol 
2015 
 
 
Controls  
HC n=30 
NMO n=48 
MS n=64 including 8 
paediatric (CIS n=28, 
RRMS n=17, SPMS 
n=9, PPMS n=10) 
CSF in 4 HEK293 cells concurrent with glycine 
receptor antibodies in 3 
patients 
 
4/48 (8%) NMO patients, and 
concurrent with AQP4 
antibodies in 2 patients 
 
glycine receptor 
antibodies in serum 
only in 1 patient 
Elong 
Ngono et 
al{Elong 
Ngono, 
2015 #964 
J Immunol 
Res 
2015 
Adult MS: 
RRMS n=27 
SPMS n=8 
HC n=50 
 
 
Plasma Full length 
human MOG-
GFP transfected 
HEK293 cells 
Microscopy 
on live cells 
Visual scoring High titre MOG IgG positive: 
 
RRMS 1/27 (4%) and  
HC 1/50 (2%) 
Not assessed  Not assessed 
Ketelsleger
s et al193 
Mult Scler 
2015 
117 paediatric 
demyelination 
 
ON n=20 
TM n=7 
other monofocal 
demyelination n=22 
polyfocal 
demyelination without 
encephalopathy n=44 
ADEM n=24 
 
OND n=13 
HC paediatric n=313 
Adult ADEM n=29 
Serum Human full 
length MOG 
stably 
transfected 
LN18 cells 
(glial cell line) 
Flow 
cytometry on 
live cells 
Cut off defined as 
mean ΔMFI of 
controls + 3 SD 
MOG IgG positive: 21/117 
(18%) children with 
demyelination  
Of these: 
ON n=2 
Polyfocal demyelination 
without encephalopathy n= 8 
Paediatric ADEM n=10 
Hemiparesis n=1 
 
Adult ADEM 1/29 
0 in control groups (OND and 
HC paediatric) 
 
Only 1/47 children who went 
on to get a diagnosis of MS 
was seropositive 
Not assessed Not assessed 
Hoftberger 
et al231 
Adults with 
demyelination (n=174) 
Serum 
and CSF 
Full length 
MOG-GFP2 
Microscopy 
on live cells  
Visual scoring 
 
MOG IgG positive: 
 
8 patients had CSF 
tested, of whom all 8 
Persistent 
seropositivity in 
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Reference Description of  
Cohort 
Sample Antigen 
characteristics 
Detection  Analysis 
approach 
Prevalence of MOG 
antibody positivity 
Concordance for 
MOG antibodies 
between CSF and 
serum 
Longitudinal 
evaluation of 
seropositivity 
Mult Scler 
2015 
including: 
 
NMO n=48 
LETM n=84 
ON n=39 
ADEM n=3 
 
Controls: 55 adults 
with MS (20 CIS, 15 
RRMS, 10 SPMS, 10 
PPMS) 
 
Paediatric 
demyelination (n=30) 
including: 
NMO n=4 
LETM n=7 
ON n=8 
ADEM n=10 
MS + LETM relapse 
n=1 
transfected 
HEK293 cells 
17/174  (9.8%) adults with 
demyelination of which 
NMO 4/17  
LETM 5/17 
ON 7/17 
ADEM 1/17 
 
adult MS controls 0/55 (0%) 
12/30 (40%) paediatric 
demyelination patients of 
whom 36% had ADEM 
were serum MOG Ab-
positive. 5 CSF 
samples were MOG Ab 
positive (all 5 were 
serum MOG Ab-
positive) 
 
 
12/14 MOG Ab-
positive patients 
without correlation 
between titres and 
outcome 
Hacohen et 
al194 
Neurol 
Neuroimm
unol 
Neuroinfla
mm 2015 
Paediatric first episode 
acquired demyelination  
ADEM n=12 
ON n=24 
TM n=18 
Other CIS n=11 
 
Controls: 
Adult MS n=100 
Adult AQP4 Ab-
positive n=100 
Serum Full length 
human MOG 
transfected 
HEK293 cells 
Microscopy 
on live cells 
Visual scoring MOG IgG positive: 
23/65 (35%) 
of which 
ADEM 4/12 (33%) 
ON 12/24 (50%) 
TM 4/18 (22%) 
other CIS 3/11 (27%) 
 
No MOG IgG positive 
controls 
 
2/23 (9%) of MOG Ab-
positive patients had a 
diagnosis of MS in 1 year 
Not assessed Not assessed 
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Reference Description of  
Cohort 
Sample Antigen 
characteristics 
Detection  Analysis 
approach 
Prevalence of MOG 
antibody positivity 
Concordance for 
MOG antibodies 
between CSF and 
serum 
Longitudinal 
evaluation of 
seropositivity 
 
16/42 (38%) of MOG Ab-
negative patients had a 
diagnosis of MS in 1 year 
Waters et 
al263 
Neurol 
Neuroimm
unol 
Neuroinfla
mm 2015 
1109 consecutive sera 
sent for AQP4 Ab 
testing 
Serum Full length 
human MOG 
transfected 
HEK293 cells5 
Microscopy 
on live cells     
(n=1109) 
 
Flow 
cytometry on 
live cells 
(n=15) 
 
Visual scoring 
 
 
 
ΔMFI = median 
green 
fluorescence 
transfected – 
untransfected 
cells; cut off 
identified as the 
mean MFI of 
HC+ 6 SD 
MOG IgG1 positive: 
65/1109 patients positive for 
full length MOG Abs, with no 
full length MOG Ab 
seropositivity in AQP4 Ab-
positive and control patients 
 
 
 
Not assessed Not assessed 
Hino-
Fukuyo279 
Brain Dev 
2015 
Japanese paediatric 
demyelination patients 
 
ADEM n=7 
ON n=5 
MS n=4 
NMO n=1 
Serum Full length 
human MOG 
transfected 
HEK293 cells 
Microscopy 
on live cells  
Visual scoring  MOG IgG positive: 
ADEM 3/7 (43%) 
ON 3/5 (60%) 
MS 3/4 (75%) 
Not assessed Not assessed 
Probstel et 
al249 
J 
Neuroinfla
mmation 
2015 
NMO/NMOSD n=48 
RRMS n=48 
HC n=39 
Serum Full length 
human MOG 
transfected 
human 
rhabdomyosarco
ma cell line (TE 
671) 
Flow 
cytometry on 
live cells 
BR of the GMCF 
of the MOG-
transfected: empty 
vector- 
transfected cell 
line; cut off = 
mean GMCF ratio 
plus two SD of 
HC 
MOG IgG positive: 
NMO/NMOSD 4/48 (8%) 
RRMS 0/48 (0%) 
HC 0/39 (0%) 
Not assessed Longitudinal analyses 
in 2 Ab-positive 
patients showed 
increase with relapse 
in one patient, but 
was independent of 
disease activity in 
another 
Chalmouk
ou et al259 
AQP4 Ab-negative ON 
n=111 
Serum Full length 
human MOG-
Microscopy 
on live cells 
Visual scoring  MOG Abs positive3: 
 
Not assessed Not assessed 
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Reference Description of  
Cohort 
Sample Antigen 
characteristics 
Detection  Analysis 
approach 
Prevalence of MOG 
antibody positivity 
Concordance for 
MOG antibodies 
between CSF and 
serum 
Longitudinal 
evaluation of 
seropositivity 
Neurol 
Neuroimm
unol 
Neuroinfla
mm 
2015 
 
Controls: 
PPMS n=12 
RRMS n=30 
GFP transiently 
transfected 
HEK293T cells 
ON patients 8/111 (7%) 
- 5/8 had rON 
MS controls 0/42 (0%) 
Cobo-
Calvo et 
al234 
Mult Scler 
2015 
Adults 
First episode LETM 
(AQP4 Ab-negative) 
n=56 
Serum Full length 
human MOG-
GFP2 transfected 
HEK293 cells 
Microscopy 
and flow 
cytometry on 
live cells 
(complete 
concordance)  
Visual scoring for 
microscopy 
 
Flow cytometry 
analysis not 
specified 
MOG IgG positive:  
13/56 (23%)  
Not assessed Follow up samples in 
6/13 MOG Ab-
positive patients – 
one patient (mLETM) 
was negative at 43 
months, 5 remained 
seropositive (3 
mLETM, 1 rLETM, 1 
converted to NMO) 
Ramanatha
n et al162 
Mult Scler 
2016 
Paediatric and adults 
 
Japanese AQP4-4 Ab-
negative patients with 
OSMS n=50 
 
HC n=20 
OND n=19 
Serum Full length 
human MOG-
ZsGreen4  
lentivirus 
transduced 
HEK293 
cells 
Flow 
cytometry on 
live cells 
Positive threshold 
defined as mean 
ΔMFI + 3 SDs of 
controls 
MOG IgG positive: 
OSMS 2/50 (4%) 
OND+HC 1/39 (3%) 
 
MOG IgM positive: 
OSMS 1/50 (2%) 
OND+HC 0/30 (0%) 
Not assessed  Not assessed 
Fernandez-
Carbonell 
et al190 
Mult Scler 
2015 
Paediatric 
demyelinating 
syndromes n=74 
including: 
 
ADEM n=7 
CIS n=12 
MS n=45 
NMO n=4 
RIS n=2 
Other demyelination 
n=4 
Serum Full length 
human MOG-
GFP stably 
transfected 
Jurkat cells  
Flow 
cytometry on 
live cells  
Mean BR of 
patients – healthy 
controls, patients 
with corrected BR 
> 3 SD from 
controls were 
positive (BR>5) 
MOG IgG positive: 
13/74 patients (18%) 
 
Of which 
ADEM 3/7 (43%) 
CIS 2/12 (17%) 
MS 4/45 (9%) 
NMO 2/4 (50%) 
Other demyelination 2/4 
(50%) 
RIS 0/2 (0%) 
 
Not assessed Not assessed 
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Reference Description of  
Cohort 
Sample Antigen 
characteristics 
Detection  Analysis 
approach 
Prevalence of MOG 
antibody positivity 
Concordance for 
MOG antibodies 
between CSF and 
serum 
Longitudinal 
evaluation of 
seropositivity 
 
Paediatric HC n=23 
And in 0/23 HC (0%) 
Matsuda et 
al260 
Neuroopht
halmology  
2015 
Adults 
 
ON n=70 
Serum Full length 
human MOG 
transfected 
HEK293 cells 
Microscopy 
on fixed cells 
Visual scoring MOG IgG positive: 
18/70 patients (26%) 
Of which 
CRION 2/18 (11%) 
AQP4 antibody-positive NMO 
2/18 (11%) 
Idiopathic ON 12/18 (67%) 
ON with MS 2/18 (11%) 
Not assessed Not assessed 
Siritho et 
al280 
Mult Scler 
2016 
70 patients with CNS 
demyelination  
CDMS n=14 
CIS n=12  
definite NMO n=14 
AQP4 antibody-
positive NMOSD n=5 
BON n=8  
LETM n=9 
Serum Full length 
human MOG 
transiently 
transfected 
HEK293 cells 
Microscopy 
on live cells  
Visual scoring  MOG IgG positive in 6/70 
(8.6%) 
 
BON 3/6 (50%) 
UON + TM 1/6  
UON1/6 
Recurrent UON 1/6 
1 patient positive for 
MOG antibodies in 
serum and CSF 
Not assessed 
Kim et 
al258 
Neurol 
Neuroimm
unol 
Neuroinfla
mm 2015 
Adults 
 
270 patients with 
inflammatory 
demyelinating 
disorders (including 
MS, definite NMO, 
NMOSD, ADEM, CIS, 
TM, ON) 
Serum Full length 
human MOG 
transfected 
HEK293 cells 
Microscopy 
on live cells      
Visual scoring 
 
 
 
MOG IgG1 positive: 
17/270 (6.3%) 
 
 
 
 
 
49/270 (18%) positive for 
AQP4 antibodies 
Not assessed Not assessed 
Van Pelt et 
al250 
Eur J 
Neurol  
2016 
102 adults with  
NMOSD  
 
AQP4 antibody 
negative n=61 
AQP4 antibody 
positive n=41 
Serum Full length 
human MOG 
stably 
transfected 
LN18 cells 
Flow 
cytometry on 
live cells 
Positive threshold 
defined as mean 
MFI + 10 SDs of 
8 controls 
MOG IgG positive: 
20/61 AQP4 antibody-
negative patients 
 
0/41 AQP4 antibody-positive 
patients 
Not assessed Not assessed 
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Reference Description of  
Cohort 
Sample Antigen 
characteristics 
Detection  Analysis 
approach 
Prevalence of MOG 
antibody positivity 
Concordance for 
MOG antibodies 
between CSF and 
serum 
Longitudinal 
evaluation of 
seropositivity 
Lechner et 
al253 
J Neurol 
Neurosurg 
Psychiatry 
2016 
Paediatric (n=45) 
 
NMO n=12 
RON n=12 
BON n=6 
LETM n=14 
Brainstem n=1 
 
 
Serum Full length 
human MOG-
GFP transiently 
transfected 
HEK293A cells 
 
 
 
 
 
 
 
Microscopy 
on live cells 
 
 
 
 
 
 
 
 
 
Visual scoring  
 
MOG antibody 
titres ≥ 1:160 
classified as 
seropositive 
 
 
 
 
 
 
 
 
 
 
MOG IgG positive: 
25/45 (56%)  
[NMO n=7/12, BON n=4/6, 
RON n=8/12, LETM n=6/14] 
 
AQP4 IgG positive: 
5/45 (11%) 
[NMO n=3/12, LETM n=1/14, 
brainstem n=1/1] 
 
Double seronegative 15/45 
(33%) 
Not assessed 17/23 MOG antibody 
positive children still 
seropositive after a 
median follow up of 
20 months 
Piccolo et 
al252 
J Neurol  
2016 
Paediatric and adults 
 
69 patients with ON 
 
AQP4 antibody 
positive n=37 
 
AQP4 antibody 
negative n=32 
Serum Full length 
human MOG 
transfected 
HEK293 cells 
Microscopy 
on live cells 
 
Visual scoring  
 
MOG IgG1 positive: 
 
8/32 AQP4 antibody-negative 
patients (25%) 
Not assessed Not assessed 
Baumann 
et al238 
Mult Scler 
2016 
Paediatric 
 
10 patients with 
MDEM identified out 
of a 295 children with 
acute demyelinating 
Serum Full length 
human MOG –
GFP2 transiently 
transfected 
HEK293A cells 
Microscopy 
on live cells 
Visual scoring 
 
MOG antibody 
titres ≥ 1:160 
classified as 
seropositive 
MOG IgG positive:  
 
8/8 MDEM patients (100%) 
66/295 patients with other 
acute demyelinating 
syndromes (including 
Not assessed MDEM patients 
remained persistently 
seropositive, with a 
decrease in titres over 
time, 3 children 
showed an increase in 
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Reference Description of  
Cohort 
Sample Antigen 
characteristics 
Detection  Analysis 
approach 
Prevalence of MOG 
antibody positivity 
Concordance for 
MOG antibodies 
between CSF and 
serum 
Longitudinal 
evaluation of 
seropositivity 
events; 8/10 tested for 
MOG antibodies 
 
 
 
 
 
 
NMOSD or limited forms, and 
ADEM) 
tires with acute 
relapses 
 
33/66 non MDEM 
patients remained 
persistently 
seropositive, 14/66 
became seronegative, 
and 19/66 had no 
follow up samples 
Hacohen et 
al254 
Dev Med 
Child 
Neurol  
2016 
Paediatric 
 
57 children with 
brainstem encephalitis 
Serum Full length 
human MOG 
transfected 
HEK293 cells 
Microscopy 
on live cells 
 
Visual scoring  
 
MOG IgG: 
5/57 positive  
ADEM n=4 
CIS n=1 
 
Note other antibodies 
identified: 
GQ1b n=6, NMDAR n=7, 
GlyR n=5, AQP4 n=1, VGKC 
complex n=3 
Not assessed Not assessed 
Sepulveda 
et al251 
Neurol 
Neuroimm
unol 
Neuroinfla
mm 
2016 
Mainly adult, few 
paediatric 
 
181 patients (fulfilling 
2006 NMO criteria 
n=127, NMO/limited 
forms with AQP4 
antibodies n=54) 
Serum Full length 
human MOG2 
transfected 
HEK293 cells  
 
Microscopy 
on live cells  
Visual scoring 
 
MOG IgG positive: 
9/181 (5%) 
 
2 patients double-positive for 
AQP4 and MOG IgG 
Not assessed Not assessed 
Spadaro et 
al255 
Neurol 
Neuroimm
unol 
Neuroinfla
mm 
Adults with clinically 
definite MS 
 
Severe 
brainstem/spinal 
cord/optic nerve 
involvement n=104 
Serum Full length 
uman MOG 
transiently 
transfected HEK 
cells 
Flow 
cytometry on 
live cells 
Positive threshold 
defined as mean 
ratio of MFI 
MOG transfected/ 
untransfected 
HEK cells+ 3 SDs 
of 39 healthy 
MOG IgG positive: 
5/104 (5%) 
0/104 MOG IgM positive 
 
None of the unselected MS 
patients or biopsy proven CNS 
demyelination patients 
Not assessed Fluctuations in anti-
MOG reactivity over 
time, with occasional 
periods where below 
the positive 
threshold, followed 
by a period of 
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Reference Description of  
Cohort 
Sample Antigen 
characteristics 
Detection  Analysis 
approach 
Prevalence of MOG 
antibody positivity 
Concordance for 
MOG antibodies 
between CSF and 
serum 
Longitudinal 
evaluation of 
seropositivity 
2016  
Unselected patients 
with clinically definite 
MS n=55 
 
Biopsy proven CNS 
demyelination n=22 
controls seropositivity 
Jarius et 
al232, 240, 248 
 
J 
Neuroinfla
mmation 
2016 
Paediatric and adult 
 
Group 1 300 patients 
(ON + TM n=54, 
monophasic ON n=66, 
RON n=37, LETM 
n=45, RRMS n=50, 
SPMS n=2, PPMS n=2, 
OND n=44) 
 
Group II 83 AQP4 IgG 
positive patients 
 
Group III 85 MS 
patients 
 
Group IV controls 
(OND n=9, healthy 
n=45) 
Serum 
 
(CSF in 
a 
minority
) 
Full-length 
human MOG 
transfected 
HEK293A cells 
Microscopy 
on live cells 
Visual scoring 
 
titres ≥ 1:160 
classified as 
seropositive 
 
 
MOG IgG positive: 
50/300 (16.7%) of patients 
from Group 1 
 
- history of ON and 
myelitis 22/54 (41%) 
- myelitis only 22/103 
(21%) 
- ON only 6/45 
(13.3%) 
 
0/83 AQP4 IgG positive 
patients 
0/85 MS patients 
1/54 controls 
12/15 MOG antibody-
positive patients were 
positive on testing CSF 
18/22 (82%) of 
patients with follow 
up samples remained 
seropositive, in 4 
patients, MOG IgG 
tested negative at 
least once 
Pandit et 
al281 
Ann Indian 
Acad 
Neurol 
2016 
Paediatric and adult 
NMOSD 
N=125 
Serum Full-length 
human MOG 
stably 
transfected 
HEK293 cells 
Microscopy 
on live cells  
Visual scoring  MOG IgG positive: 
AQP4 antibody-positive 
30.4% 
MOG antibody-positive 
20% 
Double seronegative 
49.6% 
Not assessed Not assessed 
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Reference Description of  
Cohort 
Sample Antigen 
characteristics 
Detection  Analysis 
approach 
Prevalence of MOG 
antibody positivity 
Concordance for 
MOG antibodies 
between CSF and 
serum 
Longitudinal 
evaluation of 
seropositivity 
Ogawa et 
al241 
Neurol 
Neuroimm
unol 
Neuroinfla
mm 
2017 
Adults with steroid 
responsive encephalitis 
of unknown aetiology 
N=24 
Serum Full-length 
human MOG 
transfected 
HEK293 cells 
Microscopy 
on live cells  
Visual scoring  MOG IgG positive: 
n=4 with unilateral cortical 
encephalitis with seizures 
Not assessed Not assessed 
 
 
 
 
Adapted from Ramanathan et al 20161 
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Ab antibody, BR binding ratio, CHO Chinese hamster ovary, DEM demyelination, DM diabetes 
mellitus, E Coli Escherichia coli, FL-MOG full length myelin oligodendrocyte glycoprotein, GFP 
green fluorescence protein, GMCF geometric mean channel fluorescence, Gmean geometric mean 
intensity, HC healthy controls, HR-NMO high risk neuromyelitis optica, MCF mean channel 
fluorescence, MFI mean fluorescence intensity, ΔMFI Delta mean fluorescence intensity, MDEM 
multiphasic disseminated encephalomyelitis, mLETM monophasic longitudinally extensive 
transverse myelitis, mON monophasic optic neuritis, nd not done, OD optical density, OIND other 
inflammatory neurological diseases, OND other neurological diseases, OSMS opticospinal multiple 
sclerosis, PPMS primary progressive multiple sclerosis, RIS radiologically isolated syndrome, 
rLETM recurrent longitudinally extensive transverse myelitis, rON recurrent optic neuritis, RRMS 
relapsing remitting multiple sclerosis, SLE systemic lupus erythematosis, SL-MOG short length 
myelin oligodendrocyte glycoprotein, SPMS secondary progressive multiple sclerosis, VE viral 
encephalitis 
 
1 These studies used a 3 step immunofluorescence method for signal amplification with biotinylated 
anti-human IgG and streptavidin-PE. All other studies used a 2 step immunofluorescence method. 
2C-terminal fusion with GFP 
3MOG antibody isotype not specified 
4MOG and fluorescent protein not fused 
5Comparison between short length and full length MOG, DsRed pIRES2 plasmid used for flow  
  cytometry 
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a b s t r a c t
The knowledge of immune dysregulation and autoimmunity in neurological disorders has expanded con-
siderably in recent times. Recognition of clinical syndromes, reliable methods of diagnosis, and early tar-
geted immunotherapy can lead to a favourable outcome in acute and subacute neurological disorders
that may be associated with significant morbidity and mortality if left untreated. This review focuses
on the rapidly expanding field of autoimmune encephalitis. We describe the differences between limbic
encephalitis associated with antibodies targeting intracellular antigens, and neuronal surface antibody
syndromes (NSAS) where the antigens are primarily receptors or synaptic proteins located on the neuro-
nal cell surface. We chronologically highlight important developments in NSAS by focusing on voltage
gated potassium channel complex-associated antibody mediated encephalitis, anti-N-methyl-D-aspartate
receptor (anti-NMDAR) encephalitis, and anti-dopamine 2 receptor antibody-associated basal ganglia
encephalitis. Contentious issues such as the complexities of using serum antibodies as biomarkers, the
initiation of central nervous system autoimmunity, and possible pathogenic mechanisms of these anti-
bodies will be reviewed. The therapeutic challenges that clinicians face such as the timing of therapy
and the role of second-line therapy will be discussed, with crucial concepts highlighted in the form of
clinical vignettes. Future directions will involve the identification of novel antigens and methods to
establish their pathogenicity, as well as evaluation of the most efficacious therapeutic strategies in
patients with established NSAS.
! 2013 Elsevier Ltd. All rights reserved.
1. Introduction
The role of immune dysregulation and autoimmunity in neuro-
logical disorders has been the subject of considerable research in
recent times. This review focuses on the rapidly expanding field
of autoimmune encephalitis.
Limbic encephalitis (LE) was first described in the 1960s and
refers to the subacute onset of episodic memory loss, confusion,
and agitation [1]. LE is frequently associated with hallucinations,
seizures, sleep disturbance, and signal change in the medial tem-
poral lobe and hippocampi on imaging. LE is classically described
as being paraneoplastic [1]. Antibodies to onconeural intracellular
antigens which are nuclear or cytoplasmic proteins such as Hu, Ma,
and Ri are associated with certain malignancies such as lung cancer
and testicular tumours [1,2]. These antibodies are clearly demon-
strated by standardised tests, associated with limited subtypes of
malignancies, and have a variety of neurological manifestations
[2]. The clinical course is usually monophasic and relentlessly
progressive with a guarded prognosis, and treatment is directed
to the underlying malignancy [3,4]. The antibodies targeting onco-
neural antigens are believed to be biomarkers of associated tu-
mours rather than being directly pathogenic, and their detection
should prompt investigation for an associated underlying malig-
nancy [2,4,5]. Previous studies including passive transfers or active
vaccination with the antigen in animal models have failed to repro-
duce these clinical syndromes, and newly published results have
shown that neuronal cell death was due to T-cell mediated cyto-
toxicity, lending further weight to the contention that this group
of antibodies is not directly pathogenic [2,4].
There is a second distinct group of patients with autoimmune
encephalitis, where autoantibodies targeting neuronal cell surface
antigenic epitopes that are extracellular rather than intracellular
have been identified [2,3,6,7]. This group of antibodies are collec-
tively referred to as ‘‘neuronal surface antibodies’’ (NSAbs), and
the neurological manifestations associated with them as ‘‘neuronal
surface antibody syndromes’’ (NSAS) [5]. Lancaster et al. character-
ised NSAbs as demonstrating five features – the epitopes are extra-
cellular, antibody binding is visible in cells transfected with the
target antigen, the antibodies should alter the function or structure
of the neural antigen, the downstream effects of the antibody are
0967-5868/$ - see front matter ! 2013 Elsevier Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.jocn.2013.07.017
⇑ Corresponding author. Tel.: +61 2 9845 0000; fax: +61 2 9845 3389.
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often reversible, and the clinical picture corresponds with genetic
or pharmacologic models in which the antigen is disrupted [3].
The antigens are often receptors or synaptic protein complexes
intimately involved with mechanisms of synaptic transmission
and plasticity [8]. Identified targets include components of the
voltage gated potassium channel complex (VGKC) such as leu-
cine-rich glioma inactivated 1 (LGI1) and contactin-associated pro-
tein-like 2 (Caspr2); the N-methyl-D-aspartate receptor (NMDAR),
the a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
receptor (AMPAR), the c-aminobutyric acid receptor (GABABR),
and the glycine receptor [3,8,9]. NSAS collectively appear to be
far more prevalent than LE, are associated with onconeural anti-
bodies, often have a relapsing course, have an overall better prog-
nosis, and are less commonly paraneoplastic [3,4]. The prevalence
of an associated malignancy varies depending on the antibody in
question, however, this is rarely more than 70% [2]. A more
detailed description of the clinical and laboratory features of each
of the syndromes associated with established and emerging NSAbs
is outlined in Tables 1 and 2. As some NSAbs such as AMPAR,
GABABR and those identified in Table 2 have been identified in
relatively small numbers of patients, it is possible that with the
increasing recognition of such syndromes and greater patient
numbers the clinical phenotype associated with these NSAbs will
evolve and expand.
Glutamic acid decarboxylase (GAD), another antigen of interest,
is dissimilar to the intracellular onconeural antigens as anti-GAD
antibody associated neurological syndromes are usually non-
paraneoplastic and immune responsive. Anti-GAD antibody-asso-
ciated syndromes do not fulfill the criteria for a NSAS as GAD is
an intracellular antigen. Anti-GAD antibodies have been identified
in some patients with LE (including those with other confirmed
NSAbs such as AMPAR), as well as being associated with type 1
diabetes mellitus, stiff person syndrome, temporal lobe epilepsy,
and cerebellar ataxia [2,10–12]. Anti-GAD antibodies associated
with neurological disorders are typically of much higher titre
(>1000 international units/mL) compared with the titres found in
patients with Type 1 diabetes.
2. Specific syndromes
2.1. VGKC complex-associated antibody mediated encephalitides
VGKC on cell surface membranes have been identified as being
a key protein determining neuronal excitability [1]. Antibodies
against this target were initially associated with disorders of the
peripheral nervous system such as acquired neuromyotonia or
Isaacs’ syndrome, and cramp-fasciculation syndrome [13]. Subse-
quently, involvement of the central nervous system (CNS) in pa-
tients with VGKC complex-associated antibodies was also
described such as in Morvan’s syndrome where neuromyotonia is
accompanied by cognitive impairment, sleep disturbance, and
Table 1
Clinical, laboratory and imaging characteristics associated with established neuronal surface antibody syndromes
Antigen NMDAR LGI1 Caspr2 AMPAR GABABR Glycine R
Age Infancy–elderly, frequently 2–
40 years
30–80 years (median
60 years)
45–80 years (median
60 years)
40–90 years
(median
60 years)
25–75 years
(median
60 years)
5–69 years
(median 49 years)
Sex Up to 80% female 65% male 85% male 90% female 50% female Unknown
Neurological
manifestations
Behavioural disturbance,
psychosis, catatonia, seizures,
aphasia, movement disorders
including orolingual dyskinesias,
central hypoventilation,
dysautonomia
Faciobrachial dystonic
seizures, limbic encephalitis,
epilepsy (often tonic
seizures), myoclonus, rapidly
progressive dementia (can
mimic CJD), sleep disorders
Peripheral nerve
hyperexcitability or
neuromyotonia (Isaacs’
syndrome), Morvan’s
syndrome, limbic
encephalitis (less
common), sleep disorders
Limbic
encephalitis,
atypical
pychosis
Limbic
encephalitis,
prominent
seizures in
up to 80% of
patients
Progressive
encephalomyelitis
with rigidity, stiff
person syndrome
CSF abnormalities 90% abnormal – CSF
lymphocytosis, intrathecal
oligoclonal bands and elevated
protein
40% abnormal 25% abnormal, often bland
CSF
90%
abnormal,
often
intrathecal
oligoclonal
bands
80–90%
abnormal,
often
intrathecal
oligoclonal
bands
Variable CSF
elevated protein,
lymphocytosis,
and oligoclonal
bands; can be
normal
Imaging Up to 50% abnormal; medial
temporal lobe hyperintensity,
focal cortical T2-weighted/FLAIR
hyperintensity
85% medial temporal lobe
FLAIR high signal
40% abnormal, medial
temporal lobe FLAIR high
signal
90%
abnormal,
medial
temporal lobe
FLAIR high
signal
65% medial
temporal
lobe FLAIR
high signal
Frequently normal
Tumour frequency and
association
Ovarian teratomas in women
>15 years, can be other tumours
(thymomas, mediastinal or
testicular teratomas, Hodgkin
lymphoma), significant portion
non-paraneoplastic (particularly
children and males)
Rare, <20% (lung, thymus) Thymomas in 20–40% Tumours in
70% (small
cell lung
cancer, breast
cancer,
thymic
cancer)
Tumours in
45–60%
(small cell
lung cancer)
Reported lung
cancer, Hodgkin
lymphoma,
thymoma; usually
not paraneoplastic
Relapse rate 12–25% Uncommon Limited experience 50–60% Uncommon Unknown
Other – Associated hyponatraemia – – – Can have
concurrent
GAD65–IgG
antibodies
AMPAR = a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor, Caspr2 = contactin-associated protein-like 2, CJD = Creutzfeldt–Jakob disease, CSF = cerebrospi-
nal fluid, FLAIR = fluid attenuated inversion recovery, GABABR = c-aminobutyric acid receptor, GAD = glutamic acid decarboxylase, Glycine R = glycine receptor,
IgG = immunoglobulin G, LGI1 = leucine-rich glioma inactivated 1, NMDAR = N-methyl-D-aspartate receptor.
Adapted from [2,3,11], [92, 93].
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dysautonomia [1,14,15]. VGKC complex-associated antibody titre
levels are usually higher (>1000 pM) in patients with CNS condi-
tions compared to those with peripheral nerve hyperexcitability
[16]. Subsequently, VGKC complex-associated antibodies were also
described in patients with LE in the context of an acute or subacute
amnestic encephalopathy with associated confusion, seizures, ra-
pid eye movement sleep behavior disorder, cognitive disturbance,
hyponatraemia, and signal change in the medial temporal lobe
on MRI [1,17,18]. An unremarkable cerebrospinal fluid (CSF) exam-
ination should not dissuade consideration of this diagnosis as
many patients do not demonstrate a lymphocytic pleocytosis, ele-
vated protein level, or oligoclonal bands [2,19]. While some pa-
tients with VGKC complex-associated antibody mediated LE have
been reported to have malignancies such as thymomas or lung can-
cer, this entity is typically non-paraneoplastic [19–22]. Uncommon
manifestations such as chorea and chronic pain have also been re-
ported in association with VGKC antibodies [23,24]. Antibodies
against the VGKC complex have been identified in a subgroup of
patients with epilepsy, suggesting some epileptics who are poorly
responsive to conventional anticonvulsants may have an immune-
mediated aetiology [25].
To understand the evolution of the VGKC complex-associated
antibody story, it is important to understand the antibody
methodology. Unlike other NSAb assays, the VGKC complex assay
does not involve transfection of the antigen into a cell line. Instead,
a complex of VGKC including associated proteins is bound using
dendrotoxin, and antibody binding is measured using immunopre-
cipitation. It has now been clarified that the majority of anti-VGKC
antibody positive sera did not bind to the VGKC complex directly,
but rather to proteins that are closely associated with the VGKC
complex such as LGI1, Caspr2, and contactin 2 [13,16,26].
LGI1 is a secreted synaptic neuronal protein that binds to pre-
synaptic disintegrin and metalloproteinase domain-containing
protein (ADAM) 23 and postsynaptic ADAM22, and regulates
Kv1.1 and Kv1.2 subunits [10,11]. Genetic mutations in LGI1 have
been associated with autosomal dominant temporal lobe epilepsy
[10]. The majority of patients with LE previously thought to be tar-
geting VGKC were in fact targeting LGI1 [27]. LGI1 antibodies have
been most recently associated with adult-onset brief but frequent
motor events which comprise unilateral upper limb jerking and
ipsilateral facial grimacing, termed ‘‘faciobrachial dystonic sei-
zures’’ [28,29]. The use of the terminology ‘‘seizures’’ has been
deemed controversial as there are often no electroencephalogram
correlates to these events [29]. This presentation most often pre-
cedes the development of a more classical LE, and is an important
differential in patients with rapidly progressive dementia. A pro-
portion of patients can have spontaneous remission without ther-
apy. Other patients may have a variable response to anticonvulsant
therapy, and some patients are refractory to anticonvulsants but
eminently treatable with immunotherapy, with early therapy
shown to prevent evolution to complete LE [28].
Caspr2 is a transmembrane axonal protein of the neurexin IV
superfamily, and is strongly expressed at the juxtaparanodes of
myelinated axons in both the central and peripheral nervous
systems [11,30]. Mutations in the human gene encoding Caspr2
(CNTNAP2) have been associated with autism, epilepsy,
obsessive-compulsive disorders, and Tourette syndrome [11].
Caspr2 antibody-related neurological syndromes include cramps
and fasciculations. Caspr2 antibodies have also been identified in
10% of patients with idiopathic cerebellar ataxia [31].
Although some overlap was noted, patients with LGI1 antibod-
ies more frequently demonstrated LE or epilepsy, and were
primarily non-paraneoplastic, while those with Caspr2
antibodies manifested Morvan’s syndrome or peripheral nerve
hyperexcitability-neuromyotonia spectrum disorders, and had
associated thymomas [2,16,32]. When selectively studying
Morvan’s syndrome, patients were shown to have high-titre Cas-
pr2 antibodies, occasionally lower-titre LGI1 antibodies, and up
to 40% had tumours (usually thymomas) [30,33].
2.2. Anti-NMDAR encephalitis
A particular clinical phenotype of patients with encephalitis,
prominent neuropsychiatric symptoms, and movement disorders
has been described for some time, particularly in children, under
a variety of terms including immune mediated chorea encephalop-
athy syndrome, coma associated with intense bursts of abnormal
movements, and dyskinetic encephalitis lethargica [6,34–37]. This
was first characterised as a cohesive syndrome termed anti-
NMDAR encephalitis by Dalmau et al. [38]. These patients were
Table 2
Clinical, laboratory and imaging characteristics associated with emerging neuronal surface antibody syndromes
Antigen D2R [66] DPPX [94] mGluR5 [95,96]
Age 0.4–15 years; mean 6.7 years 45–76 years 15–46 years
Sex M:F 9:8 M:F 1:1 Described in both men and women
Neurological
manifestations
Movement disorders (dystonia, parkinsonism,
chorea, ocular flutter, motor tics), psychiatric
features (agitation, depression, psychosis,
emotional lability), and associated symptoms
(encephalopathy, sleep disturbance, mutism,
reduced consciousness)
Protracted encephalitic illness
characterised by agitation, myoclonus,
tremor, seizures
Ophelia syndrome – psychiatric symptoms,
cognitive and memory impairments
CSF abnormalities Variable CSF lymphocytic pleocytosis CSF lymphocytic
pleocytosis ± oligoclonal bands
CSF lymphocytic pleocytosis
Imaging 6/12 patients had abnormalities on MRI including
basal ganglia enhancement acutely, and gliosis
with chronicity
MRI normal or nonspecific white matter
disease, one patient had evidence of a
new area of infarction without vasculitis
MRI features vary – mesial temporal T2-weighted
hyperintensity, cortical hyperintensity, and
pontine hyperintensity and post-contrast
enhancement have all been described
Tumour frequency and
association
No tumours described in initial case series No tumours described in initial case
series
Hodgkin lymphoma
Relapse rate 3/12 basal ganglia patients relapsed after initial
improvement
Unknown Unknown
Other Significant proportion of patients (7/12) of non-
Caucasian ethnicity
A subunit of Kv4.2 potassium channels;
prodromal diarrhoea thought to be
secondary to the expression of DPPX in
the myenteric plexus
Improvement with antitumour therapy ± steroids
CSF = cerebrospinal fluid, DPPX = dipeptidyl-peptidase-like protein-6, D2R = dopamine 2 receptor, F = female, mGluR5 = metabotropic glutamate receptor 5, M = male.
Adapted from [11,66], [94–96].
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found to have antibodies in their serum or CSF which targeted
extracellular epitopes of the NR1 subunits of the NMDAR [39,40].
This syndrome was initially described in young women who
presented with a viral prodrome followed by psychiatric and cog-
nitive disturbances as well as seizures early in the disease course,
with dysautonomia, movement disorders, and central hypoventila-
tion occurring at a later stage, thus suggesting an initial cortical
pathology later giving way to a more subcortical process [40].
The cognitive and psychiatric features included short-term mem-
ory loss, personality and behavioural changes, agitation, paranoia,
catatonia, and frank psychosis. Stereotypical hyperkinetic move-
ments included rabbit mouth movements, repetitive limb move-
ments such as cycling, and catatonic posturing such as waxy
flexibility. While orofacial and lingual dyskinesias were thought
to be characteristic, other hyperkinetic movement disorders
including oculogyric deviation, opisthotonus, chorea, dystonic limb
posturing and rigidity, and opsoclonus-myoclonus have also been
described [41–43]. Interruption of corticostriatal pathways and
disinhibition of brainstem pattern generators have been postulated
as a mechanism for the prominent movement disorders [41].
Since the initial descriptions, further studies have expanded the
clinical phenotype of this syndrome. Some patients with
anti-NMDAR antibodies have predominant or isolated psychiatric
features, dystonia, or epilepsy, without the classic multistage pre-
sentation, potentially representing a forme fruste of anti-NMDAR
encephalitis [44,45]. Anti-NMDAR encephalitis is far more preva-
lent than initially recognised, and is in fact the most common cause
of non-infectious encephalitis (apart from acute disseminated
encephalomyelitis in children), with 577 patients being identified
and followed up by the group that originally described the syn-
drome [44,46]. In a retrospective study up to 1% of patients in
intensive care units, previously classified as an encephalitis of
unknown aetiology, were subsequently shown to have anti-
NMDAR encephalitis [47]. In the California Encephalitis Project
the incidence of anti-NMDAR encephalitis exceeded that of viral
aetiologies such as herpes simplex virus (HSV)-1 [48]. Importantly,
anti-NMDAR encephalitis is not limited to women as males with
testicular teratomas and a ‘‘classic’’ presentation have been identi-
fied [49,50]. Other malignancies including mediastinal and testicu-
lar teratomas, Hodgkin lymphoma, small cell lung carcinoma, and
neuroblastomas have also been identified in association with anti-
NMDAR encephalitis [51,52]. This syndrome has been widely re-
ported in infants and children [53–55], although the tumour asso-
ciation is less strong and the female over-representation is absent
in young children [2,36,46,51,54]. The association with ovarian ter-
atomas is also not as strong as initially thought, with one series
finding up to 80% of patients had non-paraneoplastic anti-NMDAR
encephalitis [40].
Investigations demonstrate variable CSF lymphocytic pleocyto-
sis, elevated protein levels, and oligoclonal bands, although in a
number of patients the CSF can be unremarkable. MRI can be nor-
mal or demonstrate medial temporal fluid attenuated inversion
recovery high signal or focal areas of hyperintensity in the frontal
or parietal cortex. Other studies have demonstrated that [18F]-
fluorodeoxyglucose positron emission tomography (FDG-PET) can
show cortical hypermetabolism in acute stages, and hypometabo-
lism in more subacute stages of the illness [10,56].
The model that has been proposed to explain the clinical man-
ifestations of anti-NMDAR postulates a decrease of NMDAR in
inhibitory GABAergic neurons and glutamatergic synapses that re-
sults in the increase of extracellular glutamate which in turn leads
to a frontostriatal syndrome accounting for the neuropsychiatric
manifestations, disinhibition of brainstem central pattern genera-
tors accounting for the complex movement disorders, and disrup-
tion of the medullary-pontine network accounting for central
hypoventilation [3,41,57]. The NMDAR plays a crucial role in
synaptic plasticity, learning and memory, which may explain the
extensive cognitive consequences of this condition [11].
A pathogenic role for the NSAbs as a group is clinically sug-
gested by a positive response to immunomodulatory therapy,
and a strong correlation between antibody titres and patient out-
comes [2,4,6]. Autoantibodies targeting the NMDAR have been
shown to result in a reversible decrease in NMDAR synaptic local-
isation and surface density, by mechanisms including antibody-
mediated capping and internalisation of surface NMDAR [5,8]. This
effect was specific to the NMDAR and its function, and did not af-
fect other glutamate receptors or synaptic proteins, or cell survival.
The hippocampus and amygdala which have a high concentration
of NMDAR may be more vulnerable to antibodies which breach
the blood–brain barrier (BBB) [38]. This demonstration of a revers-
ible process is mirrored clinically with complete recovery in a
number of patients, and further distinguishes this process from
the encephalitides associated with onconeural antibodies to intra-
cellular antigens. However, some patients do not recover and it is
theoretically possible that other non-reversible pathogenic mecha-
nisms may be operating.
In terms of downstream effects, NMDAR autoantibodies may
have a role in alteration of surface trafficking and distribution of
GluN2-NMDAR subtypes as well as a disruption of receptor tyro-
sine kinase (EPHB2R) expression, which normally regulates synap-
tic plasticity and function [8,58]. More recent studies with mutant
receptors have shown that the amino acids N368/G369 of the
extracellular N-terminus of NR1 are crucial in determining immu-
noreactivity, and suggest that they may play a significant role in
epitope formation and antibody recognition [59].
Outcomes in anti-NMDAR encephalitis have been studied with
many patients recovering or having mild sequelae [39,44]. How-
ever, despite the widely reported excellent response to immuno-
therapy in the literature, as well as the reversible nature of
NMDAR disruption noted in studies suggesting pathogenicity,
45% of patients have only incomplete recovery, and 30% do poorly
with a mortality rate of approximately 4% [44,54]. Tumour removal
and immunotherapy are not essential for recovery, as some pa-
tients recover without any immunotherapy. However this sponta-
neous recovery occurs at the expense of prolonged hospitalisation
and significant complications thus favouring early and targeted
therapy, suggesting that in patients in whom the syndrome has
been recognised and antibodies have been identified, targeted
immunotherapy should be commenced without delay [42]. Only
48% of patients without a tumour, compared to 80% of patients
with a tumour, had substantial improvement after first-line immu-
notherapy [44]. Within the paraneoplastic group, there is a signif-
icant correlation between oophorectomy and time to clinical
improvement [40]. A comprehensive multicenter observational co-
hort study of 577 patients with anti-NMDAR encephalitis demon-
strated that only 53% responded to first-line therapy with
steroids, intravenous (IV) immunoglobulin (Ig), or plasma ex-
change [46]. Significant persistent cognitive impairment was ob-
served in many patients in whom comprehensive cognitive
assessments were performed, particularly in the domains of exec-
utive function and memory where the role of NMDAR is pivotal
[60,61]. Earlier initiation of therapy resulted in a significant
improvement in cognition scores. These observations suggest that
the outcome of treated autoimmune encephalitis, such as anti-
NMDAR encephalitis, might not always be favourable and the
long-termmorbidity of these syndromes might be underestimated.
Predictors of a good outcome included early administration of
therapy and avoidance of an intensive care admission [46]. Patients
who did not improve with first-line therapy and underwent
second-line therapy had a significantly better outcome and a
reduced rate of relapse compared to those who did not receive
any additional treatment. Improvement has also been documented
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up to 18 months after presentation, suggesting that recovery can
be prolonged [46].
It is apparent that early diagnosis and immunotherapy at first
presentation decreases the levels of circulating anti-NMDAR anti-
bodies, reduces the chance of relapses, and improves neurological
outcomes [40,62]. Relapses are noted in up to 12–25% of patients,
with risk factors including lack of immunotherapy at first episode
and absence of a tumour diagnosis [40,46,62]. While relapses can
be suggestive of tumour recurrence, they can occur independently
of tumour activity, and up to 15 years after the initial presentation
[10,63]. Tumour diagnosis can be remote from the time of clinical
presentation, by as much as 7 years after the initial encephalitic
illness [42]. CSF and serum anti-NMDAR antibodies have been
described in a normally functioning female 15 years after anti-
NMDAR encephalitis, suggesting that disease expression is depen-
dent on factors other than CSF or serum antibody status [64].
2.3. Basal ganglia encephalitis
Regional encephalitic syndromes specifically affecting the basal
ganglia have been described under a number of previous names
including ‘‘basal ganglia encephalitis’’ and ‘‘encephalitis lethargica’’
[35]. These disorders have been proposed to have an autoimmune
aetiology [35].
Unlike the anti-NMDAR encephalitis patients who tend to have
a panencephalitis with cortical and subcortical involvement, basal
ganglia encephalitis patients more often demonstrate isolated sub-
cortical features including movement disorders such as parkinson-
ism, dystonia, or chorea [36]. They also exhibit hypersomnolence
and psychiatric features such as attention deficit, emotional labil-
ity, obsessive-compulsive disorder, and psychosis.
The presence of an inflammatory CSF (lymphocytic pleocytosis
and oligoclonal bands) in some patients and lymphocytic cuffing
in histopathology of the basal ganglia, as well as clinical improve-
ment in response to immunotherapy, supports an autoimmune
process targeting deep grey matter neurons [35,65]. FDG-PET in
such patients most frequently demonstrates basal ganglia hyper-
metabolism [65]. MRI in some patients reveals basal ganglia swell-
ing and T2-weighted hyperintensity and sometimes brainstem
signal change, with follow-up scans showing basal ganglia atrophy
and gliosis [36,66].
Based on the crucial role of dopamine as a neurotransmitter and
its influence on movement and psychiatric disorders, Dale et al.
analysed the dopamine receptor as a target for autoantibodies in
such patients [66]. Twelve of seventeen children with basal ganglia
encephalitis who were negative for anti-NMDAR antibodies had
elevated levels of antibodies referred to as immunoglobulin G
(IgG) to the extracellular dopamine 2 receptor (D2R), compared
to none of 67 paediatric controls. There was no binding demon-
strated in the D2R positive patients to the dopamine 1, 3, or 5
receptors, dopamine transporter, or NMDAR. Immunolabelling
was markedly reduced in D2R knock-out brains, thus adding fur-
ther evidence to the role of D2R as the target antigen. Interestingly,
basal ganglia encephalitis patients identified in recent years have
been given early immunotherapy and have demonstrated com-
plete clinical recovery with a corresponding reduction in antibody
titres (Dale et al. personal communication) [66]. In contrast, the
patients who were retrospectively diagnosed and only received
steroid therapy or no immunomodulatory therapy have residual
neurological and psychiatric sequelae and ongoing high serum
antibody titres. Some patients with persisting anti-D2R antibodies
have subsequently relapsed, a feature increasingly described in
autoimmune encephalitis (unpublished observations). Although
these antibodies bind to the extracellular domain of D2R, their
pathogenicity has not yet been demonstrated. Further work needs
to be done to evaluate the role of anti-D2R antibodies in adult pa-
tients, and other disease subtypes.
3. Challenges and questions
3.1. Serum or CSF antibodies as biomarkers?
While obtaining serum to test for autoantibodies is extremely
convenient and relatively non-invasive, the caveats of using serum
antibodies as a diagnostic tool need to be considered. One should
remainwary of the potential non-specificity of NSAbs. Anti-NMDAR
antibodies have been described in patients with presentations
consistent with multiple sclerosis, seronegative neuromyelitis
optica, and even Creutzfeldt–Jakob disease [67–69]. Similarly,
VGKC complex-associated antibodies have been described in
patients that do not represent the typical presentation of LE. Low
titres of VGKC complex-associated antibodies have been found in
up to 5% of healthy elderly subjects, and in 13% of patients with
thymomas without a diagnosed neurological disorder [1,21].
Antibodies against VGKC complex have also been described in pa-
tients with amyotrophic lateral sclerosis [70], Bickerstaff encepha-
litis and Miller–Fisher syndrome [71], and acute influenza A [72].
Patientswho have been positive for twoNSAbs have been described
[73,74]. These examples suggest that serumNSAb are not 100% spe-
cific. In particular, lower serum titres should be interpreted with
caution, and the role of evaluating CSF NSAbs rather than serum ti-
tres may increase diagnostic specificity [11]. The presence of NSAbs
should always be correlated with the clinical picture.
3.2. What initiates CNS autoimmunity?
The vulnerability of patients of non-Caucasian extraction in
both anti-NMDAR encephalitis and anti-D2R associated basal gan-
glia encephalitis, and the detection of abnormalities in the HLA
cluster in patients with anti-NMDAR encephalitis may suggest
the presence of racial and genetic factors determining disease sus-
ceptibility [40,66,75].
What initiates CNS autoimmunity? Current theories favour a
peripheral initiator (such as a tumour or infection) stimulating
lymphocyte production, the disruption of the BBB allowing passage
of immune cells into the CNS, and subsequent clonal expansion of
lymphocyte populations within the CNS resulting in intrathecal or
intraparenchymal antibody production. In anti-NMDAR encephali-
tis associated with ovarian teratomas, neural components of the
tumour ectopically expressing NMDAR may trigger immune toler-
ance breakdown [38,40]. While this might act as the antigenic
stimulus in the paraneoplastic cases, there are clearly unknown
triggers that have the same effect in the non-paraneoplastic cases.
The presence of a preceding viral prodrome has led to suggestions
of an infectious viral trigger or vaccination. Serological and CSF
studies have found evidence of acute infections or reactivation of
Mycoplasma, HSV, and Epstein Barr virus in some patients with
confirmed anti-NMDAR antibodies [76–78].
Activated B-cells that cross the BBB may then undergo clonal
expansion and differentiate into plasmablasts and plasma cells,
thus accounting for the presence of intrathecal CSF oligoclonal Ig
production in anti-NMDAR encephalitis [79,80]. Malter et al. found
that CSF oligoclonal bands, and to a lesser extent lymphocytic ple-
ocytosis, were useful markers in patients with a presentation of LE
to prompt investigation for specific NSAbs [81]. The presence of
mirrored and intrathecal oligoclonal bands, while not specific for
a particular diagnosis, are suggestive of an inflammatory CNS pro-
cess [82]. When present, CSF lymphocytosis usually occurs in the
early stages of anti-NMDAR encephalitis whereas oligoclonal
bands are present at later stages of the disease thus supporting
the hypothesis that there is a peripherally triggered immune re-
sponse with subsequent passage of activated B-cells across the
BBB [40].
S. Ramanathan et al. / Journal of Clinical Neuroscience 21 (2014) 722–730
303 
3.3. When should autoimmune encephalitis be suspected?
In contrast to the approach of Lancaster et al. [11] which is more
laboratory based, Zuliani et al. [5] propose clinical diagnostic crite-
ria. They recommend that one should suspect a diagnosis of a NSAS
when a patient presents with the acute or subacute onset of symp-
toms, evidence of inflammation supported by CSF, imaging, or his-
topathological investigations, and the exclusion of other infectious,
metabolic, and toxic aetiologies. Supportive criteria include a his-
tory of other autoimmune comorbidities, and a preceding infec-
tious prodrome. Using a combination of these criteria as well as
response to therapy, they suggest a model whereby patients are
classified as having definite, probable or possible neuronal cell sur-
face antibody related pathology [5,83].
3.4. Therapeutic strategies and outcomes
Although there are no definitive therapeutic guidelines for most
of the NSAS, treatment is usually in the form of pulsed steroids fol-
lowed by high dose oral prednisone, and IVIg and/or plasmaphere-
sis as first-line therapy [3,51]. The authors recommend
simultaneous treatment with 3–5 days of pulsed IV methylpred-
nisolone (30 mg/kg/day up to 1 g/day) followed by high dose oral
prednisone (1–2 mg/kg/day) and 2 g/kg of IVIg administered over
two to five doses. Failure to respond within 1–2 weeks should lead
to consideration of three to five exchanges with plasmapheresis, or
commencement of second-line therapy such as cyclophosphamide
or rituximab [84]. It is unclear whether rituximab, a depleter of the
B-cell population, or cyclophosphamide, a broader immunosup-
pressant, is more efficacious [79]. Response to therapy is best
judged by the patient’s clinical status, rather than by focusing on
antibody titres in isolation, as the latter may not always directly
correlate with clinical progress.
The role of long-term steroid sparing agents such as mycophen-
olate or azathioprine on relapse rates is unclear, with their use
being largely anecdotal at the time of writing [51]. Tumour surveil-
lance both at initial presentation and during regular follow-up is
also recommended [3,44]. This may be in the form of whole body
PET scanning coregistered with CT scanning, and in the case of
anti-NMDAR encephalitis, a pelvic MRI. When there is a strong sus-
picion for an autoimmune process targeting cell surface antibodies,
it would be reasonable to commence first-line therapy as soon as
infectious aetiologies have been excluded, while concurrently
awaiting the results of antibody and tumour screening [5]. Opin-
ions vary, but many groups advocate early treatment in patients
where there is a high index of suspicion of a NSAS even in the ab-
sence of specific autoantibodies, as this might improve patient out-
comes [85].
Understanding the pathogenic mechanisms behind a disease
process is important in therapeutic decision-making. It is possible
that different autoimmune CNS diseases have different antibody
mediated pathogenic mechanisms. For example, antibody associ-
ated complement activation is crucial in neuromyelitis optica
while antibody associated natural killer cytotoxicity is important
in myelin oligodendrocyte glycoprotein antibody associated paedi-
atric inflammatory demyelination [86,87]. Bien et al. demonstrated
in a histopathological study that patients with autoimmune
encephalitis and anti-Hu and anti-Ma2 antibodies demonstrated
a higher CD8/CD3 ratio and more cytotoxic T-cell induced neuronal
loss, consistent with primarily T-cell mediated mechanisms of ac-
tion [4]. In contrast, in the VGKC complex-associated antibody po-
sitive patients studied, complement deposition with secondary
neuronal loss appeared to be the prominent mechanism. In anti-
NMDAR there was a low density of inflammatory cells and no clear
evidence of antibody or complement mediated injury cell medi-
ated mechanisms. However, these were chronic patients whereas
other studies demonstrate that acute anti-NMDAR encephalitis in-
volves B-cell and plasma cell inflammatory infiltrates [79]. Other
studies support this notion that not all autoimmune encephalitides
have the same pathogenic mechanisms [88–90]. Further work to
clarify this is essential, as therapeutic strategies might need to be
tailored to the individual syndrome.
4. Therapeutic challenges: Clinical vignettes
There remain many practical challenges in the field of therapeu-
tics of NSAS. What defines failure of first-line treatment? At what
stage is it reasonable to escalate therapy to second-line agents?
Do patients who have a particularly significant clinical episode
warrant second-line therapy despite improvement with first-line
therapy? To what degree does second-line therapy reduce the re-
lapse rate? What role does maintenance immunosuppression
have? The following clinical vignettes further expand on these
therapeutic challenges.
4.1. Patient 1: Treatment of antibody negative patients
An 8-year-old boy presented with a 3 week history of focal sei-
zures, a hyperkinetic movement disorder, and mutism, requiring a
2 month intensive care unit and hospital admission. CSF showed
20 ! 106/L monocytes but viral studies, and serum and CSF anti-
NMDAR, VGKC complex, and D2R antibody testing was negative.
Given this was a severe presentation and the clinical phenotype
was reminiscent of autoimmune encephalitis, he was treated with
first-line therapy in the form of IV steroids and IVIg. Ten days after
first-line therapy there was no improvement so second-line ther-
apy with rituximab was commenced. Within 5 days of rituximab
he began improving and subsequently made a good clinical recov-
ery over 6 weeks, returning to baseline function.
This patient had a syndrome suggestive of anti-NMDAR enceph-
alitis but antibody testing was negative. Occasionally, initial anti-
body testing can be negative yet repeated testing can become
positive. After viral causes were excluded, first-line therapy was
trialed but was ineffective. Despite negative autoantibodies, as
the patient remained unwell in intensive care, rituximab was used.
While there is a small possibility that recovery was spontaneous,
this patient highlights the fact that antibody negative ‘‘autoim-
mune’’ encephalitis can benefit from immune therapy, as has been
recently proposed [77]. In addition, this patient prompts discussion
of the timing of second-line therapy. Patients with autoimmune
encephalitis often respond slowly to immune therapy (weeks
rather than days). Determining when to escalate therapy is
difficult. The clinician needs to balance three opposing clinico-
therapeutic issues in the treatment of autoimmune encephalitis
which are: (1) improvement in autoimmune encephalitis is often
slow and can take weeks to months, (2) patients who fail first-line
therapy require second-line therapy, and (3) delay in therapy can
worsen clinical outcomes.
4.2. Patient 2: Role of second-line therapy
A 4-year-old girl presented with a 2 week history of focal sei-
zures and psychosis. CSF analysis revealed 12 ! 106/L monocytes
and was positive for anti-NMDAR encephalitis. She was treated
with first-line therapy in the form of IV steroids and IVIg. She
started to improve rapidly within 2 weeks of therapy, and returned
to baseline by 8 weeks. Her serum anti-NMDAR antibody status re-
mained positive 1 year after presentation although the patient was
clinically well.
This case highlights the issues raised by a patient who responds
well to first-line therapy. Her rapid and complete recovery made it
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difficult to justify the risks of more significant immunosuppression
such as rituximab or cyclophosphamide. Are there a subset of pa-
tients who respond well to first-line therapy alone or should all pa-
tients with anti-NMDAR encephalitis receive second-line therapy
such as rituximab to reduce the risk of relapses? The clinician
needs to balance the risks of therapy with the benefits of a long-
term reduction in relapse rate in an individual patient. If a patient
is treated with rituximab, what is the optimal method to monitor
response – should rituximab therapy be repeated when B-cells
are detectable, or should the clinician adopt the approach of
watchful waiting and only repeat therapy if a relapse occurs? This
patient also raises the issue of the significance of ongoing serum
antibody positivity. This phenomenon has been described in pa-
tients who are antibody positive but clinically well up to 15 years
after their initial presentation [63,64].
4.3. Patient 3: Management of relapsing anti-NMDAR encephalitis
A 4-year-old girl presented in 2007 with a 3 week history of fo-
cal seizures, speech disturbance, chorea, and agitation. CSF oligocl-
onal bands were positive. This presentation was prior to the initial
descriptions of anti-NMDAR encephalitis, however given the high
index of suspicion for autoimmune encephalitis, she was treated
with IV steroids and IVIg. Her diagnosis was confirmed as anti-
NMDAR encephalitis in 2009 with retrospective testing of acute
serum and CSF samples. She has had three subsequent relapses
which were treated successfully with IV and oral steroids. Given
the relapsing course and steroid responsiveness, she was started
on oral mycophenolate mofetil and has been free of relapses for
the last 2 years.
This patient raises the important issue of the optimal treatment
of relapses – should one use rituximab with its B-cell depleting ef-
fect, a broader immunosuppressant like cyclophosphamide, or per-
haps a steroid sparing agent such as mycophenolate which has a
better side effect profile? Risk factors for relapses that have been
identified include failure of therapy at the time of the initial epi-
sode, absence of a tumour diagnosis, and lack of immune therapy
[62]. Should all patients who respond well to steroids be com-
menced on steroid sparing agents such as mycophenolate mofetil
or azathioprine? Further studies evaluating the efficacy of long-
term therapy on relapse rate is required, but until this is available,
the clinician needs to undertake a risk-benefit analysis on an indi-
vidual basis.
5. Future directions
It is clear that they are many patients who have a clinical and
laboratory phenotype suggestive of an autoimmune process who
respond to immunomodulatory therapy, but are negative for the
existing panel of NSAbs [77,91]. Such patients provide a compelling
argument to pursue the identification of novel antigens. We be-
lieve that in patients with a clinical history and investigation find-
ings that support an autoimmune basis, the lack of detection of an
established NSAb should not dissuade clinicians from early initia-
tion of immune therapy, as this is likely to have a significant im-
pact on neuronal cell death and patient outcome. More research
is required not only to pursue the identification of novel antigens
and establish their pathogenicity, but also to evaluate the most
efficacious therapeutic strategies in established NSAS.
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Myelin oligodendrocyte glycoprotein (MOG) is a protein exclusively expressed on the surface of oligodendrocytes
and myelin in the central nervous system. MOG has been identiﬁed as a putative candidate autoantigen and auto-
antibody target in demyelination for almost three decades, with extensive literature validating its role in murine
models of experimental autoimmune encephalomyelitis. Seminal studies using murine anti-MOG antibodies have
highlighted the fact that antibodies that target epitopes of native MOG in its conformational state, rather than line-
arized or denature`d MOG, are biologically relevant. However, the relevance of anti-MOG antibodies in humans has
been difﬁcult to decipher over the years due to varyingmethods of detection as well as the fact that it was assumed
that these antibodies would be clinically associated with multiple sclerosis. There is now international consensus
that anti-MOG antibodies are important in both pediatric and adult demyelination, and the clinical association of
MOG antibody-associated demyelination has been reﬁned to include acute disseminated encephalomyelitis, relaps-
ing and bilateral optic neuritis, and transverse myelitis. Anti-MOG antibodies are now thought not to be associated
with multiple sclerosis in adults. Patients with MOG antibody-associated demyelination appear to have a unique
clinical, radiological, and therapeutic proﬁle, which represents amajor advance in their diagnosis andmanagement.
It is imperative to understand whether anti-MOG antibodies are indeed pathogenic, and if so, their mechanisms of
action. As it has become apparent that there are differences inMOG epitope binding between species, translation of
animal studies to human demyelination should be analyzed in this context. Further work is required to identify the
speciﬁc epitope binding sites in humandisease andpathogenicmechanisms of anti-MOGantibodies, aswell optimal
therapeutic strategies to improve prognosis and minimize disability in these patients.
© 2015 Elsevier B.V. All rights reserved.
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1. Introduction
Myelin oligodendrocyte glycoprotein (MOG) is a member of the
immunoglobulin superfamily and a component of myelin, making up
less than 0.05% of total myelin proteins [1–4]. Full length human MOG
is made up of 218 amino acids and is expressed exclusively in the
central nervous system (CNS). Its relatively late expression in neural
development suggests that it may serve as an important surfacemarker
of oligodendrocyte maturation, as well as playing a role in myelin
integrity, adhesion and cell surface interactions [3,5]. MOG has been
studied as a target CNS autoantigen for both humoral and cell-
mediated immune responses. The putative role of MOG and antibodies
to MOG in CNS demyelination has been explored for decades, with
immunization usingMOG inducing experimental autoimmune enceph-
alomyelitis (EAE), an important animal model of multiple sclerosis
(MS). MOG is sequestered to the external surface of myelin and the
plasma membranes of oligodendrocytes [1], with its highest antigen
density in the outermost lamellae of myelin sheaths, thereby serving
as a biologically plausible and accessible antigen target for the action
of autoantibodies [1,6]. Herein we explore the evolution of MOG as a
candidate CNS autoantigen in demyelination, the methodological
complexities of MOG antibody detection, and its role as a potential
biomarker in human disease. Furthermore, we highlight the existing
deﬁciencies in our understanding of the pathophysiological mecha-
nisms and classiﬁcation of MOG antibody-associated autoimmunity.
2. The evolution of MOG as a candidate autoantigen in demyelination
In order to evaluate anti-MOG antibodies in the context of the exten-
sive published literature on MOG and demyelination, several factors
need to be considered. Firstly, it has been animal studies, particularly
the EAE model, which have led the way to identify MOG as a candidate
autoantigen. The EAE model is a complex system with a strong T cell
driven component in which anti-MOG antibodies are produced, but do
not necessarily transfer disease. Secondly, it is important to note that
while autoantibodies can bind to both linear and conformational
epitopes, in the case of anti-MOG antibodies, only thosewith conforma-
tion dependent binding have been shown to be pathogenic in animal
studies. Thirdly, the translation of animal studies to humans should be
evaluated carefully as autoantibody epitope binding sites can differ in
rodents and humans. Lastly, although previous studies have focused
on MS, the clinically relevant associations of anti-MOG antibodies in
human demyelination have only recently been reported.
2.1. Rationale for the search for autoantibodies in MS
Previous research largely focused on T cell mediated immune
mechanisms in MS. However, ﬁndings such as elevated intrathecally
synthesized immunoglobulins found in the cerebrospinal ﬂuid (CSF)
of MS patients [7]; the presence of B cells, immunoglobulin (Ig) deposi-
tion, Ig associated receptor mediated phagoycytosis of myelin debris by
macrophages, and complement activation in the vicinity of MS plaques
[8,9,10,11]; as well as immunohistological evidence of autoantibodies
binding to disintegrating myelin around axons of acute MS lesions and
contributing to their destruction [12], have all been compelling reasons
to pursue a role for autoantibodies in the pathogenesis of demyelination
in MS.
2.2. Animal studies: MOG and EAE
EAE has been extensively used as a disease model that represents
features of MS, and is induced by immunization in animal models
with CNS tissue or puriﬁed myelin components, and Freund's complete
adjuvant [13]. The model is complex but has largely contributed to the
understanding of the role of MOG as an autoantigen and autoantibody
target [13]. MOG was originally identiﬁed as a minor CNS glycoprotein
by the mouse IgG1 monoclonal antibody 8-18C5 (8-18C5 mAb) raised
against rat cerebellar glycoproteins [14]. While animal models of
demyelination and EAE were largely initiated by the transfer of activat-
ed encephalitogenic T cells, the identiﬁcation of the 8-18C5 mAb per-
mitted the evaluation of anti-MOG antibodies in CNS inﬂammation
[14]. Passive transfer of the 8-18C5 mAb resulted in a hyperacute
inﬂammatory response in animals with acute EAE, and in fatal relapses
in those with chronic relapsing EAE, as well as the formation of
extensive demyelinating plaques, suggesting that antibodies to MOG
may amplify and modify CNS inﬂammation in EAE [2,6,14]. This effect
was dependent on the weakening of the blood–brain barrier (BBB) by
encephalitogenic T cells, thus indicating that both humoral and cell-
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mediated immunity might be at work in the MOG-directed autoim-
mune response.
Early animalmodels of chronic relapsing EAE showed that anti-MOG
antibody titers, as determined by enzyme linked immunosorbent assays
(ELISA), correlated with in vivo demyelinating activity [15]; however
there was no correlation between antibody titers and the course of
clinical disease in murine models [15,16].
2.3. The antibody binding epitope in animal studies using linear MOG
peptides
Interestingly, MOG triggers both an encephalitogenic T cell response
and an antibody-mediated demyelinating response in a synergistic way
which renders it unique when compared to other potential target
antigens in myelin that are more quantitatively present such as myelin
basic protein (MBP), proteolipid protein (PLP), or neurofascin [17,18].
Very early on, after immunization of rodents with puriﬁed recombinant
murine MOG, the encephalitogenic T cell response leading to acute
demyelinating EAE was shown to target the Ig-like extracellular N-
terminal domain (aa 1–125), especially MOG35-55 [17,19]. The
immunodominant antibody epitope has been more challenging to
decipher, and using ELISA, the dominant linear epitopes were shown
to be to either MOG1-25, MOG35-55, or MOG202-218 [16,17,20]. Therefore,
while early animal studies certainly establishedMOG35-55 as a dominant
immunogenic region in CNS demyelination, they were less clear on the
importance of the B cell response in the disease. Anti-MOG antibodies
were identiﬁed as being present in the sera and CSF of immunized
animals [15,16]. However, the role of anti-MOG antibodies in the
pathogenicity of EAE was unclear. For example, although titers in sera
correlated with disease activity [15], their presence alone was not
sufﬁcient to result in severe disease [16].
2.4. The antibody binding epitope in animal studies using conformational
MOG
Major advances came from the recognition that experimental
animals mount a complex antibody response to the extracellular Ig-
like domain of MOG, and these antibodies are now known to target
both linear epitopes of MOG, detected using ELISAs and Western blots,
as well as discontinuous conformational epitopes of MOG, which may
not be detected using these techniques [21]. Animal studies have
found that pathogenic demyelinating MOG-speciﬁc autoantibodies
recognize only conformation-dependent epitopes, while MOG
peptide-speciﬁc autoantibodies were unable to recognize the native
protein [22–26]. Crystallography of rat MOG revealed that a dominant
component of the epitope binding site of the 8-18C5 mAb included
amino acids 101–108 that comprise the FG loop, and protrudes from
the top of the Ig domain of MOG as a hairpin loop [24]. The failure of
linear peptides to replicate this loop structure may account for the
inability of antibodies to MOG-speciﬁc linear peptides to detect this
antigenic region [24]. The same team subsequently identiﬁed His103
and Ser104 as the two central amino acids of the FG loop which form
the antibody epitope [21]. Mutations of these two residues led to
reduced binding of conformation-dependentmonoclonal antibodies in-
cluding 8-18C5, compared to the binding to wild-typeMOG, suggesting
that the pathogenic demyelinating anti-MOG antibody response targets
this immunodominant region centered at the tip of the surface-exposed
FG loop ofMOG in rodents [21]. Interestingly, the correct folding ofMOG
does not only inﬂuence the B cell and antibody response, but also the T
cell response. For example, rats immunized with correctly refolded re-
combinant human MOG developed severe acute EAE and had a higher
amount of conformational anti-MOG antibodies present in serum, as
well as enhanced T cell responses against the encephalitogenic MOG
91-108 peptide [27]. Antibodies to cell-membrane expressed MOG,
which is native and glycosylated, were associated with demyelination
in rat EAE models and were associated with clinical severity, whereas
antibodies to recombinant MOG detected by ELISA were not found to
be associated with inﬂammation or demyelination [28]. Other EAE
models, such as the non-human primate marmoset, also conﬁrmed
that conformation-dependent antibodies to MOG were associated
with in vivo demyelinating activity, with IgG deposition, complement
activation, and dissemination of white matter lesions occurring
predominantly in the presence of conformational rather than linear
peptide-recognizing anti-MOG antibodies [23,25].
As seen above, studies using linear and conformational MOG have
yielded different results. Taken together, these ﬁndings suggest that
anti-MOGantibodies that are relevant to disease pathogenesis in animal
models may target conformational MOG, rather than MOG that has
been linearized or denatured. Given the inability of ELISAs andWestern
blots to differentiate between autoantibodies to likely pathogenic
conformational epitopes, and those targeting linear epitopes, the
method of detection of anti-MOG antibodies has been shown to be
crucial [29].
2.5. Translation of animal studies to human demyelination
While the predicted sequence of the mature MOG protein is highly
conserved among mammalian species including humans, rats, mice,
and bovine animals [3], the applicability of animal models to human
demyelination needs to be carefully evaluated. Marta et al. found that
a single amino acid substitution in human MOG at position 42
(huP42S) from proline (found in humans) to serine (found in rodents)
changed the mechanism of encephalitogenicity from B cell dependent
to independent [30]. Although immunization with rat, human, or
huP42S all generated antibodies targeting recombinant mouse MOG
which were detectable by ELISA, only the antibodies targeting human
MOG were encephalitogenic in vivo, and bound to glycosylated MOG
in immunoblots and to live rodent oligodendrocytes in culture. Thus,
anti-MOG antibodies may recognize different antigenic target epitopes
on conformational MOG, which may account for variations in pathoge-
nicity. For example, the human MOG-speciﬁc antibody repertoire was
shown to target multiple epitopes in immunized C57BL/6 mice [31].
Despite 90% sequence homology between recombinant rat and
human extracellular MOG (aa 1–125), and a difference of only seven
amino acids in length in two constructs of recombinant human MOG,
Menge et al. [32] found that each of these isoforms had unique
immunodominant epitopes recognized by a panel of monoclonal
antibodies, suggesting that certain epitopes are length or species
dependent. Studies such as this further highlight the fact that translat-
ing the ﬁndings in animal models to human disease requires some
consideration, even with the use of native conformational MOG.
3. The MOG immune response in MS
3.1. MOG antibody detection in MS
Given the interest inMOG antibody-associated demyelination in an-
imal studies, the evaluation of anti-MOG antibodies in patients withMS
has been of interest for many years. Using Western blots and ELISA, a
number of early studies found the presence of antibodies to recombi-
nant human MOG or native full length mouse MOG in the serum and
CSF of patients with MS [33–39]. One study [40] evaluated 103 patients
with clinically isolated syndrome (CIS). Using recombinant human
MOG analyzed by Western blots, they found that 21% of patients were
both anti-MOG and anti-MBP IgM antibody positive, while 41%were se-
ropositive for anti-MOG IgM antibodies alone. The relapse rate was
higher in the seropositive patients compared to the seronegative pa-
tients, suggesting that these antibodies predicted early conversion to
clinically deﬁnite MS. Seropositive patients developed earlier relapses
[41], and these results were reproduced in a few studies using similar
methodology [42,43]. Using ELISA, anti-MOG antibodies were found to
be present in higher concentrations in CNS parenchyma derived from
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postmortem samples of MS lesions, compared with CSF and serum in
MS patients, suggesting that local production of antibodies may play a
role in CNS demyelination [44].
While these studies highlighted the importance of MOG in the
immune response of patients with demyelination, other studies found
a similar prevalence of seropositivity with anti-MOG IgM and IgG
antibodies in patients with other inﬂammatory neurological diseases
as well as healthy controls, varying results on the dominant Ig subtype,
and the fact that anti-MOG antibodies were found to have low afﬁnity
when detected at low titers. Additionally, a comparative study in 72
patients with pathologically proven inﬂammatory demyelination
showed that correlations between Western blot and ELISA results
were poor, adding further concerns regarding the reproducibility of
results obtained by these methods [45]. Overall, these studies illustrate
the technical difﬁculty in detecting anti-MOG antibodies that are
speciﬁc and disease relevant in humans [33–35,37–39,41,46–51].
3.2. The antibody binding epitope in humans using linear MOG peptides
The accurate detection of the antigen target and epitope speciﬁcity
of demyelinating anti-MOG antibodies in patients with MS is of
signiﬁcant interest. Initial studies evaluating the binding epitopes to
the extracellular immunoglobulin V-like domain of human MOG using
ELISA, yielded variable results. Using synthetic overlapping linear
MOG peptides revealed that the B cell epitope speciﬁcity of puriﬁed
antibodies from both seropositiveMS patients and healthy controls var-
ied between studies. Some groups found a heterogenous response with
no association between MS and any particular peptide speciﬁcity, and
each donor often recognizing multiple linear epitopes [22], while
other studies suggested the linear epitopes aa 37–48 and aa 42–53 are
immunodominant in relapsing remitting MS patients compared to
healthy controls [52]. Furthermore, there was signiﬁcant heterogeneity
in the anti-MOG antibody repertoires detected by different assay
techniques [53].
3.3. Controversies in the methodology of antibody detection
There are a number of possible explanations for the variation in
ﬁndings of both the presence of anti-MOG antibodies as well as the
dominant binding epitopes between different study groups. Patient
populations in many studies were heterogenous and groups evaluated
different immunoglobulin isotypes. The discrepancies in results are
now mainly thought to be due to technical differences in antigen
preparation and antibody determination [47], but also to the fact that
MS is now clearly recognized not to be the main disease associated
with anti-MOG antibodies. Some groups [26,40] used recombinant
human MOG corresponding to the extracellular Ig domain, expressed
in Escheria coli. However, post-translational modiﬁcation, including
glycosylation, differs in prokaryotes and eukaryotes; hence the MOG
protein produced could lack glycosylation and the correct membrane
topology. Other groups translated native full length MOG but without
glycosylation [47]. Glycosylated proteins conserve their tertiary
structure better [54]. Nonspeciﬁc binding is also problematic in direct
ELISAs [54].
The methodology of antibody detection is important. Most early
studies for anti-MOG antibody detection and epitope recognition
performed assays that utilized linearized or denatured MOG antigen,
such as ELISAs andWestern blots, respectively. These assays potentially
alter protein conformation and render the immunodominant epitopes
that depend on the tertiary structure of the folded protein inaccessible.
As discussed previously, animal studies revealed that antibodies to
conformational rather than linear or denatured MOG were shown to
be more relevant. Therefore, an assay that detects antibodies targeting
epitopes of native human MOG in its conformational state, taking into
account the tertiary structure of folded MOG as it is expressed in vivo
on myelin sheaths, is essential. The fact that this was not the case in
many early studies that used ELISA and Western blot for anti-MOG an-
tibody detection likely accounts for the low speciﬁcity of these antibod-
ies in patient groups and controls, and variability in epitope speciﬁcity.
4. The clinical spectrum of MOG antibody-associated demyelination
4.1. Introduction of cell-based assays
In cell-based assays, native humanMOG is transfected or transduced
in mammalian cell lines. Surface MOG expressing cells are incubated
with the sample to be tested, and then with a secondary anti-human
IgG antibody, followed bymicroscopy or ﬂow cytometry to qualitatively
or quantitatively analyze antibody binding [55]. The MOG antigen is
therefore presented to the autoantibody repertoire in its native state,
with positive antibodies identiﬁed using this methodology more likely
to have disease relevance [22,26].
As in all cell-based experiments, numerous factors inﬂuence the
sensitivity and speciﬁcity for anti-MOG antibody detection. C-terminal
truncation of the human MOG antigen resulting in short length (SL)
MOG, as compared to full length (FL) MOG, has been found to reduce
the sensitivity of the cell-based assay [56]. Given the extracellular
domains are identical in SL- and FL-MOG with the only difference
being the former is shorter by 73 cytosolic amino acids at the intracellu-
lar C-terminus than the latter, the differences in assay sensitivitymay be
secondary to surface expression of the construct, glycosylation or the
ability to multimerize [56]. Waters et al. identiﬁed low speciﬁcity with
the use of FL-MOG that they attributed to cross-reactivity of the anti-
human IgG antibody with the IgM antibody [56]. They found that the
speciﬁcity increased signiﬁcantly with the use of an IgG1-speciﬁc
antibody. In our hands, we ﬁnd that IgG antibodies targeting FL-MOG
have a high speciﬁcity and sensitivity when analyzed using ﬂow cytom-
etry, and low cross-reactivitywith IgM [57–59]. The low sensitivitywith
the use of SL-MOG implies that it should not be used in diagnostic assays
[56]; therefore the association between SL-MOG antibody and clinical
features in patients would need conﬁrmation with FL-MOG antibody.
Between centers, there is diversity in the technicalities of cell-based
assays used and methods of analysis and interpretation of results, as
highlighted in Table 1. Importantly and in contrast to previous studies
using ELISAs, with the use of cell-based assays, anti-MOG antibodies
were rarely found in healthy controls, other inﬂammatory neurological
diseases like viral encephalitis, or other immune systemic diseases like
type 1 diabetes mellitus [60–65], thus indicating a speciﬁcity for CNS
demyelination.
4.2. The absence of anti-MOG antibodies in MS using cell-based assays
Although a few studies identiﬁed increased serum IgG anti-MOG
antibodies in patients with MS compared to controls using cell-based
assays [65–67], the majority of studies conﬁrmed that both the
prevalence and intensity of MOG antibody titers are low in Caucasian
adult patients with MS [60,65,68] (Table 1). Furthermore, anti-MOG
antibodies did not appear to have a prognostic or predictive value in
adults with MS [69].
4.3. The ﬁrst identiﬁcation of MOG antibody-positive demyelination in
humans: the case of acute disseminated encephalomyelitis (ADEM)
Using a MOG tetramer radioimmunoassay, O'Connor et al. [60] ﬁrst
identiﬁed the association of anti-MOG antibodies in children presenting
with acute disseminated encephalomyelitis (ADEM). High-titer anti-
MOG antibodies have been found to be more frequently positive in
pediatric-onset demyelination including ADEM and clinically isolated
syndromes (CIS) than adult-onset MS, with the presence of antibodies
correlated with a younger age of disease onset, and an initial presenta-
tion with ADEM [61–65,70]. The high speciﬁcity (up to 97%) for
demyelinating disease and moderate sensitivity (40%) for a diagnosis
S. Ramanathan et al. / Autoimmunity Reviews 15 (2016) 307–324
311 
Ta
bl
e
1
Co
m
pa
ri
so
n
of
th
e
pr
ev
al
en
ce
of
an
ti-
M
O
G
an
tib
od
ie
s
in
pa
tie
nt
s
w
ith
de
m
ye
lin
at
io
n
us
in
g
ce
ll-
ba
se
d
as
sa
ys
an
d
as
so
ci
at
ed
m
et
ho
do
lo
gi
es
.
Re
fe
re
nc
e
D
es
cr
ip
ti
on
of
co
ho
rt
Sa
m
pl
e
A
nt
ig
en
ch
ar
ac
te
ri
st
ic
s
D
et
ec
ti
on
A
na
ly
si
s
ap
pr
oa
ch
Pr
ev
al
en
ce
of
M
O
G
an
ti
bo
dy
po
si
ti
vi
ty
Co
nc
or
da
nc
e
fo
r
M
O
G
an
ti
bo
di
es
be
tw
ee
n
CS
F
an
d
se
ru
m
Lo
ng
it
ud
in
al
ev
al
ua
ti
on
of
se
ro
po
si
ti
vi
ty
La
liv
e
et
al
.[
66
]
A
du
lt
CI
S
n
=
36
RR
M
S
n
=
35
SP
M
S
n
=
33
PP
M
S
n
=
24
H
C
n
=
37
Se
ru
m
Fu
ll
le
ng
th
hu
m
an
M
O
G
tr
an
sf
ec
te
d
CH
O
ce
lls
Fl
ow
cy
to
m
et
ry
on
liv
e
ce
lls
BR
=
G
m
ea
n
va
lu
e
of
Ig
G
bi
nd
in
g
to
M
O
G
tr
an
sf
ec
te
d
CH
O
ce
lls
/I
gG
bi
nd
in
g
to
no
nt
ra
ns
fe
ct
ed
CH
O
ce
lls
,n
or
m
al
iz
ed
to
th
e
va
lu
e
of
a
po
si
ti
ve
co
nt
ro
l
M
O
G
Ig
G
ti
te
rs
co
m
pa
re
d
w
it
h
H
C
w
er
e
si
gn
iﬁ
ca
nt
ly
in
cr
ea
se
d
in
CI
S
(P
b
0.
00
1)
,R
RM
S
(P
b
0.
01
)
an
d
SP
M
S
(P
b
0.
05
)
N
ot
as
se
ss
ed
N
ot
as
se
ss
ed
Zh
ou
et
al
.[
67
]
A
du
lt
O
IN
D
n
=
47
M
S
n
=
47
H
C
n
=
14
0
RR
M
S
n
=
54
SP
M
S
n
=
80
PP
M
S
n
=
29
Se
ru
m
Fu
ll
le
ng
th
hu
m
an
M
O
G
tr
an
sd
uc
ed
hu
m
an
gl
io
bl
as
to
m
a
ce
ll
lin
e
LN
18
Fl
ow
cy
to
m
et
ry
on
liv
e
ce
lls
M
FI
LN
18
M
O
G
–
M
FI
LN
18
C
tr
,p
os
it
iv
e
if
ov
er
po
si
ti
ve
th
re
sh
ol
d
(m
ea
n
+
2S
D
of
H
C
or
O
IN
D
)
M
O
G
Ig
G
po
si
ti
ve
:
O
IN
D
2/
47
(4
%)
M
S
15
/4
7
(3
2%
)
N
ot
as
se
ss
ed
N
ot
as
se
ss
ed
H
C
6/
14
0
(4
%)
RR
M
S
12
/5
4
(2
2%
)
SP
M
S
20
/8
0
(2
5%
)
PP
M
S
12
/2
9
(4
1%
)
O
'C
on
no
r
et
al
.[
60
]
A
D
EM
n
=
69
Pe
d
M
S
n
=
19
A
si
an
M
S
n
=
12
RR
M
S
n
=
76
SP
M
S
n
=
17
PP
M
S
n
=
16
CI
S
n
=
32
V
E
n
=
58
H
C
n
=
75
Se
ru
m
an
d
CS
F
Fi
rs
tm
et
ho
d:
fo
ld
ed
hu
m
an
M
O
G
te
tr
am
er
(e
xt
ra
ce
llu
la
r
do
m
ai
n
of
hu
m
an
M
O
G
,C
D
2,
an
d
st
re
pt
av
id
in
co
m
pl
ex
)
Te
tr
am
er
ra
di
oi
m
m
un
oa
ss
ay
Sa
m
pl
es
th
at
pr
ec
ip
it
at
ed
N
10
%
of
th
e
M
O
G
te
tr
am
er
w
er
e
po
si
ti
ve
.
Th
is
th
re
sh
ol
d
fo
r
po
si
ti
vi
ty
w
as
eq
ua
lt
o
4
SD
ab
ov
e
th
e
m
ea
n
of
H
C
M
O
G
A
b
po
si
ti
ve
Ig
G
;I
gM
Co
nc
or
da
nc
e
in
pr
es
en
ce
of
M
O
G
an
ti
bo
di
es
in
se
ru
m
an
d
CS
F
in
8
A
D
EM
pa
ti
en
ts
N
ot
as
se
ss
ed
A
D
EM
13
/6
9
(1
9%
);
1/
29
(3
%)
Pe
d
M
S
1/
19
(5
%)
;
0/
4
(0
%)
A
si
an
M
S
1/
12
(8
%)
;
nd RR
M
S
1/
76
(1
%)
;
0/
12
(0
%)
SP
M
S
0/
17
(0
%)
;n
d
PP
M
S
0/
16
(0
%)
;n
d
CI
S
0/
32
(0
%)
;0
/2
8
(0
%)
V
E
0/
58
(0
%)
;0
/2
0
(0
%)
H
C
1/
75
(1
%)
;0
/3
2
(0
%)
Fl
ow
cy
to
m
et
ry
on
liv
e
ce
lls
⁎
Se
co
nd
m
et
ho
d:
Fu
ll
le
ng
th
hu
m
an
M
O
G
-G
FP
tr
an
sf
ec
te
d
Ju
rk
at
ce
lls
M
cL
au
gh
lin
et
al
.
[6
1]
Pe
d
pa
ti
en
ts
M
S
n
=
13
1
O
N
D
n
=
34
N
on
ne
ur
ol
og
ic
al
co
nt
ro
ls
n
=
37
Ju
ve
ni
le
D
M
n
=
28
Se
ru
m
an
d
CS
F
Fu
ll
le
ng
th
hu
m
an
M
O
G
-G
FP
tr
an
sf
ec
te
d
Ju
rk
at
ce
lls
Fl
ow
cy
to
m
et
ry
on
liv
e
ce
lls
⁎
BR
=
M
FI
of
M
O
G
:G
FP
cl
on
e,
BR
N
5
co
ns
id
er
ed
po
si
ti
ve
M
O
G
Ig
G
po
si
ti
ve
:
13
Pa
ti
en
ts
ha
d
CS
F
te
st
in
g,
of
w
ho
m
3
w
er
e
se
ru
m
M
O
G
A
b
po
si
ti
ve
.O
ft
he
se
3,
1
pa
ti
en
th
ad
M
O
G
an
ti
bo
di
es
de
te
ct
ed
in
bo
th
se
ru
m
an
d
CS
F
(l
at
te
r
w
it
h
a
lo
w
er
BR
).
N
ot
as
se
ss
ed
Pe
d
M
S:
28
/1
31
(2
1%
)
O
N
D
:2
/3
4
(6
%)
N
on
ne
ur
ol
og
ic
al
co
nt
ro
ls
:0
/3
7
(0
%)
Ju
ve
ni
le
D
M
:0
/2
8
(0
%)
A
du
lt
pa
ti
en
ts
M
S
n
=
25
4
Co
nt
ro
ls
n
=
86
CI
S
n
=
30
N
M
O
n
=
13
V
E
n
=
29
A
du
lt
M
S
11
/2
54
(4
%)
Co
nt
ro
ls
4/
86
(4
.7
%)
CI
S
2/
30
(7
%)
N
M
O
0/
13
(0
%)
V
ir
al
en
ce
ph
al
it
is
0/
29
(0
%)
Br
ilo
te
t
al
.[
62
]
Pe
d
A
D
EM
n
=
19
Pe
d
CI
S
n
=
28
(O
N
n
=
7,
he
m
is
ph
er
ic
n
=
6,
br
ai
ns
te
m
n
=
2,
ce
re
be
lla
r
n
=
2,
TM
n
=
1,
m
ul
ti
fo
ca
ln
=
10
)
Se
ru
m
an
d
CS
F
Fu
ll
le
ng
th
hu
m
an
M
O
G
tr
an
sd
uc
ed
hu
m
an
gl
io
bl
as
to
m
a
ce
ll
lin
e
LN
18
Fl
ow
cy
to
m
et
ry
on
liv
e
ce
lls
Δ
M
FI
=
M
FI
LN
18
-M
O
G
-
M
FI
co
nt
ro
ls
;c
ut
of
f
de
te
rm
in
ed
as
m
ed
ia
n
+
95
%
of
H
C
an
d
O
N
D
gr
ou
ps
M
O
G
Ig
G
po
si
ti
ve
:
D
EM
22
/4
7
(4
6.
8%
)
(b
ot
h
A
D
EM
an
d
CI
S)
O
N
D
2/
29
(6
.9
%)
Pa
ir
ed
sa
m
pl
es
in
5
pe
d
CI
S
an
d
3
A
D
EM
pa
ti
en
ts
,w
it
h
se
ru
m
an
d
CS
F
bo
th
po
si
ti
ve
fo
r
M
O
G
A
bs
in
al
lp
at
ie
nt
s;
A
b
ti
te
rh
ig
he
ri
n
se
ru
m
in
al
l
N
ot
as
se
ss
ed
(c
on
tin
ue
d
on
ne
xt
pa
ge
)
S. Ramanathan et al. / Autoimmunity Reviews 15 (2016) 307–324
312 
Ta
bl
e
1
(c
on
tin
ue
d)
Re
fe
re
nc
e
D
es
cr
ip
ti
on
of
co
ho
rt
Sa
m
pl
e
A
nt
ig
en
ch
ar
ac
te
ri
st
ic
s
D
et
ec
ti
on
A
na
ly
si
s
ap
pr
oa
ch
Pr
ev
al
en
ce
of
M
O
G
an
ti
bo
dy
po
si
ti
vi
ty
Co
nc
or
da
nc
e
fo
r
M
O
G
an
ti
bo
di
es
be
tw
ee
n
CS
F
an
d
se
ru
m
Lo
ng
it
ud
in
al
ev
al
ua
ti
on
of
se
ro
po
si
ti
vi
ty
N
ot
fo
un
d
in
H
C,
ty
pe
1
D
M
,o
r
ad
ul
t
M
S
co
ho
rt
s
A
D
EM
pa
ti
en
ts
,a
nd
hi
gh
er
in
CS
F
in
3/
5
CI
S
pa
ti
en
ts
M
O
G
Ig
M
po
si
ti
ve
:
3/
47
D
EM
(a
ll
A
D
EM
)
N
ot
fo
un
d
in
ot
he
r
gr
ou
ps
Pe
d
O
N
D
n
=
29
Pe
d
ty
pe
1
D
M
n
=
15
Pe
d
H
C
n
=
30
A
du
lt
M
S
n
=
54
La
liv
e
et
al
.[
63
]
Pe
d
A
D
EM
n
=
11
Pe
d
M
S
n
=
22
V
E
n
=
7
H
C
n
=
13
Se
ru
m
Re
co
m
bi
na
nt
hu
m
an
M
O
G
1-
12
5
ex
tr
ac
el
lu
la
r
Ig
do
m
ai
n
ex
pr
es
se
d
by
E.
co
li
H
um
an
fu
ll
le
ng
th
M
O
G
tr
an
sf
ec
te
d
CH
O
ce
lls
EL
IS
A
an
d
Li
Ph
EL
IA
(l
iq
ui
d
ph
as
e
as
sa
y
ba
se
d
on
bi
ot
in
yl
at
io
n
of
rM
O
G
)
BR
=
O
D
ag
ai
ns
tM
O
G
/O
D
ba
ck
gr
ou
nd
M
O
G
Ig
G
(%
po
si
ti
ve
)
N
ot
as
se
ss
ed
N
ot
as
se
ss
ed
By
EL
IS
A
:
A
D
EM
55
%
Pe
d
M
S
14
%
H
C
0%
BR
=
M
FI
of
M
O
G
tr
an
sf
ec
te
d
ce
lls
/M
FI
of
co
nt
ro
lc
el
ls
;c
on
si
de
re
d
po
si
ti
ve
if
in
di
vi
du
al
's
BR
N
m
ea
n
+
2
SD
of
co
nt
ro
ls
Fl
ow
cy
to
m
et
ry
on
liv
e
ce
lls
By
Li
Ph
EL
IA
:
A
D
EM
0%
Pe
d
M
S
0%
H
C
0%
By
ﬂo
w
cy
to
m
et
ry
:
A
D
EM
27
%
Pe
d
M
S
5%
H
C
0%
D
iP
au
li
et
al
.[
64
]
A
D
EM
n
=
34
(2
7
pe
d,
7
ad
ul
t)
CI
S
n
=
38
(1
8
pe
d,
20
ad
ul
t)
M
S
n
=
89
(1
8
pe
d,
71
ad
ul
t)
O
N
D
n
=
58
(1
5
pe
d,
43
ad
ul
t)
H
C
n
=
47
(a
ll
ad
ul
t)
Se
ru
m
Fu
ll
le
ng
th
hu
m
an
M
O
G
-G
FP
tr
an
si
en
tl
y
tr
an
sf
ec
te
d
H
EK
29
3A
ce
lls
M
ic
ro
sc
op
y
on
liv
e
ce
lls
V
is
ua
ls
co
ri
ng
Cu
to
ff
va
lu
e
of
hi
gh
ti
te
r
M
O
G
Ig
G
id
en
ti
ﬁe
d
as
1:
16
0
an
d
pr
es
en
ti
n
se
ru
m
in
:
In
an
ti
-M
O
G
Ig
G
se
ro
ne
ga
ti
ve
pa
ti
en
ts
,t
he
co
rr
es
po
nd
in
g
CS
F
sa
m
pl
es
w
er
e
ne
ga
ti
ve
Co
rr
el
at
io
n
be
tw
ee
n
di
se
as
e
se
ve
ri
ty
or
re
la
ps
e
an
d
an
ti
-M
O
G
A
b
ti
te
r
in
A
D
EM
pa
ti
en
ts
(n
=
10
),
bu
tn
ot
cl
ea
r
in
th
e
ot
he
r
gr
ou
ps
(C
IS
n
=
4,
M
S
n
=
9,
O
N
D
n
=
2)
O
D
at
49
2
nm
,c
ut
of
f
de
te
rm
in
ed
by
va
lu
es
fr
om
ag
e
an
d
se
x
m
at
ch
ed
co
nt
ro
ls
EL
IS
A
In
th
e
lo
w
ti
te
r
ra
ng
e,
an
ti
-M
O
G
an
ti
bo
di
es
w
er
e
on
ly
pr
es
en
ti
n
se
ru
m
,b
ut
no
ti
n
th
e
CS
F.
A
D
EM
15
/3
4
(4
4%
)
CI
S
3/
38
(8
%)
M
S
2/
89
(2
%)
O
N
D
1/
58
(2
%)
H
C
0/
47
(0
%)
A
ll
pa
ti
en
ts
w
it
h
hi
gh
er
ti
te
r
va
lu
es
(N
/1
:6
40
)
in
se
ru
m
sh
ow
ed
de
te
ct
ab
le
re
ac
ti
vi
ty
to
M
O
G
in
th
e
CS
F.
CS
F
12
/3
3
po
si
ti
ve
N
on
-s
pe
ci
ﬁc
re
su
lt
s
w
it
h
se
ru
m
an
ti
-M
O
G
an
ti
bo
di
es
by
EL
IS
A
in
:
A
D
EM
5/
21
(2
4%
)
CI
S
3/
36
(8
%)
M
S
13
/8
9
(1
5%
)
O
N
D
6/
54
(1
1%
)
H
C
2/
47
(4
%)
Re
co
m
bi
na
nt
hu
m
an
M
O
G
1-
12
5
ex
tr
ac
el
lu
la
r
Ig
do
m
ai
n
ex
pr
es
se
d
by
E.
co
li
CS
F
in
33
pa
ti
en
ts
(A
D
EM
n
=
8,
CI
S
n
=
13
,
M
S
n
=
12
)
M
ad
er
et
al
.[
68
]
Pe
d
an
d
ad
ul
t
N
M
O
n
=
45
H
R-
N
M
O
n
=
53
(2
8
m
LE
TM
,1
3
rL
ET
M
,1
2
rO
N
)
A
D
EM
n
=
33
CI
S
n
=
32
M
S
n
=
71
(4
4
RR
M
S,
19
SP
M
S,
8
PP
M
S)
Co
nt
ro
ls
n
=
10
1
(2
4
O
N
D
,2
7
SL
E,
50
H
C)
Se
ru
m
Fu
ll
le
ng
th
hu
m
an
M
O
G
-G
FP
⁎⁎
tr
an
si
en
tl
y
tr
an
sf
ec
te
d
H
EK
29
3A
ce
lls
M
ic
ro
sc
op
y
on
liv
e
ce
lls
V
is
ua
ls
co
ri
ng
H
ig
h
ti
te
r
(N
/1
:1
60
)
M
O
G
Ig
G
po
si
ti
ve
:
N
ot
as
se
ss
ed
N
ot
as
se
ss
ed
N
M
O
3/
45
(7
%)
H
R-
N
M
O
7/
53
(3
%)
A
D
EM
14
/3
3
(4
2%
)
CI
S
2/
32
(6
%)
M
S
2/
71
(3
%)
Co
nt
ro
ls
3/
10
1
(3
%)
S. Ramanathan et al. / Autoimmunity Reviews 15 (2016) 307–324
313 
Pr
ob
st
el
et
al
.[
65
]
Pe
d
M
S
n
=
65
A
D
EM
n
=
54
CI
S
n
=
7
Co
nt
ro
ls
n
=
35
Se
ru
m
Fu
ll
le
ng
th
hu
m
an
M
O
G
tr
an
sf
ec
te
d
hu
m
an
rh
ab
do
m
yo
sa
rc
om
a
ce
ll
lin
e
(T
E
67
1)
Fl
ow
cy
to
m
et
ry
on
liv
e
ce
lls
G
eo
m
et
ri
c
M
CF
of
tr
an
sf
ec
te
d
ce
ll
lin
e/
un
tr
an
sf
ec
te
d
ce
ll
lin
e
fo
r
ea
ch
pa
ti
en
t;
cu
t
of
f4
SD
ab
ov
e
m
ea
n
of
pe
di
at
ri
c
co
nt
ro
ls
(g
eo
m
et
ri
c
M
CF
ra
ti
o
=
1.
45
)
M
O
G
Ig
G
po
si
ti
ve
:
N
ot
as
se
ss
ed
A
nt
i-
M
O
G
an
ti
bo
di
es
ra
pi
dl
y
an
d
co
nt
in
uo
us
ly
de
cl
in
ed
in
m
on
op
ha
si
c
A
D
EM
Pe
d
M
S
10
/6
5
(1
5%
)
A
D
EM
19
/5
4
(3
5%
)
CI
S
2/
7
(2
9%
)
Co
nt
ro
ls
0/
35
(0
%)
an
ti
-M
O
G
an
ti
bo
di
es
pe
rs
is
te
d
in
th
e
m
aj
or
it
y
of
ch
ild
re
n
w
ho
w
en
to
n
to
be
di
ag
no
se
d
w
it
h
ch
ild
ho
od
M
S
A
du
lt
M
S
n
=
62
Co
nt
ro
ls
n
=
28
A
du
lt
M
S
4/
62
(6
%)
Co
nt
ro
ls
0/
28
(0
%)
N
on
e
po
si
ti
ve
fo
r
M
O
G
Ig
M
Ki
tl
ey
et
al
.[
94
]
A
du
lt
AQ
P4
Ab
-n
eg
at
iv
e
N
M
O
/N
M
O
SD
n
=
27
AQ
P4
Ab
-p
os
iti
ve
N
M
O
/N
M
O
SD
n
=
44
Se
ru
m
H
um
an
C-
te
rm
in
al
tr
un
ca
te
d
M
O
G
tr
an
sf
ec
te
d
H
EK
29
3
ce
lls
M
ic
ro
sc
op
y
on
liv
e
ce
lls
V
is
ua
ls
co
ri
ng
M
O
G
A
b-
po
si
ti
ve
#
N
ot
as
se
ss
ed
N
ot
as
se
ss
ed
A
Q
P4
A
b-
ne
ga
ti
ve
N
M
O
/N
M
O
SD
4/
27
(1
5%
)
no
ne
of
th
e
ot
he
r
gr
ou
ps
A
du
lt
M
S
n
=
75
H
C
n
=
47
Ro
st
as
y
et
al
.[
95
]
Pe
d
O
N
n
=
37
Se
ru
m
Fu
ll
le
ng
th
hu
m
an
M
O
G
-G
tr
an
sf
ec
te
d
H
EK
29
3A
ce
lls
M
ic
ro
sc
op
y
on
liv
e
ce
lls
V
is
ua
ls
co
ri
ng
M
O
G
Ig
G
po
si
ti
ve
:
12
/1
5
rO
N
(8
0%
)
2/
10
m
O
N
(2
0%
)
3/
12
CI
S
(2
5%
)
N
ot
as
se
ss
ed
N
ot
as
se
ss
ed
Ro
st
as
y
et
al
.[
96
]
Pe
d
de
m
ye
lin
at
io
n
n
=
10
6
(N
M
O
n
=
8,
m
O
N
n
=
14
,r
O
N
n
=
3,
TM
n
=
6,
A
D
EM
n
=
29
,C
IS
n
=
32
,
M
S
n
=
11
,c
er
eb
el
lit
is
n
=
3)
Se
ru
m
Fu
ll
le
ng
th
hu
m
an
M
O
G
-G
FP
tr
an
sf
ec
te
d
H
EK
29
3A
ce
lls
M
ic
ro
sc
op
y
on
liv
e
ce
lls
V
is
ua
ls
co
ri
ng
M
O
G
Ig
G
po
si
ti
ve
:
3/
8
N
M
O
(3
8%
)
2/
14
m
O
N
(1
4%
)
2/
3
rO
N
(6
7%
)
0/
6
TM
(0
%)
13
/2
9
A
D
EM
(4
5%
)
1/
32
CI
S
(3
%)
1/
11
M
S
(9
%)
0/
3
ce
re
be
lli
ti
s
(0
%)
0/
20
O
N
D
(0
%)
N
ot
as
se
ss
ed
Pe
rs
is
te
nt
hi
gh
ti
te
r
M
O
G
A
b
se
ro
po
si
ti
vi
ty
id
en
ti
ﬁe
d
in
lo
ng
it
ud
in
al
sa
m
pl
es
of
M
O
G
A
b
po
si
ti
ve
N
M
O
pa
ti
en
ts
O
N
D
n
=
20
Ki
tl
ey
et
al
.[
98
]
1s
te
pi
so
de
CN
S
de
m
ye
lin
at
io
n
po
si
ti
ve
fo
r
M
O
G
or
A
Q
P4
A
bs
fr
om
20
10
to
20
13
,
n
=
46
Se
ru
m
H
um
an
C-
te
rm
in
al
tr
un
ca
te
d
M
O
G
tr
an
sf
ec
te
d
H
EK
29
3
ce
lls
M
ic
ro
sc
op
y
on
liv
e
ce
lls
V
is
ua
ls
co
ri
ng
M
O
G
Ig
G
po
si
ti
ve
:
9/
46
(2
0%
)
N
ot
as
se
ss
ed
N
ot
as
se
ss
ed
Ba
um
an
n
et
al
.[
72
]
Pe
d
A
D
EM
n
=
33
Se
ru
m
Fu
ll
le
ng
th
hu
m
an
M
O
G
-G
FP
tr
an
sf
ec
te
d
H
EK
29
3A
ce
lls
M
ic
ro
sc
op
y
on
liv
e
ce
lls
V
is
ua
ls
co
ri
ng
H
ig
h-
ti
te
r
(N
/1
:1
60
)
M
O
G
Ig
G
po
si
ti
ve
:1
9/
33
pa
ti
en
ts
(5
8%
)
N
ot
as
se
ss
ed
Pe
rs
is
te
nt
M
O
G
A
b
pe
rs
is
te
nc
e
in
4/
19
M
O
G
A
b-
po
si
ti
ve
pa
ti
en
ts
w
it
h
re
la
ps
in
g
di
se
as
e
D
al
e
et
al
.[
57
]
Pe
d
de
m
ye
lin
at
io
n
n
=
73
(A
D
EM
n
=
28
,T
M
n
=
15
,O
N
n
=
15
,
ot
he
r
CI
S
n
=
15
)
O
N
D
n
=
24
Se
ru
m
(a
nd
pa
ir
ed
CS
F
in
22
sa
m
pl
es
)
Fu
ll
le
ng
th
hu
m
an
M
O
G
-Z
sG
re
en
+
le
nt
iv
ir
us
tr
an
sd
uc
ed
H
EK
29
3
ce
lls
Fl
ow
cy
to
m
et
ry
on
liv
e
ce
lls
Po
si
ti
ve
th
re
sh
ol
d
de
ﬁn
ed
as
m
ea
n
ΔM
FI
+
3
SD
of
co
nt
ro
ls
M
O
G
Ig
G
po
si
ti
ve
:
22
Pa
ti
en
ts
ha
d
CS
F
te
st
ed
,o
f
w
ho
m
5
w
er
e
se
ru
m
M
O
G
A
b-
po
si
ti
ve
.3
CS
F
sa
m
pl
es
w
er
e
M
O
G
A
b
po
si
ti
ve
(2
w
ho
w
er
e
se
ru
m
M
O
G
A
b-
po
si
ti
ve
an
d
1
w
ho
w
as
se
ru
m
M
O
G
A
b-
ne
ga
ti
ve
).
Pe
rs
is
te
nt
se
ro
ne
ga
ti
vi
ty
in
tw
o
pa
ti
en
ts
tr
ea
te
d
w
it
h
m
yc
op
he
no
la
te
D
em
ye
lin
at
io
n
31
/7
3
(4
2%
)
A
D
EM
11
/2
4
(4
6%
)
O
N
6/
7
(8
6%
)
rO
N
3/
4
(7
5%
)
TM
4/
13
(3
1%
)
CI
S
0/
10
(0
%)
M
S
7/
15
(4
7%
)
O
N
D
0/
24
(0
%)
Sa
to
et
al
.[
97
]
Pe
d
an
d
ad
ul
ts
N
M
O
/N
M
O
SD
n
=
21
5
Se
ru
m
Fu
ll
le
ng
th
hu
m
an
M
O
G
tr
an
si
en
tl
y
tr
an
sf
ec
te
d
H
EK
29
3
ce
lls
M
ic
ro
sc
op
y
on
liv
e
ce
lls
V
is
ua
ls
co
ri
ng
M
O
G
Ig
G
po
si
ti
ve
:
16
/2
15
(7
.4
%)
N
ot
as
se
ss
ed
Pe
rs
is
te
nt
se
ro
po
si
ti
vi
ty
in
se
ve
n
pa
ti
en
ts
O
ft
he
se
16
:
O
N
+
TM
1/
16
LE
TM
5/
16
rO
N
5/
16
BO
N
5/
16
(c
on
tin
ue
d
on
ne
xt
pa
ge
)
S. Ramanathan et al. / Autoimmunity Reviews 15 (2016) 307–324
314 
Ta
bl
e
1
(c
on
tin
ue
d)
Re
fe
re
nc
e
D
es
cr
ip
ti
on
of
co
ho
rt
Sa
m
pl
e
A
nt
ig
en
ch
ar
ac
te
ri
st
ic
s
D
et
ec
ti
on
A
na
ly
si
s
ap
pr
oa
ch
Pr
ev
al
en
ce
of
M
O
G
an
ti
bo
dy
po
si
ti
vi
ty
Co
nc
or
da
nc
e
fo
r
M
O
G
an
ti
bo
di
es
be
tw
ee
n
CS
F
an
d
se
ru
m
Lo
ng
it
ud
in
al
ev
al
ua
ti
on
of
se
ro
po
si
ti
vi
ty
Ra
m
an
at
ha
n
et
al
.
[5
8]
23
A
du
lt
s
w
it
h
A
Q
P4
A
b-
ne
ga
ti
ve
N
M
O
/N
M
O
SD
:
BO
N
n
=
11
LE
TM
n
=
10
BO
N
an
d
LE
TM
n
=
2
Se
ru
m
Fu
ll
le
ng
th
hu
m
an
M
O
G
-Z
sG
re
en
+
le
nt
iv
ir
us
tr
an
sd
uc
ed
H
EK
29
3
ce
lls
Fl
ow
cy
to
m
et
ry
on
liv
e
ce
lls
Po
si
ti
ve
th
re
sh
ol
d
de
ﬁn
ed
as
m
ea
n
ΔM
FI
+
3
SD
s
of
co
nt
ro
ls
M
O
G
Ig
G
po
si
ti
ve
:
9/
23
(3
9%
)
of
w
hi
ch
BO
N
(n
=
8)
an
d
BO
N
an
d
LE
TM
(n
=
1)
N
ot
as
se
ss
ed
Pe
rs
is
te
nt
se
ro
po
si
ti
vi
ty
(a
lb
ei
t
w
it
h
re
du
ce
d
ΔM
FI
)
de
sp
it
e
cl
in
ic
al
re
co
ve
ry
an
d
tr
ea
tm
en
t
in
2
pa
ti
en
ts
,ΔM
FI
in
cr
ea
si
ng
w
it
h
re
la
ps
es
in
1
pa
ti
en
t,
an
d
re
tu
rn
to
no
rm
al
in
1
pa
ti
en
ti
n
w
ho
m
se
ri
al
sa
m
pl
es
w
er
e
ob
ta
in
ed
A
du
lt
M
S
1/
76
(1
%)
O
N
D
0/
20
(0
%)
H
C
0/
32
(0
%)
A
du
lt
M
S
n
=
76
O
N
D
n
=
20
H
C
n
=
32
Ta
na
ka
et
al
.[
11
7]
Ja
pa
ne
se
ad
ul
ts
Se
ru
m
Fu
ll
le
ng
th
hu
m
an
M
O
G
tr
an
sf
ec
te
d
H
EK
29
3
ce
lls
M
ic
ro
sc
op
y
on
ﬁx
ed
ce
lls
V
is
ua
ls
co
ri
ng
M
O
G
Ig
G
1
po
si
ti
ve
:
4/
48
(8
%)
A
Q
P4
A
b-
ne
ga
ti
ve
pa
ti
en
ts
on
ly
N
ot
as
se
ss
ed
N
ot
as
se
ss
ed
A
Q
P4
A
b-
ne
ga
ti
ve
TM
or
O
N
n
=
48
A
Q
P4
A
b-
po
si
ti
ve
N
M
O
/N
M
O
SD
n
=
14
M
ar
ti
ne
z
H
er
na
nd
ez
et
al
.[
11
8]
Is
ol
at
ed
O
N
n
=
51
(3
6
ad
ul
ts
,1
5
pe
d)
Se
ru
m
Fu
ll
le
ng
th
hu
m
an
M
O
G
-G
FP
⁎⁎
tr
an
sf
ec
te
d
H
EK
29
3
ce
lls
M
ic
ro
sc
op
y
on
liv
e
ce
lls
V
is
ua
ls
co
ri
ng
M
O
G
Ig
G
po
si
ti
ve
:
M
O
G
A
b
po
si
ti
ve
in
se
ru
m
an
d
CS
F
fo
r
on
e
pa
ti
en
t;
M
O
G
an
d
gl
yc
in
e
re
ce
pt
or
an
ti
bo
di
es
in
se
ru
m
on
ly
in
1
pa
ti
en
t
N
ot
as
se
ss
ed
10
/5
1
(2
0%
)
O
N
pa
ti
en
ts
,a
nd
co
nc
ur
re
nt
w
it
h
gl
yc
in
e
re
ce
pt
or
an
ti
bo
di
es
in
3
pa
ti
en
ts
Pa
ir
ed
CS
F
in
4
Co
nt
ro
ls
H
C
n
=
30
N
M
O
n
=
48
M
S
n
=
64
in
cl
ud
in
g
8
pe
d
(C
IS
n
=
28
,
RR
M
S
n
=
17
,S
PM
S
n
=
9,
PP
M
S
n
=
10
)
4/
48
(8
%)
N
M
O
pa
ti
en
ts
,a
nd
co
nc
ur
re
nt
w
it
h
A
Q
P4
an
ti
bo
di
es
in
2
pa
ti
en
ts
El
on
g
N
go
no
et
al
.
[1
39
]
A
du
lt
RR
M
S
n
=
27
SP
M
S
n
=
8
H
C
n
=
50
Pl
as
m
a
Fu
ll
le
ng
th
hu
m
an
M
O
G
-G
FP
tr
an
sf
ec
te
d
H
EK
29
3
ce
lls
M
ic
ro
sc
op
y
on
liv
e
ce
lls
V
is
ua
ls
co
ri
ng
H
ig
h
ti
te
r
M
O
G
Ig
G
po
si
ti
ve
:
N
ot
as
se
ss
ed
N
ot
as
se
ss
ed
RR
M
S
1/
27
(4
%)
an
d
H
C
1/
50
(2
%)
Ke
te
ls
le
ge
rs
et
al
.
[7
3]
11
7
Pe
d
de
m
ye
lin
at
io
n
O
N
n
=
20
TM
n
=
7
ot
he
r
m
on
of
oc
al
de
m
ye
lin
at
io
n
n
=
22
po
ly
fo
ca
ld
em
ye
lin
at
io
n
w
it
ho
ut
en
ce
ph
al
op
at
hy
n
=
44
A
D
EM
n
=
24
O
N
D
n
=
13
H
C
pe
d
n
=
31
3
A
du
lt
A
D
EM
n
=
29
Se
ru
m
H
um
an
fu
ll
le
ng
th
M
O
G
tr
an
sf
ec
te
d
LN
18
ce
lls
(g
lia
lc
el
l
lin
e)
;s
ta
bl
e
ex
pr
es
si
on
Fl
ow
cy
to
m
et
ry
on
liv
e
ce
lls
Cu
to
ff
de
ﬁn
ed
as
m
ea
n
ΔM
FI
of
co
nt
ro
ls
+
3
SD
M
O
G
Ig
G
po
si
ti
ve
:
21
/1
17
(1
8%
)
ch
ild
re
n
w
it
h
de
m
ye
lin
at
io
n
O
ft
he
se
:
O
N
n
=
2
Po
ly
fo
ca
l
de
m
ye
lin
at
io
n
w
it
ho
ut
en
ce
ph
al
op
at
hy
n
=
8 Pe
di
at
ri
c
AD
EM
n
=
10 H
em
ip
ar
es
is
n
=
1
N
ot
as
se
ss
ed
N
ot
as
se
ss
ed
A
du
lt
A
D
EM
1/
29
0
in
co
nt
ro
lg
ro
up
s
(O
N
D
an
d
H
C
pe
d)
O
nl
y
1/
47
ch
ild
re
n
w
ho
w
en
to
n
to
ge
t
a
di
ag
no
si
s
of
M
S
w
er
e
se
ro
po
si
ti
ve
S. Ramanathan et al. / Autoimmunity Reviews 15 (2016) 307–324
315 
H
of
tb
er
ge
r
et
al
.
[9
9]
A
du
lt
s
w
it
h
de
m
ye
lin
at
io
n
(n
=
17
4)
in
cl
ud
in
g:
Se
ru
m
an
d
CS
F
Fu
ll
le
ng
th
M
O
G
-G
FP
⁎⁎
tr
an
sf
ec
te
d
H
EK
29
3
ce
lls
M
ic
ro
sc
op
y
on
liv
e
ce
lls
V
is
ua
ls
co
ri
ng
M
O
G
Ig
G
po
si
ti
ve
:
8
Pa
ti
en
ts
ha
d
CS
F
te
st
ed
,o
f
w
ho
m
al
l8
w
er
e
se
ru
m
M
O
G
A
b-
po
si
ti
ve
.5
CS
F
sa
m
pl
es
w
er
e
M
O
G
A
b
po
si
ti
ve
(a
ll
5
w
er
e
se
ru
m
M
O
G
A
b-
po
si
ti
ve
)
Pe
rs
is
te
nt
se
ro
po
si
ti
vi
ty
in
12
/1
4
M
O
G
A
b-
po
si
ti
ve
pa
ti
en
ts
w
it
ho
ut
co
rr
el
at
io
n
be
tw
ee
n
ti
te
rs
an
d
ou
tc
om
e
17
/1
74
(9
.8
%)
ad
ul
ts
w
it
h
de
m
ye
lin
at
io
n
of
w
hi
ch
N
M
O
4/
17
LE
TM
5/
17
O
N
7/
17
A
D
EM
1/
17
A
du
lt
M
S
co
nt
ro
ls
0/
55
(0
%)
12
/3
0
(4
0%
)
pe
d
de
m
ye
lin
at
io
n
pa
ti
en
ts
of
w
ho
m
36
%
ha
d
A
D
EM
N
M
O
n
=
48
LE
TM
n
=
84
O
N
n
=
39
A
D
EM
n
=
3
Co
nt
ro
ls
:5
5
ad
ul
ts
w
it
h
M
S
(2
0
CI
S,
15
RR
M
S,
10
SP
M
S,
10
PP
M
S)
Pe
d
de
m
ye
lin
at
io
n
(n
=
30
):
N
M
O
n
=
4
LE
TM
n
=
7
O
N
n
=
8
A
D
EM
n
=
10
M
S
+
LE
TM
re
la
ps
e
n
=
1
H
ac
oh
en
et
al
.[
74
]
Pe
d
ﬁr
st
ep
is
od
e
ac
qu
ir
ed
de
m
ye
lin
at
io
n
A
D
EM
n
=
12
O
N
n
=
24
TM
n
=
18
O
th
er
CI
S
n
=
11
Co
nt
ro
ls
:
A
du
lt
M
S
n
=
10
0
A
du
lt
A
Q
P4
A
b-
po
si
ti
ve
n
=
10
0
Se
ru
m
Fu
ll
le
ng
th
hu
m
an
M
O
G
tr
an
sf
ec
te
d
H
EK
29
3
ce
lls
M
ic
ro
sc
op
y
on
liv
e
ce
lls
V
is
ua
ls
co
ri
ng
M
O
G
Ig
G
po
si
ti
ve
:
23
/6
5
(3
5%
)
of
w
hi
ch
A
D
EM
4/
12
(3
3%
)
O
N
12
/2
4
(5
0%
)
TM
4/
18
(2
2%
)
ot
he
r
CI
S
3/
11
(2
7%
)
N
ot
as
se
ss
ed
N
ot
as
se
ss
ed
N
o
M
O
G
Ig
G
po
si
ti
ve
co
nt
ro
ls
2/
23
(9
%)
of
M
O
G
A
b-
po
si
ti
ve
pa
ti
en
ts
ha
d
a
di
ag
no
si
s
of
M
S
in
1
ye
ar
16
/4
2
(3
8%
)
of
M
O
G
A
b-
ne
ga
ti
ve
pa
ti
en
ts
ha
d
a
di
ag
no
si
s
of
M
S
in
1
ye
ar
W
at
er
s
et
al
.[
56
]
11
09
co
ns
ec
ut
iv
e
se
ra
se
nt
fo
r
A
Q
P4
A
b
te
st
in
g
Se
ru
m
Fu
ll
le
ng
th
hu
m
an
M
O
G
tr
an
sf
ec
te
d
H
EK
29
3
ce
lls
$
M
ic
ro
sc
op
y
on
liv
e
ce
lls
(n
=
11
09
)
V
is
ua
ls
co
ri
ng
M
O
G
Ig
G
1
po
si
ti
ve
:
65
/1
10
9
pa
ti
en
ts
po
si
ti
ve
fo
r
fu
ll
le
ng
th
M
O
G
A
bs
,
w
it
h
no
fu
ll
le
ng
th
M
O
G
A
b
se
ro
po
si
ti
vi
ty
in
A
Q
P4
A
b-
po
si
ti
ve
an
d
co
nt
ro
lp
at
ie
nt
s
N
ot
as
se
ss
ed
N
ot
as
se
ss
ed
ΔM
FI
=
m
ed
ia
n
gr
ee
n
ﬂu
or
es
ce
nc
e
tr
an
sf
ec
te
d–
un
tr
an
sf
ec
te
d
ce
lls
;c
ut
of
fi
de
nt
iﬁ
ed
as
th
e
m
ea
n
M
FI
of
H
C
+
6
SD
Fl
ow
cy
to
m
et
ry
on
liv
e
ce
lls
(n
=
15
)
H
in
o-
Fu
ku
yo
[1
40
]
Ja
pa
ne
se
pe
d
de
m
ye
lin
at
io
n
Se
ru
m
Fu
ll
le
ng
th
hu
m
an
M
O
G
tr
an
sf
ec
te
d
H
EK
29
3
ce
lls
M
ic
ro
sc
op
y
on
liv
e
ce
lls
V
is
ua
ls
co
ri
ng
M
O
G
Ig
G
po
si
ti
ve
:
A
D
EM
3/
7
(4
3%
)
O
N
3/
5
(6
0%
)
M
S
3/
4
(7
5%
)
N
ot
as
se
ss
ed
N
ot
as
se
ss
ed
A
D
EM
n
=
7
O
N
n
=
5
M
S
n
=
4
N
M
O
n
=
1
Pr
ob
st
el
et
al
.[
10
0]
N
M
O
/N
M
O
SD
n
=
48
RR
M
S
n
=
48
H
C
n
=
39
Se
ru
m
Fu
ll
le
ng
th
hu
m
an
M
O
G
tr
an
sf
ec
te
d
hu
m
an
rh
ab
do
m
yo
sa
rc
om
a
ce
ll
lin
e
(T
E
67
1)
Fl
ow
cy
to
m
et
ry
on
liv
e
ce
lls
BR
of
th
e
G
M
CF
of
th
e
M
O
G
-t
ra
ns
fe
ct
ed
:e
m
pt
y
ve
ct
or
-t
ra
ns
fe
ct
ed
ce
ll
lin
e;
cu
to
ff
=
m
ea
n
G
M
CF
ra
ti
o
pl
us
tw
o
SD
of
H
C
M
O
G
Ig
G
po
si
ti
ve
:
N
M
O
/N
M
O
SD
4/
48
(8
%)
RR
M
S
0/
48
(0
%)
H
C
0/
39
(0
%)
N
ot
as
se
ss
ed
Lo
ng
it
ud
in
al
an
al
ys
es
in
2
A
b-
po
si
ti
ve
pa
ti
en
ts
sh
ow
ed
in
cr
ea
se
w
it
h
re
la
ps
e
in
on
e
pa
ti
en
t,
bu
tw
as
in
de
pe
nd
en
to
f
di
se
as
e
ac
ti
vi
ty
in
an
ot
he
r
(c
on
tin
ue
d
on
ne
xt
pa
ge
)
S. Ramanathan et al. / Autoimmunity Reviews 15 (2016) 307–324
316 
Ta
bl
e
1
(c
on
tin
ue
d)
Re
fe
re
nc
e
D
es
cr
ip
ti
on
of
co
ho
rt
Sa
m
pl
e
A
nt
ig
en
ch
ar
ac
te
ri
st
ic
s
D
et
ec
ti
on
A
na
ly
si
s
ap
pr
oa
ch
Pr
ev
al
en
ce
of
M
O
G
an
ti
bo
dy
po
si
ti
vi
ty
Co
nc
or
da
nc
e
fo
r
M
O
G
an
ti
bo
di
es
be
tw
ee
n
CS
F
an
d
se
ru
m
Lo
ng
it
ud
in
al
ev
al
ua
ti
on
of
se
ro
po
si
ti
vi
ty
Ch
al
m
ou
ko
u
et
al
.
[1
03
]
A
Q
P4
A
b-
ne
ga
ti
ve
O
N
n
=
11
1
Se
ru
m
Fu
ll
le
ng
th
hu
m
an
M
O
G
-G
FP
tr
an
si
en
tl
y
tr
an
sf
ec
te
d
H
EK
29
3T
ce
lls
M
ic
ro
sc
op
y
on
liv
e
ce
lls
V
is
ua
ls
co
ri
ng
M
O
G
A
bs
po
si
ti
ve
#
:
N
ot
as
se
ss
ed
N
ot
as
se
ss
ed
O
N
pa
ti
en
ts
8/
11
1
(7
%)
–
5/
8
ha
d
rO
N
M
S
co
nt
ro
ls
0/
42
(0
%)
Co
nt
ro
ls
:
PP
M
S
n
=
12
RR
M
S
n
=
30
Co
bo
-C
al
vo
et
al
.
[1
02
]
A
du
lt
s
Fi
rs
te
pi
so
de
LE
TM
(A
Q
P4
A
b-
ne
ga
ti
ve
)
n
=
56
Se
ru
m
Fu
ll
le
ng
th
hu
m
an
M
O
G
-G
FP
⁎⁎
tr
an
sf
ec
te
d
H
EK
29
3
ce
lls
M
ic
ro
sc
op
y
an
d
ﬂo
w
cy
to
m
et
ry
on
liv
e
ce
lls
(c
om
pl
et
e
co
nc
or
da
nc
e)
V
is
ua
ls
co
ri
ng
fo
r
m
ic
ro
sc
op
y
M
O
G
Ig
G
po
si
ti
ve
:
13
/5
6
(2
3%
)
N
ot
as
se
ss
ed
Fo
llo
w
up
sa
m
pl
es
in
6/
13
M
O
G
A
b-
po
si
ti
ve
pa
ti
en
ts
–
on
e
pa
ti
en
t(
m
LE
TM
)
w
as
ne
ga
ti
ve
at
43
m
on
th
s,
5
re
m
ai
ne
d
se
ro
po
si
ti
ve
(3
m
LE
TM
,1
rL
ET
M
,
1
co
nv
er
te
d
to
N
M
O
)
Fl
ow
cy
to
m
et
ry
an
al
ys
is
no
ts
pe
ci
ﬁe
d
Ra
m
an
at
ha
n
et
al
.
[5
9]
Pe
d
an
d
ad
ul
ts
Se
ru
m
Fu
ll
le
ng
th
hu
m
an
M
O
G
-Z
sG
re
en
+
le
nt
iv
ir
us
tr
an
sd
uc
ed
H
EK
29
3
ce
lls
Fl
ow
cy
to
m
et
ry
on
liv
e
ce
lls
Po
si
ti
ve
th
re
sh
ol
d
de
ﬁn
ed
as
m
ea
n
ΔM
FI
+
3
SD
s
of
co
nt
ro
ls
M
O
G
Ig
G
po
si
ti
ve
:
O
SM
S
2/
50
(4
%)
O
N
D
+
H
C
1/
39
(3
%)
N
ot
as
se
ss
ed
N
ot
as
se
ss
ed
Ja
pa
ne
se
A
Q
P4
A
b-
ne
ga
ti
ve
pa
ti
en
ts
w
it
h
O
SM
S
n
=
50
M
O
G
Ig
M
po
si
ti
ve
:
O
SM
S
1/
50
(2
%)
O
N
D
+
H
C
0/
30
(0
%)
H
C
n
=
20
O
N
D
n
=
19
Fe
rn
an
de
z-
Ca
rb
on
el
l
et
al
.[
70
]
Pe
d
de
m
ye
lin
at
in
g
n
=
74
:
A
D
EM
n
=
7
CI
S
n
=
12
M
S
n
=
45
N
M
O
n
=
4
RI
S
n
=
2
O
th
er
de
m
ye
lin
at
io
n
n
=
4
Pe
d
H
C
n
=
23
Se
ru
m
Fu
ll
le
ng
th
hu
m
an
M
O
G
-G
FP
tr
an
sf
ec
te
d
Ju
rk
at
ce
lls
(s
ta
bl
e)
Fl
ow
cy
to
m
et
ry
on
liv
e
ce
lls
M
ea
n
BR
of
pa
ti
en
ts
–
he
al
th
y
co
nt
ro
ls
,p
at
ie
nt
s
w
it
h
co
rr
ec
te
d
BR
N
3
SD
fr
om
co
nt
ro
ls
w
er
e
po
si
ti
ve
(B
R
N
5)
M
O
G
Ig
G
po
si
ti
ve
:
13
/7
4
pa
ti
en
ts
(1
8%
)
N
ot
as
se
ss
ed
N
ot
as
se
ss
ed
O
fw
hi
ch
A
D
EM
3/
7
(4
3%
)
CI
S
2/
12
(1
7%
)
M
S
4/
45
(9
%)
N
M
O
2/
4
(5
0%
)
O
th
er
de
m
ye
lin
at
io
n
2/
4
(5
0%
)
RI
S
0/
2
(0
%)
an
d
in
0/
23
H
C
(0
%)
Ab
,a
nt
ib
od
y;
AD
EM
,a
cu
te
di
ss
em
in
at
ed
en
ce
ph
al
om
ye
lit
is
;A
Q
P4
,a
qu
ap
or
in
-4
;B
O
N
,b
ila
te
ra
lo
pt
ic
ne
ur
iti
s;
BR
,b
in
di
ng
ra
tio
;C
H
O
,C
hi
ne
se
ha
m
st
er
ov
ar
y;
CI
S,
cl
in
ic
al
ly
is
ol
at
ed
sy
nd
ro
m
e;
CN
S,
ce
nt
ra
ln
er
vo
us
sy
st
em
;C
SF
,c
er
eb
ro
sp
in
al
ﬂu
id
;
D
EM
,d
em
ye
lin
at
io
n;
D
M
,d
ia
be
te
s
m
el
lit
us
;E
.c
ol
i,
Es
ch
er
ic
hi
a
co
li;
EL
IS
A,
en
zy
m
e-
lin
ke
d
im
m
un
os
or
be
nt
as
sa
y;
FL
-M
O
G
,f
ul
ll
en
gt
h
m
ye
lin
ol
ig
od
en
dr
oc
yt
e
gl
yc
op
ro
te
in
;G
FP
,g
re
en
ﬂu
or
es
ce
nc
e
pr
ot
ei
n;
G
M
CF
,g
eo
m
et
ri
c
m
ea
n
ch
an
ne
lﬂ
uo
re
s-
ce
nc
e;
G
m
ea
n,
ge
om
et
ri
c
m
ea
n
in
te
ns
ity
;H
C,
he
al
th
y
co
nt
ro
ls
;H
EK
29
3,
hu
m
an
em
br
yo
ni
c
ki
dn
ey
29
3
ce
lls
;H
R-
N
M
O
,h
ig
h
ri
sk
ne
ur
om
ye
lit
is
op
tic
a;
Ig
,i
m
m
un
og
lo
bu
lin
;L
ET
M
,l
on
gi
tu
di
na
lly
ex
te
ns
iv
e
tr
an
sv
er
se
m
ye
lit
is
;M
CF
,m
ea
n
ch
an
ne
l
ﬂu
or
es
ce
nc
e;
M
FI
,m
ea
n
ﬂu
or
es
ce
nc
e
in
te
ns
ity
; ΔM
FI
,D
el
ta
m
ea
n
ﬂu
or
es
ce
nc
e
in
te
ns
ity
;m
LE
TM
,m
on
op
ha
si
c
lo
ng
itu
di
na
lly
ex
te
ns
iv
e
tr
an
sv
er
se
m
ye
lit
is
;M
O
G
,m
ye
lin
ol
ig
od
en
dr
oc
yt
e
gl
yc
op
ro
te
in
;m
O
N
,m
on
op
ha
si
c
op
tic
ne
ur
iti
s;
M
S,
m
ul
tip
le
sc
le
ro
si
s;
nd
,n
ot
do
ne
;N
M
O
,n
eu
ro
m
ye
lit
is
op
tic
a;
N
M
O
SD
,n
eu
ro
m
ye
lit
is
op
tic
a
sp
ec
tr
um
di
so
rd
er
;O
D
,o
pt
ic
al
de
ns
ity
;O
IN
D
,o
th
er
in
ﬂa
m
m
at
or
y
ne
ur
ol
og
ic
al
di
se
as
es
;O
N
,o
pt
ic
ne
ur
iti
s;
O
N
D
,o
th
er
ne
ur
ol
og
ic
al
di
se
as
es
;O
SM
S,
op
tic
os
pi
na
l
m
ul
tip
le
sc
le
ro
si
s;
Pe
d,
pe
di
at
ri
c;
PP
M
S,
pr
im
ar
y
pr
og
re
ss
iv
e
m
ul
tip
le
sc
le
ro
si
s;
RI
S,
ra
di
ol
og
ic
al
ly
is
ol
at
ed
sy
nd
ro
m
e;
rL
ET
M
,r
ec
ur
re
nt
lo
ng
itu
di
na
lly
ex
te
ns
iv
e
tr
an
sv
er
se
m
ye
lit
is
;r
O
N
,r
ec
ur
re
nt
op
tic
ne
ur
iti
s;
RR
M
S,
re
la
ps
in
g
re
m
itt
in
g
m
ul
tip
le
sc
le
ro
si
s;
SD
,s
ta
nd
ar
d
de
vi
at
io
n;
SL
E,
sy
st
em
ic
lu
pu
s
er
yt
he
m
at
os
is
;S
L-
M
O
G
,s
ho
rt
le
ng
th
m
ye
lin
ol
ig
od
en
dr
oc
yt
e
gl
yc
op
ro
te
in
;S
PM
S,
se
co
nd
ar
y
pr
og
re
ss
iv
e
m
ul
tip
le
sc
le
ro
si
s;
TM
,t
ra
ns
ve
rs
e
m
ye
lit
is
;V
E,
vi
ra
le
nc
ep
ha
lit
is
.
⁎
Th
es
e
st
ud
ie
s
us
ed
a
3
st
ep
im
m
un
oﬂ
uo
re
sc
en
ce
m
et
ho
d
fo
r
si
gn
al
am
pl
ic
at
io
n
w
ith
bi
ot
in
yl
at
ed
an
ti-
hu
m
an
Ig
G
an
d
st
re
pt
av
id
in
-P
E.
Al
lo
th
er
st
ud
ie
s
us
ed
a
2
st
ep
im
m
un
oﬂ
uo
re
sc
en
ce
m
et
ho
d.
⁎⁎
C-
te
rm
in
al
fu
si
on
w
ith
G
FP
.
#
an
ti-
M
O
G
an
tib
od
y
is
ot
yp
e
no
ts
pe
ci
ﬁe
d.
+
M
O
G
an
d
ﬂu
or
es
ce
nt
pr
ot
ei
n
no
tf
us
ed
.
$
Co
m
pa
ri
so
n
be
tw
ee
n
sh
or
tl
en
gt
h
an
d
fu
ll
le
ng
th
M
O
G
,D
sR
ed
pI
RE
S2
pl
as
m
id
us
ed
fo
r
ﬂo
w
cy
to
m
et
ry
.
S. Ramanathan et al. / Autoimmunity Reviews 15 (2016) 307–324
317 
of ADEM [71] was thought to be useful for distinguishing a presentation
of pediatric monophasic ADEM from CIS which would later progress to
fulﬁll criteria for MS, thus guiding therapeutic decision-making which
differs between these two entities. Probstel et al. [65] showed that the
highest titers of anti-MOG antibodies were associated with an initial
presentation of ADEM, and that the majority of children with
monophasic ADEM had a rapid decline of anti-MOG antibody titers,
with 63% reducing to undetectable levels within a year, which has
been corroborated in further studies [72]. Pediatric ADEM patients
with high titer anti-MOG antibodies had MRIs characterized by large
hazy bilateral cerebral lesions and/or longitudinally extensive
transverse myelitis (LETM), compared to the seronegative ADEM
children, and were more likely to have complete lesion resolution and
a better outcome [72]. Corpus callosal lesions were more common in
seronegative children with demyelination than seropositive children
[70]. When reviewing pediatric patients with a ﬁrst presentation of
demyelination, MOG antibody-positive patients were less likely to go
on to fulﬁll criteria for clinically deﬁnite MS than the seronegative
patients [73,74]. While some MOG antibody-positive children with
relapsing demyelination do fulﬁll existing pediatric MS criteria, it is
conceivable that they do not have typical MS, with recurrent demyelin-
ation with ON and LETM more suggestive of a neuromyelitis optica
spectrum disorder (NMOSD).
4.4. Anti-aquaporin-4 (AQP4) antibodies in neuromyelitis optica (NMO) as
a precedent for antibody-associated demyelination
NMO, as ﬁrst described by Eugene Devic, is a severe demyelinating
disorder that selectively targets the optic nerves and spinal cord, and
can be associated with a poor prognosis [75,76]. Patients can present
with recurrent or bilateral optic neuritis (ON) as well as transverse
myelitis (TM), which is often longitudinally extensive (LETM) [76].
The early diagnosis of NMO and its distinction from MS is paramount
as immunosuppressive therapy and plasma exchange are associated
with reduced relapse rates and better outcomes in NMO [77–79],
compared to the immunomodulatory agents used inMS. The identiﬁca-
tion of pathogenic IgG antibodies targeting the aquaporin-4 (AQP4)
water channel in many patients with NMO has proven to be an invalu-
able diagnostic biomarker in distinguishing NMO from MS [75,80] and
in reﬁning the revised diagnostic criteria for NMO, as well as more
limited forms of disease referred to as NMOSD [76,81].
The pathogenic potential of anti-AQP4 antibodies has been
demonstrated by passive transfer models whereby mice with EAE
injected with human NMO IgG went on to develop more severe
neurological disability and extensive demyelination in an NMO-like
distribution [82–85] and injection of human sera positive for anti-
AQP4 antibodies has been shown to exacerbate MOG-induced EAE in
mice [86].
AQP4 antibody-associated NMO has thus been an important
precedent in highlighting the role of antibodies in CNS demyelination
[87]. However, anti-AQP4 antibodies are not found in 12–30% of
patients with suspected NMO/NMOSD despite the reﬁnement of
detection assays [88–90]. The role for alternate immune antigen targets
including MOG in this group of patients is compelling, with occasional
reports of antibodies to rarer antigens such as CV2-CRMP5 and the N-
methyl-D-aspartate receptor (NMDAR) [91–93].
4.5. Anti-MOG antibodies in NMO and NMOSD
4.5.1. The clinical phenotype associated with anti-MOG antibodies in
children and adults
Using cell-based assays, anti-MOG antibodieswereﬁrst identiﬁed by
Mader et al. [68] as being present in a subgroup of patients with AQP4
antibody-negative NMO/NMOSD, which has been conﬁrmed by
follow-up studies (Table 1) [94–96]. These patients, both pediatric and
adult, have been identiﬁed most frequently as having a clinical
phenotype of recurrent ON or LETM [57,58,94–96]. In particular, there
is a strong association between anti-MOG antibodies and simultaneous
bilateral ON (BON), a relatively rare clinical presentation in MS [57,58,
97]. Some patients have the presentation of classic simultaneous or
rapidly sequential ON and TM that was ﬁrst described by Devic and in
reality appears to be fairly uncommon in AQP4 antibody-associated dis-
ease [58,94,98]. MOG antibody-positivity is uncommon in Japanese
opticospinal MS, similar to Caucasian MS, despite the predilection for
optic nerve and spinal cord involvement in the former [59].
MOG antibody-positive NMO/NMOSD patients have a younger age
of onset and exhibit less of a female preponderance than AQP4
antibody-positive patients [58,97–100]. They have been shown to
have prominent optic disk swelling visible both on fundoscopy and
radiology, which distinguishes this condition from AQP4 antibody-
positive and MS-associated ON [58,101]. In patients with ﬁrst episode
LETM, those who were MOG antibody-positive were more likely to
have further episodes of ON compared to those who were seronegative
[102]. While MOG antibody-positive NMO/NMOSD has been described
as more frequently being monophasic compared to AQP4 antibody-
positive patients [97,98], our group and others have described that a
number of MOG antibody-positive patients can have a relapsing disease
course [58,99,103].
4.5.2. Laboratory and radiological ﬁndings
MOG antibody-positive patients were shown to be more likely to
have an elevated ESR [57] and an absence of intrathecal IgG oligoclonal
band production [57,58,74,95], which is suggestive of an alternate diag-
nosis toMS.MOG antibody-positive LETMpatientsmore frequently had
CSF pleocytosis compared to seronegative LETMpatients [102]. Cerebral
imaging is abnormal in about a third of MOG antibody-positive patients
[97,101] with a variety of ﬁndings described including large lesions
typical for ADEM as well as widespread cortical lesions, deep gray
matter involvement such as bilateral thalamic and basal ganglia lesions,
and cerebellar and brainstem changes not typical for MS [95,96,98,101,
104]. In some patients, rapid resolution of radiological cerebral changes,
particularly following steroid therapy, has been described [98,101].
Radiological evaluation conﬁrmed bilateral and longitudinally extensive
involvement of the optic nerves, especially of the anterior visual
pathway, with optic nerve head swelling and retrobulbar optic nerve in-
volvement being common inMOG antibody-associated ON [101]. Spinal
imaging shows more involvement of the conus and thoracolumbar
region in MOG antibody-positive patients, compared to cervicothoracic
involvement in AQP4 antibody-positive patients [97,98]. Optical
coherence tomography suggests that MOG antibody-positive patients
have severe optic nerve swelling, but experience less retinal neuronal
loss than AQP4 antibody-positive patients [105].
Given the emerging clinical phenotype and investigation ﬁndings
that may assist in the early distinction of MOG antibody-associated
demyelination from AQP4 antibody-associated disease and MS, we
have proposed a diagnostic algorithm for the evaluation of ON (Fig. 1).
4.5.3. Therapeutic regimes
MOG antibody-positive patients appear to have a rapid response to
steroids and plasma exchange [94], although a tendency to relapse
rapidly on steroid withdrawal or cessation is also present, necessitating
maintenance immunosuppression in some patients [57,58,94,103].
Following treatment and clinical resolution, persistent seropositivity
has been reported in some patients [58,96,99]. However, immunosup-
pressive therapy such asmycophenolate has also been shown to induce
clinical and radiological remission andmaintain a seronegative status in
other patients [57]. With other autoimmune CNS disorders, such as the
autoimmune encephalitides, and indeed, AQP4 antibody-associated
NMO/NMOSD, ﬁrst line therapy is often with intravenous and/or oral
steroids, intravenous immunoglobulin, and/or plasmapheresis, follow-
ed by second-line therapy with steroid sparing immunosuppressants
including mycophenolate or azathioprine, followed in refractory cases
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by rituximab [106]. While some therapeutic agents used for the man-
agement of MS including interferon, natalizumab and ﬁngolimod have
been shown to have a detrimental effect when used in AQP4
antibody-associated disease [107–109], their effect in MOG antibody-
associated demyelination is as yet unknown. In the case of MOG
antibody-associated demyelination, controlled prospective studies
evaluating the optimal therapeutic pathways are not available, and
should be the target of future studies.
4.5.4. Outcomes and prognosis
Visual andmotor outcomes have been reported as beingmore favor-
able in MOG antibody-associated demyelination compared to AQP4
First episode
Optic Neuritis (ON)
Unilateral ON Bilateral ON
Clinical examination
MRI
+/- Lumbar Puncture
Clinical examination
MRI
+/- Lumbar Puncture
If MRI suggestive of MS +/-
intrathecal oligoclonal bands +/-
more focal optic nerve involvement
If MRI atypical for MS +/
no intrathecal oligoclonal bands +/-
longitudinally extensive ON
Consider antibody
associated ON
optic disc swelling +/-
prominent retrobulbar optic
nerve changes +/-
rapid steroid sensitivity
no optic disc swelling +/-
prominent intracranial optic nerve
changes +/-
chiasmal involvement +/-
optic tract involvement
Test for MOG antibodies
(serum +/- CSF)
Test for AQP4 antibodies
(serum +/- CSF)
Positive Negative
Positive Negative
AQP4
antibody-associated
ON
MOG
antibody-associated
ON
Test for AQP4
antibodies
(serum +/- CSF) Test for MOG
antibodies
(serum +/- CSF)
Positive Negative
Positive Negative
MOG
antibody-associated
ON
AQP4
antibody-associated
ON
Consider repeat antibody testing if antibody
associated-ON still considered possible,
consider glycine receptor antibodies +/-
evaluate for atypical causes as detailed above
Without systemic
involvement
Atypical ON +/- with systemic
involvement
Consider:
* Sarcoidosis
* Vasculitis/connective
tissue diseases (lupus,
Sjogrens, polyarteritis
nodosa, Wegener’s
granulamotosis)
* Infectious (Bartonella,
Toxoplasmosis, syphilis, viral
etc)
* Post vaccination
* Genetic (eg Lebers)
* Unclassified
CIS, monitoring and management
as for MS
(possible steroids for acute episode
+/- immunomodulatory MS therapy)
If recurrent ON +/-
progresses atypically
for MS
First line therapy with steroids +/- IVIg +/-
plasmapheresis; consider second-line
therapy with immunosuppression (mycophe-
nolate, azathioprine etc) more proactively
with AQP4 Abs, and in the presence of
relapses or delayed recovery with MOG Abs;
consider third-line therapy with rituximab if
refractory
Fig. 1. A proposed algorithm for investigating the etiology of ﬁrst episode ON based on clinical, radiological, and laboratory features. While this provides a stratiﬁed approach to antibody
testing, many clinicians are testing for both AQP4 and MOG antibodies simultaneously if they suspect an “antibody-associated ON.” Atypical ON refers to ON with associated systemic
features, and/or radiological involvement of other orbital structures in addition to the optic nerve. Abs antibodies; AQP4 aquaporin 4; CIS clinically isolated syndrome; CSF
cerebrospinal ﬂuid; IVIg intravenous immunoglobulin; MOGmyelin oligodendrocyte glycoprotein; MRI magnetic resonance imaging; MS multiple sclerosis; ON optic neuritis.
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antibody-positive NMO/NMOSD [94,96–99,101,102], but the failure to
recognize and appropriately treat the former can still be associated
with severe and sustained visual loss and retinal nerve ﬁber layer
atrophy, or poor mobility [58,70]. MOG antibody-positive patients
with LETM had a better follow-up expanded disability status scale
(EDSS) than seronegative patients, despite a similar frequency of
episode severity at onset andmore relapses [102]. It is possible that out-
comemeasures that are frequently used in patientswith demyelination,
such as EDSS, have a bias towards locomotor function, and as a conse-
quence, visual loss alone which may be the case for many MOG
antibody-positive patients who only present with ON, may not score
very highly using the EDSS despite signiﬁcant disability to patients.
Thus far, there is no deﬁnitive evidence between MOG antibody
positivity and disease progression or severity, and long-term follow up
of visual and global outcomes should be undertaken.
4.5.5. Animal studies: anti-MOG antibodies consistent with an NMO/
NMOSD phenotype
Keeping theMOGantibody-associated clinical phenotype in patients
inmind, one can look back at previous animal studies that yield interest-
ing supporting evidence. Immunopathological analyses of LEW.1AV1
rats who developed EAE following immunization with recombinant
rat MOG showed that 60% of the rats had optic nerve involvement,
and all had spinal cord involvement, with relative sparing of the cere-
brum [110], raising the interesting possibility that this EAE model is
more reminiscent of NMO/NMOSD rather than MS. In another study,
more than 30% of MOG-speciﬁc T cell receptor (TCR) transgenic mice
spontaneously develop isolated ON in the absence of EAE either clinical-
ly or histologically [111]. MOGwas found to have a higher expression in
the optic nerve than the spinal cord of these transgenicmice, suggesting
increased autoantigen expression in the optic nerves as a reason for
their predilection to spontaneous ON histologically [111]. Prevalent
ON in mice immunized with MOG peptides has also been shown
[112]. Both active and adoptive transfer of disease by immunization
with encephalitogenic MOG peptides or transfer of MOG-speciﬁc T
cells into naïve B6mice respectively, resulted in ON bothwith andwith-
out concurrent EAE inmousemodels,with ON frequently being bilateral
in the latter group [113]. Histopathological examination revealed initial
inﬂammation withminimal demyelination in the early stages, followed
by predominant demyelination in the latter stages with minimal T cell
lymphocytic inﬁltration, and the presence of foamy macrophages, in
keeping with a proposed role for humoral immunity [110].
In two in vivo studies, double transgenic mouse models expressing
MOG-speciﬁc T and B cell receptors demonstrated spontaneous demye-
lination in half the mice, speciﬁcally targeting the spinal cord and optic
nerves and sparing the brain and cerebellum, closely replicating NMO/
NMOSD [114,115]. Thesemicewere found to harbor high seropositivity
for anti-MOG IgG1 antibodies. These ﬁndings in animal models are
therefore supportive of the ﬁndings of anti-MOG antibodies in humans
with NMO/NMOSD.
4.6. Double seropositivity
Cases of patients being seropositive for both AQP4 and MOG
antibodies were reported when anti-MOG antibodies were detected
by ELISA [116] but are uncommon when using cell-based assays, with
the few patients described having severe visual loss from recurrent
ON or a picture of simultaneous bilateral ON and LETM [68,97–99,
117–119]. Glycine receptor α1 subunit antibodies have been recently
described in patients with ON, although some of these patients have
concurrent antibodies to MOG or AQP4 [118]. Additionally, glycine
receptor antibodies are present in a minority of MS controls (5/64,
8%), and hence their signiﬁcance is as yet unclear.
Interestingly, there have been recent reports of anti-MOG antibodies
being associated with other immune mediated CNS presentations. For
example, demyelination preceding, concurrent with, or following
autoimmune encephalitis has been described, in patients with anti-
NMDAR antibody-associated encephalitis who also have anti-AQP4 or
MOG antibodies [120,121].
5. TheMOGantibodybinding epitope in humandemyelinationusing
conformational MOG
Based on the evidence gathered to highlight the importance of utiliz-
ing nativeMOG in its conformational state, the epitope determination of
native human MOG is likely to provide more insights than using linear
MOG peptides. Importantly, the epitope binding site in rodents and
humans may be different. Mayer et al. [122] identiﬁed that the amino
acids (H103;S104) bound by the 8-18C5 mAb were in fact not the
most frequently recognized residues in humans. However, this study
also showed that the 8-18C5 mAb did compete with patient autoanti-
bodies, which is difﬁcult to explain in light of the previous ﬁndings. In
more detail, Mayer et al. [122] used various human MOG mutants to
evaluate the epitope speciﬁcity of 111 primarily pediatric patients
with demyelinating syndromes including ADEM, MS, CIS, and NMOSD
who were conﬁrmed to be positive for anti-MOG antibodies on cell-
based assays. The most frequently recognized single epitope by patient
anti-MOG antibodies was identiﬁed as P42 on the membrane proximal
CC′-loop, a site that is not present in murine MOG. Eighty percent of
patients show little or no binding to a mutation of this site. This is in
contrast to the main target of conformation-dependent anti-MOG anti-
bodies inmice, such as the 8-18C5mAb,which is located at the tip of the
FG loop. In humans, this region was the second most frequently bound
single epitope (H103;S104), recognized by 20% of patients. The absence
of the single glycosylation site at N31 did not signiﬁcantly reduce bind-
ing, which corroborates previous ﬁndings [60]. Approximately half the
patients had an antibody response targeting a single epitope, with no
association between epitope speciﬁcity and disease presentation.
Follow up of a small number of patients with persistent seropositivity
did not reveal intramolecular epitope spreading or epitope loss over
time, at leastwithin the 36months of follow-up of the study. Important-
ly, most patient anti-MOG antibodies did not recognize murine MOG,
which has major repercussions on the translation of animal models of
demyelination to humans.
6. Insights into possible pathogenic mechanisms of anti-MOG
antibodies
It is yet to be establishedwhether anti-MOG antibodies have a path-
ogenic role in demyelinating disease, or whether their presence is an
epiphenomenon secondary to myelin destruction. The difference be-
tween epitopes in humans and rodents raises the question of whether
human anti-MOG antibodies are indeed pathogenic as much of the evi-
dence in animal studies supportive of pathogenicity has been obtained
using the 8-18C5 mAb, which binds to an epitope that most human
anti-MOG antibodies do not appear to recognize.
6.1. Histopathological evidence
There is very little literature on the histopathology of human MOG
antibody-associated demyelination. A brain biopsy on a patient with
MOG antibody-associated demyelination characterized by recurrent
episodes of TM followed by extensive white matter involvement
showed inﬂammatory demyelination consistent with a type II MS pat-
tern, with partial axonal preservation and reactive astrocyte scarring,
an inﬂammatory inﬁltrate of T lymphocytes, activated macrophages or
microglia, and complement deposition in areas of demyelination
[123]. As yet, there is no adequate data to identify a suggestive pattern
of histopathology in human MOG antibody-associated disease.
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6.2. Possible mechanisms of pathogenicity
While there is good evidence to suggest a pathogenic role for anti-
AQP4 antibodies in NMO/NMOSD, the literature is largely lacking in
the area of anti-MOG antibodies. A few studies have started to explore
the effector mechanisms of anti-MOG antibodies.
IgG from MOG antibody-positive pediatric patients has also been
shown to induce natural killer (NK) mediated killing of surface MOG
expressing cells suggesting a cytotoxic effect, as well showing a cor-
relation between the antibody titer and extent of antibody-
dependent cell-mediated cytotoxicity (ADCC) [62]. The presence of
complement in mediating demyelination due to anti-MOG antibod-
ies has been suggested in both in vitro and in vivo animal studies
[124,125]. The majority of anti-MOG antibodies identiﬁed have
been the IgG1 isotype, which is able to ﬁx complement and bind to
Fc receptors [61]. Mader et al. [68] identiﬁed that high titer anti-
MOG antibodies from seropositive patients were able to activate
the complement cascade in vitro with complement-mediated lysis
of MOG transfected cells, while low titer anti-MOG antibodies and
MOG antibody-negative samples could not, further suggesting a
role for complement mediated cytotoxicity. Additionally, puriﬁed
anti-MOG IgG from seropositive patients has been shown to result
in a loss of organization of the thin ﬁlaments and the architecture
of the microtubule cytoskeleton of oligodendroctyes but not in-
creased cell death [57].
Injection of patient anti-MOG antibodies into mouse brains resulted
in myelin changes and altered expression of axonal proteins that were
reversible, but not the complement-mediated myelin loss and death of
neurons and astrocytes with limited recovery seen with the injection
of AQP4-IgG [126], suggesting differing pathogenic mechanisms. Zhou
et al. [67] found that anti-MOG antibodies induced the death of MOG
expressing target cells in vitro. The same group found that sera with
high anti-MOG antibody titers enhanced demyelination when
transferred to rats with EAE. Given that anti-MOG antibodies in humans
have been largely shown to not bind tomurineMOG [122], these results
are difﬁcult to explain.
While there may be early evidence for pathogenicity in MOG
antibody-associated demyelination, this is a long way from being
established in the literature and further work needs to be done to
address this deﬁciency. Importantly, passive transfer models may be
difﬁcult to interpret given the differences in binding epitopes for
conformational anti-MOG antibodies to the murine versus human MOG
antigen.
7. HowMOG speciﬁc autoimmunity can be triggered
7.1. Detection of anti-MOG antibodies in CSF versus serum
MOG antibody detection has been found to be more sensitive in
serum when compared to CSF. One study found that, in anti-MOG
IgG seronegative patients, the corresponding CSF samples were
negative; in the low titer range anti-MOG antibodies were only
present in the serum but not in the CSF; but in patients with serum
titer values greater than or equal to 1:640, there was detectable
reactivity to MOG in the CSF, suggesting a peripheral production of
MOG speciﬁc autoantibodies [64]. Similarly in other studies, patients
positive for serum anti-MOG antibodies were shown to be negative
for CSF anti-MOG antibodies, which could either represent a lack of
sensitivity of the assay or a lack of intrathecal immunoglobulin
production [57,99]. Anti-MOG antibodies are less likely to be
associated with intrathecal oligoclonal bands [57,58,64], once again
supporting the notion of peripheral rather than intrathecal
production. This is similar to the ﬁnding that NMO IgG autoanti-
bodies often have a much higher serum than CSF concentration, con-
sistent with peripheral production of antibodies [127]. However,
while AQP4 as a target antigen is present both in the CNS as well as
other organ systems peripherally [128], MOG is exclusively conﬁned
to the CNS [129]. This raises questions regarding what may consti-
tute a peripheral trigger of autoimmunity in MOG antibody-
associated demyelination given the MOG antigen is exclusively
centrally expressed, and how the effector immune cells migrate
between the periphery and the CNS. Interestingly, the EAE animal
model of demyelination is similarly peripherally stimulated, with
peripheral injection and immunization with myelin peptides and
Freund's complete adjuvant resulting in an encephalitogenic trigger,
which in the context of a breached BBB, results in encephalomyelitis
[13].
7.2. The peripheral versus central trigger in CNS autoimmunity
For an antibody to be pathogenic in human CNS demyelination, it
either needs to be produced within the CNS, or to be permitted passage
through the BBB from the periphery, into the CNS [55]. It is possible that
a direct CNS infection could be associated with an inﬂammatory
response, a breakdown of the BBB, and a subsequent leakage of CNS
antigens into the peripheral circulation, where a peripheral immune
response could be mounted against now accessible central antigens
such as MOG [129].
Alternatively, a peripheral initiator such as an infection could
stimulate adaptive immune responses with activation of B and T
cells, with the resultant inﬂammation disrupting the BBB and
allowing passage of circulating lymphocytes to the CNS with
restimulation upon contact with the antigen MOG, and subsequent
clonal expansion within the CNS [106,129]. There is the suggestion
of an increased incidence of an infectious prodrome in patients
with MOG antibody-associated demyelination [58]. The association
of a prodrome in many children with ADEM also leads one to consid-
er the role of infection triggering immunity in MOG antibody-
positive disease. While previous studies [51] suggested possible
cross-reactivity between MOG antibody seropositivity and Epstein
Barr virus (EBV) nuclear antigen, implying molecular mimicry to
EBV might be a trigger for demyelination, this has not been
reproduced [63,130].
It is now becoming apparent that under resting healthy
conditions, the brain is not “immune privileged” and devoid of
immune and inﬂammatory cells as previously thought, but rather a
site where there is continuous slow trafﬁcking of immune cells, in-
cluding memory T cells, resulting in an environment of “immune
surveillance” [131,132]. Leucocyte transendothelial migration, or
diapedesis, occurs largely paracellularly at the endothelial cell
borders, although some evidence points to transcellular migration
as well through the endothelial cell body [133]. The long-standing
view has been that the brain lacks a classic lymphatic system. CNS
interstitial ﬂuid drains via perivascular spaces into the CSF, as well
as soluble CNS antigens accessing afferent lymphatics in the deep
cervical lymph nodes, thus permitting antigen presenting cells in
the subarachnoid, meningeal, and lymphatic spaces access to CNS
antigens [131]. Classic neuroimmunological concepts have been
recently challenged by emerging research. Firstly, the identiﬁcation
of functional meningeal lymphatic vessels lining the dural sinuses
of the brain suggests that there may be more accessibility of CNS
antigens to the peripheral immune milieu than previously thought
[132]. Secondly, novel pathways for migration of dendritic cells
from the CNS to the cervical lymph nodes to present antigens to T
cells have also been described [134]. Lastly, B cells from MS patients
were shown to be able to trafﬁc to and from the CNS and mature
outside the CNS within the draining cervical lymph nodes [135]. It
is as yet unclear how the process of CNS inﬂammation is initiated
and propagated in the case of MOG antibody-associated
demyelination, and further work is required to explore this impor-
tant question.
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8. Conclusions
8.1. The nomenclature of MOG and AQP4 antibody-associated demyelination
The recent ﬁnding of MOG antibodies in patients with the clinical
syndromeofNMO/NMOSDhas led to some controversy regarding the no-
menclature and classiﬁcations of these patients. Using the revised
diagnostic criteria for NMO [81], it is possible for a patient to be diagnosed
with “deﬁnite NMO” without being AQP4 antibody-positive. As a conse-
quence, both MOG and AQP4 antibody-positive patients, who frequently
present with prominent ON and/or TM, are intuitively distinguished from
MS and classiﬁed under the umbrella terminology of “NMO/NMOSD” as a
syndrome. However, AQP4 antibody-associated disease is an astro-
cytopathy with a distinct histological and immunopathological proﬁle,
while MOG antibody-associated disease targets oligodendrocytes [119,
136]. Increasingly, there is an awareness of differences in epidemiology,
clinical associations, radiological characterization, therapeutic responses,
and prognoses of these two antibody-associated disorders,which indicate
that the underlying disease pathophysiology is likely to be divergent, and
they are separate biological entities. This has led to the notion that it is
more appropriate, particularly given the extensive clinical spectrum of
MOG antibody-positive patients to include non-NMO/NMOSD presenta-
tions including pediatric ADEM, to classify these patients as “MOG
antibody-associated demyelination” instead.
8.2. The value of anti-MOG antibodies as a biomarker in human
demyelination
For more than three decades, MOG has been identiﬁed as being a
potentially important antigen in demyelination. Optimization of the
methodology of antigen preparation and antibody detection has
enabled the identiﬁcation of MOG antibodies as being reliably
associated with a spectrum of demyelinating disorders including
relapsing pediatric demyelination, ADEM, and bilateral and recurrent
ON as well as LETM in both children and adults. Standardization of the
methodology of MOG antibody detection across centers is crucial to
ensure that seropositivity is of clinical and biological relevance. Early
distinction of MOG antibody-associated demyelination from both MS
and AQP4 antibody-positive demyelination is paramount as therapeutic
pathways can differ in both the acute and chronic setting, with
signiﬁcant prognostic implications. An association of MOG antibodies
and certain clinical phenotypes is now emerging, highlighting its role
as a valuable serum biomarker, but further work is required to build
on existing literature and deﬁne its “predictive” and “prognostic”
value [137]. While there is early evidence regarding the effect of MOG
antibodies on effector cells, major criteria to establish pathogenicity
including antibody transfer of disease in humans and transfer of disease
to animal models using human autoantibodies are lacking [138]. Future
studies could expand on this and shed light on how MOG antibody-
associated immunity is initiated, the migration of immune cells
between the CNS and the periphery in triggering demyelination, the
epitope binding speciﬁcity of MOG antibodies, and pathogenic mecha-
nisms of action. Further work is also required to identify optimal thera-
peutic strategies in these patients to maximize their visual and global
outcomes.
Take-home messages
• Animal models of experimental autoimmune encephalomyelitis have
been crucial in establishing the importance of MOG as an autoantigen
in demyelination. However, due to differences in epitope binding be-
tween species, the pathogenicity of these autoantibodies in humans
requires further exploration.
• Live cell-based assays using full length human MOG as the antigen
have been shown to be the gold standard for the detection of biolog-
ically relevant MOG antibodies in human demyelination.
• In adults, anti-MOG antibodies have not been found to be associated
with multiple sclerosis. The clinical association now includes acute
disseminated encephalomyelitis, recurrent and bilateral optic
neuritis, and transverse myelitis in both children and adults.
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Antibodies to myelin oligodendrocyte
glycoprotein in bilateral and recurrent
optic neuritis
ABSTRACT
Objective: We examined a cohort of adults with aquaporin-4 (AQP4) antibody–negative neuromy-
elitis optica/neuromyelitis optica spectrum disorder (NMO/NMOSD) for antibodies to myelin
oligodendrocyte glycoprotein (MOG).
Methods:We performed a flow cytometry cell-based assay using live human lentivirus–transduced
cells expressing full-length surface MOG. Serum was tested in 23 AQP4 antibody–negative
NMO/NMOSD patients with bilateral and/or recurrent optic neuritis (BON, n 5 11),
longitudinally extensive transverse myelitis (LETM, n 5 10), and sequential BON and LETM
(n 5 2), as well as in patients with multiple sclerosis (MS, n 5 76) and controls (n 5 52).
Results: MOG antibodies were detected in 9/23 AQP4 antibody–negative patients with NMO/
NMOSD, compared to 1/76 patients with MS and 0/52 controls (p , 0.001). MOG antibodies
were detected in 8/11 patients with BON, 0/10 patients with LETM, and 1/2 patients with
sequential BON and LETM. Six of 9 MOG antibody–positive patients had a relapsing course.
MOG antibody–positive patients had prominent optic disc swelling and were more likely
to have a rapid response to steroid therapy and relapse on steroid cessation than MOG
antibody–negative patients (p 5 0.034 and p 5 0.029, respectively). While 8/9 MOG
antibody–positive patients had good follow-up visual acuity, one experienced sustained
visual impairment, 3 had retinal nerve fiber layer thinning, and one had residual spinal
disability.
Conclusions: MOG antibodies have a strong association with BON and may be a useful clinical
biomarker. MOG antibody–associated BON is a relapsing disorder that is frequently steroid
responsive and often steroid dependent. Failure to recognize the disorder early and institute
immunotherapy promptly may be associated with sustained impairment.
Classification of evidence: This study provides Class II evidence that MOG antibodies are
associated with AQP4 antibody–negative BON (sensitivity 69%, 95% confidence interval [CI]
42%–87%; specificity 99%, 95% CI 93.7%–99.8%). Neurol Neuroimmunol Neuroinflamm
2014;1:e40; doi: 10.1212/NXI.0000000000000040
GLOSSARY
ADEM 5 acute disseminated encephalomyelitis; AQP4 5 aquaporin-4; BON 5 bilateral and/or recurrent optic neuritis; CI 5
confidence interval; CRION 5 chronic relapsing inflammatory optic neuropathy; EDSS 5 Expanded Disability Status Scale;
FACS 5 fluorescence-activated cell sorting; HEK293 5 human embryonic kidney 293; Ig 5 immunoglobulin; LETM 5 lon-
gitudinally extensive transverse myelitis; MD 5 mean deviation; MFI 5 mean fluorescence intensity; MOG 5 myelin oligo-
dendrocyte glycoprotein; mRS 5 modified Rankin Scale; MS 5 multiple sclerosis; NMO 5 neuromyelitis optica; NMOSD 5
neuromyelitis optica spectrum disorder; OCT 5 optical coherence tomography; ON 5 optic neuritis; RNFL 5 retinal nerve
fiber layer; VFSS 5 visual functional system score.
Neuromyelitis optica (NMO) is a demyelinating disorder that preferentially affects the optic
nerves and spinal cord and results in severe disability.1 The identification of immunoglobulin
(Ig) G antibodies targeting aquaporin-4 (AQP4) in patients with NMO has distinguished this con-
dition from multiple sclerosis (MS).1–3 The term NMO spectrum disorder (NMOSD) encompasses
patients with more limited forms of NMO.4,5 Despite the refinement of detection methods,
Authors’ affiliations are listed at the end of the article.
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12%–30% of patients with NMO/NMOSD
remain AQP4 antibody–negative.6–8 Investigat-
ing this cohort has important diagnostic and ther-
apeutic implications.
Myelin oligodendrocyte glycoprotein (MOG)
is a component of myelin and an antigen target
in CNS demyelination. Immunization with
MOG induces experimental autoimmune
encephalitis, and MOG antibodies contribute
to CNS demyelination in animal models.9–13
MOG is expressed by oligodendrocytes on the
external surface of myelin, providing an accessible
antigenic target for circulating autoantibodies.
Using cell-based assays, antibodies against
native MOG have been identified in 20%–
40% of pediatric patients with acute dissemi-
nated encephalomyelitis (ADEM), optic neuritis
(ON), and relapsing demyelination disorders,
including NMO/NMOSD.14–18 In contrast, the
clinical relevance of MOG antibodies in adults is
unclear, as only a minority of patients with MS
and NMO/NMOSD are seropositive.16,18–24
Herein, we provide evidence that MOG anti-
bodies are a clinical biomarker of bilateral and/
or recurrent optic neuritis (BON) in adults
and describe the characteristic clinical course,
response to therapy, and visual outcomes of this
condition.
METHODS Patients and controls. Patients. We retrospec-
tively investigated 23 patients who presented to neuroimmunol-
ogy and neuro-ophthalmology clinics at 4 tertiary referral centers
in Sydney, Australia (2004–2014) with AQP4 antibody–negative
NMO/NMOSD (12 female; median age 38 years, range 17–59).
These patients did not satisfy the 2010 McDonald diagnostic
criteria for MS.25 They presented with BON (n 5 11), longi-
tudinally extensive transverse myelitis (LETM, n 5 10),
or sequential BON and LETM (n5 2). All patients with LETM
had longitudinally extensive disease, with spinal cord involvement
greater than 3 vertebral segments in length on MRI. The 2 patients
with sequential BON and LETM satisfied the revised diagnostic
criteria for NMO4 but were AQP4 antibody–negative. Nine of
11 patients with BON had simultaneous BON at least once,1/2
additional episodes of unilateral ON, while 2/11 had recurrent
episodes of unilateral ON sequentially involving both eyes. In total,
among the 11 patients with BON, there were 30 ON episodes
(18 unilateral and 12 simultaneous and bilateral). All 23 patients
were negative for NMO-IgG antibodies tested by indirect immu-
nofluorescence on monkey cerebrum, cerebellum, and stomach,
and rat kidney,1,2 as well as for AQP4 antibodies by cell-based assay
using the M23 isoform (Euroimmun, Lübeck, Germany).
Twelve of 23 AQP4 antibody–negative patients with NMO/
NMOSD had a relapsing presentation (6/11 BON, 4/10 LETM, 2/2
sequential BON and LETM). The relapses in the 6 patients with
BON were either recurrent unilateral ON or BON, while
the 4 patients with LETM had only spinal relapses. The 2 patients
with sequential BON and LETM had relapses involving both the
optic nerves and spinal cord. The breakdown of diagnoses in
all patients with BON and/or LETM who presented to the collabo-
rating centers is presented in appendix e-1 at Neurology.org/nn.
Stored acute serum (280°C) taken during the first presenta-
tion (n 5 13), within 1 month of a relapse (n 5 5), or during
remission (n 5 5) was tested. The serum of 16/23 patients was
collected on no treatment. Of these, 9/16 patients had samples
obtained at initial presentation, 3 within a month of an acute
relapse, and 4 while in remission.
At sample collection, 4 patients had completed a course
of pulsed steroids within the preceding 3 months, and 3 were expe-
riencing relapses on long-term steroids and mycophenolate mofetil.
The AQP4 antibody–negative NMO/NMOSD cohort was
investigated for infectious, inflammatory, and autoimmune
differential diagnoses (tables e-1 and e-2). 3T MRI brain (n 5 21)
and whole spine (n5 17) scans were reviewed by neuroradiologists.
Steroid responsiveness was defined as a greater than 50% improve-
ment in visual acuity or Expanded Disability Status Scale (EDSS)
score within 24 hours of commencing IV (intravenous) steroids, and
a relapse on steroid cessation was defined as acute worsening within
48 hours of cessation of IV steroids.
The sera of 76 patients with clinically definite MS as defined by
the revisedMcDonald criteria25 were also tested (59 female; median
age 43 years, range 22–71). These patients were classified as having
relapsing-remitting (n 5 68), secondary progressive (n 5 6), or
primary progressive (n5 2) MS. Serum was collected pretreatment
(n5 23) or while on therapy including interferon b-1a (n5 12),
interferon b-1b (n 5 9), glatiramer acetate (n 5 5), natalizumab
(n 5 15), fingolimod (n 5 11), or alemtuzumab (n 5 1).
Controls. Fifty-two adult control patients (35 female; median
age 55 years, range 24–79) were tested, including patients with
other neurologic diseases (epilepsy, Parkinson disease, and periph-
eral neuropathy; n 5 20) as well as healthy controls (n 5 32).
Visual outcomes. All patients received a visual functional
system score (VFSS) based on their visual acuity (rated from
0 to 6) during their acute presentation and at latest follow-up
(median follow-up 24 months, mean 20 months, range 2–48
months). This score was based on the VFSS from the EDSS26
(table e-3).
Visual field sensitivity was assessed using the central 30-2
program on a Humphrey Visual Field Analyzer (Carl Zeiss
Meditec, Dublin, California) at acute presentation and at latest
follow-up. The mean deviation (MD) was obtained as a measure
of overall visual field sensitivity. A negative MD corresponds to a
loss in sensitivity, with normal values ranging from 0 to23 dB.27
As the visual field deficit increases, the MD value becomes pro-
gressively negative. We graded the sensitivity loss in each eye as
mild (MD greater than 23.0 dB but less than 26.0 dB), mod-
erate (MD greater than 26.0 dB but less than 220.0 dB), or
severe (MD greater than 220.0 dB), as described in the Optic
Neuritis Treatment Trial.27 We assigned scores of 0 (normal),
1 (mild), 2 (moderate), and 3 (severe) to sensitivity loss as deter-
mined by MD grades at acute presentation and follow-up
(median follow-up 4 months, mean 5.4 months, range 1–13
months).
Optical coherence tomography (OCT) images of the peripap-
illary retinal nerve fiber layer (RNFL) were acquired using a Stratus
OCT (Carl Zeiss Meditec, software version 6.00.599) using the
Optic Disc Cube protocol. OCT performed at acute presentation
and at latest follow-up (median follow-up 4 months, mean 4.2
months, range 1.5–7 months) was evaluated for the average RNFL
thickness for each eye and was compared to age-appropriate nor-
mative data provided by the manufacturer. Values above this range
reflect swelling, while values below this range reflect thinning of the
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RNFL.28 OCT images were rejected if an individual eye had a
signal strength less than 8 or if there was a difference of greater
than 2 between the 2 eyes. All patients were imaged adequately
using fixation with the fellow eye if needed. The fundus was well-
imaged from edge to edge within the imaging field. All OCT stud-
ies available adhered to these parameters.
Standard protocol approval, registrations, and patient
consents. Ethics approval for this study was granted by the
Sydney Children’s Hospitals Network Human Ethics Committee
(12/SCHN/395, SSA/13/WMEAD/53, SSA/13/CRGH/257,
SSA/13/RPAH/599), and informed consent was obtained from
all patients.
Cloning and expression of human MOG. Full-length
human MOG cDNA was cloned from a human fetal brain
RNA library (gift from Dr. Monkol Lek). Sequence-verified
MOG cDNA was subcloned into pIRES2-ZsGreen1 lentivirus
vector, enabling both MOG and ZsGreen to be co-expressed
in cells (gift of Dr. Stuart Turville). We used published
protocols to transduce and obtain MOG-expressing human
embryonic kidney 293 cells (HEK293MOG1).29 Control cells
(HEK293CTL) were obtained by transduction of particles with
empty pIRES2-ZSGreen vectors.
Cell-based assay for the detection of serum antibodies to
cell surface MOG. We used fluorescence-activated cell sorting
(FACS) analysis to detect antibody binding of patient serum IgG
to surface MOG transduced in HEK293 cells as we have
previously described (methodology presented in appendix
e-2).30,31 Samples were considered positive if they were above
threshold on at least 2 of 3 repeated experiments, and the intra-
assay variation is summarized in appendix e-2.
Statistical analysis. The x2 test with Yates correction was used
to compare MOG antibody positivity between patient and
control groups, as well as binary clinical features between
MOG antibody–positive and –negative groups. No adjustment
for multiple testing was performed. The Mann-Whitney test was
used to compare continuous variables. Statistics and figures were
generated using Prism software version 6.0 (GraphPad Software,
La Jolla, CA).
Classification of evidence. This study provides Class II
evidence that MOG antibodies are associated with AQP4-
antibody–negative BON (sensitivity 69%, 95% confidence inter-
val [CI] 42%–87%; specificity 99%, 95% CI 93.7%–99.8%).
The study is Class II because of the case-control design.
Sensitivity was calculated from the proportion of patients with
BON positive for MOG antibody (9/13). Specificity was
calculated from the proportion of non-BON autoimmune
patients (MS and isolated LETM patients) without MOG
antibodies (85/86).
RESULTS MOG antibodies and BON in adults. We
used FACS to detect antibody binding of patient IgG
to surfaceMOG transduced inHEK293 cells. Themean
fluorescence intensity (MFI) was associated with anti-
body concentration (figure 1A). Using the mean 1
3 3 SDs of our control population to establish the
threshold for positivity, MOG antibodies were detected
in 9/23 AQP4 antibody–negative patients with NMO/
NMOSD, compared to 1/76 patients withMS and 0/52
controls (figure 1, B–D; p , 0.0001). None of the
MOG antibody–positive patients demonstrated IgM
reactivity (figure e-1, appendix e-3). Eight of 11 patients
with BON were MOG antibody–positive, compared to
0/10 patients with LETM and 1/2 patients with sequen-
tial BON and LETM (figure 1E, table 1). None of the
MOG antibody–positive patients had a previous episode
of ADEM.
Clinical phenotyping of MOG antibody–positive
patients. MOG antibody–positive patients were more
often female and younger, often had a preceding
infectious prodrome, and were more likely to relapse
than MOG antibody–negative patients (table 1,
not significant).
The AQP4 antibody–negative NMO/NMOSD
cohort as a whole frequently had elevated markers of
inflammation or autoimmunity (table e-1), but there
were no significant differences between the MOG
antibody–positive and –negative patients. The presence
of oligoclonal bands in the CSF was uncommon, and
patients did not fulfill the revised McDonald criteria25
for MS in either group. All MOG antibody–positive
patients had brain MRIs that did not fulfill the revised
McDonald criteria. Of these, 7 had MRIs performed
during acute presentation with optic nerve gadolinium
enhancement. One MOG antibody–positive patient
had large enhancing cerebral lesions that resolved rapidly
with steroids. This patient’s imaging did not fulfill the
revised McDonald criteria for MS.
Eight of 9 MOG antibody–positive patients had
BON (table 2), with the ninth patient demonstrating
sequential BON and LETM (figure 1E). Six of 9 had a
relapsing course (median episodes 2, range 1–5),
although this was not a statistically significant differ-
ence compared to the seronegative group. All 9 MOG
antibody–positive patients had prominent optic disc
swelling, defined as papillitis or optic nerve head swell-
ing visible on fundoscopy at acute presentation. In 6/9
this disc swelling rapidly resolved with steroid therapy.
MOG antibody–positive patients were more likely to
be rapidly steroid responsive and to relapse on steroid
cessation, compared to MOG antibody–negative pa-
tients (table 1, p5 0.034 and p5 0.029, respectively).
The treatment of all MOG antibody–positive patients
is outlined in table 2. The median follow-up was 28
months (range 6–120).
One of 76 patients with MS was MOG antibody–
positive. This patient was a 55-year-old Caucasian
woman with clinical and radiologic findings consis-
tent with relapsing-remitting MS and no previous
ADEM or ON episodes. Notably, she had a strongly
positive antinuclear antibody titer of 1:2,560.
Persisting MOG antibody seropositivity and relapsing
BON. We determined the maximum serum dilution
required for a sample to still have a DMFI above the
threshold. Seven MOG antibody–positive patients
3
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were tested at serum dilutions ranging from 1:50 to
1:2,000. Six of 7 remained positive at 1:100, 5/7 at
1:200, and 4/7 at 1:400. Only one patient remained
positive at dilutions of 1:1,000 and 1:2,000. MOG
antibody–positive patients can have variably high titers
(figure 2A).
We obtained serial samples in 4 MOG antibody–
positive patients with a relapsing course (median time
between samples 22.5 months, range 4–72 months)
(figure 2, B–E). Three of them had at least one epi-
sode of simultaneous BON, with one having addi-
tional unilateral ON (figure 2, B, C, and E). One
patient (figure 2D) had recurrent episodes of unilat-
eral ON affecting both eyes. DMFI values showed an
overall decline in all patients but remained positive in
3 patients despite treatment and clinical remission.
Patient 4 (figure 2E) had an initial presentation with
BON followed within a fortnight by LETM. While his
visual recovery was satisfactory, his spinal disease was
extensive and debilitating, with a modified Rankin Scale
(mRS) score of 5. With aggressive immunosuppression
and intensive rehabilitation he made a slow recovery but
remained MOG antibody–positive at 8-month follow-
up. He is currently independently mobile with residual
sphincter dysfunction and a spastic gait (mRS 2).
MOG antibody–associated BON and visual outcomes.
Most MOG antibody–positive patients had significant
visual impairment during the acute episode, with 6/9
(67%) having a VFSS of 5 or 6 (figure 3A). While 8/9
patients had good visual acuity at follow-up with a VFSS
of 0–2, one patient (patient 7, table 2) had a significant
Figure 1 MOG antibodies are associated with BON in adults
(A) Antibody (Ab) reactivity to myelin oligodendrocyte glycoprotein (MOG) was determined by a flow cytometry live cell-based assay and demonstrated
increased immunoglobulin (Ig) G binding to MOG with an increasing MOG antibody concentration. (B, C) Representative examples of flow cytometry histo-
grams for oneMOG antibody–positive patient with an intermediate DMFI (B) and onewith a very high DMFI (C). DMFI values are noted in the legend. (D) Human
surface MOG IgG Abs were detected in 9/23 AQP4 antibody–negative patients with NMO/NMOSD, compared to 1/76 patients with multiple sclerosis (MS)
and 0/52 controls. The red line on the graph represents the threshold of positivity. MOG antibody positivity is shown between brackets. A representative
experiment out of 3 is shown. (E) DMFI values for all subgroups of AQP4 antibody–negative patients with NMO/NMOSD. AQP4 5 aquaporin-4; BON 5
bilateral and/or recurrent optic neuritis; HEK293 5 human embryonic kidney 293 cells; HEK293CTL 5 control HEK293 cells; HEK293MOG1 5 HEK293 cells
expressing MOG; LETM 5 longitudinally extensive transverse myelitis; MFI 5 mean fluorescence intensity; NMO/NMOSD 5 neuromyelitis optica /neuro-
myelitis optica spectrum disorder.
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residual deficit with a VFSS of 5 (figure 3A) (median
follow-up interval 24 months, mean 20 months, range
2–48 months).
Visual fields were assessed in 5 MOG antibody–
positive patients (10 eyes) at acute presentation and
follow-up (median follow-up 4 months, range 1–13
months) (figure 3, B and C). Seven of 10 eyes had
a moderate or severe visual field deficit at acute
presentation. Follow-up demonstrated an improve-
ment in all eyes, with the MD approaching the nor-
mal range (figure 3B) and visual field deficits scoring
as normal or mildly affected in 8/10 eyes (figure 3C).
We reviewed RNFL thickness as measured by OCT
during an acute episode of ON and at follow-up. While
acute ON can result in increased peripapillary RNFL
thickness (figure 3, D–F), RNFL thickness returns
toward the normal range with clinical resolution (figure
3D). Three patients demonstrated evidence of RNFL
thinning (figure 3, E and G), suggesting axonal loss and
irreversible damage. Patient 7 (table 2, appendix e-4)
experienced 5 relapses in a 4-year period. Delayed diag-
nosis and initiation of immunotherapy were possible
contributors to a poor follow-up VFSS and significant
RNFL thinning in this patient.
Visual outcomes in the MOG antibody–negative
patients with BON are outlined in appendix e-5.
Together these findings suggest that visual acu-
ity, visual field deficits, and RNFL thickness
improve in the majority of patients with MOG
antibody–associated BON; however, some patients
exhibit sustained visual impairment.
DISCUSSION Using a flow cytometry cell-based assay,
we found that antibodies targeting human native surface
full-length MOG may be a clinical biomarker in adults
with AQP4 antibody–negative BON. We provide
clinical characterization of this condition as a relapsing
disorder, frequently associated with prominent disc
swelling, that is steroid sensitive and often steroid
dependent. While early recognition and institution of
therapy can result in a favorable outcome, MOG
antibody-associated BON has the potential to result
in long-term visual impairment.
In recent years, microscopy or flow cytometry
cell-based assays have been crucial in establishing
MOG as an unequivocal antibody target in human
demyelination.11 In particular, flow cytometry has
emerged as a sensitive detection method,6,14,16,21,32
with recent confirmation of the surface expression
of the dominant MOG epitopes.33
We describe that surface MOG IgG antibodies
have a strong association with BON in adults.
Table 1 Clinical comparison of MOG antibody–positive and –negative patients
Clinical and investigation findings
MOG antibody–positive
(n 5 9)
MOG antibody–negative
(n 5 14) p Valuea
Sex (female) 6/9 (67) 6/14 (43) 0.492
Age at onset, median (range) 36 (22–52) 43 (17–59) 0.360b
Caucasian ethnicity 6/9 (67) 10/14 (71) 0.809
Infectious prodrome 6/9 (67) 4/14 (29) 0.171
Clinical presentation
BON 8/9 (89) 3/14 (21.5) 0.006
LETM 0/9 (0) 10/14 (71.5) 0.003
BON and LETM 1/9 (11) 1/14 (7) 0.742
Relapsing disorder 6/9 (67) 6/14 (43) 0.492
No. of episodes, median (range) 2 (1–5) 1 (1–8) 0.284b
Personal or family history of autoimmunity 2/9 (22) 2/14 (14) 0.624
CSF lymphocytosis 2/9 (22) 7/14 (50) 0.371
Presence of intrathecal CSF oligoclonal bands 1/9 (11) 1/14 (7) 0.742
MRI fulfilling revised McDonald criteria25 0/9 (0) 0/14 (0) NA
Rapid steroid responsec 6/9 (67) 2/14 (14) 0.034
Relapse with steroid cessationd 4/9 (44) 0/14 (0) 0.029
Abbreviations: BON5 bilateral and/or recurrent optic neuritis; LETM5 longitudinally extensive transverse myelitis; MOG5
myelin oligodendrocyte glycoprotein; NA 5 not applicable.
Data are n/total tested (%), unless otherwise specified.
ap Values determined using x2 test with Yates correction, unless otherwise specified.
bp Values calculated using Mann-Whitney test.
c Rapid steroid response defined as a greater than 50% improvement in visual acuity or Expanded Disability Status Scale
score within 24 hours of commencing IV steroids.
dRelapse with steroid cessation was defined as acute worsening within 48 hours of cessation of IV steroids.
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Figure 2 MOG antibody seropositivity in patients with MOG antibody–associated BON
(A) Serial dilutions of MOG antibody–positive samples show differing immunoglobulin (Ig) G binding. The end point dilution
where a sample remained above the positive threshold (red line) ranged from 1:50 to 1:2,000. For clarity, only 3 represen-
tative patients are shown. (B–E) Serial samples in 4 MOG antibody–positive patients are shown. A representative dot plot
out of 3 experiments is shown. Red lines on the graphs represent the threshold of positivity. Black circles represent times of
serum collection, arrows pointing up represent a clinical attack, arrows pointing down represent commencement of treat-
ment. (B) Patient 1 experienced a unilateral episode of left optic neuritis (ON) (normal MRI brain) that responded rapidly to
pulsed steroids; however, cessation of steroids prompted a bilateral simultaneous ON relapse requiring further treatment.
There were no further relapses and a good visual outcome. The initial sample was collected during the first presentation.
A serial sample collected during remission 4 years later remains positive, albeit with a reduced DMFI. (C) Patient 2 similarly
experienced 2 episodes of BON (normal MRI brain). The first sample was collected within 1 month of his relapse; a serial
sample 4 months later during remission remained seropositive. (D) Patient 3 experienced 4 episodes of recurrent unilateral
ON (MRI brain normal) affecting both eyes andwas treated on 2 occasions with pulsed steroids. While the first serum sample
within 1 month of her fourth relapse showed elevated MOG antibodies, 6-year follow-up revealed no further ON episodes
and a DMFI below the positive threshold at remission. (E) Patient 4 presented with sequential BON and longitudinally
extensive transverse myelitis (LETM) (MRI brain normal) and received aggressive immunotherapy. While his visual acuity
has improved, he continues to experience moderate visual field deficits and has residual motor and sphincter disability
related to spinal involvement. Serial samples were collected at initial presentation, during his relapse, and during remission.
He remains seropositive more than 8 months after presentation. Ab 5 antibody; BON 5 bilateral and/or recurrent optic
neuritis; MFI 5 mean fluorescence intensity; MMF 5 mycophenolate mofetil; MOG 5 myelin oligodendrocyte glycoprotein;
MP 5 Intravenous methylprednisolone; PE 5 plasma exchange.
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Figure 3 MOG antibody–associated BON has the potential to result in long-term visual impairment
(A) Visual functional system scores for MOG antibody–positive patients taken at the time of acute presentation and at latest
follow-up demonstrate that the majority of patients experienced an improvement in visual acuity at follow-up. (B) Visual field
deficits in 5 patients in both left (OS) and right (OD) eyes as measured by the mean deviation also demonstrate improvement
at latest follow-up and approach the normal range (gray region between red lines, 0 to 23 dB). (C) The majority of affected
eyes had a moderate to severe visual field deficit at onset but experienced an improvement in these scores. However, 2
affected eyes had a moderate residual deficit at latest follow-up. (D–G) Optical coherence tomography allowed for estima-
tion of average peripapillary retinal nerve fiber layer (RNFL) thickness. During an acute episode of optic neuritis, swelling
results in increased RNFL thickness (F). With resolution of the attack, RNFL thickness can either return toward the normal
range (shaded region) (D) or result in RNFL thinning (E and G). Ab 5 antibody; BON 5 bilateral optic neuritis; MOG 5 myelin
oligodendrocyte glycoprotein.
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The fact that 39% of AQP4 antibody–negative
patients with NMO/NMOSD in our cohort were
positive for MOG antibodies renders this a poten-
tially useful biomarker. We detected an IgG rather
than an IgM antibody response, implying this is not
an acute immunologic response to injury but rather
a more mature response. Seven of 9 MOG antibody–
positive patients had one or more episodes of simul-
taneous BON, with 2 having additional episodes of
unilateral ON. Two of 9 MOG antibody–positive
patients had recurrent episodes of unilateral ON
affecting both eyes. Our group described MOG anti-
bodies in pediatric patients with BON, further
strengthening this clinical association.34 A similar
association with MOG antibody positivity and bilat-
eral simultaneous ON was recently reported.24 MOG
antibodies should be a diagnostic consideration in any
patient with recurrent ON, whether they present uni-
laterally or bilaterally. We additionally found that
prominent optic disc swelling was noted in all
9 MOG antibody–positive patients acutely; this
appearance is not typical of ON related to MS and
should prompt testing for MOG antibodies.35
Of interest, chronic relapsing inflammatory optic neu-
ropathy (CRION) describes a group of patients with
recurrent optic neuropathy who are largely AQP4 anti-
body–negative.36,37 The diagnostic criteria for CRION
include relapsing disease, loss of visual function,
NMO-IgG seronegativity, optic nerve contrast
enhancement, response to immunosuppressive ther-
apy, and relapse on withdrawal of therapy.37 This
description is largely similar to the clinical character-
istics of our MOG antibody–positive cohort, and it is
possible that a subset of patients labeled as CRION
may indeed have MOG antibody–associated BON.
One MOG antibody–positive patient had LETM
in the context of a preceding attack of BON.
This fulminant presentation of sequential BON and
LETM is uncommon in AQP4 antibody–positive
NMO and reminiscent of the original descriptions of
Devic disease.22 A recent study23 described 9 patients
with MOG antibodies, the majority of whom had
transverse myelitis. All our MOG antibody–positive
patients had both brain and spine MRIs performed.
In our cohort, none of the patients with radiologically
defined LETM had MOG antibodies. Notably,
5 of our patients with MOG antibody–associated
BON did have symptoms suggestive of spinal involve-
ment, including Lhermitte phenomenon, limb pares-
thesia, and sphincter dysfunction, despite a normal
MRI spine. This suggests that cord involvement may
occur without clinical or radiologic evidence of myeli-
tis. The use of full-length human MOG in our cell-
based assay as opposed to C-terminal truncated human
MOG used by other groups23,38 may account for some
differences in findings. In addition, 14/23 AQP4
antibody–negative patients with NMO/NMOSD
in our cohort were also MOG antibody–negative,
suggesting there may be other antigen targets.
Our cohort of MOG antibody–positive patients
was predominantly Caucasian. This is in keeping
with recent findings and contrasts with AQP4
antibody–positive patients, who are more likely to
be non-Caucasian.7,8 A recent report of 16 MOG
antibody–positive patients of a similar median age
found that most patients were male.24 We did not
find a statistically significant association with sex,
age at onset, and MOG antibody status. In our
cohort, the 9 MOG antibody–positive patients did
not have intrathecal oligoclonal bands or radiology
consistent with MS, suggesting that this condition
may be an immunologic entity that is distinct
from both AQP4 antibody–positive NMO and MS.
While we did not test a cohort of AQP4 antibody–
positive patients for MOG antibodies in the context
of this study, AQP4- and MOG-antibody double
positivity has been seldom reported23,24,39,40; there-
fore, the evaluation of the prevalence and clinical
significance of double seropositive patients is a point
of interest for future work.
The majority of MOG antibody–positive patients
in our cohort had a propensity to relapse and
remained persistently seropositive. This is a novel
finding in adults, as 2 recently published cohorts have
suggested that MOG antibody positivity is associated
with a monophasic illness.23,24 The presence of relap-
ses has been observed in pediatric patients with MOG
antibodies and LETM or recurrent or bilateral ON.15,21
Notably, a number of our MOG antibody–positive
patients had previous treatment with short courses of
pulsed steroids alone and had a propensity to relapse.
This may indicate that early and sustained immuno-
therapy with multiple agents, including steroid-
sparing maintenance immunosuppression, may be
more effective in maintaining disease remission.
Further studies addressing the clinical implications
of persistent seropositivity on relapse risk and thera-
peutic approaches in patients with MOG antibody–
associated BON are required.
Conventional measures of disability such as the
EDSS26 or mRS may not be appropriate in patients
with BON, as visual impairment alone does not
rate highly on such scales despite causing major func-
tional disability. Previous studies highlight the favor-
able clinical outcomes of patients with MOG
antibody–positive NMO/NMOSD.22,23 The major-
ity of our MOG antibody–positive patients did
indeed demonstrate an improvement of visual acuity
and visual field deficits with early immunotherapy,
suggesting that this condition may be treatable;
however, this improvement was not universal.
A minority of our seropositive patients did have
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significant residual deficits in terms of visual acuity,
visual field loss, and RNFL thinning. Although most
patients had preserved visual acuity, some had
evidence of concomitant RNFL thinning, which
may represent a vulnerability to sustained visual
impairment in the context of relapses. In addition
to visual dysfunction, spinal cord–related disability
may also persist, as in our patient with sequential
BON and LETM. These results highlight the fact
that MOG antibody–associated demyelination may
not always have a favorable outcome.
Due to the retrospective study design, most samples
were obtained pretreatment; however, some patients
had received steroids or other immunosuppressive ther-
apy at the time of sample collection. Despite this, the
strong association of MOG antibody positivity with
the clinical phenotype of relapsing BON with promi-
nent optic disc swelling is novel and an important
contribution to the field. Evaluation of visual fields
was retrospective, and half of the antibody-positive
patients had both acute and convalescent OCT results.
Nonetheless, our study is the first attempt to objectively
define visual acuity, visual field deficits, and RNFL in
MOG antibody–positive patients and provides impor-
tant insights on disease pathogenesis.
Taken together, our findings suggest that MOG
antibody–associated BON may be a distinct immu-
nologic entity with a characteristic clinical and ther-
apeutic profile. Detection of MOG antibodies may
assist with the early differentiation of this condition
from AQP4 antibody–positive NMO and MS, and
MOG antibodies may prove to be an essential bio-
marker with diagnostic and therapeutic implications.
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Antibodies to myelin 
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uncommon in Japanese opticospinal 
multiple sclerosis
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Dear Editor
Japanese opticospinal multiple sclerosis (OSMS) has 
significant differences to MS in Caucasians.1,2 Lesions 
are confined to the optic nerve and spinal cord with 
minor brainstem lesions, no clinical evidence of cere-
bellar or cerebral involvement, and at least one relapse. 
Recent studies have shown antibodies targeting mye-
lin oligodendrocyte glycoprotein (MOG) in patients 
with simultaneous bilateral and recurrent optic neuritis 
(ON).3,4 We hypothesized that some patients with 
OSMS may be positive for MOG antibodies.
We retrospectively investigated 50 Japanese aqua-
porin-4 antibody-negative patients with OSMS (42 
female; median age at onset 30.5 years, mean 31.94, 
range 9–60). The median disease duration was seven 
years (mean 11.7, range 0.8–36 years). All patients ful-
filled clinical criteria for OSMS.2 Forty Japanese con-
trols were also tested (20 females, median age 51 
years, mean 49, range 24–69). Using a live flow 
cytometry cell-based assay to detect serum IgG to full-
length human MOG,3,4 MOG antibodies were detected 
in 2/50 patients with OSMS, compared to 0/39 con-
trols. The first MOG antibody-positive OSMS patient 
(a 62 year old male) developed left ON at the age of 
40, experienced a further episode of unilateral ON, 
one episode of simultaneous bilateral ON (BON), and 
short segment myelitis. Cerebrospinal fluid (CSF) 
analysis during remission revealed 11 mononuclear 
cells/µL, and elevated protein (60.5 mg/dL). His brain 
MRI fulfilled revised McDonald’s criteria. He has 
been on no therapy, was in remission at sample collec-
tion, has normal visual acuity at latest follow-up, and 
an Expanded Disability Status Scale (EDSS) of 1. The 
second MOG antibody-positive patient (a 40 year old 
female) developed sensory loss below the neck at the 
age of 39, following a viral illness. She consequently 
had one episode of confirmed longitudinal extended 
transmyelitis (LETM) and a subsequent episode of 
short segment myelitis. A vasculitic screen was positive 
for antinuclear antibodies and SSA antibodies. CSF 
analysis at initial presentation revealed 179 mononu-
clear cells/µL, elevated protein at 53 mg/dL, and no 
intrathecal oligoclonal bands. A brain MRI did not fulfill 
revised McDonald’s criteria. She is on no therapy and 
was in remission at sample collection. Latest follow-up 
revealed normal visual acuity and an EDSS of 2.
As in Australian patients with MS (1/76, 1.3%),4 we 
found similarly low rates of MOG antibody-positivity 
in Japanese OSMS (2/50, 4%). This was despite the 
fact that OSMS patients have dominant ON, which 
has been strongly associated with MOG antibodies.3,4 
Interestingly, the first MOG antibody-positive patient 
had recurrent episodes of unilateral ON and one epi-
sode of BON. He was one of only four patients with 
BON in this OSMS cohort. The second MOG anti-
body-positive patient was the only patient in this 
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cohort with LETM, also described to be sometimes 
associated with MOG antibodies.4
Steroids alone or in combination with maintenance 
immunosuppression may improve outcomes in MOG 
antibody-positive patients,3,4 rather than the disease-
modifying therapies used in conventional MS. 
Therefore, the recognition of this condition has thera-
peutic implications, and the clinical phenotype of 
BON and/or LETM in Japanese MS should raise sus-
picion for MOG antibody-associated demyelination 
and prompt testing for MOG antibodies.
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Introduction
Optic neuritis (ON) is characterized by visual loss and 
pain with eye movement due to inflammation of the 
optic nerve, and occurs as the presenting symptom in 
25%, or during the disease course in up to 70%, of 
patients diagnosed with multiple sclerosis (MS).1,2 
Neuromyelitis optica (NMO) is a demyelinating 
condition that selectively targets the spinal cord and 
optic nerves, resulting in transverse myelitis and ON, 
and is often associated with severe disability.3,4 The 
detection of immunoglobulin G (IgG) antibodies tar-
geting aquaporin-4 (AQP4) in patients with NMO or 
NMO spectrum disorders (NMOSD) has distinguished 
this condition from MS.4 Using cell-based assays, IgG 
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Abstract
Background: Recognizing the cause of optic neuritis (ON) affects treatment decisions and visual out-
comes.
Objective: We aimed to define radiological features of first-episode demyelinating ON.
Methods: We performed blinded radiological assessment of 50 patients presenting with first-episode 
myelin oligodendrocyte glycoprotein (MOG) antibody-associated ON (MOG-ON; n=19), aquaporin-4 
(AQP4) antibody-associated ON (AQP4-ON; n=11), multiple sclerosis (MS)-associated ON (MS-ON; 
n=13), and unclassified ON (n=7).
Results: Bilateral involvement was more common in MOG-ON and AQP4-ON than MS-ON (84% vs. 
82% vs. 23%), optic nerve head swelling was more common in MOG-ON (53% vs. 9% vs. 0%), chiasmal 
involvement was more common in AQP4-ON (5% vs. 64% vs. 15%), and bilateral optic tract involve-
ment was more common in AQP4-ON (0% vs. 45% vs. 0%). Retrobulbar involvement was more common 
in MOG-ON, whereas intracranial involvement was more common in AQP4-ON. MOG-ON and AQP4-
ON had longer lesion lengths than MS-ON. The combination of two predictors, the absence of magnetic 
resonance imaging brain abnormalities and a higher lesion extent score, showed a good ability to dis-
criminate between an autoantibody-associated ON (MOG or AQP4) and MS. AQP4-ON more frequently 
had severe and sustained visual impairment.
Conclusion: MOG-ON and AQP4-ON are more commonly bilateral and longitudinally extensive. MOG-
ON tends to involve the anterior optic pathway, whereas AQP4-ON the posterior optic pathway.
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antibodies targeting myelin oligodendrocyte glycopro-
tein (MOG), a protein expressed by oligodendrocytes 
on the external surface of myelin, have been identified 
in 20–40% of children with acute disseminated 
encephalomyelitis and relapsing demyelination 
including NMO/NMOSD.5–9 Recent studies have 
revealed that a proportion of adults with AQP4 anti-
body-negative NMO/NMOSD have antibodies target-
ing MOG.10–14 Our group has demonstrated a strong 
association between MOG antibody positivity and 
simultaneous bilateral and recurrent ON in children 
and adults.9,13 Previous animal model literature has 
revealed that immunization with MOG can result in 
features of experimental autoimmune encephalitis 
with dominant optic nerve and spinal cord involve-
ment, furthering the association between ON and the 
autoantigen MOG.15,16 Early distinction of the cause of 
ON is important, due to the varied pathogenesis, ther-
apy, and prognosis of MOG antibody-associated 
NMO/NMOSD, AQP4 antibody-associated NMO/
NMOSD, and MS.
Magnetic resonance imaging (MRI) of the brain and 
spinal cord plays an essential role in the diagnosis and 
management of patients with suspected demyelina-
tion. While MRI brain abnormalities in patients with 
NMO have been described,17–19 only a few previous 
studies have assessed the radiological features of ON 
in NMO versus MS, and these results were limited by 
small sample size, the lack of gadolinium administra-
tion, and/or the lack of dedicated orbital imaging.20–22 
These studies showed that AQP4 antibody-positive 
patients had a tendency to have bilateral and longitu-
dinally extensive ON with chiasmal involvement.20–22 
Akaishi et al.23 studied Japanese patients (n=19 MOG 
antibody-positive ON-affected eyes, and n=9 AQP4 
antibody-positive ON-affected eyes) and demon-
strated severe and extensive inflammatory changes in 
the optic nerves of MOG antibody-positive patients 
that typically spared the chiasm, while AQP4 anti-
body-positive patients had chiasmal swelling. Ours is 
the first study to directly compare the radiological 
characteristics of first-episode ON associated with 
MOG antibodies (MOG-ON), AQP4 antibodies 
(AQP4-ON), and MS (MS-ON). Herein, we demon-
strate differentiating features of ON according to 
diagnosis.
Materials and methods
Patient and control recruitment and clinical 
characterization
We retrospectively assessed 55 patients who had MRI 
during a first presentation of ON, and who were 
assessed at nine tertiary referral MS/neuroimmunol-
ogy centers in Australia and the United States from 
January 2001 to September 2014. Inclusion criteria 
were a presentation consistent with the first episode 
of clinical ON;22 MRI within 4 weeks of symptom 
onset wherein acute radiological features including 
contrast enhancement may persist;20 and access to 
clinical follow-up. Patients were excluded if there 
was a lack of dedicated orbital imaging, lack of clini-
cal follow-up, symptom resolution in less than 24 h, 
or an alternate diagnosis. Five patients were excluded 
from further analysis due to the lack of dedicated MRI 
orbital imaging. In total, 50 patients (41 female, mean 
age at onset 24 years, median 15 years, range 3–58 
years) had dedicated orbital and brain imaging with a 
3T (n=32) or 1.5T (n=18) MRI scanner.
Prior to study commencement, a diagnosis of MOG 
antibody-positive ON had been made in 19 patients, 
using a cell-based assay analyzed by flow cytometry 
to detect antibody binding of patient serum IgG to 
surface full-length human MOG as we have previ-
ously described.9,13 A diagnosis of AQP4 or NMO 
IgG antibody-positive ON had been made in 11 
patients. NMO IgG antibodies were tested by indirect 
immunofluorescence on monkey cerebrum, cerebel-
lum and stomach, and rat kidney.3,4 AQP4 antibodies 
were tested by cell-based assays using the M23 iso-
form (Euroimmun, Lübeck, Germany). Thirteen 
patients with MS-ON served as the control group, and 
were recruited from three MS referral centers in 
Sydney. We reviewed files of patients with MS from 
2001 to 2013 presenting with first-episode ON, and 
included only patients where MRI brain and dedi-
cated orbital imaging was available. These patients 
were diagnosed with MS as defined by the revised 
2010 McDonald criteria.24 Of these, 2/13 MS patients 
fulfilled McDonald radiological criteria at their first 
presentation of ON, 8/13 had subsequent clinical 
relapses, while 3/13 fulfilled revised McDonald crite-
ria on follow-up due to radiological evidence of dis-
semination in space and time. Finally, seven patients 
were seronegative for both MOG and AQP4 antibod-
ies and did not fulfill diagnostic criteria for MS, were 
defined as ‘unclassified’, and were not included in the 
statistical analyses due to their likely heterogenous 
etiologies. Clinical and radiological data on these 
seven patients are provided in Supplementary Tables 
1 and 2. Patients were tested for MOG antibodies 
(n=19/19 MOG-ON patients, n=2/11 AQP4-ON 
patients, n=9/13 MS-ON patients, n=7/7 unclassified 
ON patients) and AQP4 antibodies (n=17/19 
MOG-ON patients, n=11/11 AQP4-ON patients, 
n=6/13 MS-ON patients, n=4/7 unclassified ON 
patients) depending on the availability of serum from 
Stephen W Reddel 
Department of Neurology, 
Concord Repatriation 
General Hospital, Sydney, 
Australia/Brain and Mind 
Research Institute, University 
of Sydney, Sydney, Australia
Andrew PD Henderson
Department of Neurology, 
Westmead Hospital, 
and Sydney Medical 
School, University 
of Sydney, Sydney, 
Australia/Department of 
Ophthalmology, Westmead 
Hospital, Sydney, Australia
Steve Vucic  
Department of Neurology, 
Westmead Hospital, and 
Sydney Medical School, 
University of Sydney, 
Sydney, Australia/Western 
Clinical School, University of 
Sydney, Sydney, Australia
Mark P Gorman  
Leslie A Benson  
Boston Children’s Hospital, 
Boston, United States of 
America
Gulay Alper  
Children’s Hospital of 
Pittsburgh, Department 
of Pediatrics, University 
of Pittsburgh, School of 
Medicine, Pittsburgh, United 
States of America
Catherine J Riney 
Neurosciences Unit, Lady 
Cilento Children’s Hospital, 
Brisbane, Australia; School 
of Medicine, University 
of Queensland, Brisbane, 
Australia
Michael Barnett  
Brain and Mind Research 
Institute, University of 
Sydney, Sydney, Australia/
Department of Neurology, 
Royal Prince Alfred Hospital, 
Sydney, Australia
John DE Parratt 
Department of Neurology, 
Royal North Shore Hospital, 
Central Clinical School, 
University of Sydney, 
Sydney, Australia
Todd A Hardy  
Brain and Mind Research 
Institute, University of 
Sydney, Sydney, Australia/
Department of Neurology, 
Concord Repatriation 
General Hospital, Sydney, 
Australia
Richard J Leventer 
Department of Neurology, 
University of Melbourne 
Department of Paediatrics, 
Murdoch Children’s 
Research Institute, The 
Royal Children’s Hospital, 
Melbourne, Australia
341 
Multiple Sclerosis Journal 22(4)
http://msj.sagepub.com
the patient during their index episode of ON. A total 
of 28 patients in this cohort were tested for both MOG 
and AQP4 antibodies and none were seropositive for 
both antibodies. A retrospective review of clinical 
information was performed.
Eight patients (MOG-ON n=1, AQP4-ON n=4, 
MS-ON n=3) had previous demyelinating episodes 
such as transverse myelitis, preceding their first epi-
sode of ON. Following the first episode of ON, most 
patients commenced de novo therapy (MOG-ON 
n=17, AQP4-ON n=7, MS-ON n=10) while those 
who had previous non-ON demyelinating episodes 
switched therapy (MOG-ON n=1, AQP4-ON n=4, 
MS-ON n=3) (Supplementary Table 3). One 
MOG-ON patient declined therapy. As detailed in 
Supplementary Table 3 the one MOG-ON patient had 
previous treatment with pulsed steroids, weaning oral 
prednisone, and monthly IVIg. The four AQP4-ON 
patients had previous treatment including pulsed ster-
oids (n=4), rituximab (n=4), weaning oral prednisone 
(n=3), plasmapheresis (n=3), maintenance mycophe-
nolate mofetil (n=3), and maintenance oral steroids 
(n=2). The three patients with MS had pulsed steroids 
(n=2), fingolimod (n=2), dimethyl fumarate (n=1), 
and glatiramer acetate (n=1).
All patients received a visual functional system score 
(VFSS) based on their visual acuity (rated from 0–6) 
during their initial presentation with ON and at latest 
follow-up. This score was based on the VFSS from 
the Expanded Disability Status Scale (EDSS) 
(Supplementary Table 4).25
Radiological characterization
Neuroradiology assessment was carried out by a 
neuroradiologist (KP) blinded to diagnoses, and the 
scans were presented in a random order. All patients 
had standardized imaging including axial T2 
weighted and/or fluid attenuated inversion recovery 
(FLAIR) sequences, coronal T2 or FLAIR sequences 
of the whole brain, and coronal sequences with or 
without axial T2 fat suppressed (FS) sequences. In 
the majority of the patients (47/50), coronal and/or 
axial T1 weighted FS sequences were performed 
following gadolinium administration. The follow-
ing radiological parameters were assessed with 
some being incorporated or adapted from previous 
studies.20–22
1. The assessment of MRI brain abnormalities.
2. The laterality of optic pathway abnormalities 
(whether optic nerve changes including T2 
hyperintensity, optic nerve swelling, and/or 
contrast enhancement were unilateral, bilateral, 
or absent).
3. The presence of optic nerve T2 hyperintensity 
(none versus any).
4. The degree of optic nerve T2 hyperintensity 
ipsilateral to the maximally affected eye (none, 
mild, moderate, or severe) as previously 
described.20 Examples of this rating system are 
outlined in Supplementary Figure 1(a–d).
5. The presence of optic nerve enhancement with 
gadolinium (none versus any).
6. The degree of optic nerve enhancement ipsilat-
eral to the maximally affected eye. This was 
graded using the level of extraocular muscle 
(EOM) enhancement as a reference, as previ-
ously described:20 0 none, 1 subtle, 2 definite 
but <EOM, 3 definite and ⩾EOM. Examples 
of this rating system are outlined in 
Supplementary Figure 1(e–h).
7. The presence of optic nerve swelling (when 
compared with the contralateral normal optic 
nerve in unilateral ON, or an ipsilateral unaf-
fected segment of optic nerve in bilateral ON).
8. The presence of radiologically visible optic 
nerve head swelling (that is, optic nerve head 
elevation).
9. The presence of optic chiasmal involvement.
10. The presence of optic tract involvement.
11. The most affected segment of the optic nerve 
(retrobulbar, canalicular or intracranial).
12. The extent of optic nerve involvement classi-
fied as none, focal, or longitudinal. Longitudinal 
was defined as involving two or more contigu-
ous optic nerve segments, with segments com-
prising anterior orbital, posterior orbital, 
canalicular, or intracranial.22 (Supplementary 
Figure 1(i)).
13. The lesion length in the maximally affected 
eye, measured in millimeters (mm). This was 
calculated by multiplying the slice thickness 
plus inter-slice interval (10% of slice thick-
ness) by the number of coronal sections through 
which the optic nerve changes were visible.
14. The lesion extent score out of 12 adapted from 
a previous study.21 The visual pathway was 
divided into 12 segments (anterior orbital, pos-
terior orbital, canalicular, intracranial, chias-
mal, and tract segments for each of the left and 
right optic pathways). The number of segments 
involved (as determined by T2 hyperintensity, 
optic nerve swelling and/or contrast enhance-
ment) was summated. A score of 1 was given 
for each segment affected, such that a maxi-
mum lesion extent score of 12 could be reached 
(Supplementary Figure 1(i)).
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Figures were generated using Prism software version 
6.0 (GraphPad Software, La Jolla, CA) and Adobe 
Illustrator CS6 (Adobe Systems Incorporated, San 
Jose, CA).
Standard protocol approval and patient consent
Ethics approval for this study was granted by the 
Sydney Children’s Network and Westmead Hospital 
Human Ethics Committees (12/SCHN/395, SSA/13/
WMEAD/53), as well as the ethics committees for 
participating hospitals. Informed consent was 
obtained from all patients and the research protocol 
was approved as per local committee requirements.
Statistical analyses
Statistical analyses were performed using SAS 9.3. 
Chi-squared and Kruskal–Wallis tests were used to 
compare clinical characteristics between diagnostic 
groups. All categorical radiological variables were 
described by frequencies and percentages overall and 
within diagnostic groups, and compared between 
diagnostic groups using exact chi-squared tests calcu-
lated using Monte Carlo estimates. Continuous radio-
logical variables were described by median and 
interquartile ranges overall and within diagnostic 
groups, and compared between diagnostic groups 
using Kruskal–Wallis tests.
P-values are presented without adjustment for multi-
ple statistical comparisons. This is a descriptive study 
and no pre-specified significance level has been set 
for hypothesis testing. Due to the large number of 
tests performed the significance level used to catego-
rize any individual p-value as “significant” or not 
should be 0.002 using a Bonferroni correction to 
maintain an overall type I error rate of 5%.
A further analysis categorized patients as either 
autoantibody-positive (MOG and AQ4 antibody-pos-
itive) or MS patients. Univariable chi-squared analy-
ses and Kruskal–Wallis tests compared each 
radiological predictor between these two groups. 
Predictors with p-values <0.1 were included in a mul-
tivariable logistic regression using backward variable 
selection to identify independent predictors of an 
autoantibody-positive diagnosis.
Results
Clinical comparison
The clinical comparison in ON due to all three diag-
noses is summarized in Table 1.
The age at onset between diagnostic groups was similar, 
with the mean age of onset in the third decade of life, 
reflecting recruitment from both pediatric and adult 
neuroimmunology referral clinics. Previous demyeli-
nating episodes occurred in 1/19 MOG-ON patients, 
5/11 AQP4-ON, and 3/13 MS-ON patients. Previous, 
concurrent, and subsequent clinical associations are 
described in Supplementary Table 3. MOG-ON and 
AQP4-ON patients were more likely to have severe 
visual impairment at acute presentation, with some 
patients scoring a maximum VFSS of 6 (MOG-ON 
n=8, AQP4-ON n=6) (Supplementary Figure 2). In con-
trast, only one MS patient had a VFSS of 6 acutely. The 
majority of MOG-ON patients (15/19, 79%) had optic 
nerve head swelling visible on fundoscopy, while this 
was only present in a minority of AQP4-ON and 
MS-ON patients. While 6/8 (75%) of MS-ON patients 
tested had intrathecal oligoclonal bands, this was less 
common in the antibody-associated patients (Table 1). 
All AQP4-ON patients had relapses, and a larger num-
ber of total clinical demyelinating episodes compared 
with MOG-ON and MS-ON patients.
Blinded radiological review
Examples of characteristic radiological findings in ON 
due to all three diagnoses are depicted in Figure 1 and 
2, and these comparisons are highlighted in Table 2 
and Figure 3.
Brain lesions were present in the minority of 
MOG-ON patients but in the majority of AQP4-ON 
and MS-ON patients (Table 2, Figure 1(a–d)). The 
brain changes in MOG-ON patients were not typical 
of those seen in MS-ON, with some patients exhibit-
ing large enhancing tumefactive lesions, or multiple 
areas of cortical and subcortical T2 hyperintensity 
(Supplementary Figure 3(a–c)). Hypothalamic 
involvement was more common in AQP4-ON patients 
(3/11, 27%) compared with MOG-ON (2/19, 11%) or 
MS-ON patients (1/13, 8%) (Figure 1(c), 
Supplementary Figure 3(d–f)). At the time of first-
episode ON, brain MRIs fulfilled revised McDonald 
criteria24 with radiological evidence of dissemination 
in space and time in 2/19 (11%) MOG-ON patients, 
0/11 (0%) AQP4-ON patients, and 2/13 (15%) 
MS-ON patients.24
Radiological bilateral ON was present in the majority 
of patients with MOG-ON and AQP4-ON compared 
with a minority of patients with MS-ON (Table 2, 
Figure 1(e–h)). The majority of MS patients had uni-
lateral ON. There were no radiological optic nerve 
changes in three MS patients, despite clinically uni-
lateral ON.
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Optic nerve T2 hyperintensity was present in all 
patients with MOG-ON and AQP4-ON, and in 8/12 
(62%) of patients with MS-ON (Table 2, Figure 1(e–
h)). The degree of optic nerve T2 hyperintensity in the 
maximally affected eye was moderate in most patients 
with MOG-ON and AQP4-ON, but in most MS-ON 
patients was either absent or mild (Table 2). There 
was no association between the presence and degree 
of optic nerve enhancement, or the presence of optic 
nerve swelling between diagnostic groups (Table 2, 
Figure 1(i–p)).
Optic nerve head swelling was radiologically visible 
in over half of the MOG-ON patients, whereas only 
one AQP4-ON patient and none of the MS-ON 
patients had optic nerve head swelling (Table 2, 
Figure 2(a–d)). APQ4-ON patients were more likely 
to show involvement of the optic chiasm compared 
with the other diagnostic groups (Table 2, Figure 2(e–
h)). Bilateral optic tract involvement was noted in 
almost half the AQP4-ON patients, and in none of the 
MOG-ON or MS-ON patients (Table 2, Figure 
2(i–l)).
When assessing the most affected segment of the 
optic nerve, more than half of the MOG-ON patients 
had retrobulbar ON. In contrast, the majority of 
AQP4-ON patients had involvement of the intracra-
nial portion of the optic nerve (Table 2).
The majority of MOG-ON and AQP4-ON patients 
exhibited longitudinally extensive ON, compared 
Table 1. The clinical comparison of ON acutely and at follow-up in patients with MOG-ON, AQP4-ON, and MS-ON.
Clinical variable assessed MOG-ON (n=19) AQP4-ON (n=11) MS-ON (n=13) p-valuea
Gender 15/19 (79%) 9/11 (82%) 12/13 (92%) p=0.59
number of females (%) (57–91%)b (52–95%) (67–99%)
Age at onset 20; 14 (3–55) 23; 14 (8–58) 29; 29 (12–45) p=0.11
mean; median (range) in years (13–28) (11–35) (21–37)
Number of patients for whom the ON episode was the 
first demyelinating event
18/19 (95%) 6/11 (55%) 10/13 (77%) p=0.033
number (%) (75–99%) (28–79%) (50–92%)
Worst VFSS during acute episode of ON 4.8; 5 (2–6) 5.4; 6 (4–6) 3.7; 4 (2–6) p=0.0054
mean; median (range) (4.2–5.5) (4.8–5.9) (2.9–4.5)
Presence of optic nerve head swelling on fundoscopy 15/19 (79%) 3/11 (27%) 2/13 (15%) p=0.0006
number (%) (57–91%) (10–57%) (4–42%)
Presence of intrathecal oligoclonal bands when CSF 
analyzed
1/15 (7%) 3/8 (38%) 6/8 (75%) p=0.018
number (%) (1–30%) (14–69%) (41–93%)
Clinical follow-up duration (months) 30; 18 (0.17–75) 37; 32 (5–102) 51; 44 (13–156) p=0.13
mean; median (range) (18–42) (19–56) (29–72)
Presence of any clinical demyelinating relapses 6/19 (32%) 11/11 (100%) 9/13 (69%) p=0.0008
number (%) (15–54%) (74–100%) (42–87%)
Total number of clinical demyelinating episodes 1.8; 1 (1–5) 5; 4 (3–10) 2.6; 2 (1–6) p=0.0002
mean; median (range) (1.1–2.4) (3.5–6.7) (1.6–3.6)
Subsequent number of ON episodes 0.68; 0 (0–4) 1.45; 1 (0–3) 0.69; 0 (0–3) p=0.042
mean; median (range) (0.04–1.33) (0.76–2.15) (0–1.41)
Length of VFSS follow-up after first ON episode 
(months)
19; 9 (0.13–75) 37; 26 (12–102) 36; 31 (6–120) p=0.015
mean; median (range) (8–30) (19–55) (16–55)
Final VFSS at follow-up 1.4; 1 (0–5) 2.2; 1 (0–6) 0.6; 0 (0–2) p=0.25
mean; median (range) (0.6–2.1) (0.4–4.0) (0.03–1.2)
AQP4: aquaporin-4; AQP4-ON: AQP4 antibody-associated optic neuritis; CSF: cerebrospinal fluid; MOG: myelin oligodendrocyte glycoprotein; MOG-ON: 
MOG antibody-associated optic neuritis; MS: multiple sclerosis; MS-ON: MS associated optic neuritis; ON: optic neuritis; VFSS: Visual Functional System 
Score.
a The p-values for all categorical variables were determined using chi-squared tests. The p-values for all continuous variables were determined using Kruskal–
Wallis tests.
b The 95% confidence intervals for all categorical variables and the 95% confidence limits for all continuous variables are listed in each cell within brackets and 
italicized.
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Figure 1. Examples of radiological characteristics in optic neuritis associated with MOG antibodies, AQP4 antibodies 
or MS.
Presence of MRI brain abnormalities: (A–D) (A) Normal MRI (Ax T2 TSE); (B) No brain changes in a MOG-ON patient (Ax 
T2 TSE); (C) Bilateral thalamic and hypothalamic (arrow) changes in an AQP4-ON patient (Ax T2); (D) Typical white matter 
periventricular hyperintensities in an MS-ON patient (Ax T2 FLAIR).
T2 hyperintensity and laterality: (E–H) (E) Normal optic nerves (arrows) (Cor T2 FS); (F) Bilateral optic nerve T2 hyperintensity 
(arrows) in a MOG-ON patient (Cor T2 FS TSE); (G) Bilateral optic nerve T2 hyperintensity (arrows) in an AQP4-ON patient (Cor T2 
FS); (H) Unilateral right optic nerve T2 hyperintensity (arrow) in an MS-ON patient (Cor T2 FS).
Optic nerve enhancement: (I–L) (I) Normal optic nerves (arrows) (Cor T1 FS + C); (J) Bilateral retrobulbar optic nerve 
enhancement and swelling (arrows) in a MOG-ON patient (Cor T1 FS + C); (K) Bilateral intracanalicular optic nerve enhancement 
(arrows) in an AQP4-ON patient (Cor T1 FS + C); (L) Unilateral retrobulbar left optic nerve enhancement (arrow) in an MS-ON 
patient (Cor T1 FS + C).
Optic nerve swelling: (M–P) (M) Normal optic nerves (arrows) (Cor T2 FS); (N) Bilateral optic nerve swelling (arrows) in a MOG-
ON patient (Cor T2 FS); (O) Bilateral optic nerve swelling (arrows) in an AQP4-ON patient (Cor T2 FS); (P) Unilateral left optic nerve 
swelling (arrow) in an MS-ON patient (Cor T2 FS).
Ax: axial; AQP4: aquaporin-4; AQP4-ON: AQP4 antibody-associated optic neuritis; Cor: coronal; FLAIR: fluid attenuated inversion 
recovery; FS: fat suppressed; MOG: myelin oligodendrocyte glycoprotein; MOG-ON: MOG antibody-associated optic neuritis; MRI: 
magnetic resonance imaging; MS: multiple sclerosis; MS-ON: MS associated optic neuritis; TSE: turbo spin echo; + C: with gadolinium 
contrast.
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Figure 2. Further examples of radiological characteristics in optic neuritis associated with MOG antibodies, AQP4 
antibodies or MS.
Optic nerve head swelling: (A–D) (A) normal MRI (Ax T2 FS); (B) Bilateral optic nerve head swelling (black arrows) visible in a 
MOG-ON patient (Ax T2 FS); (C) Absent optic nerve head swelling in an AQP4-ON patient (Ax T2); (D) Absent optic nerve head 
swelling in an MS-ON patient (Ax T2 FS).
Optic chiasmal involvement: (E–H) (E) Normal MRI (Cor T2 FS); (F) No chiasmal involvement in a MOG-ON patient (Cor T2 FS 
TSE); (G) Chiasmal involvement (arrow) in an AQP4-ON patient (Cor T2 FS); (H) No chiasmal involvement in an MS-ON patient (Cor 
T2 FS).
Optic tract involvement: (I–L) (I) Normal MRI (Cor T2 FS); (J) No optic tract changes in a MOG-ON patient (Cor T2 FS); (K) 
Bilateral optic tract involvement with T2 hyperintensity (arrows) in an AQP4-ON patient (Cor T2 FS); (L) No optic tract changes in an 
MS-ON patient (Cor T2 FS).
Extent of optic nerve involvement: (M–P) (M) Normal MRI (Ax T2 FS); (N) Bilateral longitudinally extensive optic nerve 
involvement (arrows) in a MOG-ON patient (Ax T2 FS TSE); (O) Bilateral longitudinally extensive optic nerve involvement (arrows) 
in an AQP4-ON patient (Ax T2 FS); (P) Unilateral focal involvement (arrow) in an MS-ON patient with focal enhancement of the 
intracanalicular portion of the left optic nerve visible (Ax T1 FS + C). Ax: axial; AQP4: aquaporin-4; AQP4-ON: AQP4 antibody-
associated optic neuritis; Cor: coronal; FS: fat suppressed; MOG: myelin oligodendrocyte glycoprotein; MOG-ON: MOG antibody-
associated optic neuritis; MRI: magnetic resonance imaging; MS: multiple sclerosis; MS-ON: MS associated optic neuritis; TSE: turbo 
spin echo; + C: with gadolinium contrast.
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Table 2. The radiological comparison of ON in patients with MOG-ON, AQP4-ON, and MS-ON.
Radiological variable assessed MOG-ON(n=19) AQP4-ON(n=11) MS-ON(n=13) p-valuea
Presence of brain abnormalities on MRI 7/19 (37%) 9/11 (82%) 12/13 (92%) P=0.0019
number (%) (19–59%)b (52–95%) (67–99%)
Presence of radiological bilateral ON 16/19 (84%) 9/11 (82%) 3/13 (23%) p=0.0012c
number (%) (62–94%) (52–95%) (8–50%)
Presence of T2 hyperintensity 19/19 (100%) 11/11 (100%) 8/13 (62%) p=0.0023
number (%) (83–100%) (74–100%) (36–82%)
Degree of optic nerve T2 
hyperintensity in maximally 
affected eye 
number (%)
None 0/19 (0%) 0/11 (0%) 5/13 (38%) p=0.0044
(0–17%) (0–26%) (18-64%)
Mild 5/19 (26%) 2/11 (18%) 5/13 (38%)
(12–49%) (5–48%) (18-64%)
Moderate 12/19 (63%) 6/11 (55%) 2/13 (15%)
(41–81%) (28–79%) (4-42%)
Severe 2/19 (11%) 3/11 (27%) 1/13 (8%)
(3–31%) (10–57%) (1-33%)
Presence of optic nerve gadolinium enhancement 
(number; %) 
17/18 (94%) 10/10 (100%) 9/12 (75%) p=0.14
(74–99%) (72–100%) (47–91%)
Degree of optic nerve 
enhancement in maximally 
affected eye number (%)
None 1/18 (6%) 0/10 (0%) 3/12 (25%) p=0.13
(1–26%) (0–28%) (9-53%)
Grade 1 3/18 (17%) 0/10 (0%) 2/12 (17%)
(6–39%) (0–28%) (5-45%)
Grade 2 3/18 (17%) 2/10 (20%) 4/12 (33%)
(6–39%) (6–51%) (14-61%)
Grade 3 11/18 (61%) 8/10 (80%) 3/12 (25%)
(39–80%) (49–94%) (9-53%)
Presence of optic nerve swelling 17/19; 89% 11/11; 100% 9/13; 69% p=0.077
number (%) (69–97%) (74–100%) (42–87%)
Presence of radiological optic nerve head swelling 
number (%) 
10/19 (53%) 1/11 (9%) 0/13 (0%) p=0.0003
(32–73%) (2–38%) (0–23%)
Chiasmal involvement 1/19; 5% 7/11; 64% 2/13; 15% p=0.0009
number (%) (1–25%) (35–85%) (4–42%)
Presence of bilateral optic tract involvement 0/19 (0%) 5/11; 45% 0/13; 0% p=0.00053
number (%) (0–17%) (21–72%) (0–23%)
The most affected segment 
of the optic nerve
None 0/19 (0%) 0/11 (0%) 3/13 (23%) p=0.0078
(0–17%) (0–26%) 8-50%)
Retrobulbar 10/19 (53%) 3/11 (27%) 3/13 (23%)
(32–73%) (10–57%) (8-50%)
Canalicular 3/19 (16%) 1/11 (9%) 5/13 (38%)
(6–38%) (2–38%) (18-64%)
Intracranial 6/19 (32%) 7/11 (64%) 2/13 (15%)
number (%) (15–54%) (35–85%) (4-42%)
Presence of focal vs. 
longitudinal optic nerve 
involvement
No involvement 0/19 (0%) 0/11 (0%) 3/13 (23%) p=0.0077
(0–17%) (0–26%) (8-50%)
Focal 1/19 (5%) 0/11 (0%) 3/13 (23%)
(1–25%) (0–26%) (8-50%)
Longitudinal 18/19 (95%) 11/11 (100%) 7/13 (54%)
number (%) (75–99%) (74–100%) (29-77%)
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with about half of the MS-ON patients (Table 2, 
Figure 2(m–p)). When looking specifically at lesion 
length, both MOG-ON and AQP4-ON patients had 
longer segment involvement of the optic nerve than 
MS-ON patients (Table 2). Likewise, the lesion extent 
score out of 12 was longer in MOG-ON and AQP4-ON 
patients when compared with MS-ON patients (Table 
2). None of the MS-ON patients had a lesion extent 
score greater than 6, while this was noted frequently 
in the MOG-ON (n=6/19, 32%) and AQP4-ON 
(n=5/11, 45%) patients. The main radiological differ-
ences between the diagnostic groups are presented in 
Figure 3.
Using multivariable logistical regression analysis to 
compare autoantibody-associated ON (MOG or 
AQP4) with MS-ON, backward selection removed all 
predictors with the exception of brain abnormalities 
on MRI (odds ratio (OR) 0.013, 95% confidence 
interval (CI) <0.001–0.306), and the lesion extent 
score (OR 2.8, 95% CI 1.37–5.65 per unit increase in 
lesion extent score). The resulting model had an area 
under the ROC curve of 0.94 (95% CI 0.88–1.0) indi-
cating that the combination of these two predictors 
showed a good ability to discriminate between 
autoantibody-associated ON and MS-ON.
Subsequent course and outcome
At latest clinical follow-up, patients with AQP4-ON 
were more likely to have clinical relapses, more total 
demyelinating episodes, and more subsequent ON 
episodes, compared with MOG-ON or MS-ON 
patients (Table 1). While 9/13 MS-ON patients had 
clinical relapses, the remainder of the MS-ON patients 
had radiological relapses during their subsequent fol-
low-up. The presence of severe and sustained visual 
impairment was mainly evident in the AQP4-ON 
group, with 3/11 patients still scoring a VFSS of 6 on 
follow-up (Supplementary Figure 2). In contrast, 
none of the MOG-ON or MS-ON patients had a VFSS 
of 6 on follow-up. In fact, 100% of MS-ON patients 
(13/13) had a VFSS of 0 or 1, revealing an excellent 
visual outcome in this group compared with the anti-
body-associated ON patients (Figure 3(h–j) and 
Supplementary Figure 2).
Discussion
With blinded neuroradiology assessment, we found 
that specific radiological parameters in ON were more 
suggestive of particular demyelinating entities. In 
particular, MOG-ON and AQP4-ON were strongly 
associated with bilateral and longitudinally extensive 
ON, in contrast to MS-ON, which was more fre-
quently unilateral with shorter segment optic nerve 
involvement. While some overlap does exist, the 
majority of patients with MOG-ON had more anterior 
optic pathway involvement with significant optic 
nerve head swelling visible both clinically on fundos-
copy, and radiologically, and the retrobulbar segment 
of the optic nerve most commonly affected. The pres-
ence of radiological optic nerve head swelling in par-
ticular was significant and highly suggestive of 
MOG-ON. Although fundoscopy and optical coher-
ence tomography are more standard ways to evaluate 
the optic nerve head, this radiological feature should 
be reported where present. In contrast, the majority of 
Radiological variable assessed MOG-ON(n=19) AQP4-ON(n=11) MS-ON(n=13) p-valuea
Optic nerve lesion length (mm) in maximally affected 
eye
(median, interquartile range)  
Median 23.1 Median 23.1 Median 9.9 p=0.016
Interquartile range Interquartile range Interquartile 
range
18–33 16.5–26.5 6.6–19.8
(20–29) (18–29) (6–21)
Lesion extent score out of 12 (median, interquartile 
range)  
Median 4 Median 6 Median 2 p=0.0008
Interquartile range 
3–7
Interquartile range 
4–9
Interquartile 
range 1–3
(3.6–5.9) (4.7–8.6) (1.1–3.5)
a The p-values for all categorical variables were determined using exact chi-squared tests. The p-values for all continuous variables were determined using 
Kruskal–Wallis tests.
b The 95% confidence intervals for all categorical variables and the 95% confidence limits for all continuous variables are listed in each cell within brackets and 
italicized.
cp-value is derived from chi-squared test of a 3×3 table (none/unilateral/bilateral involvement versus diagnostic groups).
AQP4: aquaporin-4; AQP4-ON: AQP4 antibody-associated optic neuritis; MOG: myelin oligodendrocyte glycoprotein; MOG-ON: MOG antibody-associated 
optic neuritis; MRI: magnetic resonance imaging; MS: multiple sclerosis; MS-ON: MS associated optic neuritis; ON: optic neuritis.
Table 2. (Continued)
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Figure 3. The radiological characteristics and visual outcomes of optic neuritis associated with MOG antibodies, AQP4 
antibodies, or MS. (A) The majority of patients with AQP4-ON and MS-ON exhibited MRI brain changes compared with a 
minority of patients with MOG-ON; (B) Both MOG-ON and AQP4-ON was bilateral in the majority of patients, while most 
MS-ON patients had unilateral ON; (C) Optic nerve head swelling was seen in over half the MOG-ON patients, was rare in 
AQP4-ON patients, and absent in MS-ON; (D) Chiasmal involvement was seen in the majority of AQP4-ON patients and 
infrequent in MOG-ON and MS-ON patients; (E) Bilateral optic tract involvement was exclusively seen in the AQP4-ON 
group; (F) While most patients with MOG-ON had retrobulbar ON, the intracranial portion of the optic nerve was more 
frequently affected in AQP4-ON patients; (G) The majority of MOG-ON and all of the AQP4-ON patients had longitudinal 
optic nerve involvement; (H) VFSS for MOG-ON patients at the time of acute presentation and at latest follow-up demonstrate 
that most patients experienced an improvement in visual acuity at follow-up, with only one patient having a follow-up VFSS 
⩾5; (I) VFSS for AQP4-ON patients at the time of acute presentation and at latest follow-up show that while many patients 
experienced an improvement in visual acuity, 3/11 still had sustained severe visual impairment with a VFSS of 6; (J) VFSS 
for MS-ON patients at the time of acute presentation and at latest follow-up demonstrate that all 13 patients had a good visual 
outcome with a follow-up score of ⩽1. AQP4: aquaporin-4; AQP4-ON: AQP4 antibody-associated optic neuritis; MOG: 
myelin oligodendrocyte glycoprotein; MOG-ON: MOG antibody-associated optic neuritis; MRI: magnetic resonance imaging; 
MS: multiple sclerosis; MS-ON: MS associated optic neuritis; ON: optic neuritis; VFSS: visual functional system score.
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patients with AQP4-ON had posterior optic pathway 
involvement with the intracranial segment of the optic 
nerve most affected, in addition to chiasmal and optic 
tract involvement. Posterior optic pathway involve-
ment should thus raise clinical suspicion for 
AQP4-ON. The combination of two radiological pre-
dictors, the absence of MRI brain abnormalities, and 
a higher lesion extent score, showed a good ability to 
predict an autoantibody-positive diagnosis compared 
with a diagnosis of MS.
While the retrospective design of this study, the 
potential treatment effect of steroids, and the rela-
tively small number of MS patients as a control group 
due to the stringent inclusion criteria are potential 
limitations, this is the first attempt to define and com-
pare the radiological characterization of first-episode 
ON in patients with MOG antibodies, AQP4 antibod-
ies, and MS. Further studies are required to determine 
if our observations are reproducible. Such observa-
tions are important to expedite diagnosis and permit 
the institution of the appropriate therapeutic regimes. 
This is paramount as immunosuppressive therapy and 
plasma exchange in AQP4 antibody-associated NMO/
NMOSD can reduce relapse rates and improve out-
comes, and differs significantly from immunomodu-
latory treatment used in MS.26,27 Furthermore, 
treatments used in MS such as interferon, natalizumab 
and fingolimod have been shown to be associated 
with a worse outcome in patients with NMO.28–30 We 
recently described the frequent steroid responsiveness 
and steroid dependence of MOG antibody-associated 
NMO/NMOSD.13 MOG antibody-associated relaps-
ing demyelination patients who are steroid dependent 
may benefit from the institution of steroid-sparing 
agents such as mycophenolate mofetil,9 once again 
highlighting the importance of early differentiation of 
autoantibody-associated demyelination from MS. It 
would be of interest for future studies to evaluate the 
impact of previous immunotherapy on the radiologi-
cal findings of ON we describe.
In addition, early differentiation between the etiologies 
of demyelinating ON may have prognostic significance. 
While broader disability scores such as the EDSS were 
outside the scope of this study, evaluation of visual out-
comes between the diagnostic groups in this study 
showed that AQP4-ON patients had a tendency to more 
relapses including ON episodes, as well as more severe 
and sustained visual impairment at latest clinical fol-
low-up than MOG-ON and MS-ON patients. This may 
suggest differences in pathogenic mechanisms. Studies 
demonstrating MOG antibody pathogenicity are lim-
ited, and while there is evidence of a number of differ-
ent MOG antibody-dependent mechanisms, a few have 
suggested that more reversible mechanisms may be 
associated with MOG antibodies compared with AQP4 
antibodies.31 Recent studies have suggested that patients 
with MOG antibody-associated NMO/NMOSD may 
have better clinical recovery and more favorable out-
comes than those with AQP4 antibody-associated 
NMO/NMOSD.11,12,14 However, sustained visual 
impairment has been shown in MOG-ON patients not 
given appropriate immunotherapy, and it is possible that 
some patients with MOG antibodies may have a poor 
outcome in the event of a delayed or missed diagnosis.13 
Longitudinal studies are currently lacking and would 
assist in identifying prognostic differences between 
these subgroups of patients.
Taken together, our findings demonstrate discriminat-
ing radiological findings, with MOG and AQP4 anti-
body-associated ON more frequently resulting in 
bilateral and longitudinally extensive ON. MOG anti-
bodies are more likely to be associated with anterior 
visual pathway involvement, while AQP4 antibodies 
are more commonly associated with posterior visual 
pathway involvement. This radiological characteriza-
tion may assist with an expedited diagnosis, appropri-
ate institution of immunotherapy, and have prognostic 
implications on visual outcomes.
Conflict of interest
Dr Sudarshini Ramanathan has received a postgradu-
ate scholarship from the National Health and Medical 
Research Council (Australia) and the Petre Foundation 
(Australia).
Dr Kristina Prelog reports no disclosures.
Ms Elizabeth Barnes reports no disclosures.
Dr Esther Tantsis reports no disclosures.
Dr Stephen Reddel reports grants and personal fees 
from Genzyme Sanofi, personal fees and departmen-
tal support from Biogen, CSL, and Baxter; and depart-
mental support from Novartis, outside the subject of 
the submitted work.
Dr Andrew Henderson reports no disclosures.
Professor Steve Vucic reports departmental support 
from Biogen, Novartis, Bayer, CSL and Genzyme.
Dr Mark Gorman reports research funding from the 
National Multiple Sclerosis Society and National 
Institute of Health.
Dr Leslie Benson has received the Boston Children’s 
Office of Faculty Development Award.
Associate Professor Gulay Alper reports no 
disclosures.
Dr Catherine Riney reports receipt of grants and fund-
ing for unrelated research, personal fees for serving 
350 
S Ramanathan, K Prelog et al.
http://msj.sagepub.com 
on an advisory board and conference travel support 
from Novartis. Dr Riney also reports receipt of per-
sonal fees for speaking from UCB.
Dr Michael Barnett reports grants, personal fees for 
serving on the scientific advisory board, and non-
financial support for unrelated research from Novartis 
Pharmaceuticals; grants from Genzyme Sanofi and 
Merck Serono, and personal fees for serving on the 
scientific advisory board from Genzyme Sanofi, out-
side the subject of the submitted work.
Dr John Parratt has received a fellowship from 
Multiple Sclerosis Research Australia. He has 
received honoraria and research grants from Genzyme, 
Novartis, Merck Serono and Bayer Schering and hon-
oraria from Biogen Idec and CSL.
Dr Todd Hardy reports no relevant disclosures.
Dr Richard Leventer reports no relevant disclosures.
Ms Vera Merheb reports no disclosures.
Dr Margherita Nosadini reports no disclosures.
Associate Professor Victor Fung reports no 
disclosures.
Dr Fabienne Brilot has received research funding 
from the Star Scientific Foundation, The Trish 
Multiple Sclerosis Research Foundation, Multiple 
Sclerosis Research Australia, MS Angels Melbourne 
(Australia), National Health and Medical Research 
Council (Australia), and the Petre Foundation.
Professor Russell Dale has received research funding 
from the Star Scientific Foundation, The Trish 
Multiple Sclerosis Research Foundation, Multiple 
Sclerosis Research Australia, National Health and 
Medical Research Council (Australia), and the Petre 
Foundation (Australia). Dr Dale has received hono-
raria from Biogen Idec as an invited speaker.
Funding
This work was supported by Multiple Sclerosis 
Research Australia [grant number 14-021], the Trish 
MS Research Foundation, the Star Scientific 
Foundation (Australia), MS Angels Melbourne 
(Australia), the Petre Foundation (Australia), and the 
National Health and Medical Research Council 
(Australia). This study was initiated and performed by 
the investigators, and the funding sources as listed 
above did not have any role in the design, conduct or 
data management of the study, nor writing of the report.
References
1. Compston A and Coles A. Multiple sclerosis. Lancet 
2008; 372: 1502–1517.
2. Toosy AT, Mason DF and Miller DH. Optic neuritis. 
Lancet Neurol 2014; 13: 83–99.
3. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A 
serum autoantibody marker of neuromyelitis optica: 
Distinction from multiple sclerosis. Lancet 2004; 364: 
2106–2112.
4. Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG 
marker of optic-spinal multiple sclerosis binds to the 
aquaporin-4 water channel. J Exp Med 2005; 202: 
473–477.
5. Brilot F, Dale RC, Selter RC, et al. Antibodies 
to native myelin oligodendrocyte glycoprotein in 
children with inflammatory demyelinating central 
nervous system disease. Ann Neurol 2009; 66: 
833–842.
6. Mader S, Gredler V, Schanda K, et al. Complement 
activating antibodies to myelin oligodendrocyte 
glycoprotein in neuromyelitis optica and related 
disorders. J Neuroinflamm 2011; 8: 184.
7. Rostasy K, Mader S, Schanda K, et al. Anti-myelin 
oligodendrocyte glycoprotein antibodies in pediatric 
patients with optic neuritis. Arch Neurol 2012; 69: 
752–756.
8. Rostasy K, Mader S, Hennes EM, et al. Persisting 
myelin oligodendrocyte glycoprotein antibodies in 
aquaporin-4 antibody negative pediatric neuromyelitis 
optica. Mult Scler 2013; 19: 1052–1059.
9. Dale RC, Tantsis E, Merheb V, et al. Antibodies to 
MOG have a demyelination phenotype and affect 
oligodendrocyte cytoskeleton. Neurol Neuroimmunol 
Neuroinflamm 2014; 1: e12.
10. Kitley J, Woodhall M, Waters P, et al. Myelin-
oligodendrocyte glycoprotein antibodies in adults 
with a neuromyelitis optica phenotype. Neurology
2012; 79: 1273–1277.
11. Kitley J, Waters P, Woodhall M, et al. Neuromyelitis 
optica spectrum disorders with aquaporin-4 and 
myelin-oligodendrocyte glycoprotein antibodies: A 
comparative study. JAMA Neurol 2014; 71: 276–283.
12. Sato DK, Callegaro D, Lana-Peixoto MA, et al. 
Distinction between MOG antibody-positive and 
AQP4 antibody-positive NMO spectrum disorders. 
Neurology 2014; 82: 474–481.
13. Ramanathan S, Reddel SW, Henderson A, et al. 
Antibodies to myelin oligodendrocyte glycoprotein 
in bilateral and recurrent optic neuritis. Neurol 
Neuroimmunol Neuroinflamm 2014; 1: e40.
14. Hoftberger R, Sepulveda M, Armangue T, et al. 
Antibodies to MOG and AQP4 in adults with 
neuromyelitis optica and suspected limited forms of 
the disease. Mult Scler 2015; 21: 866–874.
15. Sakuma H, Kohyama K, Park IK, et al. 
Clinicopathological study of a myelin 
351 
Multiple Sclerosis Journal 22(4)
http://msj.sagepub.com
oligodendrocyte glycoprotein-induced demyelinating 
disease in LEW.1AV1 rats. Brain 2004; 127: 
2201–2213.
16. Soares RM, Dias AT, De Castro SB, et al. Optical 
neuritis induced by different concentrations of myelin 
oligodendrocyte glycoprotein presents different 
profiles of the inflammatory process. Autoimmunity
2013; 46: 480–485.
17. Pittock SJ, Lennon VA, Krecke K, et al. Brain 
abnormalities in neuromyelitis optica. Arch Neurol
2006; 63: 390–396.
18. McKeon A, Lennon VA, Lotze T, et al. CNS 
aquaporin-4 autoimmunity in children. Neurology
2008; 71: 93–100.
19. Li Y, Xie P, Lv F, et al. Brain magnetic resonance 
imaging abnormalities in neuromyelitis optica. Acta 
Neurol Scand 2008; 118: 218–225.
20. Khanna S, Sharma A, Huecker J, et al. Magnetic 
resonance imaging of optic neuritis in patients with 
neuromyelitis optica versus multiple sclerosis. J 
Neuroophthalmol 2012; 32: 216–220.
21. Storoni M, Davagnanam I, Radon M, et al. 
Distinguishing optic neuritis in neuromyelitis optica 
spectrum disease from multiple sclerosis: A novel 
magnetic resonance imaging scoring system. J 
Neuroophthalmol 2013; 33: 123–127.
22. Graves J, Kraus V, Soares BP, et al. Longitudinally 
extensive optic neuritis in pediatric patients. J Child 
Neurol 2015; 30: 120–123.
23. Akaishi T, Sato DK, Nakashima I, et al. MRI and 
retinal abnormalities in isolated optic neuritis with 
myelin oligodendrocyte glycoprotein and aquaporin-4 
antibodies: A comparative study. J Neurol Neurosurg 
Psychiatry 2015; doi: 10.1136/jnnp-2014-310206. 
[Epub ahead of print]
24. Polman CH, Reingold SC, Banwell B, et al. 
Diagnostic criteria for multiple sclerosis: 2010 
revisions to the McDonald criteria. Ann Neurol 2011; 
69: 292–302.
25. Kurtzke JF. Rating neurologic impairment in multiple 
sclerosis: An Expanded Disability Status Scale 
(EDSS). Neurology 1983; 33: 1444–1452.
26. Keegan M, Pineda AA, McClelland RL, et al. Plasma 
exchange for severe attacks of CNS demyelination: 
Predictors of response. Neurology 2002; 58: 
143–146.
27. Kitley J, Leite MI, Nakashima I, et al. Prognostic 
factors and disease course in aquaporin-4 antibody-
positive patients with neuromyelitis optica spectrum 
disorder from the United Kingdom and Japan. Brain
2012; 135: 1834–1849.
28. Kleiter I, Hellwig K, Berthele A, et al. Failure of 
natalizumab to prevent relapses in neuromyelitis 
optica. Arch Neurol 2012; 69: 239–245.
29. Min JH, Kim BJ and Lee KH. Development of 
extensive brain lesions following fingolimod 
(FTY720) treatment in a patient with neuromyelitis 
optica spectrum disorder. Mult Scler 2012; 18: 
113–115.
30. Trebst C, Jarius S, Berthele A, et al. Update on the 
diagnosis and treatment of neuromyelitis optica: 
Recommendations of the Neuromyelitis Optica Study 
Group (NEMOS). J Neurol 2014; 261: 1–16.
31. Saadoun S, Waters P, Owens GP, et al. Neuromyelitis 
optica MOG-IgG causes reversible lesions in mouse 
brain. Acta Neuropathol Commun 2014; 2: 35.
Visit SAGE journals online 
http://msj.sagepub.com
SAGE journals
352 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
